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SUMMARY
Herpes simplex virus type 1 (HSV-1) expresses three main 
classes of genes (immediate-early [IE], early [E] and late 
[L]) in a temporal cascade upon infection of tissue culture 
cells. These three groups of genes can also be defined by 
the sensitivity of their expression to metabolic inhibitors 
of protein or DNA synthesis. IE genes are transcribed in 
the absence of de novo protein synthesis and their 
transcription is stimulated by a component of the virus 
particle, Vmw65. IE gene products are required for the 
activation of later classes of viral genes, whose expression 
varies in sensitivity to inhibitors of viral DNA 
replication. Early genes are expressed at maximal levels in 
the absence of DNA synthesis, whilst true late genes are 
critically dependent on replication for expression.
The predominant transcriptional regulatory protein 
specified by HSV-1 is the IE protein Vmwl75, whose functions 
are essential for virus growth. Studies of viruses with 
temperature sensitive lesions in this protein have shown 
that Vmwl75 is a complex multifunctional protein required 
for the transcriptional activation of many HSV-1 promoters 
and the repression of its own transcription. Cloned Vmwl75 
is a promiscuous transactivator of transcription of RNA 
polymerase type II promoters. In addition cloned Vmwl75 
represses transcription from its own promoter, probably by 
binding to a specific target sequence at the start site for 
transcription.
The aim of the work described in this thesis was to 
investigate the relationship between the structure and 
function of this protein, and to define which regions of 
the protein are involved in each of its various activities.
A panel of plasmid-borne in-frame insertion and deletion 
mutants of the gene encoding Vmwl75 were constructed and 
assayed for their ability to regulate transcription in 
transient transfection assays. Fusions of HSV promoters to 
the chloramphenicol acetyl transferase gene were used to 
assay the ability of each mutant to transactivate an HSV 
early promoter (that of the gene encoding glycoprotein gD) 
and to repress the promoter of its own gene, IE3, in 
transiently transfected cells. By this approach it was
possible to define the regions of the Vmwl75 amino acid 
sequence that are required for transcriptional activation 
and repression. Large stretches of the protein are 
relatively unimportant for either function, while the 
regions most sensitive to disruption correlate to sequences 
conserved between Vmwl75 and VZV 140K, the corresponding 
transactivating protein of another alphaherpesvirus, 
varicella-zoster virus. The region from amino acids 275 
to 495 is particularly important for both repression and 
transactivation; whilst that from around 840 to 1100 seems 
to be more important for transactivation than repression.
A monoclonal antibody directed against Vmwl75 was used 
to visualize expression and localization of Vmwl75 in 
transfected cells by indirect immunofluorescence. This 
provided confirmation that each of the mutant plasmids 
expressed Vmwl75. Each of the 3 9 insertion mutant 
proteins exhibited a pattern of nuclear localization 
indistinguishable from that of wild-type, but when amino 
acids 682-774 were deleted a signal essential for nuclear 
localization was lost. A strong candidate for a nuclear 
localization signal centres around amino acid 728 and is 
strongly conserved in the VZV homologue. This sequence 
PREGRKRKSP contains four consecutive arginine (R) and lysine 
(K) residues and is related to a signal in the SV40 large T 
antigen required for nuclear localization.
Vftiwl75 is known to bind directly to a number of HSV-1 
sequences, some of which contain the consensus sequence 
ATCGTC. The binding of Vmwl75 to this sequence at the 
transcriptional start site of IE gene 3 is thought to be 
involved in the mechanism of autoregulation. In order to 
correlate the transcriptional activity of each mutant with 
its ability to bind to DNA, the site specific DNA binding 
activity of each mutant was assayed. In these experiments 
nuclear extracts of transfected cells were incubated with a 
DNA probe spanning the IE3 cap site and protein complexes 
detected using the gel retardation technique. The results 
show that a critical region of Vmwl75, amino acid residues 
275-495, includes structures which are essential for 
specific DNA binding, transactivation and repression. This 
raises the interesting paradox that although the specific 
DNA sequence recognized by Vmwl75 is not commonly found
in its target promoters, the protein domain required for 
recognition of this sequence is required for promoter 
activation.
Work was initiated to recombine some of these 
plasmid-borne mutants back into the viral genome. To 
facilitate this an HSV-1 deletion mutant lacking both copies 
of the gene was constructed and the plasmid-borne mutations 
were transfered into this virus by homologous recombination 
in transfected cells. The long term aim of constructing 
these viruses was to use them as vectors to produce large 
amounts of mutant VSmwl75. Three novel recombinant viruses 
were constructed in this manner and their characterization 
is described. The most interesting virus contained a 68 
codon deletion in both copies of the gene encoding Vmwl75. 
Although this deletion removed a conserved serine-rich 
phosphorylation site in Vmwl75 this virus was viable when 
grown on a non-complementing cell-line, confirming the 
conclusion drawn from study of this mutation in transient 
transfection assays that this region of the protein is 
functionally non-essential.
The implication of these results regarding the structure 
of Vmwl75 and the possible mechanisms by which this protein 
might function to regulate transcription are discussed.
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1CHAPTER 1: INTRODUCTION
The research presented in this thesis concerns the role 
and function of the predominant transcriptional regulatory 
protein of HSV-1, the immediate-early protein Vmwl75. As 
such it is necessary to consider the role of Vmwl75 in 
relationship to the viral life-cycle and also in 
relationship to the host-cell transcriptional machinery.
This introduction, therefore, aims to describe briefly the 
biology of HSV-1, with particular reference to its gene 
regulation and transcriptional programme, and also to review 
the current knowledge of the eukaryotic transcriptional 
machinery and possible mechanisms by which transcriptional 
regulation may function.
SECTION 1A; THE BIOLOGY OF HSV-1
1. Classification and structure of the herpesviruses
Members of the Herpesviridae form a morphologically 
distinct virus family characterized by the inclusion of a 
linear, double-stranded DNA genome in an enveloped virion 
particle 150-200nm in diameter. The virus particle is 
composed of four distinct elements: an electron dense core 
containing the genomic DNA (Epstein, 19 62) an 
icosadeltahedral capsid comprizing of 162 capsomeres (Wildy 
et a l ., 19 60) an undefined proteinaceous tegument 
surrounding the capsid (Roizman and Furlong, 1974) enveloped 
in a trilaminar membrane deriving from the host-cell's 
nuclear membrane (Wildy et a l ., 1960) but containing 
numerous virally encoded glycoprotein spikes (Spear and 
Roizman, 19 72).
The herpesviruses comprize a large family with more than 
eighty identified members exhibiting diverse hosts and 
biological properties. Never-the-less, in addition to 
conserving a distinct morphological structure and 
intranuclear replicative cycle the herpesviruses are 
distinguished by sharing the ability to persist in a latent 
state in the infected host.
The herpesviruses have historically been subdivided on 
the basis of their biological properties into three
subfamilies (Mathews, 19 82; Roizman, 19 82). HSV-1 and 2 are 
members of the alphaherpesviruses, characterized by a short 
reproductive cycle, typically less than 24h in cell culture, 
and latency is frequently established in ganglia. 
Varicella-zoster virus, the human virus responsible for 
chickenpox and shingles is also an alphaherpesvirus.
The betaherpesviruses have a restricted host range and a 
longer reproductive cycle, with infection spreading slowly 
in culture. Latency can be established in a variety of 
tissues. The cytomegaloviruses belong to this subfamily.
Gammaherpesviruses have a narrow host range, generally 
restricted to B or T lymphocytes, and latency is frequently 
established in lymphoid tissue. Epstein-Barr virus is the 
human prototype for this subfamily and causes infectious 
mononucleosis.
More recently the evolutionary relationship between 
members of the subfamilies has been demonstrated at the 
level of genome organization and DNA sequence.
Classification on these bases and the ser^ological 
cross-reactivity of virus gene products is of increasing 
importance (Roizman, 1982). Indeed it is now apparent that 
classification on the basis of biological properties alone 
may not truely reflect phylogenetic relationships. For 
example selective sequence analysis of the recently 
discovered human lymphotropic virus, HHV-6 (Salahuddin et 
al., 19 8 6 ) has revealed that it is probably related to the 
betaherpesvirus lineage (Honess et al., XIII International 
Herpesvirus Conference) although it does share some 
reiterated sequences with Marek's Disease Virus (Kishi et 
al., 19 8 8 ) and in its tissue tropism more closely resembles 
the gammaherpesviruses.
2. HSV-1 Genome structure and organization
The herpesvirus genome can be extracted from virus 
particles as a single, linear, double-stranded DNA molecule, 
which does, however, contain single-stranded nicks and gaps 
(Kieff et al., 1971; Wilkie, 1973). The structure of these 
molecules has been of considerable interest for many years, 
since hybridization studies and electron microscopy revealed 
extensive sequence reiterations or repeats in the
herpesvirus genomes (Sheldrick and Berthelot, 19 74).
The sequence arrangements of the herpesviruses can be 
described by one of a number of models, depending on the 
extent and form of the sequence reiterations and the ability 
of the genome to isomerize (for a full description see 
Roizman and Batterson, 19 85). The original model for the 
HSV genome structure shown in Figure 1 (Sheldrick and 
Berthelot, 19 74) has been proved substantially correct by 
later studies (Wadsworth et al., 1975; Wilkie, 1976).
The genome can be considered as consisting of two
covalently linked segments L (long) and S (short) which can
invert relative to each other to give four different genome
isomers. The unique sequences of the long and short
segments (LL and (Jc ) are flanked by distinct inverted 
JLl b
repeats and R g . Each end of the genome is flanked by a 
direct repeat sequence of variable length (Davison and 
Wilkie, 1981). Whilst a single copy of this a sequence is 
found at the S terminus, multiple copies are detected at the 
L terminus, and a variable number in inverted orientation at 
the LS junction. The a sequence itself is composed of a 
complex pattern of tandemly reiterated sequences which seem 
to account for an overall variability of genome length.
Representative isolates of four herpesviruses have now 
been completely sequenced: EBV (Baer et al ., 19 84) VZV 
(Davison and Scott, 1986) HSV-1 (McGeoch et a l ., 1988b) and 
human CMV (Barrell et a l . , per.comm.). The HSV-1 strain 17 
syn+ was found to have a prototype length of 152 260 bp, 
which will vary dependent upon the sequence reiterations, 
and it has a G+C content of 68.3%. The coding potential of 
the genome has been analysed in detail making use of the 
sequence data and earlier mapping data (McGeoch et al .,
1985, 1988b). It has been proposed that there are 72 
protein-coding genes in the HSV-1 genome, comprizing 70 
unique genes of which two are represented twice (IE110 and 
IE175) (Figure 2). These open reading frames determined by 
sequence analysis have been assigned the names LJLl-56,
IE110, IE175 and US 1-12, but many of these "genes" have not 
yet been shown to direct polypeptide synthesis, nor assigned 
a function.
Study of the genome map in Figure 2 shows that HSV-1
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Fig. 2. Layout o f genes in the genome o f HS V - I . The HSV-1 genome is shown on four successive lines, 
with unique regions represented by solid lines and major repeat elements as open boxes as in Fig. 1. The 
lower scale represents kilobases, numbered from the left terminus, and the upper scale represents 
fractional map units. The sizes and orientations o f proposed functional O R Fs are shown by arrows. 
Overlaps o f adjacent, similarly oriented ORFs are not shown explicitly. Locations o f proposed 
transcription polyadenylation sites are indicated as short vertical bars. Locations o f origins of D N A  
replication are shown as X . In the U L region, on the first three lines, genes U L I  to UL56 are labelled. In 
the U s region, on the bottom line, genes USl to U S I2  are labelled. The locations o f introns in the 
coding regions o f gene UL15 and the two copies (T R L and 1RL) o f the IE110 gene are indicated.
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efficiently utilizes its coding capacity and few regions of 
the genome are noncoding. However, relatively few open 
reading frames overlap so genome size does not appear to be 
an overriding evolutionary constraint. Indeed several HSV 
encoded genes have been shown to be dispensible for growth, 
at least in actively dividing tissue culture cells (reviewed 
by McGeoch et a l ., 1988b). In particular the majority of U
O
seems to encode inessential genes (Longnecker and Roizman, 
1986; 1987; Weber et al., 1987).
It is noteworthy that comparison of the VZV and HSV-1 
DNA sequences reveals extensive conservation between these 
two alphaherpesviruses both in genome organization and in 
the sets of genes encoded, although the actual DNA sequences 
have diverged to the extent that VZV DNA is composed of 
46.0% G+C residues whilst HSV-1 is 68.3% G+C (Davison and 
Scott, 1986; McGeoch et al., 1988b). The DNA sequence of 
the gammaherpesvirus, EBV, however, shows considerable 
divergence from both of the alphaherpesviruses, both in the 
sets of genes present and in their genome arrangement 
(Davison and Taylor, 1987; McGeoch et al., 1988b).
The HSV-1 and HSV-2 genomes are highly conserved, 
showing at least 40-50% sequence homology as estimated by 
hybridization in solution (Kieff et al., 1972).
Furthermore, the genomes appear to be essentially colinear 
from the sequence data available and homology studies 
(Davison and Wilkie, 1983b). The DNA sequences of the Ug 
regions of HSV-1 and HSV-2 have been compared in detail 
(McGeoch et a l ., 19 85, 19 87) and found to be colinear and 
conserved at the sequence level, especially within the 
protein coding sequences. The colinearity and homology of 
the HSV-1 and HSV-2 genomes is demonstrated by the ability 
to readily recover intertypic recombinants between the two 
strains (Timbury and Subak-Sharpe, 1973; Halliburton et al ., 
1977; Morse et a l ., 1977).
3. Pathogenicity
Six herpesviruses are known which infect man, including 
representatives from each of the three subfamilies: HSV-1, 
HSV-2 and VZV (alpha); CMV and probably HHV6 [HBLV] (beta); 
and EBV (gamma).
The close genetic relationship between HSV-1 and HSV-2 
is reflected in some overlap of their clinical 
manifestations (reviewed by Whitley, 1985). HSV-1 typically 
causes vesicular lesions of the lips and mouth, known as 
"cold sores", whilst HSV-2 is associated with genital 
disease. Latency is commonly established in the neural 
ganglia following primary infection, with reactivation 
periodically occuring to give rise to recurrent lesions at 
the primary site of infection or other peripheral sites.
Man is the sole reservoir for the transmission of HSV, which 
occurs during close physical contact. Infection is 
generally mild and rarely fatal, except in immunosuppressed 
individuals. HSV-1 is widespread in the human population 
and it has been estimated that one third of the world's 
populations have recurrent infections.
The other human alphaherpesvirus, VZV, manifests as two 
main diseases, chickenpox (varicella) and shingles (herpes 
zoster). Varicella is the result of primary infection 
typically in childhood, whilst reactivation of latent VZV is 
the apparent cause of herpes zoster (reviewed by Gelb,
1985).
4. Latency
In common with other herpesviruses HSV can establish and 
maintain a latent infection where the viral genome remains 
associated with the host without causing symptoms until 
reactivation occurs and the lytic cycle is initiated 
(reviewed by Hill, 19 85). The viral genome is maintained in 
the cells of the neuronal ganglia in a non-infectious state 
(Stevens and Cook, 19 71; Baringer and Swoveland, 19 73; Cook 
et al., 1974). Since the terminal fragments of the HSV 
genome can not be detected in latent cells it is apparent 
that the DNA is maintained in an "endless" rather than 
linear form (Rock and Fraser, 1983; 1985; Efstathiou et al.,
1986). It is thought that this does not reflect the 
inteXgration of the HSV genome into cellular DNA but might 
indicate that the molecule is maintained in an 
extrachromosomal form, as either a circle or concatemer of 
the linear genome (Mellerick and Fraser, 1987).
Expression from the latent virus is severely restricted.
Recently, however, latency associated transcripts (LAT) have 
been detected in the nuclei of cells from latently infected 
mouse, rabbit and human ganglia (Stevens et al .,1987; Rock 
et al., 1987; Spivack and Fraser, 1987; Steiner et a l .,
19 8 8 ). These transcripts derive from a region downstream 
from IE110 in R^, an area of the genome of previously 
unassigned function, and are partially complementary to and 
overlap with the IE110 transcript. Although open reading 
frames do exist in this region, there is little evidence for 
a convincing protein coding sequence (McGeoch et a l ., 19 88b; 
Weschler et a l ., 19 8 8 ) and unique polyadenyalted LAT 
messages cannot be detected in latently infected cells 
(Wagner et al., 19 8 8 ).
Interest is currently focussed on the role that these 
two genes, LAT and IE110, may have in latency, and indeed 
whether they might interact to control establishment or 
reactivation of latency. However, it has recently been 
shown that a virus mutant unable to express LAT is able to 
cause latent infection in mice and be reactivated from 
explanted ganglia (Javier et al., 1988). Therefore it would 
appear that LAT is not an absolute requirement for 
establishment of the latent state.
The functions of HSV latency (establishment, maintenance 
and reactivation) have been studied at an organismal level 
using animal models and also at a cellular level using in 
vitro models where productive viral replication is repressed 
by drugs or elevated temperatures (Wigdahl et al., 19 82; 
Shiraki and Rapp, 1986; Russell and Preston, 1986). These 
models allow the characterization of functions required or 
dispensible for latency. So far it has not been possible to 
identify any gene products uniquely required for 
establishment of latency (Polvino-Bodnar et al., 1987; 
Meignier et a l ., 1988; Russell et al ., 1987b) but VmwllO has 
been implicated in the reactivation of HSV in vitro (Russell 
et al., 1987b).
5. Transformation and oncogenesis
The herpes simplex viruses, particularly HSV-2, have for 
a long time been associated with human cancers, especially 
squamous cell carcinoma of the cervix (reviewed Rawls, 19 85;
Macnab, 1987). Evidence supporting a direct role for HSV-2 
in the development of cervical carcinoma is hard to 
evaluate; although there is a good correlation between past 
infection with HSV-2 and later carcinoma development, the 
risk factors involved in contracting a genital HSV-2 
infection seem to be similar to those for developing 
cervical carcinoma. The expression of HSV gene products and 
indeed the presence of HSV DNA is only detectable in a low 
proportion of cervical carcinoma tissues, whereas human 
papilloma virus sequences are commonly detected and 
implicated to greater extent than HSV in carcinogenesis 
(reviewed by Macnab, 19 87).
HSV does not seem to encode a transforming oncogene 
analogous to those transduced by retroviruses or encoded by 
DNA tumour viruses such as the papova or adenoviruses. HSV 
is clearly able to transform cultured cells and one region 
of the HSV-1 genome (MTR-I) and two regions of the HSV-2 
genome (MTRs II and III) have been defined which can induce 
transformation. MTR-I spans map units 0.31-0.42, 
encompassing several genes (see Figure 2) (Reyes et al.,
19 79; Galloway and McDougall, 19 83). Various subfragments 
of this region have been investigated and been shown to be 
mutagenic and to reactivate endogenous viruses (reviewed 
Macnab, 19 87). The HSV-2 MTRs II and III span restriction 
fragments Bglll n and c, in a region of the genome which 
encodes for both ribonucleotide reductase subunits.
However, no requirement for the continuing expression of 
either subunit has been demonstrated. One favoured model 
has been that potential stem loop structures encoded in this 
region could function as a mutagen or as a transcriptional 
activator (Galloway et al., 1984). However, there is no 
evidence that these potential secondary structures have any 
significance and indeed it is possible to derive similar 
structures for many random DNA sequences (Macnab, 19 87).
The relevance of the in vitro transformation experiments 
to the in vivo carcinogenesis activity of HSV has not been 
adequately demonstrated. Suprizingly small fragments of DNA, 
unable to encode any discreet protein, are able to induce 
transformation of cultured cells and the retention of HSV 
DNA is not necessary for maintenance of the transformed
state (Cameron et al. , 1985). Similarly no set of genes is 
consistently retained or expressed in the transformed cells 
of human cervical tumours (reviewed by Galloway and 
McDougall, 19 83). This has led to the proposition that HSV 
tranforms cells by a "hit and run" mechanism whereby a 
temporary association of HSV may be sufficient to 
transiently or permanently disrupt normal cellular gene 
regulation, providing the opportunity for other events to 
occur which might cooperate to produce an oncogenically 
transformed cell (Skinner, 1976; Galloway and McDougall,
1983 ).
There are many possible mechanisms by which HSV might 
disrupt normal cellular gene regulation. Several HSV gene 
products clearly have the potential to be mutagenic, being 
involved in DNA metabolism or rearrangment. It is possible 
that such activities could disrupt the regulation of normal 
gene expression in infected cells, or perhaps even cause 
gene rearrangments or amplifications. HSV has been shown to 
act as a mutagen on a cellular reporter gene (Pilon et al ., 
19 85; 1986) and also to induce chromosome damage (Peat and 
Stanley, 1986).
HSV also has the potential to elevate the expression of 
various cellular genes upon infection (LaThangue et al ., 
1984; Kennedy et a l ., 19 85; Macnab et al., 19 85; Patel et 
al., 1986; Latchman et al., 1987). This could occur either 
as a function of the HSV encoded transcriptional regulators 
(Latchman et a l ., 1987) or as a consequence of mutagenic 
activity (discussed above). Indeed HSV-transformed cell 
lines have been shown to transcribe certain cellular genes 
at elevated levels (Filion et al., 1988) and some of the 
cellular polypeptides expressed at increased levels in 
infected cells also accumulate to higher levels in 
transformed cells (Macnab et al., 1985).
SECTION IB: LYTIC INFECTION lv/ HSV-1
1. Virus adsorption, penetration and uncoatinq.
The adsorption of virus particles onto the cell surface 
and the subsequent penetration of the virus through the cell 
membrane are separable functions of the virally encoded 
glycoproteins present on the virus envelope. Virus 
adsorption to the cell surface is a rapid process, and 
attachment may initially be fairly non-specific, leading to 
weak then irreversible binding of the virion to the cell 
membrane (Hochberg and Becker, 19 6 8 ; Rosenthal et a l .,
1984) .
The cellular receptors for HSV attachment are not yet 
known but appear to be different for HSV types 1 and 2 on 
the basis of heterotypic competition experiments (Vahlne et 
al., 19 79; Addison et a l ., 19 84). Neomycin blocks the 
receptor binding of type 1 but not type 2 HSV, implying that 
phospoinositides have a role in the type 1 virus receptor
A
interaction (Langeland et al., 1987).
Penetration of the virus into the cell cytoplasm appears 
to occur by membrane fusion rather than phagocytosis, with 
virus envelope glycoproteins being transfered to the cell 
membrane (Para et a l ., 1980). Glycoprotein gD is essential 
for virus penetration, but not attachment (Ligas and 
Johnson, 1988; Johnson and Ligas, 1988), and neutralizing 
monoclonal antibodies against gD block virus entry but not 
cell surface attachment (Highlander et al ., 1987). Cell 
lines expressing gD are also refractory to virus entry by 
fusion, with the attached particles being endocytosed and 
degraded (Campadelli-Fiume et al., 1988a). Glycoprotein D 
constitutively expressed in these cell-lines is sufficient 
to induce spontaneous fusion of cells to form polykaryocytes 
(Campadelli-Fiume et al ., 1988b). The glycoprotein gB has 
also been implicated in virus fusion (Johnson et al ., 1984; 
Cai et al., 19 8 8 ) and syncitial plaque morphology mutations 
have been mapped to the gene encoding gB (DeLuca et al.,
1982; Bond et al., 1982; Bzik et al., 1984) although no 
syncitial plaque morphology mutants have been isolated in 
the gene encoding gD.
After penetration the virus capsids are translocated to
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the nucleus where the viral DNA is uncoated and extruded 
through the nuclear pore into the nucleus (Knipe et al.,
1981; Batterson et al., 1983).
2. Effects of HSV infection on host cell macromolecular 
synthesis
Upon lytic infection of permissive cells HSV subverts 
the normal host cell metabolism to facilitate efficient 
replication of the virus genome. Host macromolecular 
synthesis declines, typically within 2-4 hours post 
infection, dependent upon virus strain and cell type 
(reviewed by Fenwick, 19 84).
Cellular DNA synthesis is inhibited (Roizman and Roane, 
1964) and indeed HSV infection induces specific chromosome 
damage at early times of infection, and more general and 
severe damage at later times (Peat and Stanley, 1986). Host 
cell mitosis is arrested (Wildy et al ., 1961).
A general decline in host mRNA accumulation is observed 
upon HSV infection (Pizer and Beard, 1976; Fenwick, 1984). 
However, the transcriptional activation of several cellular 
genes during infection has been reported. In some cases 
this activation is dependent upon expression of the viral 
immediate early transactivating protein Vmwl75 (Latchman et 
al ., 19 87; Kemp and Latchman, 19 8 8 ) and in some cases 
activation is independent of viral protein synthesis (Kemp 
et al., 1986). Of particular interest is the induction of 
cellular stress and heat shock proteins by HSV infection 
(Notarianni and Preston, 1982; LaThangue et al ., 1984; Patel 
et al ., 1986; Kennedy et a l ., 1986; Russell et a l ., 1987a) 
and cellular proteins which seem to be overexpressed in HSV 
transformed cells (Macnab et al., 1985). It has also been 
shown that cellular promoters reintroduced into the genome 
of biochemically transformed cell-lines can be activated by 
HSV infection, and that this activation involves the 
function of the IE transactivating proteins VmwllO and 
Wiwl75 (Everett, 1985 ).
A phenomenon of major interest is the efficient shut-off 
of the majority of host-specified polypeptide synthesis upon 
infection of cells with HSV (Sydiskis and Roizman, 1966,
1967) which is accompanied by degradation of cytoplasmic
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mRNAs (Nishioka and Silverstein, 1977, 1978; Schek and 
Bachenheimer, 1985) and disaggregation of host polyribosomes 
(Sydiskis and Roizman, 1967). Mitochondrial RNA species are 
also degraded by a post transcriptional mechanism (Latchman, 
19 8 8 ). The degradation of cellular mRNAs is not specific to 
host transcripts, and the resultant rapid turnover of viral 
transcripts may be important for responsive viral gene 
regulation (see below).
There are at least two components involved in the 
shut-off of host polypeptide synthesis by HSV: an "early" 
shut-off function involving a virion associated factor which 
causes a rapid degradation of host polyribosomes and 
reduction in host mRNA levels, and a delayed "late" shut-off 
function which requires expression of early and late viral 
polypeptides (Nishioka and Silverstein, 1978; Read and 
Frenkel, 1983). The mechanisms of host shut-off may differ 
in detail between HSV type 1 and 2 (Hill et al ., 1983, 1985) 
and some strains of HSV-2 seem to induce a more rapid and 
severe inhibition of host protein synthesis (Pereira et al ., 
1977; Schek and Bachenheimer, 1985). HSV-2 strain G seems 
to encode a particularly effective virion associated host 
shut-off (vhs) function, which also destabilizes viral IE 
mRNAs in the absence of de novo viral protein synthesis 
(Fenwick and Owen, 1988).
Mutants in a gene responsible for virion associated 
shut-off (vhs) have been identified (Read and Frenkel, 1983) 
but are not deficient in the delayed shut-off activity. The 
vhs factor appears to be responsible for both non-specific 
cellular and viral mRNA degradation and polyribosome 
dissagregation (Schek and Bachenheimer, 1985; Strom and 
Frenkel, 1987). Viral as well as host mRNAs are more stable 
in vhs mutants, and the failure of these mutants to shut-off 
IE polypeptide expression indicates the importance of the 
shut-off for the rapid modulation of viral gene expression 
(Kwong and Frenkel, 1987; Oroskar and Read, 1987).
The vhs gene has been mapped to UL41 (Kwong et a l .,
1988) and when this gene is cloned from a HSV-2 strain G 
into the early shut-off deficient HSV-1 strain 17 efficient 
early shut-off is restored (M.Fenwick and R.D.Everett, per. 
comm.).
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3. HSV DNA replication
Upon entry into the nucleus of the infected cell the HSV 
genome is rapidly circularized, possiby by direct ligation 
of the terminal a sequences (Jacob and Roizman, 1977;
Davison and Wilkie, 1983a). Little is known about the 
mechanism of DNA replication, but the generation of large 
head-to-tail concatemers, lacking termini, has been 
interpreted as evidence that at least the later stages of 
replication may involve a rolling-circle mechanism (Jacob et
al., 1979). The concatemers of newly replicated viral
£genomes are then cleaved within the a sequnces between 
adjacent genomes (Davison and Wilkie, 1981) a process which 
is tightly linked to the encapsidation of unit length 
genomes within the nucleus (Ladin et a l ., 1980; Deiss and 
Frenkel, 19 8 6 ).
Although the mechanistic details of HSV DNA replication 
are largely unknown, all of the cis and trans- acting 
factors essential for replication are now thought to have 
been recognized.
3.1 Viral origins of DNA replication
The origins of viral DNA replication have been mapped 
and characterized, initially by the analysis of replication 
proficient defective viral genomes (Vlazny and Frenkel,
1981; Spaete and Frenkel, 1982) and subsequently with 
greater accuracy by the characterization of these origins in 
plasmid replication systems (Stow and McMonagle, 1983;
Weller et al., 1985). Three cis-acting regions of the HSV 
genome have been defined as origins of viral replication. 
Orig is represented twice, being situated between the 
divergent IE3 and IE4/5 promoters in Rg (Stow, 1982), whilst 
ori is present in a single copy between the divergent
1j
promoters of the genes encoding DNA polymerase and the major 
DNA binding protein (Weller et a l ., 1985) (see Figure 2).
The DNA sequences important for the function of these 
regions as origins of replication have been defined by 
supplying HSV replication functions in trans to an 
ori-containing test plasmid (Stow, 1982, 1985; Stow and 
McMonagle, 19 83).
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The ori^ and orig sequences show considerable homology; 
orig consists of a 45bp palindromic sequence featuring 18 
centrally located A or T residues, flanked by G+C rich 
sequences (Stow and McMonagle, 1983). Ori conserves but
1j
extends this palindrome and is highly homologous to ori
u
over the 67bp extent of the minimal orig sequence (Weller et
al., 1985; Quinn and McGeoch, 1985; Deb and Doelberg, 1988).
The essential HSV-2 orig sequences are very similar to those
in HSV-1 (Lockshon and Galloway, 1988). Hubenthal-Voss et
a l . (1987) have reported that the HSV-1 orig is contained
within a transcribed open reading frame which could encode a
34kDa protein. The significance of this observation is
unknown and McGeoch et al. (19 88b) doubt whether this ORF
represents a true protein coding sequence.
Viruses with ori or one copy of oric deleted are viable
Li O
in cell culture (Polvino-Bodnar et a l . 1987; Longnecker and 
Roizman, 1986). It is unknown whether it is significant 
that HSV encodes multiple origins for DNA replication or 
that they are positioned between the divergent promoters of 
important regulatory and replication genes. Attention is 
again being focussed on the structure and function of the 
origins following the demonstration that the product of an 
essential DNA replication gene binds to sequences in the 
origin (see below, Elias et al ., 1986; Elias and Lehman, 
1988; Olivo et al., 1988).
3.2 Viral proteins involved in DNA replication
A number of virus-specified functions involved in DNA 
replication and metabolism have been identified in 
virus-infected cells.
(a) A virally encoded DNA polymerase, sensitive to 
phosphonoacetic acid inhibition and also directing 3' 
to 5' exonuclease proof-reading activity (Keir et al ., 
1966; Purifoy et a l ., 1977; Leinbach et a l ., 1976; 
Knopf, 19 79).
(b) The major DNA binding protein (ICP8 ) encoded by HSV is 
also essential for DNA replication and associates with 
replicating DNA (Bayliss et a l ., 19 75; Powell et al ., 
1981; Quinlan et al., 1984). Functional ICP8 is 
essential for the organization of viral DNA into
pre-replication complexes (de Bruyn Kops and Knipe, 
1988).
(c) An origin binding protein has been described (Elias et 
al., 1986; Koff and Tegtmeyer,1988) and assigned to an 
essential gene, UL9 (Elias and Lehman, 1988;
Carmichael at al., 1988; Olivo et al., 1988).
(d) An essential DNA binding protein, 65KDfip, has been 
characterized (Marsden et al., 1987; Marchetti et al., 
1988; Parris et al ., 1988).
(e) Alkaline exonuclease (Preston and Cordingley, 1982) is 
an essential virus gene product (Moss, 1986).
(f) Viral-specified ribonucleotide reductase seems to be 
essential under some growth conditions (Preston et 
al., 1984; Goldstein and Weller, 1988a,b).
(g) A virally encoded dCJTPase is non essential for growth
in tissue culture cells, but may be important for
virus growth under some conditions (Preston and 
Fisher, 1984; Williams, 1988)
(h) Virally encoded thymidine kinase (pyrimidine 
deoxyribonucleoside kinase) is also dispensible for 
virus growth (Kit and Dubbs, 1963a,b; Jamieson et al., 
19 74).
( i )  A virally encoded uracil-DNA glycosylase DNA repair 
enzyme has been identified (Caradonna et al., 19 87) 
and assigned fo UL2 (Worrad and Caradonna, 1988; 
J.Mullaney, H.W.McL.Moss and D.J.McGeoch, per. comm.).
(j-1) Virally induced DNA topoisomerase type I, helicase and
primase activities have been reported (Muller et al ., 
1985; Crute et al ., 1988; Holmes et al ., 1988) 
Challberg (19 8 6 ) has developed a plasmid amplification 
assay which has allowed the identification of all the HSV-1 
genes essential for orig directed replication (Challberg, 
1986; McGeoch et a l ., 1988a; Wu et a l ., 1988). Seven gene 
products are sufficient to direct plasmid replication on 
this assay they are the products of the (JL genes 5, 8 , 9,
29, 30, 42 and 52. All of these genes correspond to loci 
with known temperature sensitive mutations affecting DNA 
replication (McGeoch et al., 1988a) and four of them encode 
proteins with previously characterized replication
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functions: UL9 encodes the origin binding protein (Olivo et 
al., 1988; H.Weir, J.M.Calder and N.D.Stow, per.comm); UL29 
and UL30 encode the major DNA binding protein and the DNA 
polymerase (Quinn and McGeoch, 19 85); and UL42 encodes the 
65KDBp (Marchetti et a l ., 1988; Parris et al., 1988).
Interestingly none of the DNA metabolism activities 
listed above (e to i) were essential in this assay. This 
probably does not provide a true reflection of their 
importance in vivo, although in rapidly dividing cells 
cellular functions are probably able to substitute for these 
viral functions (Goldstein and Weller, 1988b; Williams, 
1988). The products of UL5 and 52 have also been shown to 
be essential for viral DNA replication and late gene 
expression, but not for early gene expression (Weller et 
al., 1987; Goldstein and Weller, 1988c; Zhu and Weller,
1988).
4. Virus maturation
The viral a sequences contain all the necessary signals 
for the site-specific cleavage and packaging of unit length 
genomes in the nucleus of the infected cell (Stow et al., 
1983; Deiss et al., 1986). These two processes-are tightly 
coupled, with cleavage of DNA being a prerequisite for, or 
occuring concurrently with, the packaging of DNA (Ladin et 
a l ., 1980; Vlazny et al., 1982; Deiss and Frenkel, 1986). 
Although the length of DNA cleaved and packaged is not 
dependent upon the capacity of the capsids, and shorter 
molecules can be encapsidated, only nucleocapsids containing 
approximately unit length DNA are enveloped (Vlazny et al ., 
1982). Encapsidation is thought to involve the formation of 
an intermediate capsid, into which DNA is inserted and wound 
around a protein core to form an electron-dense toroid 
structure (Perdue et al., 1976). Intranuclear capsids are 
enveloped in a membrane enriched in viral glycoproteins by 
budding through the inner lamella of the nuclear membrane 
into the perinuclear space (Roizman and Furlong, 1974). 
Viruses are then transported to the cytoplasmic membrane, 
possibly via the golgi apparatus (Johnson and Spear, 19 82) 
with virus egress typically initiating about eight hours 
post infection.
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SECTION 1C: THE HSV-1 TRANSCRIPTIONAL PROGRAMME
1. Overview of HSV-1 gene expression
Upon lytic infection of tissue culture cells the genes 
of HSV-1 are expressed in a temporal cascade which can be 
divided into three main phases, immediate-early (IE or 
alpha), early (E or beta) and late (L or gamma) (Honess and 
Roizman, 19 74; Clements et a l ., 19 77). In general there is 
a close correlation between the detection of individual mRNA 
transcripts and the kinetics of the expression of the 
proteins encoded by them, indicating that transcriptional 
control is the major regulatory process occuring during 
infection (Zhang and Wagner, 1987; Smith and Sandri-Goldin,
1988) .
The IE proteins are the first to be detected after 
infection, within lh p.a., and their synthesis is shut-off 
within 3-4h p.a.. The synthesis of the E proteins is 
detectable shortly after the appearance of the IE proteins, 
but peaks later at about 4-6h p.a. before being shut-off at 
late times. Late gene products are not detectable until the 
onset of DNA replication at around 2h p.a. and they continue 
accumulating in large amounts at late times without being 
shut-off. Detailed analysis of viral mRNA synthesis and 
accumulation indicates that an accurate description of the 
kinetics of mRNA transcription is more complex than the 
broad IE, E or L classification (Zhang and Wagner, 1987; 
Weinheimer and McKnight, 1987) and provides some evidence 
that post-transcriptional events do have a role in 
controlling HSV gene expression (Weinheimer and McKnight, 
1987; see Section 1C2 below).
Although the initial classification of HSV gene
expression was based on the kinetics of viral protein
synthesis, it has since been shown to have biochemical
significance in that the sequential appearance of these
protein classes is regulated in a cascade manner. That is,
expression of IE polypetides is essential for the induction
of early genes, and the function of early gene products is
essential for the expression of late genes. This can be
%
illustrated experimentally by the use of metabolic 
inhibitors which block viral DNA or protein synthesis
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(Honess and Roizman, 19 74, 19 75; Clements et al., 19 77;
Jones and Roizman, 19 79). The IE genes are the only class 
which can be expressed upon virus infection in the absence 
of de novo protein synthesis (Kozak and Roizman, 19 74; 
Clements et a l ., 1977; Jones and Roizman, 1979). Whilst the 
transcription of early and late genes is dependent upon the 
function of IE proteins, (Honess and Roizman, 1974, 1975) 
late gene expression is dependent upon viral DNA 
replication, which is itself a function of viral early gene 
products (Jones and Roizman., 19 79 ).
HSV late genes vary in the dependence of their 
expression upon viral DNA replication and their sensitivity 
to inhibitors of replication. Indeed late genes have been 
subdivided into true-lates, whose expression is critically 
dependent on DNA replication, and early-lates, which can be 
transcribed to some extent in the absence of DNA synthesis 
(Wagner, 1985; Roizman and Batterson, 1985). Subdivisions 
have also been applied to early genes to take account of 
differences in their pattern of expression and shut-off. A 
useful subclassification is the beta-gamma or "intermediate" 
genes which are expressed at early times, but accumulate 
further with DNA replication (Spear and Roizman, 1980).
Figure 3 shows a summary of the factors interacting in 
HSV gene regulation which will be discussed in more detail 
in the following sections.
2. IE gene regulation
HSV-1 encodes five IE mRNA species from the five IE 
genes shown in Figure 2 (IE175, IE110, (JS1, (JL54 and (JS12). 
The nomenclature given to the HSV IE genes, transcripts and 
proteins has become increasingly confused over the years, 
and is summarized in Table 1. The nomenclature given in the 
first two columns shall be used throughout this thesis, 
occasionally using the gene assignations given in column 3 
when referring to the genome sequence map (Figure 2).
Analysis of the IE genes by RNA transcript mapping and 
DNA sequencing has revealed several interesting features of 
these genes (Clements et al., 1979; Rixon et a l ., 1982; 
Murchie and McGeoch, 1982; McGeoch et a l ., 1985, 1986,
1988b; Perry et al., 1986). Unlike the organization of
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Table 1; Nomenclature given to HSVilE genes, transcripts and
proteins •
1 2 3 4 5 6
Gene Protein Gene Protein Gene/ Other
(M.Wt.) Protein names
I El VmwllO I El 10 ICPO alpha 0 IE-0
IE2 Vftiw63 UL54 ICP27 alpha 27 IE63
IE3 Vhiwl75 I El 7 5 ICP4 alpha 4 IE-4
IE4 Vhiw68 US1 ICP22 alpha 22 IE68
IE5 Vmwl2 US12 ICP4 7 alpha 47 IE12
Table Is Nomenclature given to HSV IE genes, transcripl
proteins. Alternative nomenclature for the five IE genes 
and their products is given. Column 2 lists the 
nomenclature system used throughout this thesis based on the 
apparent M.Wt. of the proteins on SDS gels. The Chicago 
classification of the genes and protein products is given in 
columns 4 and 5. The IE genes are generally referred to by 
the simple 1-5 description (column 1 ) but occasionally 
referred to by their gene number assignation (see Figure 2; 
McGeoch et a l ., 1988b). Some of the more common alternative 
names used to describe the genes and proteins are given in 
column 6 .
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other classes of HSV genes, which seem to be randomly 
dispersed throughout the genome, the IE genes seem to be 
localized around the internal and terminal repeats. In fact 
the genes encoding VmwllO and Vmwl75 map entirely within the 
and Rg segments respectively, and hence are diploid. The 
5' termini of IE mRNAs 4 and 5 are also located within R 
and share common promoter and RNA leader sequences which are 
spliced to the unique open reading frames US1 and US12 in 
the LJg region. Splicing is an apparently rare phenomenon in 
HSV (Wagner, 1985) and so it is interesting that the IE1 
transcript is also spliced. That the IE3 and IE 4/5 
promoters diverge from the origin of replication in R ,b
orig, is of unknown significance.
As described above (Section 1A1) the five IE early genes 
are the first to be expressed upon virus infection, and 
their transcription is not dependent upon de novo protein 
synthesis. Indeed it has been shown that the HSV-1 IE genes 
are transcribed by the unmodified host-cell RNA polymerase 
II machinery (Costanzo et a l ., 19 77) and that naked, 
deproteinized DNA is infectious (Graham et al., 1973). 
However, IE gene transcription is also stimulated by a 
component of the HSV particle (Post et al., 19 81; Garapbell 
et al., 1984, see below).
The IE proteins are first detectable within lh p.a. and 
their synthesis is shut-off at 3-4h p.a. However, recent 
studies using transcription run-on assays in isolated nuclei 
to measure accurately the rate of gene transcription have 
shown that this differs markedly from the observed mRNA and 
protein accumulation (Weinheimer and McKnight, 1987).
Indeed, only transcription of the IE3 gene seems to be 
rapidly turned off (after lh) whilst the IE1 and 4/5 genes 
are still transcribed with increasing rates from l-5h p.a.
In contrast the patterns of mRNA accumulation in the 
presence and absence of protein and DNA synthesis inhibitors 
are similar for IE genes 1, 3 and 4/5, indicating that a 
post-transcriptional level of control must be regulating 
mRNA accumulation.
Several authors have reported that the IE 4/5 mRNA 
accumulates in a similar kinetic pattern to early mRNA, 
although beginning earlier and not requiring de novo protein
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synthesis (Gelman and Silverstein, 1987a; Zhang and Wagner, 
1987; Weinheimer and McKnight, 1987). A novel IE4 
transcript has even been reported in vitro which was not 
repressed by Vmwl75 (Pizer et al., 19 8 6 ).
The expression of the HSV-1 IE promoters is regulated by 
the complicated interplay between cellular transcription 
factors and at least three viral gene products: the alpha 
transinducing factor (TIF), Vmw65, which is present in the 
virion particle, the IE transactivating protein VmwllO and 
the multifunctional IE protein Vmwl75 which may be involved 
in both IE transactivation and repression (see for example 
O'Hare and Hayward, 1985a,b, 1987; Gelman and Silverstein, 
1987a,b; and below). These control mechanisms are described 
in the proceeding sections.
2.1 Structure of IE promoters
The upstream regulatory sequences of the HSV IE genes 
have been shown to confer IE regulation on chimaeric genes 
when inserted into recombinant viruses or biochemically 
transformed cells (Post et a l ., 1981). All five of the IE 
promoter/regulatory regions have been dissected and shown to 
respond to IE regulation in transfection assays (Mackem and 
Roizman, 1982a,b; Cordingley et al., 1983; Preston et al.,
19 84) although there are reports that the IE2 promoter 
behaves more like an early promoter in certain cell-types 
( (\t'\ Aiain and S ; luerdet r\, 19 87 a ).
The promoter regions of the IE genes, like many cellular 
promoters can be dissected into two components, a minimal 
promoter which includes a "TATA box" sequence and is 
necessary for both basal and induced levels of 
transcription, and upstream regulatory sequences containing 
multiple cis-acting elements conferring enhancer function 
and responsivity to IE regulation (Mackem and Roizman,
1982a,b; Cordingley et a l ., 1983; Preston et a l ., 1984; 
Kristie and Roizman, 1984; Bzik and Preston, 1986). The 
upstream regulatory region from -174 to -331 of the IE3 
promoter has been shown to act as a constitutive enhancer 
(Lang et al. , 1984; Preston and Tannahill, 1984). However, 
the distinguishing feature of all the IE upstream regions, 
at least in transfection assays, is their responsivity to
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activation by a component of the virus particle (see Section 
1C2.2).
At least five cis-acting elements have been recognized 
in the promoters, which respond to a variety of viral and 
cellular trans-acting factors. The minimal promoter regions 
resemble those of inducible cellular promoters in containing 
the TATA box element which is bound by an essential factor 
for RNA polymerase II transcription, TFIID (see Section 
1E1). All of the IE promoters contain GC boxes (Spl binding 
sites) and in the case the IE3 and 4/5 promoters these have 
been shown to bind and respond to Spl activation of 
transcription in vitro (Jones and Tjian, 1985). One to 
three copies in either orientation of a consensus TAATGARAT 
(R=purine) are present in each of the upstream regions of 
the IE genes (within -140 to -340) and functional analyses 
have shown that this element is essential for the response 
to transinduction by the virion-associated polypeptide Vmw65 
(Mackem and Roizman, 1982b; Preston et a l ., 1984; Kristie 
and Roizman, 1984; Gaffney et al ., 1985; Bzik and Preston,
19 8 6 ; O'Hare and Hayward 19 87a). Recently another motif 
present in the IE3 enhancer, GCGGAA, has been implicated in 
the response to Vmw65, acting in cooperation with TAATGARAT 
(Triezenberg et al., 1988b). The IE TAATGARAT consensus 
sequence overlaps with a striking homology with binding 
sites for a cellular factor NFIII or octamer-binding 
transcription factor (OTF-1) (Pruijn et a l ., 1986; Fletcher 
et al., 1987) and indeed the factor that binds to the 
TAATGARAT motif appears to have identical specificity to 
OTF-1 (0*Hare and Goding, 19 8 8 ; Gerster and Roeder, 19 8 8 ). 
The interplay of these sequence elements, their cognate 
cellular binding factors and the virion transinducing factor 
is discussed below (Section 1C2.2).
In addition to the presence of sequence motifs involved 
in the activation of IE gene expression, three of the five 
IE promoters have copies of the Vmwl75 consensus binding 
site ATCGTC, which has been implicated in the repression of 
at least the IE3 promoter (Gelman and Silverstein, 1987b; 
Deluca and Schaffer, 1988). The IE1 and 3 promoters contain 
perfect copies of this ATCGTC motif and have been shown to 
bind Vmwl75 (Faber and Wilcox, 1986a, 1988; Kristie and
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Roizman, 1986a,b; Muller, 1987). The IE2 promoter contains 
an imperfect match to the ATCGTC motif and may be bound by 
Vtnwl75 with somewhat weaker affinity (Kristie and Roizman,
19 86a; Faber and Wilcox, 19 8 8 ). Only the IE3 promoter has 
been convincingly shown to be repressed by Vmwl75 (DeLuca 
and Schaffer, 1985; O'Hare and Hayward, 1985b, 1987; Gelman 
and Silverstein, 1986, 1987a; Roberts et al., 1988). 
Sequences in the IE3 promoter not containing the ATCGTC 
consensus have also been reported to bind Vmwl75 (Kristie 
and Roizman, 1986b; Michael et al., 1988).
2.2 Transactivation of IE transcription by the virion 
associated transinducing factor Vmw65.
A protein component of the HSV virion has been shown to 
transinduce IE transcription (Post et a l ., 1981) and has 
been identified as the product of gene UL48, Vmw65, also 
known as VP16 or alpha-TIF (Campbell et al., 19 84; Dalrymple 
et a l ., 1985; Pellet et al., 1985). The activity of this 
polypeptide is unaffected by (JV-irradiation of the virus 
particles; it is still functional when supplied by 
superinfection with a virus mutant unable to release DNA 
from its capsid and seems to be localized in the virus 
tegument, (Heine et a l ., 19 74; Batterson and Roizman, 1983).
HSV-1 TIF has been shown to transinduce pseudorabies 
(PrV) virus IE genes, which also conserve TAATGARAT-like 
motifs in their upstream regulatory sequences (Campbell and 
Preston, 1987). However, PrV particles do not contain an 
analagous transinducing factor that functions either on PrV 
or HSV TAATGARAT elements (Batterson and Roizman, 19 83; 
Campbell and Preston, 1987). VZV has been shown to encode a 
protein homologous to the HSV TIF (Dalrymple et al., 19 85; 
Davison and Scott, 19 8 6 ) but this 45kDa open reading frame 
lacks the carboxy-terminal 80 amino acids of Vmw65 essential 
for transactivation activity (see below).
It has also been reported that the products of HSV-1 
genes LJL46 and UL47 may be involved in modulating the 
activity of Vmw65 (McKnight et a l ., 1987).
The mechanism by which Vmw65 induces IE genes through 
the TAATGARAT responder elements has been an area of 
intensive investigation in recent years. The HSV-1
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TAATGARAT elements have been shown to be bound by a factor 
present in uninfected cells (Kristie and Roizman, 1987; 
Preston et al., 1988; O ’Hare and Goding, 1988; Triezenberg 
et a l ., 19 88b). This factor is thought to be related to the 
octamer-binding factor (OTF-1, NFIII or OBP) a previously 
recognized cellular transcription factor involved in 
mediating transcriptional activation in a variety of 
promoters and enhancers (Pruijn et al., 1986; Fletcher et 
al., 1988; O'Hare and Goding, 1988). Indeed affinity 
purified OTF-1 and OTF-2 have been shown to bind to 
TAATGARAT elements, and purified Vimw65 induces formation of 
an additional (VIC or IEC) complex involving OTF-1. Because 
the efficiency of complex formation was increased by the 
addition of cell extract it was suggested that another cell 
factor may be involved in complex formation, perhaps by 
interacting with the GARAT portion of the TAATGARAT sequence 
(Gerster and Roeder, 1988). A second element, GCGGAA, has 
recently been identified in the IE3 enhancer which binds to 
an unrelated cellular factor and seems to work in synergy 
with TAATGARAT and its cognate factor(s) to mediate IE 
transactivation in response to Vmw65 (Triezenberg et al.,
19 8 8 a , b ; tr av\d Preston ^  & & ) ■
Vmw65 does not seem to bind to DNA directly (Marsden et 
a l ., 19 87) but forms a complex (IEC) with the cellular 
proteins bound specifically to TAATGARAT (Preston et al.,
19 8 8 ). This complex can be assembled in vitro using 
extracts of infected cells or extracts of uninfected cells 
combined with vmw65 purified from virions or synthesized in 
vitro (Preston et a l ., 1988; Ace et a l ., 1988). Mutant 
forms of Vmw65 incapable of forming IEC in vitro are also 
unable to activate IE promoter transcription in transfected 
cell, demonstrating a functional link between complex 
formation and transactivation (Ace et a l ., 19 8 8 ).
Vmw65 would seem therefore to activate transcription in 
a manner similar to other viral transactivators, such as 
adenovirus Ela and HSV VmwllO and Vmwl75, which unlike many 
cellular transacting factors do not bind specific target 
sequences to mediate their action (Sections 1D1.5 and 
1E3.4). The mechanism of Vmw65 transactivation is 
distinguished, however, by exhibiting target promoter
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specificity through its interaction with a cellular factor 
exhibiting target specificity.
Vttiw65 is also an important structural component of the 
virus particle, but the domains of the protein important for 
virus assembly are distinct from those involved in 
transactivation (Ace et al., 1988). Indeed an HSV-1 mutant, 
in!814, has been constructed which is deficient in IE 
transinduction, but assembles apparently normal virus 
particles (Ace et a l ., 1989). Conversely, an HSV-2 mutant, 
ts2203, has a lesion within the 5' end of the gene encoding 
Vmw65 which causes a J^ s block in virion assembly, but does 
not affect IE transcriptional induction (Ramsay, 1987; Ace 
et a l ., 1988).
It has recently been shown that a region within the 78 
amino acid tail of Vmw65 is essential for its transinducing 
activity, (Triezenberg et al., 1988a). This tail is 
apparently not involved in IEC formation but in the 
subsequent activation of transcription, and deletion of the 
acid tail produces a dominant mutant which blocks the 
activity of wild-type Vmw65 and virus infectivity 
(Triezenberg et al., 1988a; Friedman et al., 1988). Like 
the activating domain of the yeast transactivators GAL4 and 
GCN4 (Section 1E3.3) it seems to be the acidity of the 
region per se that is necessary for transactivation. Indeed 
the acid tail of Vmw65 can substitute for the GAL4 acidic 
activating domain, without affecting GAL4's target 
specificity (SadowsJci et al . , 1988). These acid domain 
transactivators are thought to activate transcription by 
interacting with TFIID, the TATA box binding factor and it 
may be that Vmw65, in the IEC, works by a similar mechanism 
(Horikoshi et al., 1988a; Lin et a l ., 1988; Sadowski et al., 
19 8 8 ) .
Thus Vmw65 has been shown to have two separate domains 
involved in transactivation of IE promoters; the first, an 
internal domain defined by Ace et a l . (19 8 8 ) mediates the 
indirect association with target promoters through the 
formation of IEC with a cellular factor bound to TAATGARAT 
motifs; the second, carboxy-terminal domain seems to be 
responsible for transactivation of RNA polymerase II 
transcription by a common mechanism involving the
24
protein:protein interactions of a highly acidic region of 
the polypeptide (Triezenberg et al. , 1988a; Friedman et a l . , 
19 8 8 ; Sadowski et al., 19 8 8 ).
The significance of the HSV TIF to the virus life-cycle 
is currently a matter for interesting speculation. Recent 
studies with the non-transinducing mutant show that the 
transactivation function contributes to virus infectivity in 
tissue culture and pathogenicity in mice, although not 
strictly essential for growth in vitro (Ace et al., 1989). 
This phenotype resembles that of viruses with null mutations 
in the gene encoding VmwllO (Stow and Stow, 1986; Sacks and 
Schaffer, 1987; Everett, 1989). This may reflect the 
importance of these two gene products in committing the 
infecting virus to the lytic infectious cycle, and perhaps 
the function of Vmw65 has evolved to ensure adequate 
expression of VmwllO. Indeed it has been observed that in 
cells infected with _inl814 the accumulation of mRNA from 
only two IE genes, those encoding VmwllO and Vmw63, is 
significantly reduced compared to a wild-type infection (Ace 
et a l ., 1989). It is interesting that interferon-mediated 
inhibition of HSV infection in human cells involves the 
inhibition of IE transcription (Mittnacht et al., 1988; 
Oberman and Panet, 19 8 8 ).
Why HSV alone of the alphaherpesviruses seems to have 
evolved this virion protein-mediated transinduction of IE 
expression is unknown.
3. Early and late gene expression
The criteria used to define HSV early and late genes are 
somewhat ambiguous. Early genes require prior synthesis of 
IE gene products for their expression (Honess and Roizman,
19 74; Clements et al., 19 77) and respond to IE product 
transactivation; whilst late genes additionally require DNA 
synthesis for their expression. Early gene expression 
begins after the appearance of functional IE products in the 
infected cell, typically reaching a peak at 4-6h p.a. and 
may decline at late times of infection (Honess and Roizman, 
1974; Wagner, 1985; Weinheimer and McKnight, 1987; Zhang and 
Wagner, 19 87). The expression of late genes is also 
dependent upon functional Vmwl75 (Watson and Clements, 1980)
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but is also dependent upon DNA synthesis and is blocked by 
metabolic inhibitors of viral DNA replication and jts 
mutations which prevent DNA synthesis at NPT (Swanstrom and 
Wagner, 19 74; Honess and Roizman, 19 74; Powell et al., 19 75; 
Marsden et al ., 1978; Jones and Roizman, 1979; Holland et 
al., 1980; Conley et al., 1981; Pedersen et al., 1981).
Late gene expression is first detected at around 2~3h p.a., 
when viral DNA replication is initiated, and late gene 
products continue to accumulate until 10-16h p.a.. DNA 
synthesis peaks at around 8h p.a. (Munk and Sauer, 1964; 
Roizman, 1969; Wilkie, 1973).
There is not always a clear and obvious distinction 
between each temporal class of HSV gene. For example, the 
large subunit of ribonucleotide reductase (RR-^) has 
traditionally been defined as an early gene product, but is 
expressed very early in infection and accumulates in the 
absence of IE transactivation (Roizman and Batterson, 1985). 
The distinction between early and late genes is also 
somewhat confused, for example, the gene encoding gD is 
expressed very early in infection and responds to 
transactivation by IE products, but requires DNA synthesis 
for maximal expression (Gibson and Spear, 1983; Johnson et 
a l ., 19 8 6 ). VP5, often referred to as a late gene product, 
is expressed with similar kinetics to gD, but responds to 
activation by IE products less efficiently than gD (Costa et 
al., 1985; DeLuca and Schaffer, 1985; Harris-Hamilton and 
Bachenheimer, 1985; Everett, 1986). Genes exhibiting these 
kinetics are sometimes referred to as early-lates or
leaky-lates. Although the transcription of these early-late
genes is increased by DNA replication this may simply be due 
to an increase in template copy number, and not a direct 
requirement for DNA replication (Johnson and Everett,
1986a). Furthermore, the expression of these genes 
generally is decreased at late times of infection by an
unknown mechanism (Honess and Roizman, 19 74; Johnson et al.,
1986).
The synthesis of two classes of transcripts therefore 
seems to be affected by the inhibition of DNA replication: 
early-lates, which require replication for maximal 
expression, and true-lates, whose expression is almost
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these elements correspond to well defined cellular promoter 
elements which are known to interact with cellular 
transcription factors such as CCAAT-box binding factor and 
Spl, and indeed binding by these factors has been 
demonstrated in the case of the tk promoter (Jones et al.,
19 85; Graves et al., 19 8 6 ). The same promoter elements are 
required for basal and induced levels of transcription in 
transfected cells and in situ on the virus chromosome 
(Everett, 1983, 1984b; Eisenberg et a l ., 1985; El Kareh et 
a l ., 1985; Coen et al., 1986). As discussed in Section 1D2 
the most important element for IE transactivation of these 
promoters is the "TATA-box" and its cognate cellular 
transcription factor TFIID, through which the action of 
Vtnwl75 is probably mediated.
The promoter regions required for expression of two 
true-late genes, (JSll and gC, have been dissected in detail, 
(Johnson and Everett, 1986a,b; Johnson, 1987; Homa et al., 
1986, Shapira et al ., 1987). The only functionally 
identifiable element in these promoters is the TATA-box, 
which functions as a normal true-late promoter when linked 
to a functional viral origin of replication (Johnson and 
Everett, 1986a,b; Homa et al ., 1986). Although the onset of 
US11 transcription coincided with the onset of plasmid 
replication, quantitation of the results suggested that the 
stimulation of (JSll mRNA accumulation was far greater than 
could be explained by the template copy number (Johnson and 
Everett, 1986a).
Both the (JSll and gC promoters were responsive to IE 
mediated transactivation in the absence of DNA replication, 
(Johnson, 1987; Shapira et al., 1987). Furthermore, the 
early gD promoter could be converted into a true-late 
promoter simply by deletion of sequences upstream of the 
TATA-box (Johnson and Everett, 1986b) whilst a similar 
deletion of the tk promoter apparently abolished its 
responsivity to IE transactivation (Eisenberg et al., 1985; 
Shapira et al., 1987). It is unclear why these 
plasmid-borne late promoters should be responsive to IE 
transactivation in the absence of DNA replication, whilst 
promoters resident on the viral chromosome are not 
efficiently expressed in the absence of DNA replication
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(DeLuca and Schaffer, 1985; Shapira et al., 1987; Johnson,
19 87; Rice and Knipe, 19 8 8 ). It has been suggested that the 
onset of DNA replication may provide a switch for late gene 
expression, which could for example involve a transient or 
lasting structural change in the DNA template, or that 
perhaps part of the replication machinery is needed in situ 
to initiate late gene transcription.
Recent elegant experiments performed by Mavromara-Nazos 
and Roizman (1987) confirm the suggestion of Johnson and 
Everett (1986a) that replication provides an essential 
cis-acting function for late gene expression. These 
experiments demonstrated that a true-late promoter on a 
non-replicating HSV chromosome could not be activated by 
trans-acting factors specified before or during replication 
of another HSV virus. This suggests that one of the main 
requirements for DNA replication in the activation of late 
promoters may be to alter the DNA template to allow their 
transcription, perhaps by alleviating some as yet 
unrecognized negative regulation of these genes. If these 
changes permitted more promiscuous promoter usage by RNA 
polymerase (in the absence of upstream regulatory signals) 
they may explain the increase in apparently uncontrolled 
symmetric transcription at late times of infection, with an 
increase in apparently randomly initiated RNA molecules.
It seems therefore that the HSV promoters can be divided 
into three classes by virtue of their structure, and that 
this division reflects how these promoters are regulated in 
a viral infection. These model promoter structures are 
illustrated in Figure 4. Late gene promoters seem to be 
characterized by the presence of a TATA-box in the absence 
of upstream regulatory sequences, and are linked to an 
origin of replication which substitutes indirectly for 
upstream activating sequences at late times of infection. 
Both IE and early promoters contain distal regulatory 
sequences which are not virus specific and interact with a 
variety of cellular transcription factors. In addition IE 
promoters contain far upstream elements responsible for 
their transinduction by Vmw65 and which in at least some 
cases acts as enhancer-like elements (see Section 1C2.1).
It is not known whether the decline in early gene
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expression at late times of infection is the result of 
specific repression of these genes or a more general 
phenomenon. Nor is it fully understood why late genes fail 
to be expressed in the absence of DNA synthesis. A simple 
"explanation" of these phenomena may be that whilst early 
gene promoters are expressed efficiently at early times, 
under late conditions late gene promoters are expressed far 
more efficiently, to the exclusion of other promoters. 
Perhaps as the viral DNA templates replicate, cellular 
transcription factors essential for early gene expression 
are titrated out preventing efficient transcription from 
early promoters. It has been suggested that early and late 
genes may be subjected to negative regulation of expression. 
Indeed Costa et a l ., (19 85) reported that sequences from -75 
to -125 of the VP5 promoter seemed to mediate negative 
regulation of this promoter in uninfected cells. Viral gene 
products have also been implicated in a general negative 
regulation of expression, including the major DNA binding 
protein (ICP8) (Godowski and Knipe, 1983, 1985, 1986) and 
even Vmwl75 which has been reported to negatively regulate 
the gD promoter in stably transformed cells (Arsenakis et 
a l ., 19 88). It seems probable, however, that the failure to 
transcribe late genes at early times simply reflects their 
lack of upstream regulatory elements. It is more 
problematic to understand how these promoters are turned on 
by DNA replication, an effect that is not simply explained 
by an increase in copy number of the viral chromosome upon 
replication (Johnson and Everett, 1986a; Johnson, 1987).
4. Post-transcriptional regulation of HSV gene expression
Whilst successive studies have failed to provide 
conclusive evidence of wide-scale post-transcriptional gene 
regulation in HSV infection, several observations have 
implicated post-transcriptional mechanisms in the control of 
mRNA accumulation and translation.
Weinheimer and McKnight (1987) have shown that whilst 
the IE3 gene appears to be the only IE gene efficiently 
repressed at the level of transcription, the accumulation of 
mRNA of all the IE genes is shut-off, corresponding to a 
shut-off in polypeptide synthesis. Furthermore, whilst at
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late times of infection all regions of the genome appear to 
be abundantly transcribed, and "symmetric transcripts" 
homologous to all temporal classes of HSV genes are 
detected, the synthesis of IE and early polypeptides is 
shut-off at these times (Godowski and Knipe, 1986;
Weinheimer and McKnight, 1987).
In general, however, the accumulation of bona fide mRNA 
for individual genes is found to correlate well with 
synthesis of the polypeptide gene product. Smith and 
Sandri-Goldin (19 88) have demonstrated that for a variety of
early and late genes the steady state levels of mRNA
correlate closely with the levels of polysome-associated 
mRNA and polypeptide synthesis. In contrast to earlier
reports (Johnson and Spear, 1984) they found no evidence of
post-transcriptional regulation of gD synthesis.
One well characterized example of post-transriptional 
control of gene expression has been reported. Synthesis of 
DNA polymerase seems to be regulated at the level of 
translation, and although this gene is transcribed 
efficiently, very few transcripts are found on the polysomes 
(Yager and Coen, 1988). This control may be mediated by the 
occurence of a small ORF upstream of the authentic DNA 
polymerase coding sequence, deletion of which increases 
translational efficiency (Dorsky and Crumpacker, 1988) or by 
the secondary structure of the mRNA leader region 
overlapping with the translational start codon (Yager and 
Coen, 19 88).
Blair et al., (1987) have also discovered regulatory 
functions mapping to the untranslated 5' mRNA region of the 
gene encoding Vmw65. Sequences within this leader seemed to 
contribute towards the stability of the mRNA, in addition to 
contributing towards virus specific transcriptional 
activation of the promoter.
These results indicate that although HSV-1 does not seem 
to possess a general post-transriptional mechanism for 
regulating gene expression, and furthermore although vhs 
mediated mRNA degradation is not host specific (see Section 
1B2), the translation and stability of individual gene 
transcripts may contribute to the overall regulation of HSV 
gene expression.
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SECTION ID; THE HSV-1 IE GENE PRODUCTS AND THEIR FUNCTIONS
1. Properties of the HSV-1 IE gene products
Five IE proteins have been characterized in HSV infected 
cells whose genes can be expressed upon infection in the 
absence of de novo protein synthesis and whose promoters 
respond to transinduction by Vmw65 (see Section 1C2). The 
five IE gene products, their observed molecular weights and 
their predicted sizes from DNA sequence information are 
listed in Table 2.
All of the IE proteins with the exception of Vmwl2 are 
nuclear phosphoproteins which can bind to native DNA in 
vitro and are found to be tightly associated with chromatin 
in the infected nucleus (Pereira et a l ., 1977; Marsden et 
a l ., 19 78; Fenwick and Walker, 19 79; Hay and Hay, 19 80; 
Ackerman et a l ., 1984). Thus both their physical properties 
and their kinetics of expression make them strong candidates 
for regulators of the viral life cycle, and indeed four of 
the five IE proteins have now been implicated in viral gene 
regulation. However, only two of them, Vmwl75 and Vmw63, 
seem to be absolutely essential for viral multiplication in 
tissue culture (see below, reviewed Everett, 1987a).
The following subsections review the physical and 
functional properties of the IE gene products, derived 
primarily from the study of viruses with ts and deletion 
lesions in the IE genes. A more detailed consideration of 
the role of the IE gene products is given in a subsequent 
section (1D2).
1.1 Vmwl2
Vlnwl2 is the least characterized IE protein. Its 
properties are atypical of the IE proteins, being 
nonphosphorylated and cytoplasmically localized, and its 
function is obscure (Preston, 1979b; Marsden et a l ., 1982). 
Vmwl2 is dispensible for growth in tissue culture cells, 
since HSV-1 and HSV-2 recombinant viruses deleted for IE 
gene 5 are viable (Longnecker and Roizman, 1986; Umene,
19 86; Brown and Harland, 19 87).
Table 2: The HSV-1 IE gene products.
1 2  3 4
Gene Protein No. residues Predicted M.Wt.
(apparent (kDa)
M.Wt.)
I El vmwlio 775 78
IE2 vmw63 512 55
IE3 vmwl75 1298 133
IE4 vmw68 420 47
IE5 Vmwl2 88 10
Table 2: The HSV IE gene products. The IE genes and protein 
products are listed in columns 1 and 2 by the system of 
nomenclature used throughout this thesis (see Table 1). 
Column 4 records the number of amino acids in the predicted 
polypeptide sequence, and column 4 the unmodified M.Wt. 
predicted from the amino acid sequence (McGeoch et al., 
1988b) .
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1.2 Vmw68
A virus with a deletion in IE gene 4 has been 
constructed which removes a region encoding the 
carboxy-terminal third of Vmw68 (Post and Roizman, 19 81). 
Although this virus was viable in tissue culture it was 
impaired in late gene induction and showed poor growth at 
low multiplicities of infection in some cells. It also 
exhibited reduced neurovirulence in mice (Sears et al.,
1985) .
Vmw6 8 would therefore appear to have a role in late gene 
regulation, at least in some cell types, and perhaps 
substitutes for a cell type retricted host factor. However, 
a more complete study of this gene is required to determine 
whether it is truely non-essential, and whether the 
carboxy-terminal truncated vmw68 retains any activity.
1.3 Vmw63
Vimw63 is essential for virus growth in tissue culture. 
Viral mutants containing ts lesions in the Vmw63 gene show 
reduced expression of early-late genes and fail to 
accumulate late gene products at the non-permissive 
temperature (Sacks et al., 1985). Vmw63 does not seem to be 
required for the induction of early gene expression and 
these mutants are able to replicate DNA at NPT.
Furthermore, Vmw63 does not seem to transactivate the 
majority of early promoters in transient assays but does 
specifically stimulate expression from certain delayed early 
and late promoters (Everett, 1986; Rice and Knipe, 1988; 
Sekulovich et a l ., 1988).
The ts mutants of Vmw63 overexpress Vmwl75 and Vmw63 but 
not VmwllO at the NPT, suggesting that this protein may be 
directly or indirectly involved in the repression of IE 
expression (Sacks et al., 1985). At the NPT these mutants 
produce an electrophoretically abnormal form of Vmwl75 
(Sacks et al., 1985; Rice and Knipe, 1988).
Deletion mutants of HSV-1 have recently been constructed 
which express no Vmw63. These viruses are replication 
incompetent on non-complementing cell-lines, overexpress 
some early genes and fail to induce normal levels of DNA 
replication and true-late gene expression (McCarthy et al^,
1989). Vmw63, therefore, has an essential role in
33
regulating early and late gene expression and possibly 
regulating IE gene expression. Viruses with ts mutations in 
Vftiw63 have a similar phenotype to a subclass of ts mutants 
in Vmwl75 which are permissive for early gene expression and 
DNA synthesis, but underproduce late genes at NPT (DeLuca et 
al., 1984). These results imply that Vmw63 and Vmwl75 might 
function together in regulating late gene expression.
Indeed in transfection assays Everett (1986) found that 
Vttiw63 only contributed to the activation of the late VP5 
promoter in the presence of VmwllO and Vmwl75, although 
Vlmw63 does seem to be capable of the independent 
transactivation of the gB promoter (Rice and Knipe, 1988).
It has recently been reported that in certain situations 
Vmw63 can repress VmwllO and Vmwl75 activated expression of 
a variety of promoters, but activates certain delayed-early 
promoters in combination with VmwllO and Vmwl75 (Sekulovich 
et al., 19 88). Furthermore repression and activation appear 
to be separable functions of the Vmw63 polypeptide.
Intriguingly MacLean and Brown (19 87) have reported a 
viable HSV-1 variant which fails to produce detectable 
amounts of Vmw63 at IE times of infection. However, the.re 
is no evident lesion in the IE2 gene and perhaps sufficient 
Vmw63 is expressed at early times to account for the normal 
late gene expression induced by this virus.
1.4 VmwllO
No conditional-lethal mutants have been isolated in IE 
gene 1 and VmwllO does not appear to be absolutely essential 
for virus growth in tissue culture. Reduction of VmwllO 
expression to less than 10% normal levels by expressing 
antisense IE1 mRNA in infected cells had little effect on 
virus gene expression or virus yield (Sandri-Goldin et al .,
1987). Virus mutants with large deletions within the 
VmwllO coding sequence have been constructed and found to be 
viable in tissue culture, although they grew poorly at low 
multiplicities of infection (Stow and Stow, 1986; Sacks and 
Schaffer, 19 87). In common with the Vmw65
transinduction-deficient mutant described in Section 1C2.2 
(Ace et al., 19 89) the VmwllO deletion mutant has a high 
particle to infectious pfu ratio, and seems to have a defect
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in initiating virus replication at low multiplicities of 
infection. This deficiency is not seen at higher 
multiplicities, when viral gene expression and DNA 
replication ave qualitatively and quantitatively similar to 
wild-type (Stow and Stow, 19 86; Sacks and Schaffer, 19 87; 
Everett, 1989 ).
The discovery that VmwllO was inessential at least under 
some growth conditions was unexpected because VmwllO has 
been shown to be a promiscuous transactivator of both viral 
and heterologous promoters, acting both independently and in 
synergy with Vmwl75 (Everett, 1984b, 1986; O'Hare and 
Hayward, 1985a,b; Quinlan and Knipe, 1985; Gelman and 
Silverstein, 1985a). The role of VmwllO as a transactivator 
is discussed in greater detail below (Section 1D2.1), and a 
detailed analysis of its structure and function in Section 
1D2.3.
The role of VmwllO during virus infection therefore is 
an interesting and unsolved question. VmwllO clearly is a 
potent activator of gene expression and confers a strong 
growth advantage on the virus, without being absolutely
essential for growth in tissue culture. Furthermore, the 
functions of VmwllO cannot substitute for the essential 
activities of Vmwl75 in viruses carrying deletions in Vmwl75 
(DeLuca and Schaffer, 1985, 1988; Russell et al. , 1987b; 
this thesis). It would seem therefore that VmwllO might be 
important in the activation of viral gene expression in 
certain cell types, which perhaps are lacking in certain 
transcription factors. This function might be particularly 
important at very early times of infection and at low 
multiplicities of infection in order to ensure adequate 
Vimwl75 or early gene expression and therefore commit the 
virus to the lytic cycle, (Stow and Stow, 1986; Everett,
1989). It is interesting that viruses deficient in VmwllO 
expression cannot reactivate latent HSV in an in vitro 
latency system, suggesting that VmwllO is necessary to 
induce the lytic cycle (Russell et al ., 1987b).
1.5 Vmwl7 5
(i) Genetic analysis of the function of Vmwl75
The isolation and characterizatin of viruses with ts
35
lesions in Vmwl75 showed that this function has an essential 
role in the HSV transcriptional programme. These early ts 
mutants were found to overproduce IE gene products and fail 
to express early and late genes at NPT (Marsden et al.,
19 76; Courtney et al., 19 76; Watson and Clements, 19 78,
1980; Preston, 1979a; Dixon and Schaffer, 1980). Functional 
Vmwl75 was shown to be continuously required for early gene 
transcription and IE repression by performing temperature 
shift experiments with ts-Vmwl75 mutants (Watson and 
Clements, 19 80; Dixon and Schaffer, 19 80).
The isolation of a class of mutants permissive for early 
gene expression and a degree of DNA replication suggested 
that Vmwl75 may possess a distinct function required for 
late gene expression (DeLuca et a l ., 19 84). Indeed the DNA 
lesions in this class of mutants were mapped to the 
carboxy-terminal end of the coding sequence and may indicate 
that this function may be encoded by a distinct domain of 
the protein. On the other hand the DNA lesions in Vmwl75 
mutants with extremely "tight" phenotypes, non-permissive 
for early expression and DNA replication, have been mapped 
to more amino-terminal regions of the protein, including the 
tsK mutant which is caused by a single substitution at amino 
acid 475 (Dixon and Schaffer, 1980; DeLuca et al., 1984; 
Preston, 19 79a; Davison et a l ., 1984).
Viruses containing deletion or truncation mutants in IE 
gene 3 have been constructed which have to be propagated on 
a complementing cell line (DeLuca et al ., 19 85; Deluca and 
Schaffer, 1988). The analysis of these mutants will be 
considered in Section 1D2.4.
(ii) Physical properties of Vmwl75
Vhiwl75 is a large, phosphorylated, nuclear-localized 
protein (Pereira et al., 19 77) which can be purified as a 
homodimer (Metzler and Wilcox, 19 85).
Although the sequence of the gene reveals an 
uninterrupted open reading frame encoding a protein of 129 8 
amino acids with predicted molecular weight of 133kDa, the 
observed size of the modified protein recovered from 
infected cells is 175kDa on SDS polyacrylamide gels (McGeoch 
et al., 19 86, see Table 2). In common with other IE
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proteins Vmwl75 is post-translationally modified by 
phosphorylation, but also by poly(ADP)ribosylation in vitro 
(Preston and Notarianni, 1983). Three electrophoretic forms 
of Vmwl75 are distinguishable by gel electrophoresis and all 
are phosphorylated (Pereira et al., 19 77). Threonine and 
serine residues are the major sites of phosphorylation 
(Faber and Wilcox, 1986b) and phosphate appears to cycle on 
and off the protein throughout infection, perhaps altering 
its affinity for DNA (Wilcox et al., 1980).
Some _ts mutants of Vmwl75 do not seem to be 
poly(ADP)ribosylated at the NPT (Preston and Notarianni, 
1983, Faber and Wilcox, 1986b) and some mutant proteins fail 
to localize in the nucleus at the NPT, and even interfere 
with the nuclear localization of other proteins, such as 
VinwllO and the MDB protein (Preston, 19 79b; Knipe and Smith,
1986).
The pattern of nuclear localization of Vmwl75 alters 
throughout the course of infection. At early times Vmwl75 
is distributed diffusely throughout the nucleus, whilst at 
late times it colocalizes with the MDB protein in 
intranuclear, globular replication compartments (Randall and 
Dinwoodie, 1986; Knipe et a l ., 1987).
Whilst most of the IE proteins have been shown to bind 
to native calf thymus DNA in vitro (Hay and Hay, 19 80)
V5mwl75 is the only one known to interact with specific 
target sequences. A combination of filter binding, gel 
retardation, DNAse and chemical footprinting techniques have 
been used to investigate this binding, and a consensus DNA 
sequence present and protected in all the high affinity 
binding sites characterized so far has been derived:
nnATCGTCnnYnCCGRCnnCRYCR 
with the hexanucle°tide ATCGTC considered to be the most 
important invariant element (Beard et al., 1986; Faber and 
Wilcox, 1986a, 1988; Muller, 1987; Roberts et al., 1988). 
Vimwl75 has been shown to bind to this sequence in the 
promoter regions of the IE1, IE3 and gD genes (Beard et a l ., 
1986; Faber and Wilcox, 1986b, 1988; Kristie and Roizman, 
1986a,b; Muller, 1987) and also to several viral promoter 
fragments which lack this sequence, although this binding 
may be of lower affinity (Kristie and Roizman, 1986a;
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Michael et al., 1988). The ability of Vrawl75 to bind to a 
copy of the ATCGTC target sequence at the transcriptional 
start site of IE gene 3 has circumstantially been implicated 
in the ability of Vmwl75 to repress transcription from this 
promoter (Muller, 1987; DeLuca and Schaffer, 1988; Roberts 
et a l . , 1988). The functional significance, if any, of the 
upstream IE1 Vmwl75 binding site is not known (Roberts et 
al., 1988).
Less is known about the significance of Vmwl75 DNA 
binding in the activation of HSV and heterologous promoters, 
although the same protein domain is involved in 
transcriptional activation, repression and DNA binding 
(DeLuca and Schaffer, 1988; this thesis). The Vmwl75
O
binding site m  the gD prmoter lies outwith the sequnces 
required for transactivation by IE products (Everett, 1983). 
Indeed the majority of responsive promoters lack sequences 
closely related to the consensus binding site, and there is 
no evidence for any transactivation specific promoter 
sequences required for this action of Vmwl75 (Everett,
1984a; Eisenberg et al., 1985; El Kareh et al., 1985; Coen 
et a l ., 1986). This will be discussed in greater detail in 
Section 1D2.1.
Although the binding of Vmwl75 to DNA had previously 
been reported to be dependent on host cell factors (Freeman 
and Powell, 19 82) recent reports that purified Vmwl75 can 
bind to specific target sequences indicate that the protein 
can bind to DNA directly (Michael et al., 1988).
(iii) Structure of Vmwl75
The sequence of the gene encoding Vmwl75 reveals a 
number of interesting features in the predicted amino acid 
sequence and structure (McGeoch et al., 1986). The IE gene 
3 coding region has the extraordinary base composition of 
81.5% G+C and a correspondingly abnormal amino acid 
composition in the predicted primary structure. The protein 
is particularly rich in alanine, proline, glycine and 
arginine residues, together comprising 54.9% of all amino 
acids. Analysis of the codon usage in the reading frame 
suggests that the gene has evolved to maximize its G+C 
content, and indeed amino acids with G+C rich codons would
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appear to have been evolutionarily favoured. One prediction 
of these observations is that the structure of regions of 
the protein particularly rich in these amino acids may not 
be critically important for function of the protein (McGeoch 
et a l ., 1986).
A less extreme G+C content is found in the VZV gene 
ORF62, which encodes the homologous protein "IE"140K, and 
whose DNA sequence is 64.1% G+C (Davison and Scott, 1986). 
The VZV gene encodes a protein of 1310 amino acids and 
predicted M.Wt. 140kDa, which probably corresponds to the 
observed IE protein of 175-185kDa (Shiraki and Hyman, 1987? 
Felser et a l ., 1988). Expression of this protein in 
infected, transfected or biochemically transformed cells 
complements HSV-1 J^ s and deletion mutants in Vmwl75 (Felser 
et al., 1987, 1988).
The predicted amino acid sequences of Vmwl75 and VZV140K 
have been compared in detail and found to be highly 
homologous in three regions: A, B and C (McGeoch et al., 
1986, Davison and McGeoch, 1986; see Figure 5). These 
regions are also conserved in a third alphaherpesvirus IE 
protein, the PrV IE180 protein (C.Vlcek, M.Schwyer and 
V.Paces, per.comm.). On the basis of this sequence homology 
between the HSV-1 and VZV proteins the Vmwl75 protein has 
been divided into 5 structural regions, with regions 2 and 4 
containing the main regions of homology with the VZV protein 
(McGeoch et al ., 19 86; see Figure 5).
The HSV type 1 and type 2 Vmwl75 proteins are 
functionally interchangeable, and have been shown to be 
colinear and homologous by generating intertypic recombinant 
chimaeras of the type 1 and type 2 proteins (Smith and 
Schaffer, 1987a,b).
Little of Vmwl75 exhibits any marked predicted secondary 
structure; this is discussed further in Chapter 4. Region 1 
of the protein (residues 1-314) would appear to have an 
ill-defined structure of "random coil" and is not closely 
conserved between the three proteins except for a short 
serine rich tract from residues 186-204 (homology region A).
Region 2 (315-484) is closely conserved between the 
three proteins, having 35-45% identity between all three and 
a region of more than 80% identity between VZV and HSV.
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Figure 5: Structure of the protein Vmwl75 in relation to the 
VZV homologue, VZV 140K. Vmwl75 has been divided into 5 
regions, 1-5, on the basis of sequence and homology (McGeoch 
et a l ., 19 86). Amino acid residues are numbered 1-129 8 from 
amino to carboxy terminus, and the three main homology 
regions (A,B and C) are marked. Clearly homologous sections 
are shown as boxes, with the most homologous sections filled 
(at least 16 residues identical out of 20). The scale is 
shown in amino acid residues.
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Significantly the single amino acid substitution responsible 
for the phenotype of the tsK mutation maps in this area a t ' 
residue 475 (Davison et al., 1984).
Region 3 (485-796) is essentally non-conserved between 
Vinwl75 and VZV140K apart from a short basic amino acid run 
conserved in both proteins and implicated in the nuclear 
localization of Vmwl75 (DeLuca and Schaffer, 1987, 1988; 
this thesis). Vmwl75 is 214 residues longer than the VZV 
homologue in this region.
Region 4 (79 7-1224) is clearly homologous between all 
three proteins, and has regions of near identity between the 
VZV and HSV proteins, around which two ts lesions have been 
mapped (Preston, 19 81).
Region 5 (1225-1298) is largely non-conserved. 
Interestingly, however, both the amino and carboxy terminals 
of Vmwl75 are weakly conserved in VZV140K, although the 
region of the VZV protein that corresponds to the 
carboxy-terminal region of Vmwl75 is not at the 
carboxy-terminus.
The main aim of the work presented in this thesis was to 
examine whether this structural map of Vmwl75, shown in 
Figure 5, has any functional significance, and indeed 
whether the regions most conserved between the HSV-1 and VZV 
proteins correspond to regions important for functional 
activity.
2. Transcriptional regulation by the HSV IE gene products
2.1 Transactivation
(i) Early characterization of the phenomenon of 
transactivation
Genetic studies have shown that vmwl75 expression is 
required for early and late gene expression; that Vmw63 has 
a role in the activation of a subset of viral (late) genes 
and that vmw68 may also have a less critical role in 
activating subsets of viral genes (Section 1D1 above). The 
transcriptional control of early and late genes has since 
been investigated by a variety of reductionist approaches in 
order to define the viral factors responsible for their 
transactivation and the promoter sequences required for this 
response. Early studies made use of biochemically
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transformed cell lines and demonstrated that integrated 
copies of HSV early and late genes could be transactivated 
by superinfection with HSV, and that this transactivation 
was dependent upon Vmwl75 expression. However, in these 
experiments integrated late promoters behaved with early 
gene kinetics (Leiden et a l ., 1976; Kit et al., 1978; 
Sandri-Goldin et al., 1983; Dennis and Smiley, 1984; Silver 
and Roizman, 1985; Mosca et al ., 1985). A few cellular 
genes can be induced by HSV infection, some of which are 
activated in a Vmwl75 dependent fashion (Latchman et al.,
19 87; Kemp and Latchman, 19 88). The transcription of most 
cellular genes, however, is shut-off upon infection (see 
Section 1B2).
Everett (1985) showed that heterologous cellular globin 
promoters introduced into the cellular genome by stable 
transformation also responded to IE mediated transactivation 
upon HSV infection, or transfection with plasmids expressing 
IE gene products, indicating that no viral specific promoter 
sequences were necessary. Furthermore, when the rabbit 
beta-globin promoter is introduced into the HSV genome it is 
regulated upon infection as a typical viral early gene 
(Smiley et al., 19 87) although a transduced rodent aprt.gene 
was not activated upon infection (Tackney et al., 1984). 
Significantly this "housekeeping" gene lacks a TATA box 
motif in its promoter (Dush et a l ., 1985; Nalbantoglu et 
al., 1986).
Stable, biochemically tranformed cell-lines expressing 
wild-type or _ts Vmwl75 have also been used to investigate 
the phenomenon of transactivation (Persson et al., 1985; 
Persson and Bacchetti, 1987; Arsenakis et al ., 1988). Upon 
HSV infection of such cell lines, in the absence of de novo 
protein synthesis, endogenously expressed Vmwl75 was able to 
activate the expression of some early genes but not late or 
some delayed early genes (Persson et al ., 1985). Vmwl75 
expressed in similar cell-lines was also able to 
transactivate adenovirus early genes when infected with an 
Ela mutant, showing that HSV Vmwl75, like other herpesvirus 
IE transactivators, can substitute for Ela activity 
(Tremblay et al., 1985). Attempts to stably cotransform 
cell lines with the gene encoding Vmwl75 and HSV late genes
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have generated complicated results, which may indicate that 
some HSV early or late genes could be negatively regulated 
by Vmwl75 in special circumstances (Arsenakis et al., 1988).
Practical difficulties in creating stably transformed 
cell lines and theoretical questions about the nature of the 
integrated genes have led many investigators to develop 
short-term transfection assays for IE function.
(ii) Characterization of transactivation by IE products in 
transient transfection experiments
Short-term transfection assays have been used to dissect 
the functions of the- various IE gene products in great 
detail. Initial experiments showed that HSV IE proteins 
caused transcriptional activation of plasmid-borne viral 
early promoters transfected into tissue culture cells and 
superinfected with HSV (Everett, 1983; O'Hare and Hayward, 
1984). Certain plasmid-borne cellular and adenovirus 
promoters were found to be similarly responsive to HSV or 
PrV IE transactivation (Everett, 1983; Green et al., 1983; 
Imperiale et al., 1983). Cotransfection of cloned IE genes 
with plasmid-borne reporter genes identified two HSV IE 
proteins involved in this transactivation (Everett, 1984b). 
These two HSV IE gene products VmwllO and Vtnwl75 have been 
shown to transactivate a variety of cotransfected HSV early 
promoters by measuring the accumulation of mRNA or CAT 
enzyme activity produced from a promoter CAT fusion reporter 
gene (Everett, 1984b, Quinlan and Knipe, 1985; O'Hare and 
Hayward, 1985a,b; Gelman and Silverstein, 1985, 1986).
VmwllO and Vtnwl75 have both been shown to be capable of 
independent transactivation of transcription, however, in 
some circumstances the effect of each gene product alone is 
small, whilst when supplied together they have a synergistic 
effect upon transcription (Everett, 1984b, Quinlan and 
Knipe, 19 85). Some investigators report strong independent 
transactivation by each protein whilst not observing the 
synergistic cooperation (O'Hare and Hayward, 19 85a; Gelman 
and Silverstein, 1985). These differences are probably 
explained by differences in experimental detail and Everett 
(1988b) has reported that cell type, growth medium and 
transfection protocol, as well as promoter sequence, can
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effect the relative transactivation by VmwllO and Vmwl75.
Alleles of the gene encoding Vmwl75 with ts lesions have 
been cloned and their activity in transfection assays has 
been shown to reflect the phenotype of the mutation in the 
parental virus (DeLuca and Schaffer, 1985).
The characterization of VmwllO as a promiscuous 
transactivator of transcription in the transient 
transfection assays does raise an interesting paradox: why 
is the transactivating activity of VmwllO insufficient to 
replace Vmwl75 function in Vmwl75 deficient viruses? It has 
been suggested that mutant alleles of Vmwl75 are 
transdominant and that the mutant protein interferes with 
the function of wild-type Vmwl75 or with other 
transactivators (DeLuca and Schaffer, 19 85; Gelman and 
Silverstein, 19 86). It has also been observed that some 
ts-Vmw!75 mutations interfere with the nuclear localization 
of VmwllO and other proteins (Preston, 19 79b; Gelman and 
Silverstein, 1986; Knipe and Smith, 1986). Recently, 
however, viruses with large deletions in IE gene 3 have been 
constructed which express little or no Vmwl75. These 
viruses are unable to grow on non-complementing cell lines; 
the viruses are able to express other IE proteins on 
infection but do not induce early gene expression, 
indicating that VmwllO cannot substitute for Vmwl75 even in 
the absence of interfering Vmwl75 polypeptide (DeLuca et 
al., 1985; Russell et al., 1987b; DeLuca and Schaffer, 1988; 
this thesis).
It is clear therefore that Vmwl75 must perform certain 
functions for which VmwllO cannot substitute, and although 
the exact role of VmwllO in a normal infection is somewhat 
opaque, it does seem to be important at low multiplicities 
of infection (see Section 1D2.3). Differences in gene and 
template dosage in transfected cells compared to a normal 
infection might explain why VmwllO can apparently 
transactivate early promoters in transfection assays but not 
induce early gene expression in a virus infection. It is 
also possible that while Vmwl75 might increase the rate of 
transcriptional initiation, VmwllO might act at a later 
stage. This could explain the synergistic effect, and the 
absolute requirement for Vmwl75.
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The product of IE gene 2, Vmw63, has also been shown to 
transactivate a subset of viral genes in transfection assays 
(Everett, 1986; Rice and Knipe, 1988). Vmw63 has been shown 
to stimulate the activation of certain delayed early and 
late promoters in combination with VmwllO and Vmwl75 
(Everett, 1986; Sekulovich et al ., 1988) but to be capable 
of independently activating the late gB promoter (Rice and 
Knipe, 1988). These results are consistent with the 
phenotype of viruses with ts lesions in Vmw63/ which fail to 
express a subset of late genes at NPT (Sacks et al., 1985).
(iii) Promoter elements involved in IE protein 
transactivation: a model for the mechanism of 
transactivation.
The DNA sequences required for virus early and late 
promoter activity have been dissected by recombinant DNA 
techniques and assayed in transient transfection assays.
Two early promoters in particular have been studied in 
detail, those for the genes encoding gD and tk. No 
virus-specific sequences required for viral transactivation 
have been detected in either of these promoters, and indeed 
the promoter sequences essential for basal and cis-activated 
transcription are identical to those required for 
transactivated expression (Everett 1983, 1984a,b; El Kareh 
et al., 1985; Eisenberg et al., 1985). Various tk promoter 
mutants have been reintroduced into the viral chromosome and 
confirm that the same promoter elements are important for 
activity in the virus and in the transfection experiments 
(Coen et al., 1986). Significantly, an intact TATA box 
seemed to be quantitatively more important than other 
elements in the promoter for activity in the infected cell.
A novel mutation-sensitive site was detected just downstream 
of the tk transcriptional start site and it was suggested 
that this region might also be important for interactions 
with the TATA box binding factor-associated pre-initiation 
complex (Coen et al., 1986). Deletion of all the sequences 
upstream of the tk promoter TATA-box, however, apparently 
abolishes its response to IE transactivation although the 
greatly reduced basal level of expression may in fact make 
transactivation difficult to measure properly (Eisenberg et
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a l ., 19 85; Shapira et al., 19 87). On the other hand the 
true late promoters from the gC and US11 genes seem only to 
require a TATA-box element to respond to VmwllO and Vmwl75 
mediated transactivation (Johnson, 19 87; Shapira et al.,
1987).
These results, together with the observation that 
cellular promoters with TATA boxes can be activated by HSV 
IE products in biochemically transformed cells and 
recombinant viruses [see above (i )] suggest that the IE 
transactivator proteins function through common cellular 
promoter elements, perhaps even the TATA box element itself, 
which is a fundamental component of most type II promoters. 
Recent studies by Everett (1988b) have confirmed that 
changes in the TATA box sequence can alter the efficiency of 
promoter activation by the HSV IE products, and that some 
TATA boxes seem to be more responsive to transactivation 
than others, in certain circumstances.
This preference for certain TATA box sequences over 
others may reflect a direct interaction between IE proteins 
and this sequence or, alternatively, that a family of 
different cellular TATA box binding factors are involved in 
interacting with a variety of TATA box sequences, and that 
HSV IE gene products recognize these cellular factors with 
varying efficiencies. It seems probable that 
transactivation is commonly mediated through the TATA box, 
or its cognate binding factor TFIID, both by non-specific 
viral transactivators such as Ela (Wu et al., 1987; Simon et 
al., 1988) and cellular transactivators such as ATF and the 
yeast transactivator GAL4 which have been shown to interact 
with TFIID to activate transcription (Horikoshi et al.,
1988a,b; Hai et al., 1988; Lin et al., 1988).
Partially purified Vmwl75 has been shown to 
transactivate the transcription of a variety of early and 
late genes in vitro, indicating that its effect on gene 
regulation is direct (Beard et al., 1986; Pizer et al .,
1986). Only one of the promoters tested, gD, contained a 
Vmwl75 binding site, but this sequence has previously been 
shown to lie outwith the minimal region of the promoter 
responsive to transactivation (Everett, 1983, 1984a). 
Presence of this Vmwl75-DNA binding site seems to play a
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minor role in the activation of gD promoter by Vmwl75 in 
transfection assays and in vitro (Tedder and Pizer, 1988).
The closely homologous PrV IE protein IE180 has also 
been shown to stimulate transcription in vitro, and its 
direct involvement was demonstrated by using a ts mutant of 
the protein (Abmayr et al., 19 85). Temperature shift 
experiments with this ts-IE180 protein have shown that 
transactivation functions at the level of initiation and 
that inactivated ts-IE180 can compete with Ela to inhibit 
the activation of class II promoters (Ahlers and Feldman, 
1987a,b). Vmwl75 also seems to exert its effect in vitro on 
the rate of initiation of transcription (Beard et al., 1986) 
and evidence exists that Vmwl75 and Ela share a common 
mechanism or at least a common cellular component for 
transactivation. Whilst Vmwl75 can substitute for Ela 
function in activating adenovirus early genes, the presence 
of Vmwl75 interferes with Ela activation, perhaps indicating 
that they are competing for common cellular factors 
(Tremblay et al., 1985).
Recent studies with partially purified PrV IE180 protein 
have shown that this protein stimulates transcription in 
vitro by increasing the efficiency or rate of TFIID binding 
to the DNA template to form the preinitiation complex 
(Abmayr et al., 1988). PrV IE180 can potentiate TFIID DNA 
binding to the template promoter in competition with the 
assembly of the DNA template into nucleosomes by purified 
histones in vitro. This suggests a mechanism by which viral 
IE proteins may potentiate expression from infecting viral 
genomes of naked DNA, by assisting the rapid formation of 
preinitiation complexes on promoters before they are 
assembled into nucleosomes, which may preclude promoter 
recognition (Workmann et al., 1988). Transcriptional 
activation by the PrV IE180 protein and the adenovirus Ela 
protein has been shown to function through the same (TATA 
box) sequences in the adenovirus Elb promoter, suggesting 
that Ela and IE180 mediate transactivation through a common 
cellular intermediate which interacts with the TATA box (Wu 
et al., 1987; Wu and Berk, 1988). Presumably Vmwl75 
functions by a very similar mechanism to PrV IE180 as the 
important regions of the protein are highly conserved
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between PrV and HSV (Vlcek, Schwyzer and Paces, per.comm.; 
Sections 1D1.5 and 4.2).
How VmwllO and Vmwl75 might interact at a physical level 
with components of a responsive promoter is unknown. Both 
proteins are known to bind DNA (Hay and Hay, 1980) although 
in the case of VmwllO it is not known whether this binding 
is direct or mediated through other cellular or even viral 
factors. VmwllO can activate gene expression by itself in 
the absence of its carboxy-terminal DNA-binding domain, but 
requires this region to function in synergy with Vmwl75 
(Everett, 1987b, 1988a). Thus VmwllO might function in two 
different ways in the presence and absence of Vmwl75.
In contrast the regions of Vmwl75 involved in 
site-specific DNA binding, transactivation and repression 
are not separable (DeLuca and Schaffer, 1988; this thesis) 
and DNA binding may be a prerequisite for transactivation. 
This would appear not to involve site-specific DNA binding 
to consensus ATCGTC target sites, which are not commonly 
found in responsive promoters, but may involve a second DNA 
binding activity, perhaps of lower affinity, to unrelated 
sites or degenerate ATCGTC sites. Indeed binding to 
unrelated sites in IE promoters and the 5' untranslated 
regions of late genes has been reported (Kristie and 
Roizman, 1986a; Michael et al ., 1988).
These somewhat preliminary results would support a model 
for Vmwl75 function in which Vmwl75 is involved in 
activating or stabilizing the formation of pre-initiation 
complexes, or catalyzing their conversion to initiation 
complexes, perhaps through an interaction with TFIID.
2.2 Repression of IE gene expression
Viruses with _ts lesions in Vmwl75 overexpress the IE 
gene products at the NPT, and functional Vmwl75 is required 
continuously for the repression of IE expression (Preston,
19 79a, Dixon and Schaffer, 1980, Watson and Clements, 1980). 
During the course of a normal virus infection the repression 
of IE gene transcription is not completely effective and IE 
RNAs persist until late in infection (Harris-Hamilton and 
Bachenheimer, 19 85). Furthermore, there is evidence that 
only IE gene 3 is repressed at the level of transcription,
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although post-transcriptional mechanisms may control the 
accumulation of other IE transcripts (Weinheimer and 
McKnight, 19 87).
Genetic evidence exists that the major DNA binding 
protein (ICP8) functions as a negative regulator of viral 
gene expression, and that t.s mutants in this protein cause 
an overexpression of Vmwl75 at the NPT (Godowski and Knipe, 
1983, 1985, 1986). However, it is unclear whether or not 
this is a specific gene regulation function. The virion 
associated host shut-off function may also be involved in 
regulating IE expression at a post-transcriptional level by 
destabilizing IE mRNA (Fenwick and Owen, 1988).
Plasmids expressing cloned Vmwl75 have been shown to 
repress basal and cis- and trans-activated levels of 
transcription from the IE3 promoter in a dosage dependent 
manner (O'Hare and Hayward, 1985b, DeLuca and Schaffer,
1985; Gelman and Silverstein, 1986). Gelman and Silverstein 
(19 87a) have conducted an exhaustive study into the response 
of each of the four IE promoters to different combinations 
of VmwllO and Vmwl75. The response was found to be 
dependent upon the dosage of each effector protein and also 
upon cell type to a certain extent.
The IE2 promoter was found to behave abnormally in one 
cell type in that it responded in the manner of an early 
promoter, and was not repressed. Whereas VmwllO alone 
activated all of the promoters, Vmwl75 alone had little 
effect on the IE4/5 promoter and repressed the IE1 and IE3 
promoters. The combination of VmwllO and Vmwl75 gave a 
complicated response dependent upon the gene dosage, 
stimulating expression more at low concentration than at 
high concentration.
The interpretation of such experiments is fraught with 
difficulties and one is never sure how relevant such 
experiments are to the situation occuring in an infected 
cell where the number of templates is much smaller.
However, it is clear that regulation of the IE promoters is 
critically dependent upon the relative abundance of VmwllO, 
V!mwl75 and Vrnw65 in the infected cell at IE and early times 
of infection (O'Hare and Hayward, 1985a,b, 1987; Gelman and 
Silverstein, 1985, 1986, 1987a,b).
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Evidence for repression by Vmwl75 has only been reported 
for the IE3 and IE1 promoters, both of which have good 
matches to the ATCGTC motif in their promoter. Roberts et 
al., (19 88) have demonstrated a direct correlation between 
the Vmwl75 binding site at the IE3 cap site and repression 
of this gene, but have failed to find any functional 
significance for the upstream IE1 site. The IE2 promoter 
does have a degenerate match to this consensus, but is only 
marginally repressed in one of the two cell types tested by 
Gelman and Silverstein (1987a). Both the IE1 and IE3 ATCGTC 
motifs have been shown to be strong Vmwl75 binding sites 
(Faber and Wilcox, 1986b, 1988; Kristie and Roizman,
1986a,b; Muller, 1987; Roberts et al., 1988) whilst the IE2 
promoter may only possess weak Vmwl75 binding sites and the 
IE4/5 promoter is not detectably bound (Kristie and 
Roizman, 1986a; Faber and Wilcox, 1988).
The high affinity Vmwl75 binding site at the 
transcriptional start site of IE gene 3 has therefore been 
implicated in the autorepression of this gene by Vmwl75, and 
mutational studies of Vmwl75 have revealed that the same 
domain of the protein is required to bind to this site and 
to repress transcription (DeLuca 1988; this thesis).
An attractive but perhaps oversimplistic model for 
repression would be that the Vmwl75 binding site acts as a 
classical prokaryotic operator site and that protein binding 
to this site prevents transcriptional initiation, either by 
stalling the initiation complex or by preventing its 
formation. The IE1 ATCGTC motif bound by Vmwl75 is located 
between a CCAAT box motif and a potential Spl binding site, 
therefore binding of Vmwl75 to this site might interfere 
with the normal activation of this promoter by these two 
sequence elements and their cognate factors (Faber and 
Wilcox, 19 88). The IE4/5 promoter has been shown to be 
repressed by the addition of partially purified Vmwl75 in 
vitro (Pizer et al., 1986).
Intriguingly the only other HSV promoter containing a 
perfect match to the ATCGTC motif is that of the gene 
encoding gD, which is regulated as an early gene (Cohen et 
al., 1980; Ikura et al., 1983; Johnson et al., 1986). This 
sequence, located at bases -101 to -106, has been shown to
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be tightly bound by Vmwl75 (Faber and Wilcox, 1986b; Tedder 
and Pizer, 19 88) but lies outwith the minimal promoter 
responsive to Vmwl75 transactivation (Everett, 1983,
1984a,b). This promoter has been shown to be moderately 
activated by partially purified Vmwl75 in vitro (Beard et 
a l ., 1986; Pizer et al., 1986; Tedder and Pizer, 1988) but 
there has been a report that Vmwl75 negatively regulates the 
gD promoter in biochemically transformed cells (Arsenakis et 
al., 1988).
2.3 A detailed mutational analysis of the structure and 
function of VmwllO
Parallel to the mutational analysis of the structure and 
function of Vmwl75 presented in this thesis, a complementary 
analysis of VmwllO was performed in this laboratory. The 
predicted VmwllO polypeptide contains 775 amino acids, and 
two introns are spliced out of the coding region of the 
primary transcript to form the mature mRNA (Perry et al., 
1986). Like IE gene 3, the sequence of IE gene 1 is G+C 
rich (75.4%) and encodes a protein with correspondingly 
unusual amino acid composition, biased towards residues with 
G+C rich codons.
One particular region of the protein was noted to have 
an interesting potential secondary structure; a region from 
residues 99-156 contains 9 cysteine (C) residues, including 
three C-n-n-C pairs which are thought to form a structural 
motif involved in the coordination of metal ions, a metal 
finger binding domain (see Figure 6; Berg, 1986). Such 
structures are often involved in nucleic acid binding but 
also in other functions such as protein:protein interactions 
(Frankel and Pabo; 19 88). Gene 61 of VZV encodes a weakly 
homologous protein to HSV-1 VmwllO, with the conservation 
limited to the cysteine-rich region and all three of the 
C-n-n-C pairs conserved (Perry et al., 1986; Davison and 
Scott, 1986).
Like Vmwl75, VmwllO contains a serine-rich region from 
residues 554-594, this region could potentially form a major 
site for phosphorylation of the protein.
A panel of plasmid-borne, in-frame insertion and
C\
deletion mutants of the gene encoding VmwllO hve been
A
Figure 6: The potential "metal finger" binding domain of
VmwllO
(a) Cys- iCN
X1 -Cys- X 2-15 Cys/His i
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Figure 6: The potential "metal finger binding domain of
VmwllO. (a) Consensus sequence of Berg (1986). (b) to (d)
Three partially overlapping sequences in the second exon 
region of VmwllO which fit the Berg consensus. The amino 
acid residue numbers are shown. (Taken from Everett,
1988a).
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constructed and analyzed in transient transfection assays 
(Everett, 1987b, 1988a). Some of the more interesting of 
these mutants have been reintroduced into the HSV-1 
chromosome in the native IE1 loci and their function has 
been analyzed in the infected cell (Everett, 1989).
The results using the plasmid-borne mutants revealed 
that the structural integrity of at least five regions of 
VmwllO are important for the transcriptional transactivation 
of the gD promoter in synergy with Vmwl75, but that the 
regions important for activation in the absence of Vmwl75 
were somewhat different (see Figure 7). This implies that 
the mechanism for these two activities is different. The 
cysteine-rich potential metal finger binding domain was 
essential for VmwllO activity in the absence of Vmwl75, but 
contributes less critically to activity in the presence of 
Vftiwl75. In contrast the carboxy-terminal region (5) is 
essential for synergistic function, but less important for 
independent action. This could indicate that this region is 
involved in interacting directly or indirectly with Vmwl75, 
if any such physical interaction occurs.
The cellular location of the VmwllO polypeptides in 
transfected cells was also affected by some deletions in the 
coding sequence. Cells transfected with wild-type VmwllO 
exhibited a punctate pattern of nuclear immunofluorescence 
when stained indirectly with an antisera raised versus the 
carboxy-terminal of VmwllO. Several deletions spanning 
residues 474-509 were shown to be required for nuclear 
localization. This region contains a highly basic sequence 
RPRKRR similar to previously identified nuclear localization 
signals (Kalderon et a l ., 1984; Krippl et al ., 1985). This 
sequence may not be sufficient for nuclear localization as a 
mutant with a large deletion spanning residues 509-638 was 
also cytoplasmically located (Everett, 1988a). Furthermore, 
mutant VmwllO deleted from residues 4 75-54 8 is able to 
localize in the nucleus of cells infected with recombinant 
viruses expressing this polypeptide, perhaps in association 
with other IE products. This phenomenon could not, however, 
be reproduced in transfected cells (Everett, 1988a). 
Intriguingly several deletions in the carboxy terminal 125 
amino acids of VmwllO caused the polypeptide to give an
Exons
1 VmwllO
□ .  r~  i
Cys-rich GC-rich
□  Ser-rich 
■ ■ ■ <— ►
I 2 3 4 5 Regions
□
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Localizat."
2 3
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Figure 7; Structural and functional regions of VmwllO. The 
coding sequence of VmwllO is composed of three exons, and 
encodes a protein of 775 amino acids. Regions of the 
protein particularly rich in cysteine and serine residues 
are highlighted, as is a region of the coding sequence 
markedly rich in GC residues. The limits of a sequence 
required for nuclear localization of the protein, at least 
in transfected cells, is shown. Five regions (1-5) of the 
protein which are sensitive to disruption of the 
transactivating activity of this protein in synergy with 
Vmwl75 are shown.
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abnormal pattern of diffuse nuclear staining in transfected 
cells, unlike the punctate nuclear staining seen with 
wild-type VmwllO. Mutations in this region may therefore 
cause a failure of VmwllO to self-aggregate or localize in 
discrete sites of the nucleus (Everett, 1988a).
The growth properties of ten recombinant HSV-1 viruses 
encoding representative insertion and deletion mutants of 
VmwllO have been examined (Everett, 1989). Deletions in the 
cysteine-rich region (1) had the most severe effects on 
virus growth, and were as impaired as deletion of the entire 
gene. Therefore this region, which is essential for the 
independent activation of gene expression by VmwllO, is the 
most important for the biological role of VmwllO in the 
lytic cycle. The carboxy-terminal domain seemed less 
important in most cell types.
Although the viruses showed large differences in 
plaquing efficiencies and in one step growth curves, the 
mutations in VmwllO had no effect on the yield of virus 
particles. The phenotypes of the mutants were dependent 
upon the growth state and type of cells used, but the 
patterns and amounts of viral polypeptide synthesis during 
high m.o.i. infections were similar in all cell types for 
the mutant and wild-type viruses. Only at low m.o.i. in the 
least permissive cell-types did the mutations in VmwllO 
cause a reduction in viral gene expression. The defect was 
clearly shown to be at the level of gene expression when 
small numbers of particles were used to infect the less 
permissive cell-types. Furthermore, the ability of the 
viruses to activate a transfected early promoter (gD) was 
impaired in the mutant viruses. This was not cell-type 
dependent, however, and therefore did not simply reflect the 
varying efficiencies of gene activation by Vmwl75 in the 
absence of VmwllO (R.Everett, per.comm.).
Although the role of VmwllO in the viral infection is 
now less obscure as a result of these comprehensive 
mutational studies, the exact mechanism of VmwllO action is 
still a mystery, particularly its function in the absence of 
Vlmwl75 and the role of the cysteine-rich region. Clearly, 
like Vmw65, VmwllO is important in the initial stages of 
infection, in determining the fate of the infecting virus
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particle and in committing the virus to the lytic cycle. 
Whether this function is dependent upon the action of VmwllO 
on early promoters in conjunction with Vmwl75 or upon the 
promoter of the Vmwl75 gene is unknown. The importance of 
the cysteine-rich region of the polypeptide implies that it 
is the (as yet unidentified) activity of this region which 
is critical in this process.
2.4 Mutational analyses of Vmwl75
The main aim of the work presented in this thesis was to 
investigate the functionally important regions of Vmwl75 by 
performing a detailed mutational analysis of the protein.
It is therefore relevant to review previous studies which 
have contributed to our knowledge of the structure of 
Vmwl75. Properties of the IE gene 3 DNA sequence, the 
predicted amino acid sequence and homology studies of the 
protein sequence have already been described above (Section 
1D1.5).
Clues as to the functionally important regions of Vmwl75 
have been provided by fine structure mapping of a number of 
ts mutations within the coding sequence. Dixon and Schaffer 
(19 80) have mapped the order and position of 9 ts mutations 
within the Vmwl75 coding sequence using marker rescue and 
two-factor crosses. All nine mutations exhibited similar 
but not identical phentypes at the NPT. Two mutants, tsB28 
and tsB32, which mapped towards the carboxy-terminus of the 
coding sequence were found to be more permissive for late 
gene expression than others. Preston (19 81) has also mapped 
four _ts lesions by similar procedures and found that the 
least permissive (leaky) mutant, tsK, maps nearer to the 
amino terminus of the protein. The DNA change responsible 
for the phenotype of tsK has since been determined at the 
nucleotide level and found to cause a single amino acid 
substitution (alanine to valine) at residue 475 (Davison et 
al., 1984). This mutation lies within a region of Vmwl75 
strongly conserved between Vmwl75 and VZV140K (McGeoch et 
al ., 1986a; see Section 1D1.5).
DeLuca et al., (1984) isolated two ts—Vmwl75 HSV—1 
mutants, ts48 and ts303, which overexpressed IE proteins at 
the NPT but synthsized a number of early gene products not
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usually seen with other ts-Vmw!75 mutants at NPT. These 
mutants were also capable of inducing 15-50% wild-type 
levels of viral DNA synthesis at NPT, although late gene 
products were under synthesized. These ts mutations 
therefore seemed to cause a block in gene regulation at late 
times of infection, but were able to transactivate a 
plasmid-borne early promoter (that of the tk gene) by 
superinfection of transfected cells. The DNA lesions of 
these two mutants were mapped to the same carboxy-terminal 
region of the coding sequence as the lesions in tsB28 and 
tsB32, which were also permissive for some early gene 
expression (Dixon and Schaffer, 1980; DeLuca et al., 1984). 
However, tsB32-Vmw!75 did not seem to activate the cloned tk 
(early) promoter by superinfection or when subcloned onto a 
plasmid (DeLuca et al., 1984; DeLuca and Schaffer, 19 85). 
Interestingly, the majority of ts-Vmw!75 mutations seem to 
map to the more carboxy-terminal regions of the protein 
(region 4) and few have a phenotype as tightly restricted 
for viral gene expression as the more amino-terminal tsK 
lesion (in region 2) (Dixon and Schaffer, 1980; Deluca et 
al., 19 84; Preston, 19 81; McGeoch et al ., 19 86).
Viruses containing spontaneous (silent) and constructed 
(conditionally-lethal) deletions within the IE3 coding 
sequences have been isolated. Schroder et al ., (1985) 
described the characterization of a virus with a spontaneous 
deletion removing amino acids 209-236 of Vmwl75 which was 
viable on non-complementing cells, although the plaques were 
atypically small and syncitial in morphology (syn~). The 
viruses were also somewhat _ts in plaquing efficiency and 
markedly so for DNA replication. This deletion removes 28 
amino acids almost immediately adjacent to the serine and 
acidic residue-rich region of Vmwl75 (176-206) which is 
conserved in HSV, PrV and VZV (see Sections 1D1.5 and 
4.3.1). However, when attempts were made to rescue this 
virus with wild-type DNA fragments, viruses with wild-type 
plaque morphology and growth properties could be recovered 
which still possessed the 84bp deletion. This short section 
of Vmwl75 is therefore non-essential for growth in tissue 
culture, and may not have detectable phenotypic effects.
The phenotype of this spontaneous deletion mutant is very
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similar to the phenotype of the virus deletion I15HBC 
reported in this thesis (Section 3F) which is deleted for 
Vmwl75 residues 162-229.
The creation of cell lines which constitutively express 
Vmwl75 has allowed the construction of recombinant HSV-1 and 
HSV-2 viruses with conditionally-lethal mutations in IE gene 
3 (DeLuca et al.f 1985; Russell et al., 1987b; Smith and 
Schaffer, 1987a; DeLuca and Schaffer, 1988). Initially 
these were used to construct viruses with gross deletions in 
Vtnwl75 which were useful as null mutants in the 
characterization of Vmwl75 function and as parents for the 
substitution of alleles of IE gene 3 carrying more subtle 
changes in the coding sequence (DeLuca et al., 1985; DeLuca 
and Schaffer, 1987, 1988; this thesis).
The most rapid approach to investigating the structure 
and function of Vmwl75 has been to create insertion and 
deletion mutants within the Vmwl75 coding sequence and assay 
their activity in short term transfection assays 
(Mavromara-Nazos et al., 1986; DeLuca and Schaffer, 1987, 
1988; Hubenthal-Voss et a l ., 1988; Paterson and Everett, 
1988a,b; this thesis). An early intriguing observation, 
which suggested that much of the Vmwl75 protein sequence was 
inessential for at least some of its activity, was that a 
plasmid encoding a mutant Vmwl75 polypeptide truncated at 
residue 825 was capable of directing some (albeit reduced) 
transactivation of early and late promoters (Mavromara-Nazos 
et al., 1986).
A much more detailed analysis of the activity of 
truncated mutants of Vmwl75 has been conducted by DeLuca and 
Schaffer (19 87) who constructed a panel of Vmwl75 mutants by 
inserting oligonucleotides encoding translational stop 
codons in all three reading frames into various positions of 
the cloned IE gene 3. By assaying the activity of these 
mutants in transfection assays they showed that the amino 
terminal 60% of Vmwl75 was sufficient to direct 
transactivation of the (early) HSV-1 tk promoter and 
autorepression of the IE3 promoter linked to the CAT gene. 
Furthermore, the amino-terminal 9 0 amino acids of the 
protein proved to be innessential both in transient assays 
and when this mutation was recombined back into virus.
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Insertion of a stop codon within the first 90 codons seemed 
to permit translational initiation at the second methionine 
codon, located at amino acid 90, and direct synthesis of a 
polypeptide lOkDa smaller than wild-type (DeLuca and 
Schaffer, 1987). The ability of the truncated mutants to 
complement growth of a virus with a large deletion within IE 
gene 3 was also assayed. All, apart from the 9 0 residue 
amino-terminal deletion, were severely impaired. This 
indicated that the carboxy-terminal 40% of Vmwl75 may be 
directing functions not revealed by the transient assays 
(see results Section 3C3).
An interesting phenomenon observed in both the 
transactivation and complementation assays was that mutants 
expressing 60% of the protein had greater activity than ones 
expressing 80%. This suggests that a domain of the protein 
between these sites inhibits or negatively regulates Vmwl75 
function, either directly, or as a consequence of abnormal 
protein conformation.
Several of these mutated genes were recombined back into 
the HSV genome in their correct chromosomal loci, and the 
growth properties of the recombinant viruses investigated 
(DeLuca and Schaffer, 1988). The properties of the 
truncated and deleted Vmwl75 polypeptides produced by these 
recombinant viruses are shown in Table 3. The mutants were 
found to belong to one of three classes with respect to 
their growth properties and gene regulation:
Is Identical to wild-type with respect to gene expression 
and replication; only recombinant n6 (the amino 
terminal 9 0 amino acid deletion, see Table I) showed 
this phenotype.
II: Mutants express only IE gene products; derivatives of
Vmwl75 with deletions extending into the first 60% of 
the coding sequence possess this phenotype.
Ills Mutants able to induce some early protein synthesis but 
not to wild-type levels. IE3 mRNA and Vmwl75 protein 
overaccumulates although repression at the level of 
transcription, as measured by transcription run-on 
assays in isolated nuclei, is not seen. Deletion 
mutants expressing derivatives of Vmwl75 with the first
Table 3: Properties of recombinant viruses expressing 
truncated or deleted Vmwl75 polypeptides (DeLuca and 
Schaffer, 1988).
1 2 3 4 5 6
Virus Truncation/ Comments 
Deletion
Class Localiz DNA
Binding
n6 11 Restarts at 9 0 I _ +
nl2 251 II c —
n214 590 II c ( + )
n208 773 III n +
nl8 818 III n +
n215 1028 III n +
dl20 171 (Deletion) II ? -
d202 680 (Out of frame 
deletion)
II ? ““
dl56 680-857 (In frame 
deletion)
II c —
d2 185-309 (In frame 
deletion)
II n
Table 3: Properties of recombinant viruses expressing 
truncated or deleted vmw!75 polypeptides (DeLuca and
Schaffer, 1988). Column 2 records the position of the
inserted translational stop codon or the deletion end-points 
of the mutated Vmwl75 polypeptides produced by the 
recombinant viruses (column 1). These mutations are further 
described in column 3. The phenotypic class (as described
in the text) of each mutant is given in column 4. Column 5
describes the cellular localization of the mutant 
polypeptides expressed in the infected cell (n: nuclear; c: 
cytoplasmic) and column 6 records the ability of the mutant 
proteins to bind to the IE3 cap site (n214 only binds at 
elevated salt concentrations, see text).
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60% of the coding sequence uninterupted possess this 
phenotype.
None of the class II or III mutants were able to grow on 
non-complementing cell lines. The nuclear localization 
signal of Vmwl75 seemed to be located between the ends of 
the n214 and n208 polypeptides (residues 590-773), however, 
all of the mutant forms were impaired with respect to 
subnuclear localization and failed to localize to discrete 
areas of the nucleus as seen with wild-type or n6-Vmwl75.
All of the polypeptides with the exception of dl20 were 
phosphorylated at near normal levels, implicating the amino 
acids between the end points of dl20 and nl2 (171-251) in 
phosphorylation. This would support the involvement of the 
serine-rich tract (186-204) in phosphorylation.
DeLuca and Schaffer (1988) also examined the ability of 
the mutant polypeptides to bind to the ATCGTC consensus 
binding site at the IE3 start site. Viral specific 
complexes, containing Vmwl75, were seen with all of the 
class I and III mutants capable of autoregulation of IE3 
transcription. Under the conditions of binding used in 
these assays the Vmwl75 DNA complexes were salt-labile when 
the concentration of NaCl was raised from 15 to 65mM; this 
contrasts with the results presented in tnis thesis and by 
others (Faber and Wilcox, 19 88) that show that DNA binding 
is stable at much higher salt concentrations. However, at 
these elevated salt concentrations some of their mutants 
were able to form novel complexes of greater mobility in gel 
retardation assays, including a class II mutant truncated at 
amino acid 59 0. It was suggested that this complex may 
represent monomer binding , whilst the larger, more 
salt-labile complex represents multimers of Vmwl75 bound to 
DNA.
DeLuca and Schaffer (19 88) presented a map of the 
physical and functional domains of Vmwl75 based on their own 
and earlier studies. This map is reproduced in Figure 8.
The results and conclusions presented in this thesis are in 
good agreement with their results (see Chapters 3 and 5).
It is also relevant here to briefly consider some 
attempts that have been made to accurately map the Vmwl75
Vmwl75
NUCLEAR LOCALP 
PHOSPHORYLATION
INESSENTIAL
DNA BINDING 
TRANSACTIVATION & 
AUTOREGULATION
DNA SYNTHESIS & 
LATE GENE EXPRESSP
Figure 8: Functional domains of Vmwl75 (after DeLuca and 
Schaffer, 1988). The Vmwl75 sequence is divided into the 
five structural domains proposed by McGeoch et al., (19 86) 
(see Figure 5). The extent of the functionally important 
regions of the molecule as suggested by DeLuca and Schaffer 
(1988) are shown beneath the protein sequence.
□
□
C
□
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DNA binding domain by a variety of approaches. Kristie and 
Roizman (1986b) have reported that binding of monoclonal 
antibody H950 to Vftiwl75 abolishes DNA-binding to the IE1 
promoter. The epitope for this antibody has been mapped to 
within amino acids 21-36 (Hubenthal-Voss et al., 1988) and 
therefore lies within a section of region 1 shown not to be 
required for DNA binding by the results of DeLuca and 
Schaffer (1988) and the results presented in this thesis 
(Paterson and Everett, 1988b; Section 3D). Therefore it is 
likely that the antibody is blocking DNA binding through 
longer range steric affects.
Hubenthal-Voss et al ., (19 8^) have also attempted to map 
the DNA binding domain of Vmwl75 by using short synthetic 
oligopeptides to interfere or compete with functional 
protein domains involved in binding to the DNA recognition 
sites in the IE1 promoter. Their results, which mapped 
regions important for DNA binding activity near to the amino 
terminus, are at variance with the results presented in this 
thesis (Paterson and Everett, 1988b; Section 3D). Indeed it 
has been shown that the region they investigated seems to be 
of little importance, at least in binding the IE3 
recognition site (Paterson and Everett, 1988b; this thesis). 
Hubenthal-Voss et al ., (1988) showed that Vmwl75 in 
transfected nuclear extracts could bind to DNA and that 
Vhiwl75 truncated at residue 825, but not residue 519, could 
also bind to DNA. From this result they suggested that a 
DNA binding domain lay between residues 519 and 825, a 
hypothesis not borne out by results presented in this thesis 
(Paterson and Everett, 1988b). Furthermore, it is not clear 
how the interpretation of their results using nuclear 
extracts to assay Vmwl75 DNA binding is affected by the 
mapping of a nuclear localization signal to within this 
region (DeLuca and Schaffer, 19 88; Paterson and Everett,
19 88a).
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SECTION IE: The mechanism and regulation of transcriptional 
initiation by RNA polymerase II.
1. RNA polymerase II and factors required for initiation of 
transcription of class II promoters.
Regulation of the initiation of gene transcription is 
the fundamental level at which eukaryotic gene expression is 
controlled. In this section of the thesis I shall attempt 
to review transcription from inducible class II promoters.
Three separate enzymes have been defined which 
transcribe DNA to form RNA in the nucleus of eukaryotic 
cells. These eukaryotic RNA polymerases are large, 
multisubunit complexes composed of 9-14 polypeptides. The 
RNA polymerases I and III have specialized roles in cellular 
gene expression and transcribe a small subset of the genomic 
DNA, recognizing well defined promoter elements. RNA 
polymerase II transcribes a much greater portion of genomic 
DNA sequences and responds to a greater diversity of gene 
expression signals.
The two largest subunits of RNA polymerase II share
structural homology with the two largest subunits of
prokaryotic RNA polymerases. However, the carboxy-terminal 
domain of the largest subunit is unique in that it is 
composed of a long tandem repeat of a heptapeptide consensus 
sequence [YSPTSPS]. The exact number of repeat units varies 
both within and between species, from 27 to 52 (in yeast and 
mouse respectively) (Corden et al., 1985; Allison et al.,
1985; Nonet et al., 1987). Studies in yeast have shown that
the length of this tandem repeat element is functionally 
redundant, and yeast strains encoding polymerases with 10-13 
repeats are viable (Nonet et al., 1987). In Drosophila a 
longer repeat domain appears to be essential (Zehring et 
al., 1988).
This repeat unit appears to form a well defined 
secondary structure rich in hydrophilic (hydroxyl) side 
chains, which may project out from the globular RNA 
polymerase holoenzyme. In a minimal in vitro system this 
structure is non-essential for RNA synthesis and can be 
removed by proteolysis without disrupting the accurate 
initiation of transcription. This domain may therefore be
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involved in the regulation of transcription (Zehring et al.,
1988). It has been suggested that the exact size and 
sequence of this carboxy-terminal regulatory domain is not 
critically important, but that the hydroxyl groups might be 
involved in interacting in a fairly non-specific manner with 
transcription activating proteins. In particular it has 
been suggested that the acidic activating regions found on 
many transactivating proteins (Section 1E3.3) would be able 
to form multiple non-specific carboxylate-hydroxyl contacts 
with this structure (Sigler, 1988). These carboxyl groups 
might also be the target for phosphorylation by protein 
kinases, perhaps catalyzed by the acidic residues of the 
transcriptional activators.
In addition to purified RNA polymerase II holoenzyme a 
number of ancillary factors have been defined in vitro which 
are essential for the accurate initiation of transcription 
from templates encoding a class II promoter which include a 
TATA box element (see Section 1E2.1). Three partially 
purified transcription factors TFIIB, D and E are required 
in addition to RNA polymerase II for the transcription of
such a template in vitro (Matsui et al ., 19 80; Sawadogo and
Roeder, 1985a; Moncollin et al., 1986).
Kinetic studies have defined several stages in the
process of transcriptional initiation. Commitment to 
transcription involves recognition of the promoter by TFIID 
which binds to the TATA box element to form a stable complex 
in the absence of other transcription factors and RNA 
polymerase (Davison et al., 1983; Sawadogo and Roeder,
1985b; Moncollin et al., 1986; Zheng et al ., 1987). 
Recognition of the promoter by TFIID allows the association 
of RNA polymerase II to form an intermediate, stable 
preinitiation complex, which is converted to an activated 
complex by the addition of TFIIB and E. DNA binding studies 
have shown that protein/protein and protein/DNA interactions 
are important in the formation of these complexes, and that 
the extent of DNA sequences bound by TFIID are extended by 
TFIIB and E (Van Dyke et al., 1988). An energy dependent 
step, involving the hydrolysis of ATP, then alters the 
conformation of the activated complex, perhaps involving the 
loss of TFIIB and E, and allows initiation of transcription
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upon the addition of rNTPs (Fire et al ., 19 84; Van Dyke et 
al., 1988).
Binding of TFIID to the TATA box appears to be the 
critical step in the formation of the preinitiation complex 
and is certainly important in determining the rate at which 
transcription is initiated. It is therefore not suprizing 
that recent studies have shown that this factor seems to be 
the target for activation by both viral and cellular 
transcriptional activator proteins (Section 1E3.5).
2. DNA sequences involved in the control of RNA polymerase 
II initiation.
The genes transcribed by RNA polymerase II can be 
divided into two subclasses on the basis of their expression 
and the promoter sequences controling their transcription. 
Genes encoding so called "housekeeping" products, common to 
all cell-types, are transcribed at low levels in most cells 
and have poorly defined promoters devoid of obvious 
recognition elements. The majority of class II promoters, 
however, share a basic structure which generally includes a 
TATA box element and various upstream regulatory elements. 
These promoters are responsive to various forms of 
regulation, determined both by tissue type and developmental 
stage, and in many cases respond to transient forms of 
induction.
The DNA sequences required for the accurate and 
efficient initiation of transcription are generally located 
within 100 bases upstream of the transcriptional start site 
(+1). The efficiency of the basal level of transcription 
from a promoter is determined by its constitutive promoter 
elements.
2.1 The TATA box.
The minimal promoter includes an AT rich region 
designated the TATA box located at around -25 to -30 bases 
upstream from the start site. This forms aft essential 
component of the transcriptional machinery and is essential 
for accurate initiation of transcription in vitro (reviewed 
Maniatis et al., 1987; Nakajima et al., 19 88). The TATA box 
is bound by a factor, or family of factors, called TFIID
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(Davison et al.# 1983; Sawadogo and Roeder, 1985b; Moncollin 
et a l ., 1986). TFIID has been partially purified and shown 
to interact with a variety of class II promoters and is 
necessary for their transcription in vitro. However, there 
may be multiple forms of this TATA box binding factor, as 
TFIID was found to interact differently with distinct 
promoters (Nakajima et al., 1988). There is also evidence 
that there is actually a family of TATA box sequences, which 
react differently to viral transactivation and therefore may 
be bound by different members of a TFIID family (Simon et 
al., 1988; Everett, 1988b). In addition the TATA box has 
been implicated in mediating the response to viral IE 
transactivators in vivo and in vitro (Coen et a l ., 1988; 
Simon et a l ., 1988; Wu et a l ., 1987; Wu and Berk, 1988; 
Abmayr et al., 1985, 1988).
2.2 Upstream promoter elements.
Promoters contain one or more upstream promoter elements 
(UPEs) usually positioned within 100 bases upstream from the 
TATA box sequence (reviewed by Maniatis et al., 1987).
These sequences are modular in nature, consisting of arrays 
of short (10-12bp) recognition elements which interact with 
specific cellular DNA binding proteins (transcription 
factors). Several of these UPE sequences are common to a 
wide variety of promoters and are bound by factors which are 
found in many cell-types (for example CCAAT, bound by CPI, 
CP2 or NFI; GGCGGG, bound by Spl). Other elements are found 
less frequently and may have a role in determining cell-type 
specificity. UPEs have also been characterized which confer 
inducibility on a promoter and may be considered as 
inducible enhancer elements. The response elements to heat 
shock (HRE), heavy metals (MRE) and steroid hormones are all 
examples of this type of regulatory motif, which are only 
bound by their cognate transcription factor in response to 
an intracellular signal.
Although the orientation relative to and distance from 
the TATA box of UPEs does not in general appear to be 
critical for their function, in some instances the spacing 
between elements has been observed to be important, 
especially when these elements are closely juxtaposed. For
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example the introduction of half turns in the DNA helix 
between UPEs in the SV40 early promoter interferes with 
transcription from the normal start site. This provides 
evidence that the activity of UPEs is mediated through the 
proteins bound at the site, not the DNA sequence itself 
(Takahashi et al., 1986). It has also been suggested that 
at least one of the upstream regulatory elements must lie 
close to the TATA box, to mediate interaction with the TATA 
box binding factor TFIID (Lin et al., 1988).
2. 3 Enhancer elements
Enhancers are DNA sequence elements which can activate 
transcription from a cis-linked promoter in an orientation 
and distance independent manner. Like promoters, enhancer 
elements are also composed of multiple DNA sequence elements 
bound by ubiquitous or cell-type specific transcription 
factors, and indeed the mechanisms by which these sequences 
and their cognate transcription factors activate 
transcription may be indistinguishable. Furthermore, at 
least some UPEs can function as components of enhancers as 
well as of promoters. One such element is the octamer 
binding site which is found in a variety of promoters and 
immunoglobulin enhancers (Bohmann et a l ., 1987a; Parslow et 
a l ., 19 87). The functional distinction between enhancers 
and UPEs (that is the "action at a distance" property of 
enhancers) probably reflects the arrangement and number of 
transcription factor recognition elements in enhancers, 
rather than the mechanism by which they act.
The structure and function of the enhancer encoded by 
the papovavirus SV40 has been dissected in detail. This 
enhancer is composed of multiple sequence motifs that 
stimulate transcription synergistically and are organized at 
a higher level into two or three functional domains which 
are active when multimerized (Zenke et al., 1986). These 
motifs are bound by a variety of ubiquitous and cell-type 
specific factors, which probably accounts for the wide 
"host-range" of this enhancer. Binding of these factors to 
their cognate sites is strongly correlated to their 
trancriptional activity (Davidson et al., 1986; Wildeman et 
al., 1986; Nomiyama et al., 1987). Unlike the inducible
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motifs bound by the steroid hormone receptors, the 
individual SV40 enhancer motifs have no independent 
activity, but enhance transcription only when oligomerized 
in association with themselves or a second motif to form a 
multi domain enhancer (Fromental et al., 19 88; Davidson et 
al., 1988).
3. Transcriptional activation.
3.1 Factors interacting with upstream promoter elements and 
enhancers.
Cellular proteins ("transcription factors") capable of 
binding to 10-12bp DNA motifs in the upstream regulatory 
regions of promoters and enhancers have been identified by a 
variety of in vitro DNA binding assays. These proteins are 
generally inferred to mediate transcriptional regulation, 
and in many cases a direct correlation between DNA binding 
and transcriptional activation has been demonstrated both in 
vivo and in vitro (reviewed by McKnight and Tjian, 1986; 
Maniatis et al., 1987; Jones et al., 1988; Ptashne, 1988; 
Wingender, 19 88).
(i) Spl
The first cellular transcription factor to be 
characterized in detail was Spl, which binds to GC box 
motifs (GGCGGG) in various promoters and activates this 
subset of genes in mammalian cells (reviewed Kadonoga et 
al., 1986; McKnight and Tjian, 1986). Spl has been purified 
by DNA affinity chromatography and shown to bind to GC boxes 
in vitro and stimulate transcription (Briggs et al., 1986).
A cDNA for the transcript encoding Spl has been cloned and 
shown to encode a protein with a carboxy-terminal DNA 
binding domain. This region has three continuous zinc 
finger motifs which seem to be involved in DNA binding 
(Kadonoga et al., 19 87). Two regions of the protein 
identified as being involved in mediating transcriptional 
activation are distinguished by containing an unusually high 
proportion of glutamine residues (Courey and Tjian, 1988).
Recently it has been shown that Spl bears multiple 
O-linked N-acetylglucosamine (GlcNAc) monosaccharide 
residues and that this post-translational modification may
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contribute towards the transactivating activity of Spl 
(Jackson and Tjian, 1988). A large number of other cellular 
class II transcription factors were also demonstrated to be 
GlcNAc glycosylated, including Apl, Ap2, and CCAAT binding 
factor, raising the interesting possibility that this is an 
important conserved modification of class II transcription 
factors.
(ii) CCAAT box binding factors CPI, CP2 and NFI.
The CCAAT box sequence motif is found in the upstream 
regulatory regions of many class II promoter and has been 
demonstrated to be important for promoter function (Jones et 
al., 1985; Graves et al ., 1986; McKnight and Tjian, 1986).
It has been shown that there is a family of at least three 
multisubunit CCAAT-binding proteins composed of heterologous 
subunits, and that these bind to distinct CCAAT box 
recognition sequences which vary in their flanking DNA 
sequences. DNA binding is correlated with potentiation of 
transcription (and in one case with viral replication) 
(Chodosh et al., 1988a).
The protein CPI is composed of two heterologous subunits 
which are conserved between yeast and human cells. The 
yeast and human proteins have identical specificities and 
the subunits are functionally interchangeable (Chodosh et 
a l ., 1988b). Recognition of the CCAAT box motifs is 
therefore more complicated than binding of Spl to the GC box 
motif, with a variety of different proteins recognizing 
variants on a common core element. It remains to be seen 
how the different CCAAT binding proteins are related.
Studies on the regulation of the human thymidine kinase 
gene have revealed variations in the nature of the complexes 
with the CCAAT box, which are implicated in the cell-cycle 
dependent control of transcription (Knight et al., 1987).
(iii) Apl and c-Fos
The transcription factor Apl interacts with the 
TPA-inducible promoter and enhancer element TGACTCA (Lee et 
al., 19 87a,b) and is encoded by the cellular proto-oncogene 
c-jun (Bohmann et al., 19 87b; Angel et al ., 19 88; Bos et 
al., 1988). The tumour-promoting agent TPA stimulates Apl
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DNA binding activity by a post-translational mechanism, 
which may involve the TPA mediated stimulation of protein 
kinase C (Angel et a l ., 1987). The product of a second 
cellular proto-oncogene c-Fos has been shown to interact 
with Apl and to cooperate in the stimulation of 
transcription of Apl responsive genes (Sassone-Corsi et al., 
1988; Rauscher et a l . , 1988; Chiu et a l . , 1988).
Furthermore c-Fos can function as a transcriptional 
activator in yeast when fused to a site specific binding 
domain (Lech et a l ., 1988), perhaps indicating that c-Fos 
requires Apl to localize at responsive promoters in much the 
same way as Vmw65 interacts with the octamer binding protein 
to activate transcription from cis-linked promoters (Section 
1 C 2 ). Apl and c-Fos interact together to form a heterodimer 
which has greater affinity for DNA than Apl homodimers; 
c-Fos homodimers do not bind to DNA (Nakabeppu et al., 1988; 
Halazonetis et a l . , 1988). The DNA binding specificity of 
Apl is identical to that of the yeast transcriptional 
activator GCN4 and the amino acid sequence of their DNA 
binding domains is conserved; indeed the DNA binding domain 
of Apl can substitute for that of GCN4 (Struhl, 1987). 
Clearly, like the CCAAT binding protein CPI, this 
transcriptional regulatory system has been conserved in 
evolution, which has important implications not only in the 
study of gene regulation but also of oncogenesis. The cAMP 
response eleme nt (CRE) is similar in sequence to the Apl 
binding site motif, but is bound by a protein (ATF or CREB) 
unrelated to Fos or Jun (reviewed, Curran and Franza, 1988).
(iv) ATF and TFIID interactions.
ATF is a mammalian transcription factor which binds to 
sequences found in many adenovirus and other promoters 
(Jones et a l . , 1988). Studies on the in vitro activity of 
the purified ATF have suggested a mechanism by which 
transcription factors binding to upstream sequences may 
activate transcription. Purified ATF can bind to upstream 
promoter elements in the adenovirus E4 promoter to 
potentiate transcription. In vitro DNA binding assays have 
revealed cooperative interactions between ATF and TFIID 
binding to this promoter. ATF binding does not increase the
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rate of TFIID binding but appears to stabilize the 
preinitiation complex and facilitate RNA polymerase and 
TFIIB and E promoter recognition. The cooperative 
interactions between ATF and TFIID extend the DNA sequences 
bound by both proteins. The role for ATF appears to be 
transient, and dissociation of ATF from the complete 
initiation complex does not destabilize the initiation 
complex (Horikoshi et al., 1988b; Hai et al., 1988a).
(v) Factors interacting with enhancer elements.
The transcription factors that interact with recognition 
elements within enhancers are thought to be functionally 
equivalent to those binding to upstream promoter sites.
This has been demonstrated experimentally by cloning the 
recognition element for NF-^B from an immunoglobulin 
enhancer to a new position next to a TATA box to create a 
novel NF-^B responsive promoter (Wirth and Baltimore, 1988).
Indeed there is overlap between the control elements 
found in promoters and enhancers. For example the binding 
sites for octamer binding protein OTF-1 (OCT-1) are found in 
a variety of promoters and enhancers (Rosales et al., 1987; 
Bohmann et al ., 19 87a) and overlap with the HSV Vmw65- 
responsive TAATGARAT elements (O'Hare and Goding, 1988; 
Gerster and Roeder, 1988). This same octamer element, 
however, can be bound by two or more proteins with different 
tissue distributions (Rosales et al., 1987). The ubiquitous 
octamer binding protein OTF-1 has been purified and binds to 
the histone H2B promoter in vitro to activate transcription 
(Fletcher et al ., 1987) whilst the lymphoid specific factor 
OTF-2 (OCT-2) activates transcription of the immunoglobulin 
promoter in vitro (Scheidereit et a l ., 1987). The sequence 
of OTF-2 reveals that it encodes a homoeobox domain involved 
in DNA binding (Ko et al., 19 88). OTF-1, OTF-2 and another 
transcription factor Pit-1 or GHF-1 share a conserved 160 
amino acid element (POU) including the 60 amino acid 
homoeobox domain. This region is also conserved in the 
evolutionarily distant C.elegans developmental control 
protein Unc-86. The whole POU region appears to be involved 
in DNA binding (reviewed Marx, 1988; Robertson, 1988; Levine 
and Hoey, 19 88).
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In addition to exhibiting tissue specific distributions 
many transcription factors recognizing enhancer elements 
show further levels of control, and respond to variety of 
signal tranduction pathways. OTF-1 (like a CCAAT binding 
protein) has been reported to be active in a cell-cycle 
dependent manner (Fletcher et al., 1987). The activity of 
other enhancer binding proteins is modulated by treatment of 
the cells with TPA (Apl, Ap2) or in response to cAMP (Ap2) 
(Angel et a l ., 1987; Lee et al., 1987b; Imagawa et al.,
19 87). Heat shock induces the response to heat shock 
transcription factor (Parker and Topol, 1984) whilst hormone 
binding receptors only activate transcription when liganded 
to their cognate hormone (Section 1E3.2).
3.2 Hormone binding receptors.
Study of the steroid and thyroid hormone receptor 
transcription factors has been of particular interest 
because these receptors directly respond to intercellular 
messages to modulate cellular gene expression. Vertebrates 
encode a conserved superfamily of receptors for steroid and 
thyroid hormones and retinoic acid related ligands (reviewed 
by Evans, 19 88; Green and Chambon, 19 88). Each protein 
encodes a central DNA binding domain of about 70 amino acids 
which includes two conserved potential zinc binding fingers, 
the first of which determines the specificity of DNA binding 
to upstream promoter elements (Green and Chambon, 19 87;
Green et al., 1988). This short DNA binding domain may also 
encode the hormone inducible activation function of the 
steroid hormone receptors (Hollenberg et al., 19 87, Kumar et 
al., 1987). A large carboxy-terminal domain, separated from 
the DNA binding domain by a hinge region, binds to the 
hormone ligand. The amino-terminal domain is not conserved 
in size or sequence between different receptors and does not 
seem to be very important for function but may contribute 
towards the efficiency of activation (Giguere et al., 1986, 
Kumar et al., 1987). Transcriptional activation by the 
hormone receptors is mediated through upstream promoter 
elements which are bound by specific receptors and function 
as inducible enhancers.
The activity of the receptor proteins is regulated by
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hormone binding. Nuclear localization of the glucocorticoid 
steroid receptor (GR) requires hormone binding, and the 
unliganded GR may be complexed with the heat shock protein 
hsp90 in the cytoplasm (Picard and Yamamoto, 19 87; Denis et 
a l ., 19 88). Upon hormone binding the receptor can 
dissociate from hsp9 0 and translocate to the nucleus where 
its DNA binding activity is unmasked. Hormone liganding may 
also potentiate the dimerization of receptors (Kumar and 
Chambon, 1988). Although unliganded steroid receptors can 
bind to DNA in vitro, it appears that the unliganded steroid 
binding domain represses the transcriptional activation by 
the receptors in vivo by directly or indirectly interfering 
with DNA binding (Becker et al ., 1986; Willmann and Beato, 
1986; Denis et al ., 1988). If the steroid binding domain is 
deleted this control is alleviated and the receptor becomes 
constitutively active (Hollenberg et al., 1987; Godowski et 
a l ., 1987; Picard et al ., 1988). The unliganded steroid 
binding domain represses transcriptional activation and DNA 
binding whether positioned at the carboxyl or amino 
terminus, and when fused to Ela also regulates the activity 
of this transcriptional activator, possibly by associating 
with hsp90 (Picard et al., 1988).
The virally transduced oncogene v-erbA is homologous to 
the cellular thyroid T^ hormone receptor c-erbA (Sap et al., 
1986; Weinberger et al., 1986) but is truncated for the 
carboxy-terminal hormone binding domain and does not bind 
thyroid hormone (Munoz et al ., 1988). The oncogenic 
activity of v-ErbA appears to depend on the DNA binding 
domain suggesting that its activity may be due to 
constitutive (non-hormone regulated) transcriptional 
regulation (Privalsky et al ., 1988). v-ErbA has been shown 
to specifically repress the transcription of at least one 
gene (Zenke et al., 19 88).
The hormone receptor proteins are capable of 
transcriptional repression, which seems to operate by a 
variety of different mechanisms. The T^ receptor (T^R, 
c—ErbA) recognizes a similar sequence motif to the oestrogen 
receptor (ER), but whilst T^R can bind to the ERE (oestrogen 
responsive element) this binding does not result in 
activation, but inhibits oestrogen dependent activation
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(Glass et al., 19 88). Therefore T^R would appear to repress 
this ERE by binding in an inactive form. However, steroid 
receptor mediated repression of the rat prolactin gene does 
not require the DNA binding domain. In this case
repression is mediated through the binding site for a 
separate transcription factor Pitl, suggesting that 
inhibition can be mediated by protein/protein interactions 
between steroid receptors and other transcription factors, 
and does not require direct DNA binding (Adler et al.,
19 88) .
Glucocorticoid response elements (GREs) have been 
demonstrated to mediate repression of transcription in vitro 
and appear to be bound by an unidentified cellular factor, 
suggesting that GREs may be negatively regulated in the 
absence of GR binding (Langer and Ostrowski, 1988).
Little is known about how steroid hormone receptors 
activate transcription other than that this activation is 
correlated with DNA binding. However, glucocorticoid 
induction of the MMTV promoter has been shown to involve 
receptor mediated establishment of a transcription factor 
complex, not activation of a pre-existing complex, 
(Cordingley et al., 19 87). Furthermore, it has recently 
been shown that GR and a cellular transcription factor bind 
cooperatively to their adjacent GRE and CACCC box binding 
sites. This cooperativity depended upon the exact spacing 
between the binding sites, which was thought to indicate 
that cooperativity was achieved by protein/protein 
interactions (Schule et al., 1988a). The action of steroid 
hormone receptors may therefore, at least in some cases, 
involve or require participation of other transcription 
factors bound to the upstream regulatory region. 
Glucocorticoid and steroid responsive elements (GRE and ERE) 
have been shown to confer hormone inducibility on a minimal 
promoter when placed immediately upstream of the TATA box, 
suggesting that the receptor protein in conjunction with 
TFIID is able to form an active transcription complex. 
However, if the GRE is placed 350 bases upstream from the 
TATA box a second adjacent transcription factor binding site 
was required to confer hormone inducibility. Binding sites 
for Spl, NF1, CCAAT-binding protein, CACCC-binding protein
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and the glucocorticoid receptor itself could modulate this 
activity, suggesting that GR can function in synergy with a 
large number of transcription factors (Strahle et al., 1988; 
Schule et al., 1988b).
Regions of the hormone receptors involved in activation 
and distinct from those involved in DNA binding have been 
defined. Mutational analysis has defined one region towards 
the amino terminus of the GR that is involved in the 
activation of transcription (Giguere et al., 1986).
Although this region is acidic, like the activating regions 
of other transactivating proteins (Section 1E3.3), it is not 
conserved between different receptor proteins. A recent 
study has identified a carboxy-terminal 30-amino acid 
peptide of GR which also acts as an activating domain 
(Hollenberg and Evans, 1988). This peptide is also acidic 
but structurally unrelated to the amino-terminal region. 
Other studies indicate that multiple regions of the receptor 
proteins may be involved in activating transcription (Green 
and Chambon, 19 88).
3.3 Transcriptional activators in yeast.
Recent studies have shown that transcriptional 
regulation in the yeast S .cerevisiae shares many properties 
with transcriptional regulation in higher eukaryotic cells. 
Indeed several mammalian transcription factors have been 
shown to have yeast homologues as discussed in the preceding 
sections. However, most attention has been focussed on two 
yeast transcription factors, GAL4 and GCN4, which bind to 
upstream activating sites (UASs) to activate transcription 
from an adjacent gene. Like mammalian enhancers these UASs 
are modular sequence elements which can be moved relative to 
the critical cis-element, the TATA box (reviewed by 
Guarente, 19 88).
Both the GAL4 and GCN4 proteins have been demonstrated 
to consist of distinct domains specifying site-specific DNA 
binding (to the cognate UAS) and transcriptional activation 
from a cis-linked promoter (reviewed by Struhl, 1987). The 
DNA binding activities are specified by short domains at the 
amino and carboxyl termini of GAL4 and GCN4 respectively.
The GAL4 DNA binding domain contains two potential zinc
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fingers which might be involved in DNA binding (Hope and 
Struhl, 19 86; Keegan et al., 19 86). The DNA binding domain 
of either protein can be substituted by that of a 
heterologous E.coli protein, LexA, and the novel fusion 
proteins activate transcription from promoters linked to 
LexA binding sites (Brent and Ptashne, 19 85; Hope and 
Struhl, 1986).
The DNA binding activity of the GAL4 and GCN4 proteins
does not itself cause transcriptional activation. This is
dependent upon distinct activating regions of the protein.
Indeed DNA binding by mutant GAL4 polypeptides deficient in
transactivation causes repression when the UAS^„, is
* GAL
appropriately positioned in front of a gene (Keegan et al. ,
1986) .
The activating regions of GAL4 and GCN4 have been 
defined as stretches of 60-100 amino acids bearing a net 
negative charge. These regions activate transcription when 
fused to a DNA binding domain (Hope and Struhl, 1986; Ma and
Ptashne, 1987a). It seems to be the acidic character of
these activating regions that is their most important
feature, perhaps when presented on an amphipathic helix, and
as such these activating regions are less precisely defined 
structures than DNA binding domains (Ma and Ptashne, 1987a; 
Gill and Ptashne, 1987; Hope et al., 1988). Indeed short 
acidic oligopeptides cloned at random from E.coli or 
synthesized chemically can act as efficient activating 
regions when fused to the GAL4 DNA binding domain (Ma and 
Ptashne, 1987c; Giniger and Ptashne, 1987). The 78 amino 
acid highly acidic tail of the HSV-1 transinducing factor 
Vmw65 has also been shown to function as an activating 
region when fused to the GAL4 DNA binding domain (Sadowski 
et al., 1988). This acid tail is essential for the 
transactivation activity of Vmw65 (Friedman et al., 1988;
Ace and Preston, per.comm.) and presumably activates 
transcription in human cells by a similar mechanism to other 
acid activating regions (Section 1C2.2).
The ability of this type of structural motif to activate 
transcription is therefore not restricted to yeast, and 
furthermore the GAL4 protein will function in Drosophila and 
mammalian cells to activate transcription from promoters
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linked to the sequence (Webster et al., 19 88;
Kakidani and Ptashne, 1988; Fischer et al., 1988). Other 
activating regions from mammalian transcription factors will 
function when fused to the GAL4 binding domain, including 
the Ela activating region (*Lillie and Green, cited in 
Ptashne, 1988), and the GAL4 and GCN4 activating regions 
function when fused to the ER DNA binding domain (Webster et 
al., 1988).
Evidence is now emerging as to how these acidic 
activating regions may function to increase transcription. 
Over expression of these domains seems to cause a general 
suppression of transcription from promoters not responding 
to these factors, suggesting that the acid domain is 
competing for an essential component of the transcriptional 
apparatus, possibly TFIID or RNA polymerase itself (Gill and 
Ptashne, 1988; Ptashne, 1988). The acidic domain from GAL4 
seems to be able to function synergistically with other 
mammalian transcription factors, when, for example, an 
UAS^a l  is positioned next to the SV40 enhancer or a GRE 
(Webster et a l ., 1988; Kakidani and Ptashne, 1988).
Recent reports suggest that at least in mammalian cells 
TFIID is the direct target for GAL4 mediated activation. 
Binding of GAL4 in vitro to a UAS^,Ar-TATA promoter templaten CjAL i
qualitatively alters the TFIID/TATA box interactions to 
extend DNA binding beyond the region -15 to +1. Mutants of 
GAL4 lacking an acid activating region bind to DNA but fail 
to transactivate and do not induce these changes in TFIID 
binding (Horikoshi et al., 1988a). GAL4 protein has also 
been shown to function in synergy with the TATA box binding 
factor in vitro to stimulate transcription, providing that 
the binding site is positioned adjacent to the TATA
box. Alternatively, more remotely bound GAL4 can exert a 
synergistic effect through a second transcription factor 
(ATF or (JSF) bound adjacent to the TATA box (Lin et al., 
1988). Both these studies indicated that GAL4 has a third 
cryptic acid activating domain, which effects TFIID binding 
and transactivation in vitro, but does not function in vivo.
3.4 Viral transactivators.
A common feature of many viruses is that they encode
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transcriptional activator proteins which regulate the 
expression of viral genes. The effect of these proteins is 
sometimes specific to viral promoter sequences, but more 
often non-selective in the promoter sequences they 
transactivate. These gene products are generally encoded by 
immediate early or early genes and potentiate the expression 
of later temporal classes of genes. The adenovirus Ela 
protein is one of the best studied examples of a promiscuous 
transactivator protein.
(i) Structure of the Ela proteins.
The adenoviruses Ad2 and Ad5 encode a family of related 
proteins derived from alternative splicing of the Ela gene 
transcript. The major products are translated from 13S and 
12S mRNAs and encode 289 and 243 residue polypeptides 
respectively. The larger protein is essential for 
adenovirus growth.
The Ela products are complex multifunctional proteins 
which can activate a variety of viral and cellular genes in 
trans, repress the effect on transcription of viral and 
cellular enhancers, induce cellular DNA synthesis and 
mitosis, and participate in transformation (in conjunction 
with adenovirus Elb products or the ras gene product).
Mutational studies have been performed in order to 
define the domains of the protein which are essential for 
each individual function and a functional map of the protein 
has been derived (Figure 9). Three critical functional 
domains have been defined, which are conserved between 
different adenovirus serotypes. Protein domains (PD) 1 and 
2 are essential for the induction of DNA synthesis, 
transformation and the repression of enhancer function, 
activities that may not be essential for virus growth as PD1 
is non-essential (Smith and Ziff, 1988). PD2 seems to be 
involved in the association of Ela with various cellular 
proteins, including the retinoblastoma gene product (an 
anti-oncogene product) (Yee and Branton, 1985; Whyte et al., 
1988b; Egan et al., 19 88) and this region can be 
functionally substituted by a structurally related 18 amino 
acid portion of SV40 T antigen (Moran, 19 88). Sequences 
outwith the conserved domains have also been reported to be
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involved in transformation (Whyte et al,, 1988a; Velcich and 
Ziff, 1988), the rapid turnover of Ela (Slavicek et al., 
1988) and nuclear localization (see Figure 9).
PD3 is a 46 amino acid region unique to the larger Ela 
protein and is essential for transactivation. A synthetic 
49 amino acid oligopeptide spanning PD3 acts as an efficient 
activator of Ela inducible promoters in vitro and when 
injected into cells in the absence of de novo protein 
synthesis (Lillie et al., 1987; Green et al., 1988). This 
region encodes a zinc binding finger and single amino acid 
sub;ti tut ions in the conserved cysteine residues abolish the 
transactivation activity of both the full-length polypeptide 
and the synthetic 49 amino acid peptide (Culp et al., 1988; 
Green et al., 1988). Ela, however, is not a DNA binding 
protein (Ferguson et al ., 1985) so this transactivating 
region would seem to function by another mechanism.
Although the Ela transforming regions correlate more 
closely with repression than with transactivation a recent 
report suggests that the transformation and repression 
activities can be separated, and that mutants incapable of 
repression can still cooperate with Ras protein to induce 
transformation (Velcich and Ziff, 1988). The mutants still 
retain intact PDs 1 and 2, so it would seem that no single 
domain is responsible for repression function.
(ii) The mechanism of Ela transcriptional regulation.
Ela gene products stimulate transcription from a number
of viral and cellular genes, but although Ela mediated
transactivation has been studied intensely the mechanism of 
Ela function is still unclear.
Ela does not bind directly to DNA (Ferguson et al.,
1985) nor have any promoter sequences required specifically 
for Ela responsivity been detected. It seems therefore that 
Ela mediates its activity through the promoter sequences 
necessary for uninduced transcriptional activity. The 
factors binding to regulatory elements upstream of Ela 
responsive genes have been studied in depth, but although 
Ela seems to modulate the binding activity of some of these 
factors (in the absence of de novo protein synthesis) no 
common mechanism for Ela activation has been revealed
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(reviewed Jones et al., 1988). The ability of a small 49 
amino acid subdomain of Ela to mediate transactivation 
(Lillie et a l . , 1987; Green et a l . , 1988) contrasts markedly 
with the activity of the short acidic activating regions of 
yeast transcription factors, which only function when fused 
to a DNA binding domain (Section 1E3.3). The Ela activating 
region is neither acidic nor DNA binding and may function 
through protein/protein interactions with cellular 
transcription factors, mediated by the potential zinc finger 
binding domain. It is intr icj^ing that the activating domain 
of Ela is a very potent specific transactivator when fused 
to the GAL4 protein DNA binding domain, but still retains 
some activating activity on promoters lacking the GAL4
binding site UAS (Lillie and Green, cited in Ptashne,
CjrAJLi
1988).
It has been suggested that Ela may interact with and 
perhaps modify individual transcription factors to modulate 
their DNA binding activity. This modification could involve 
protein phosphorylation, and Ela mediated stimulation of 
transcription by RNA polymerase type III has been shown to 
involve the conversion of TFIIIe. to a more potent DNA 
binding form associated with phosphorylation of this protein 
(Hoeffler et a l ., 1988). Ela activation has also been 
observed to function through an upstream promoter element 
involved in response to induction by the cAMP-dependent 
protein kinase II pathway. However, Ela activation was not 
protein kinase II dependent and it was suggested that Ela 
acivation might be achieved by directly or indirectly 
phosphorylating the transcription factor binding to this UPE 
by an alternative mechanism (Sassone-Corsi, 1988).
Factors responsible for the higher transcriptional 
activity of extracts of adenovirus infected cells 
co-fractionate with TFIID (Leong et al., 1988) and it has 
been suggested that Ela may exert its effect on RNA 
polymerase II transcription directly or indirectly through 
TFIID. Indeed the TATA box has been implicated in the 
mechanism of Ela mediated transactivation by two independent 
studies which have shown that the TATA box is the only 
promoter element involved in the response to Ela (Wu et al ., 
1987; Simon et al., 1988). Ela would appear to mediate
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transactivation preferentially through a subset of TATA box 
sequences, with the hsp70 TATA box responding to Ela 
transactivation whilst the SV40 early promoter TATA box does 
not. This suggests that Ela may only interact with a subset 
of a family of TFIID factors (Simon et al., 1988). (A 
similar situation may be found for the HSV transactivator 
Vmwl75, Everett, 1988b). In these experiments 
transactivation seemed to be mediated directly through the 
TATA box sequence in the absence of upstream regulatory 
regions. It is likely, however, that Ela does interact with 
or modify factors binding to upstream regulatory elements, 
such as E2F (Kovesdi et a l ., 1986; Yee et al ., 1987).
The Ela protein is also able to repress transcription 
from a variety of cellular and viral enhancers (including 
the Ela enhancer), a function that is distinct from its 
transactivation activity. (Borrelli et al., 1984; Hen et 
a l ., 1985; Hearing and Shenk, 1985; Velcich and Ziff, 1985). 
The mechanism for this repression is unknown, but it seems 
to be fairly nonspecific.
3.5 A general mechanism for transactivation; the importance 
of the TATA box.
The TATA box is found upstream of the majority of class 
II promoters and is bound by the essential transcription 
factor TFIID (Sections 1E1 and 1E2.1). It appears to be 
mechanistic component of the promoter and not a regulatory 
element per se. However, as reviewed in the previous 
sections TFIID and its TATA box binding activity seems to be 
a common target for the action of eukaryotic transcriptional 
activators, including:
- the acidic activating regions of GAL4, GCN4, etc.
(Horikoshi et al., 1988a; Lin et al., 1988)
- the PrV immediate early protein
(Abmayr et al ., 1988)
- the cellular transcription factor ATF
(Horikoshi et al., 1988b; Hai et al., 1988).
In addition the TATA box appears to be the only identifiable 
important promoter element for the transactivation of a 
number of promiscuous viral transactivators (Ela: Section 
1E3.4; Vmwl75: Section 1D2.1; PrV IE180: Section 1D2.1).
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Interactions between transcription factors bound at 
upstream promoter elements and TFIID seem to change the 
conformation of TFIID bound at the TATA box region, 
extending the region of DNA covered by the protein. It 
appears that these interactions may have to be mediated 
through a transcription factor bound close to the TATA box, 
but that more distally bound transcription factors can 
interact synergistically with this proximal factor, (Lin et 
al,, 1988).
If TFIID (or indeed RNA polymerase or associated 
factors) is a direct target for transactivating interactions 
by a multitude of activating proteins, this would imply that 
the interactions between transcription factors and the 
responsive TFIID are fairly non-specific. The acidic or 
glutamine rich activating regions of many transactivators 
could provide such a non-specific signal.
How the activity of transcription factors themselves is 
controlled is an equally important question. This could be 
controlled at the level of synthesis (transcription) or by 
modulating the activity of constitutive transcription 
factors. Phosphorylation would appear to be an important 
mechanism for modulating the activity of at least-some 
transcription factors. Phosphorylation of the serum 
response (transcription) factor is required for DNA binding 
(Prywes et al ., 1988), and phosphorylation also modulates 
the DNA binding activity of the RNA polymerase III 
transcription factor TFIIlc (Hoeffler at al., 1988). 
Alternatively phosphorylation may modulate the activation 
activity of some transcription factors since both 
phosphorylated and non-phosphorylated forms of the heat 
shock transcription factor can bind to DNA (Sorger and 
Pelham, 19 88). Other forms of post translational 
modifications including GlcNAc glycosylation may be 
important for regulating the activity of transcription 
factors (Jackson and Tjian, 1988). The direct liganding of 
cellular messengers such as the steroid hormones provides an 
important means of controlling the activity of the hormone 
receptors superfamily (Section 1E3.2).
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4. Mechanisms for the repression of transcription.
Whilst the activation of transcription is probably the 
major level of gene regulation in eukaryotic cells, 
repression of RNA polymerase II mediated transcription also 
has a role in regulating gene expression and activation. 
Although several examples of transcriptional repression have 
been documented little is known about how repression is 
mediated and it is likely that repression can function at 
several different levels.
"Repression" can be mediated by blocking or preventing 
transcriptional activation. The activity of the unliganded 
steroid hormone receptors appears to be inhibited by being 
bound by cytoplasmic heat shock factors which prevent 
nuclear localization and DNA binding (Picard and Yamamoto, 
1987; Denis et al., 1988; Section 1E3.2). A similar control 
mechanism is exerted on the transcription factor NF^B which 
is bound by an inhibitory factor, I^B, in the cytoplasm, and 
only released in an active form upon phorbol ester 
activation (Baeuerle and Baltimore, 1988). The yeast 
repressor protein GAL80 also functions to inhibit 
transcriptional activation by interacting with an activating 
protein, GAL4 (see Section 1E3.3). Association of GAL80 
with GAL4 does not prevent GAL4 binding to its cognate 
upstream activating sequences, (JAS^^, but the activating 
surfaces on the GAL4 protein do appear to be masked (Ma and 
Ptashne, 1987b). If an acidic activating region is fused 
onto GAL80, this protein, in complex with GAL4, now 
functions as an activator of transcription (Ma and Ptashne, 
1988). This novel activator protein functions in an 
analogous manner to HSV Vmw (^5 by associating indirectly 
with target promoters through the formation of a complex 
with a site specific DNA binding protein (Section 1C2.2).
The steroid hormone receptor superfamily foro^ an 
interesting group of transcription factors in that they can 
repress as well as activate specific promoters at the 
transcriptional level. As discussed above (Section 1E3.2) 
repression may be mediated by a variety of mechanisms. In 
some cases repression appears to operate through binding to 
elements related to their activating sequences (Glass et 
al., 19 88) and in other cases appears to be mediated through 
an interaction with other transcription factors and to
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function independently from the receptor DNA binding 
activity (Adler et a l . , 1988).
It has also been proposed that repression can be 
mediated by cellular factors which bind to upstream 
regulatory elements in competition with activating 
transcription factors. Separate DNA binding nuclear factors 
have been identified which seem to bind to a GRE and a 
CCAAT-box element in the histone H2B promoter. These 
proteins may mediate repression by preventing the activating 
transcription factors from binding to their cognate upstream 
sequences (Langer and Ostrowski, 1988; Barberis et a l . , 
1987). It has also been suggested that a protein specific 
for binding to TA rich sequences may regulate the 
recognition of certain TATA boxes by competing for TFIID 
binding (Hobson et a l ., 1988).
The adenovirus Ela protein is also capable of repressing 
enhancer mediated transcriptional activation (Section 
1E3.4). The mechanism for is obscure and appears to be 
fairly non-specific. Repression is not dependent on DNA 
binding, nor mediated by the same region of the protein 
involved in the activation of transcription, and presumably 
operates through protein/protein interactions or 
modifications of other transcription factors. It has been 
proposed that Ela may mimic a cellular factor with similar 
negative function in undifferentiated embryonal carcinoma 
cells (Imperiale et a l ., 1984). The SV40 early gene product 
T antigen is able to repress SV40 transcription by 
specifically binding to its own promoter region, but it has 
recently also been shown that T antigen can repress 
activation of transcription by the celluar transcription 
factor A p 2 . This repression does not require DNA binding by 
T antigen, but appears to be the result of a direct 
interaction between T antigen and Ap2 (Mitchell et a l .,
1987). The function of viral repressors could have some 
relationship to the phenomenon of "squelching" proposed by 
Gill and Ptashne (1988) where overexpression of activating 
domains seems to cause general transcriptional repression by 
competing for essential components of the transcriptional 
apparatus.
As discussed earlier in this introduction (Section
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1D1.5) HSV-1 Vmwl75 is a specific repressor of transcription 
from its own promoter, and this activity is dependent upon 
the Vmwl75-DNA binding site at the IE gene 3 cap site.
Vmwl75 may act like a classical bacterial repressor and the 
strong DNA binding site present at the cap site function as 
an "operator", with tightly bound Vmwl75 interfering with 
promotion through this region.
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SECTION IF: AIMS OF THE RESEARCH PRESENTED THIS THESIS.
The initial aim of the work described in this thesis was 
to define the regions of the HSV-1 IE protein Vmwl75 
involved in functional activity by performing a detailed 
mutational analysis of a plasmid-borne copy of the gene, and 
assaying the activity of the mutants in transient 
transfection assays. Four phenotypes of Vmwl75 were 
investigated, transactivation of an early promoter, 
repression of the IE3 promoter, cellular localization and 
site specific DNA binding. It was hoped to be able to 
correlate these results with known structural features of 
this protein based on its predicted amino acid sequence and 
homology with other herpes transactivators. In particular 
it was hoped to determine whether transactivation and 
repression were separable functions of the protein and 
whether DNA binding activity correlated more strongly with 
one transcriptional activity than the other.
Having completed this analysis of Vmwl75 function in 
transiently based expression experiments it was planned to 
recombine some of the more interesting plasmid-borne mutants 
back into the virus genome in order to investigate their 
behaviour in the virally infected cell.
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CHAPTER 2; MATERIALS AND METHODS
SECTION 2A: MATERIALS
1. Cells
(i) BHK-21 clone 13 (MacPherson and Stoker, 1962), a 
fibroblastic cell line derived from baby hamster kidney 
cells, was generally used for growth of virus stocks and 
viral gene expression experiments.
(ii) WS HeLa cells (obtained from Dr.W.Schaffner,
Zurich) were mainly used for transient transfection assays.
(iii) Flow HeLa cells (from the ATCC via Flow 
Laboratories) were mainly used for nuclear extract 
experiments. These cells differed significantly in 
morphology, growth conditions and behaviour compared to WS 
HeLas.
( i v ) Vero cells (also obtained from the ATCC via Flow 
Laboratories) were used for transient transfection assays.
(v) M64A cells (obtained from Dr.N.D.Stow of this 
Institute) express HSV-1 Vmwl75 and were used to complement 
the growth of viruses carrying lethal mutations in IE gene
3. M64A cells are equivalent to the cell line M65 described 
by Davidson and Stow (19 85) and are a mixed cell line 
derived from BHKtk cells cotransformed with the HSV-1 
large Hindlll-Xhol subfragment*of XhoIC, and the HSV-1 
thymidine kinase (tk) gene and selected for thymidine kinase 
expression. (*tv\is, is c\e|-ei€c( -lor o n s
2. Tissue Culture Media
(i) BHK cells were grown in Glasgow Modified Eagle's 
Medium (GMEM) (Busby et al., 19 64) supplemented with 100 
units/ml penicillin, 100 ug/ml streptomycin, 0.2ug/ml 
amphotericin, 0.002% phenol red and 10% calf serum or 
newborn calf serum. (= EC10)
(ii) WS HeLa cells were grown in Dulbecco's Modified 
Eagle's Medium (DMEM) (supplied by Gibco) supplemented with 
100 units/ml penicillin, 100 ug/ml streptomycin, 0.2 ug/ml 
amphotericin, 2.5% foetal calf serum and 2.5% calf serum or 
newborn calf serum.
(iii) Flow HeLa cells were grown in supplemented GMEM as
83
for BHKs but with 10% foetal calf serum replacing the calf 
serum. (= EF10)
(iv) Vero cells were also grown in EF10.
(v) M64A cells were grown in EF10 supplemented with 
lng/ml Aminopterin, 5ng/ml Thymidine, 15ng/ml Hypoxanthine
* and 15ng/ml glycine. (= HAT medium)
(vi) Viral titrations were overlaid with GMEM 
supplemented as above and with 5% human serum (EH5), or with 
0.6% Noble agar in GMEM without antibiotics or phenol red 
and with the appropriate serum.
3. Viruses
All viruses used in this study were derivatives of the 
HSV-1 Glasgow strain 17 syn+ , which forms non-syncitial 
plaques on BHK cells (Brown et a l ., 19 73). Derivative in!411 
which produces no Vmwl75 (Russell et a l ., 1987b) was 
constructed by inserting an Xbal linker encoding stop codons 
in all three reading frames into the PvuII site of both 
copies of IE gene 3. The 17+ derivative d!1403 (Stow and 
Stow, 19 86) has a large deletion created within both copies 
of IE gene 1 and produces no VmwllO.
4. Bacteria
All plasmids used in this study were propagated in 
E.coli K12 strain HB101 ramCl, proA2, galK2, strA,
recA; Boyer and Roulland-Dussoix, 19 69).
5. Bacterial Culture Media
All strains of bacteria were grown on L-broth (177mM 
NaCl, 10g/l Difco Bactopeptone, 5g/l yeast extract (pH7.5 
prior to sterilization). Agar plates contained 1.5% (w/v) 
agar in L-broth and where appropriate the medium was 
supplemented with lOOug/ml ampicillin.
6. Plasmids
The following plasmids were kindly provided by the 
acknowledged authors.
pl75 (Everett, 1987b) The HSV-1 IE3 gene is cloned on a 
BamHI-SstI fragment (HSV-1 coordinates 125.1-133.0) under 
the control of the SV40 early promoter and enhancer (SV40
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coordinates 5171-346).
pill (Everett, 1987b) The HSV-1 IE1 gene is cloned on a 
Hpal-Sstl fragment (HSV-1 coordinates 120.4-125.1).
P63 (Everett, per.comm.) The HSV-1 IE2 gene is cloned on a 
BamHI-SstI subfragment of the plasmid pGX152 (EcoRIc) 
(Everett, 1986).
pIE3CAT (Stow et al., 19 86) The promoter of the HSV-1 IE3 
gene is cloned on a Hindlll-BamHI fragment (-331-+26) fused 
to the CAT gene in a vector derived from pBLW2 (Gaffney et 
al., 1985).
pgDCAT (Everett, 19 86) The promoter of the gene encoding gD 
(US6) is cloned on a Sstl-Hindlll (-392-+11) fragment fused 
to the CAT gene in the vector pBLW2 (Gaffney et al., 1985). 
pGEM-2 (Promega Biotech, Madison, Wis., USA) A dual T7/SP6 
RNA polymerase expression vector.
pGEMTIF (Ace et al., 19 88) The HSV-1 gene encoding Vmw65 
cloned under the control of the T7 promoter in pGEM-2 (see 
Figure 13a).
pSVEB (Everett, unpublished) The SV40 promoter and enhancer 
(coordinates 5171-346) cloned into pBR322. 
pRED112 (Everett, 19 83) Plasmid encoding a 5'-truncated 
version of the gD promoter with a Xhol linker inserted at 
-109.
pGX156 Contains the HSV-1 EcoRI h fragment spanning Ug .
The structures of the plasmids pill, pl75 and pgDCAT are 
shown in Figure 10.
7. Reagents
Oligonucleotides were purchased from PL Biochemicals or 
synthesized in this Institute by Dr. John McLauchlan using a 
Biosearch 8600 DNA Synthesizer.
Most analytical grade chemicals were purchased from BDH 
Chemicals UK or Sigma Chemical Co.; TEMED and ammonium 
persulphate were obtained from BIO-RAD Laboratories; caesium 
chloride, acrylamide, sodium hydroxide and boric acid were 
obtained from Koch-Light Laboratories; nitrocellulose paper 
from Schleicher and Schuell Inc.; 0.25mm silica gel TLC 
plates were obtained from Camlab; unlabelled dNTPs were from 
PL Biochemicals; Tris was supplied by Boehringer Mannheim; 
double stranded poly dlipoly dC and poly d(N)g were
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purchased from Pharmacia; Formamide from Fluka; Actinomycin 
D was from Merck Sharp and Dohme and Cycloheximide was from 
Sigma. Reagents for in vitro transcription were from 
Promega Biotech and Pharmacia, Rabbit reticulocyte lysate 
was from Arnersham.
8. Radiochemicals
Biochemical radionuclides were obtained from NEN DuPont
at the following specific activities:
5' [alpha-32P] dNTPs, 3000 Ci/mmol (lOuCi/ul)
5' [gamma-32P] ATP, 5000 Ci/mmol (lOuCi/ul)
14 C Chloramphenicol, 45mCi/mmol 
35L- S-Methionine, around 800mCi/mmol (from Amersham pic) 
32
P Orthophosphate, 200mCi/mmol
9. Enzymes
DNase, RNase and lysozyme were supplied by Sigma; 
Proteinase K, Klenow fragment DNA Polymerase (LFP), DNA 
polymerase holoenzyme, T4 polynucleotide kinase and T4 DNA 
ligase were from Boehringer Mannheim; Bacterial Alkaline 
Phosphatase (BAP) was obtained from Worthington and purifed 
by M.Dunlop; most restriction enzymes were purchased from 
Bethesda Research Laboratories or New England Biolabs.
10. Antibodies
The anti-Vmwl75 monoclonal antibody 58S was a kind gift 
from Dr. M.Zweig (Showalter et al ., 1981). Horse-radish 
peroxidase conjugated anti-mouse Immunoglobin and 
Fluoroscein conjugated swine anti-mouse imunoglobulin were 
purchased from BIO-RAD. Antipeptide antisera, listed below, 
were produced in this institute, and kindly supplied by Dr. 
M.Frame.
14711 Anti-carboxyl terminus vmwllO
11666 Anti-amino terminus Vmwl75 (Palfreyman et al., 
1984 )
18817/18818/19825/19826 Anti-carboxyl terminus Vmwl75 
18815/18816 Anti-carboxyl terminus Vmw63 
139 63 Anti-carboxyl terminus HSV-1 US9 ORF 
14996 Anti-carboxyl terminus RR2 (38kDa ribonucleotide 
reductase subunit)
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2180V Rabbit antiserum raised against undefined fusions 
of Vmwl75 (possibly including amino terminal 
regions) and E.coli beta-galactosidase (kindly 
supplied by Dr. A.Buchan of Birmingham 
University).
11. Solutions
ABTS Buffer: lOOmM Na2HP04 , 80mM Citric acid, pH 4.0
5X BALI buffer: 50mM Tris.HCl (pH7.6), 25mM MgCl2 ,
0.5mM(NH4 )2SO4 , 5mM 2-mercaptoethanol, 
500ug/ul BSA, 25mM KC1,
2X BBS: 50mM BES, 280mM NaCl, 1.5mM Na_HPO„,
2 4 '
(pH6.95)
Bradford's Reagent: 0.01% Coomassie brilliant blue G, 
0.003% SDS, 4.75% (v/v) ethanol, 8.5% 
(v/v) phosphoric acid
CLB (Cell lysis buffer): 0.5% SDS, 20mM TrisHCl (pH7.5), 
2mM EDTA
50X Denhardt's: 1% Polyvinylpyrrolidone, 1% BSA, 1%
Ficol
20X dNTPs: ImM dATP, dCTP, dGTP, and dTTP.
ELISA coating mix: 1% ovalbumin, 1% BSA, 0.1% Tween20 in 
PBS. (With or without 0.05% Sodium 
Azide).
5X Gel Loading buffer: IX TBE, 1% SDS, 50% glycerol, 
plus bromophenol blue.
Gel soak I: 200mM NaOH, 600mM NaCl,
Gel soak II: 1M Tris.HCl (pH7.5), 600mM NaCl
Gel elution buffer: 0.5M Ammonium Acetate, 20mM Tris.HCl
(pH7.5), 2mM EDTA
Giemsa stain: 1.5% suspension of Giemsa in glycerol,
heated at 56°C for 2h and diluted with an 
equal volume of methanol.
200X HAT: 0.2mg/ml Aminopterin, lmg/ml Thymidine,
3mg/ml Hypoxanthine, 3mg/ml Glycine, pH 
to -10 to dissolve.
2X HBS: 280mM NaCl, 50mM Hepes, 1.5mM Na2HP04 , pH
to 7.12.
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Hybridization mix: 6X SSC, 5X Denhardt's, 0.1% SDS, 
50ug/ml denatured calf thymus DNA 
HZ Stop: 0.3M NaAcetate (pH5.5), O.lmM EDTA,
25ug/ml tRNA
5X Kinase buffer: 350mM Tris.HCl (pH7.5), 50mM MgCl2 , 
25mM DTT
5X Ligase buffer: 250mM Tris.HCl (pH7.5), 50mM MgCl2 , 
lOOmM DTT, 50ug/ml BSA 
5X Nae buffer: lOOmMNaCl, 50mM Tris.HCl pH8, 50mM MgCl2 ,
25mM 2-mercaptoethanol, 500ug/ml BSA 
NE buffer A: lOmM HEPES (pH7.9), 1.5mM MgCl2 , lOmM
KC1, 0.5mM DTT, 0.5% NonidetP40 
NE buffer C: 20mM HEPES (pH7.9), 25% glycerol, 0.42M
NaCl, 1.5mM MgCl2 , 0.5mM PMSF, 0.5mM DTT 
10X NT buffer: 0.5M Tris.HCl (pH7.5), lOOmM MgCl2 , lOOmM 
DTT, 500ug/ml BSA 
NT Stop: TE plus 1% SDS
PBS-A: 170mM NaCl, 3.4mM KC1, lOmM Na2HP04 , 2mM
KH2P04 (pH7.2)
PBSc: PBS-A plus CaCl2H20 and MgCl26H20 at
lg/i.
5X Primer extension mix: see Section 2B22.4
5X Pst buffer: 30mM Tris.HCl(pH7.8), 30mM MgCl2 , 250mM
NaCl, 30mM 2-Mercaptoethanol
TMBRL REact Buffers (IX concentration):
REact 1: 50mM Tris.HCl (pH8), lOmM MgCl2
REact 2: 50mM Tris.HCl (pH8), lOmM MgCl2 , 50mM
NaCl
REact 3: 50mM Tris.HCl (pH8), lOmM MgCl2 , lOOmM
NaCl
REact 4: 20mM Tris.HCl (pH8), 5mM MgCl2 , 50mM KCl
REact 10: lOOmM Tris.HCl(pH8), lOmM MgCl2 , 150mM
NaCl
RGB (SDS-PAGE resolving gel buffer): 181.5g Tris, 4g 
SDS, 11 H20 pH to 8.9 at RT with (HCl)
SDS boiling mix: 1ml SGB, 0.8ml 25% SDS, 0.5ml
2-mercaptoethanol, bromophenol blue.
SDS tank buffer: 6.32g Tris, 4g glycine, lg SDS, 11 H20 
SGB (SDS-PAGE stacking gel buffer):
59g Tris/ 4g SDS/ 11 H20 pH to 6.7 at RT
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20X SSC: 174g/l NaCl,88.2g/l TriSodium Citrate.
5X Smal buffer: 30mM Tris.HCl (pH8), 30mM MgCl2 , lOOmM
KCl, 30mM 2-mercaptoethanol, 500ug/ml BSA
STET: 8% Sucrose, 5% Triton X-100, 50mM EDTA
(pH8),60mM Tris.HCl (pH8).
Sucrose gradient solution: 200mM NaCl, 25mM Tris.HCl
(pH7.5), 5mM EDTA, 0.15 Sarkosyl, 5ug/ml 
Ethidium Bromide, plus 5% or 20% Sucrose.
TBE: 125mM Tris, 40mM boric acid, 2.7mM EDTA,
not pH'd.
TBS: 25mm Tris.HCl (pH7.5), 137mM NaCl, 5mM
KCl, 0.7mM CaCl2 , 0.5mM MgCl2, 0.6mM 
Na2HP04 , pH to 7.4 with HCl.
TE: lOmM Tris.HCl, ImM EDTA, pH 8.0
TEN: 150 mM NaCl, 40mM Tris.HCl, ImM EDTA, pH
7.5
TEP: ImM Tris.HCl (pH7.5), 0.05mM EDTA.
T4 Pol Buffer: 33mM Tris Acetate (pH7.9), 66mM Na
Acetate, lOmM MgAcetate, lOOmg/ml BSA,
0.5mM DTT.
Trypsin: 0.25% w/v Trypsin dissolved in
Tris-Saline
Versene: 0.6mM EDTA in PBS-A plus 0.002% w/v
phenol red
Zweig's extraction buffer: lOOmM TrisHCl (pH8), 10% 
glycerol, 0.5% NonidetP40, 0.2mM PMSF
SECTION 2B: METHODS
1. Tissue Culture
BHK cells were routinely passaged in 850cm roller 
bottles seeded with approximately 5xl0^cells at 37°C in 
100ml EC10 and an atmosphere of 5% C02 in air. Confluent 
monolayers were harvested in 20ml EC10 after two Versene 
washes and brief trypsinization with Trypsin:versene (1:4). 
Cells were resuspended by pipetting and remained viable for 
at least five days stored at 4°C.
Vero, HeLa and M64A cells were routinely passaged in 
175cm^ (Nunclon) flasks in appropriate medium and harvested
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in 10ml. Cells did not remain viable at 4°C and for long 
term storage harvested cells were pelleted and resuspended 
in medium plus 5% glycerol and 15% foetal calf serum, 
aliquoted and frozen slowly to -140°C. Recovery was by 
rapid thawing and resuspension in growth medium.
2. Preparation of Stocks of Infectious Virus
An 80% confluent monolayer of BHK or M64A cells was 
seeded with 10 pfu of virus per roller bottle in 40ml EC5 
or HAT medium (a moi of 0.003pfu/cell) and incubated for 2-4 
days until the cells exhibited obvious CPE. The cells were 
shaken into the medium and pelleted at 3K rpm/ 15 min/ 4°C. 
Cell associated virus (CAV) was prepared by sonicating the 
pellet in 2ml supernatant. Cell released virus (CRV) was 
pelleted from the supernatant at 12K rpm/ 2 hours/ 4°C and 
gently resuspended in 2ml supernatant and sonicated. 
Sterility checks were performed by streaking virus 
preparations on blood agar plates and incubating at 31°C for 
5 days. Virus stocks were stored at -70°C.
3. Titration of Virus Stocks
Appropriate indicator cells were seeded at 10 cells per 
35mm plate in 2.5ml medium. The following day cells were 
infected with serial 10-fold virus dilutions in 0.3ml 
medium; after lh absorption time (gently mixing every 10 
minutes) plates were overlaid with 2ml EH5, to prevent 
secondary plaque formation, and incubated for 2-3 days prior 
to fixing with Cidex and staining with Giemsa stain. The 
plates were washed after 15 minutes and plaques counted 
using a dissection microscope. Usually titrations on M64A 
cells were overlaid with 0.6% Noble agar in HAT medium 
lacking phenol red, and plaques visualized by staining 
living cells for 6h with neutral red.
4. Preparation of Cell Released Viral DNA
CRV were pelleted as described in 2 above and 
resuspended in 1ml TE plus lOOmM NaCl. SDS was then added 
to 1% v/v and viruses disrupted by gentle inversion at 37 C. 
DNA was then extracted by serial 30 minute extractions, with 
gentle inversion (2x phenol, lx phenol/chloroform, lx
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chloroform). DNA was precipitated with .05 vol 5M NaCl and
2.5 vol ethanol, washed twice, dessicated and resupended 
overnight in TE. DNA was quantitated on agarose gels 
compared to known standards and stored at -20°C.
CRV DNA was prepared on a miniature scale from 35mm 
plate harvests in a similar manner, but disrupting the virus 
particles in 20 mM Tris pH7.5, lOOmM NaCl, 2mM EDTA, 0.2% 
SDS, 0.25mg/ml proteinase K.
5. Preparation of Total Infected Cell DNA
10mm linbro wells were seeded with about 4x10^ 
permissive cells and infected the following day with half of 
a picked plaque or a moi of 0.001 pfu/cell. After 2-3 days 
when cpe became apparent, the supernatant was removed and 
stored as CRV stock. 0.2ml of Cell Lysis Buffer (CLB) 
containing 0.25mg/ml proteinase K was added to the cell 
layer and incubated at 37°C for 3-5 hours. The glutinous 
extract was transferred to 1.5ml Eppendorf tubes and 15ul 5M 
NaCl added. Serial 30 minute phenol then chloroform 
extractions were performed, with gentle inversion; followed 
by precipitation with 2.5 vols ethanol, resuspension in 0.3M 
Na Acetate pH5, a further ethanol precipitation, one wash 
with 70% ethanol, dessication and finally resuspension 
overnight at 4°C in 50ul TE.
6. Plaque Purification of Virus
Permissive cells were infected with virus dilutions as 
for virus titrations, but overlaid with 2ml molten 0.6%
Noble agar in growth medium (100ml 1.3x Eagles A, 20ml 
Eagles B without phenol red, 30ml 3.2% Noble Agar, 5ml 
appropriate serum, with or without HAT). After the agar 
set, plates were incubated for 2-3 days at 37°C. Plaques 
were visualized by dark field microscopy or by staining 
living cells with neutral red for 6 hours. Isolated plaques 
were picked using a sterile Pasteur pipette to draw up a 
plug of agar and infected cells and then ejecting this into 
200ul of medium. lOOul was used to infect a linbro well to 
make CRV and infected cell DNA.
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7. [ P]orthophosphate Labelling of Viral DNA
The technique of Lonsdale (1979) modified by Brown et
al.# (1984) was used. Cells were seeded at 5x10^ cells per
linbro well in phosphate-free Eagles medium plus 1% calf
serum (PIC). The following day wells were infected with 10
pfu/cell virus, and after absorption the cells washed twice
with PIC and overlaid with 450ul PIC and incubated at 31°c
for 2h prior to addition of 50ul of PIC containing 2MBq of 
3 2
[ P]orthophosphate. After incubation at 31°C for 2 days 
cells were harvested by adding 0.5ml 5% SDS to each well for 
5 mins at 37°C. Disrupted cells were then scraped into 10ml 
tubes and phenol extracted gently for 10 minutes before 
ethanol precipitating the DNA, washing, drying and 
resuspending in 200ul 1^0; 20-30ul aliquots were digested to 
analyse on agarose gels. After running gels as described 
below (Section 19.1) Gels were dried down at 80°C and 
autoradiographed.
8. Analysis of Virus Induced Polypeptides
8.1 Immediate-early polypeptides
o 5IE extracts were generally made at 38.5 C. 2x10 BHK
cells on 50mm Petri dishes were pretreated with lOOug/ml
cycloheximide in growth medium (EC10/CHX) for 15-30min prior
to infection at a moi of 5-20 pfu/cell, also in EC10/CHX.
After a lh absorption the cells were washed and overlaid
again with EC10/CHX. At 5h p.a. cells were washed 4x with
prewarmed PBSc, with the final wash containing 2.5ug/ml
3 5Actinomycin D. 50uCi of [ S]methionine was then added for 
a one hour incorporation period before a final wash with
PBSc prior to harvesting at 4°C for lh in 400ul Zweig's
extraction buffer. The lysate was sonicated and debris spun 
out with a 5min microfuge spin. Extracts were stored at 
-70°C.
8.2 Long labelling of polypeptides
Sub—confluent BHK cells (10 cells on a 50mm Petri dish) 
in methionine-free EC10 were infected at a moi of 10 and 
after a lh absorption the cells washed and then overlaid 
with methionine—free EC10 plus 50uCi [^^S]methionine. The
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cells were harvested after an overnight incubation and 
protein extracts made as described in section 8.2 above.
8.3 Pulse labelling of polypeptides
Sub-confluent BHK cells (106 cells on a 50mm Petri dish)
were infected at a moi of 10 and overlaid with EC10 after a
lh absorption. At the appropriate time p.a. the cells are 1
washed with PBSc and labelled for 30min with PBS containinq 
35
50-100uCi [ S]methionine. Cells are then washed and 
harvested as above.
8.4 SDS polyacrylamide gel electrophoresis
35
[ S]methionine labelled poypeptides were resolved on 
7.5% or 10% single concentration gels crosslinked with 1 
part in 12 (w/w) N - N 1-methylenebisacrylamide in resolving 
gel buffer. Gel plates were carefully washed with Decon, 
ImM HC1 and ethanol. The resolving gels were made up as 
follows:
7.5% gel 10% gel
narrow wide narrow wide
30% (a+b) stock 9ral 13.5ml 12ml 18ml
RGB 9ml 13.5ml 9 ml 13.5ml
distilled water 18ml 27ml 15ml 22.5ml
10% APS 200ul 200ul 300ul 300ul
TEMED 20ul 20ul 30ul 30ul
The resolving gel was overlaid with butan-2-ol and allowed 
to set. After washing, the stacking gel (5% a+b, 0.25xSGB) 
was prepared and overlaid, wells were created with a teflon 
comb.
Protein samples were boiled for 2min in 1 or 2 volumes 
of SDS boiling mix prior to loading. Gels were run at 
0.45mA/cm2 for 4h or 0.09mA/cm2 for 18h in freshly prepared 
SDS tank buffer. Gels were fixed for lh in methanol:acetic 
acid:water (50:7:50) before drying down under vacuum at 80°C 
onto a sheet of Whatman 3mm paper and exposing to Kodak 
X-Omat S XS-1 film for 3-24h.
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9. Transfection of Cells with DNA
9.1 Transfection of HeLa and Vero cells for CAT assays 
Freshly split cells were seeded at 10^ cells per 50mm
Petri dish and the following day the rapidly dividing, 
subconfluent monolayers were transfected by the calcium 
phosphate precipitation method (Corsalo and Pearson, 1981). 
Transfections used 4 ug of the CAT and pill plasmids, 8ug of 
the pl75 derivatives in the transactivation studies and 
variable amounts to titrate repression; pUC9 was used to 
equalize the amount of DNA within experiments. TEP buffer 
was added to the plasmid DNA to final volume of 140ul, then 
20ul of 2M C a C ^  added dropwise to the solution whilst 
vortexing. In turn this was added dropwise to 160ul of 2xHBS 
(or sometimes 2x BBS). After standing for 30min the 
precipitate was sprinkled onto the cell monolayers which 
were then incubated at 38.5°C. The cells were washed after 
24 h and fresh medium replaced, after a further 24 h 
incubation at 37°C extracts were prepared by washing the 
cells in PBS-A then scraping into 3ml TEN. The cells were 
pelleted at 2K rpm/ 4°C/ lmin, then resuspended in 75ul 
0.25M Tris pH 7.8 and sonicated. The sonicates were cleared 
by a 2min microfuge spin and stored at -20°C.
9.2 Transfection of HeLa cells for Protein Extracts 
Transfections were carried out in exactly the same
manner as described above (9.1) but the volumes increased 3 
fold for 90mm plates or 7 fold for 135mm plates. 30 or 60ug 
of pl75 derived plasmids were used, with 15 or 30ug pUC9 as 
carrier.
9.3 Transfection of Cells with Viral DNA for Marker Rescue 
BHK or M64A cells were tranfected on 35mm plates seeded
at subconfluence. 0.5ug of intact viral DNA plus a 10 fold 
molar excess of linearized plasmid and 2-5ug calf thymus 
carrier DNA were precipitated as described above (9.1).
After standing for 30min the medium was removed from the 
cells and the precipitate added, the cells were then 
incubated at 38.5°C for 4h, being overlaid with 2ml medium 
after 40min. The cells were then washed once with growth
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medium and overlaid with 25% DMSO in HBS for 4min (for M64A 
cells 20% glycerol was used). The cells were then washed a 
final time and overlaid with growth medium. After 2-4 days 
incubation at 31 or 37°C and the monolayers exhibited 
extensive cpe, or plaques, the cells were scraped into the 
medium and sonicated to release infectious virus.
10. CAT Assays
Cell sonicates produced as described above (9.1) were
assayed for chloramphenicol acetyl transferase (CAT)
activity essentially as described by Gorman et al. (1982).
Assay mixtures contained lul 50mM acetyl-CoA, 0.5ul stock 
14
[ C]CAP (45uCi/mm) and 14ul together with 25ul neat or
diluted sonicate. After incubation for 30 or 60min at 37°C 
the products were extracted with 200ul ethyl acetate, dried 
down and resuspended in 20ul ethyl acetate to spot onto thin 
layer chromatography (TLC) plates. TLCs were run in 95% 
chloroform/ 5% methanol, air dried and autoradiographed at 
room temp. The percentage conversion to product was 
determined by cutting out non-acetylated substrate and 
3'-monoace tylated product from the TLC and counting 
scintillation in 2ml ecoscint. The protein concentration of 
the extract was determined by the method of Bradford (19 76) 
(see section 11 below) in order to calculate the percentage 
conversion from substrate to product per ug protein. In the 
transactivation experiments the activity of the mutants was 
expressed as a percentage of the wild-type control; the 
results of the repression titrations were plotted and 
activity qualitatively compared to a wild-type control (as 
described in the Results Section 3C2).
11. Determination of Protein Concentration in Cell Extracts 
The protein concentration of CAT extracts and nuclear
protein extracts was determined by the method of Bradford 
(19 76). 5-10ul of extract was made up to lOOul in 0.05M
Tris.HCl pH7.8 and 1ml of Bradford's Reagent added and 
mixed. After a 15min incubation the OD at 59 5nm was 
measured in disposable plastic cuvettes by
spectrophotometry. The protein concentration per ul extract 
was determined by constructing a standard curve using
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standard concentrations of BSA (5-80ug) assayed as above, 
and OD plotted against concentration mg/ml.
12. Immunofluorescent Staining of Vmwl75 in Transfected 
Cells
HeLa cells were seeded into 50mm Petri dishes and 
transfected with lOug of pl75 and its derivatives as 
described above (9.1), washing and re-feeding after 24 h. 
After a further 24 h the cells were fixed and stained 
(essentially as described by Everett, 1987b). The cells 
were washed twice with 1%CS in PBSA then fixed for 10 
minutes in 2% formaldehyde, 2% sucrose in PBSA. After 3 
further washes with PBSA/1%CS the cells were permeabilized 
with 0.5% NP40, 10% sucrose, 1% CS in PBSA for 5min. After 
3 further PBSA/1%CS washes the cells were stained with a 
1/50 dilution in PBS of the anti-Vmwl75 monoclonal antibody 
58S (kindly supplied by M.Zweig; Showalter et al., 1981). 
After a further 3 PBSA/1%CS washes the cells were stained 
with fluorescein-conjugated swine anti-mouse immunoglobulin 
(1/30 dilution) before examining by u.v. fluorescent 
microscopy.
13. Preparation of Nuclear and Cytoplasmic Extracts for DNA 
Binding Studies
Nuclear extracts from cells infected or transfected as 
in section 9.2 above were prepared by a procedure modified 
from that of Dignam et al.,(1983). Cells scraped from 135 
or 9 0mm culture dishes were washed in phosphate buffered 
saline (PBSc) and resuspended in 2 volumes NE buffer A 
without NP40. 0.5% NP40 was then added and the cells lysed
on ice for 10 min. Nuclei were then pelleted by successive 
2K/10min and 12K/20min spins. Proteins were eluted from the 
nuclei by incubating for 30 minutes on ice in 2 volumes 
buffer C before clearing with a 30 minute 15K spin. The 
supernatants were flash frozen and stored at -140 C and 
retained their activity for at least 12 months.
In order to recover proteins from the cytoplasm some 
extracts were produced by lysing cells directly with buffer 
C plus 0.5% NP40. Nuclear binding activity was also 
recovered using this procedure and this much more rapid
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protocol was used for many extracts where it was unimportant 
to distinguish between nuclear and cytoplasmic fractions.
14. Determination of the Relative Quantities of vmw!75 in 
Nuclear Extracts
5ul samples of each nuclear extract were assayed by the 
ELISA technique. Microtitre wells were coated overnight 
with extract plus lOOul ELISA coating mix with 0.05% sodium 
azide. A 1/5000 dilution in coating mix of the monoclonal 
antibody 58S was adsorbed to the coated wells for lh shaking 
at 37°C and a 1/3000 dilution in coating mix of BIO-RAD 
horseradish peroxidase labelled goat anti-mouse IgG was 
bound to this at 20°C for lh. Extensive washes with 
PBS/0.1% Tween 20 were carried out between all steps. The 
absorbance at 405 or 410nm was measured 10 minutes after 
addition of colourimetric substrate for peroxidase (ABTS) by 
spectrophotometry or on a plate counter.
15. Gel Retardation Assay
The binding of Vmwl75 to the IE gene 3 cap site was 
assayed as described by Muller(1987). The 45bp Ava I/BamHI 
fragment spanning the IE3 cap site (-17 to +27) was end 
labeled by filling in using T4 DNA polymerase and purified 
on an 8% polyacrylamide gel and a Sephadex G-50 column. 
Binding reactions were generally carried out at 20°C for 20 
minutes in a 20-30ul mix containing lug poly(dl).poly(dC), 
about O.lng probe (2000cpm) and l-4ul nuclear extract 
(4-20ug protein) in lOmM TrisHCl pH7.6, ImM EDTA, 0.1% NP40. 
Samples were resolved on 4% polyacrylamide gels (3.3% cross 
linker) run in 0.5x TBE, and dried down before 
autoradiography.
Antibody shifts were carried out by incubating the 
binding reaction for an additional 10-15 minutes after 
adding a 1/100 or 1/200 dilution of monoclonal 58S.
16. Large Scale Plasmid DNA Preparation
Isolated single colonies on plates selective for a 
plasmid-borne resistance marker were inoculated into 5ml 
L-broth and grown overnight. These were added to 3 50 or 
700ml L-broth in 21 flasks and grown shaking at 37°C until
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the cells reached an of approximately 0.8. Then
chloramphenicol was added to a final concentration of 
lOOug/ml and the cultures left shaking overnight to amplify 
the plasmids.
Plasmid DNA was prepared by the "maxi— boiling" technique 
of Holmes and Quigley, 19 81. Cells were pelleted at lOkrpm/ 
6min (Sorvall GS3 rotor) and resuspended in 17ml STET per 
350ml culture. 2ml lOmg/ml lysozyme in STET was added for a 
1 minute incubation prior to bringing the suspension to the 
boil for 45sec. The lysate was cleared with a 45min/ 
20krpm/ 4°C spin (Sorvall SS34 rotor) and DNA precipitated 
from the supernatant by addition of 0.9vol isopropanol.
After pelleting at 3krpm/ 4min/ RT (MSE coolspin) the 
drained pellets were resuspended in TE, and CsCl added to 
give a final density of 1.6g/ml and EtBr to 0.5mg/ml. The 
solution was cleared by spinning at 3krpm/ lOmin/ 4°C after 
a 15min incubation on ice. The DNA was banded by spinning 
at 40krpm/ 15°C in the angled Ti50 or Type65 rotors (48+h) 
or the vertical TV865 rotor (16+h). The DNA was visualized 
by daylight or long-wave uv illumination and the lower, 
supercoiled plasmid DNA band recovered with a large bore 
needle and syringe, after removal of the upper, linearized 
chromosomal DNA band. The DNA was extracted twice with 
butan-l-ol (TE saturated), dialyzed against TE at RT for 3h, 
treated with 50ug/ml RNAase (lh/65°C), then 50ug/ml 
proteinase K plus 0.1% SDS (lh/37°C) before extraction with 
phenol/chloroform then chloroform and precipitation twice 
with ethanol. The DNA was lyophilized, resuspended in TE 
and its concentration determined by spectrophotometry (OD26o 
1.0 = 50ug DNA/ml).
17. Miniprep Plasmid DNA Preparation
Single plasmid-transformed bacterial colonies were grown 
overnight in 5ml L-broth. 1.5ml stationary phase culture 
was pelleted 12krpm/ 15sec (benchtop minicentrifuge) and 
cells resuspended in 200ul STET. The cell suspension was 
immediately placed in a 100°C water bath for 45sec after 
addition of 5ul lysozyme (lOmg/ml), then centr/fuged at 
12krpm for lOmin. The pellet was removed and DNA 
precipitated and pelleted from the supernatant by addition
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of 0.9vol isopropanol and spinning at 12krpm for 5min. The 
pellets were washed with 70% ethanol, dried and resuspended 
in 20ul TE. Miniprep DNA was stored at -20 or 4°C and 2-5ul 
was used for restriction enzyme analysis. (0.2ul lmg/ml 
RNAase was added to digestions of miniprep DNA).
18. Restriction Enzyme Digests
Restriction enzyme (RE) digests were generally carried
out in 20ul volumes of the appropriate RE buffer, using
0.5ug DNA and 1 unit of enzyme for lh. Originally most
digests were carried out in lx Pst buffer, with the
exception of REs requiring radically different conditions
TM(see below). Laterly the BRL REact system has been used, 
with commercially supplied lOx REact buffers. The buffer 
conditions used for each enzyme are given below.
REact 1: Alui, Narl, Rsal
REact 2: Aval , Avail, Bgll, Bglll, BstEII, Hindlll,
PstI , SstI, Sstll, TagI, Xbal, Xhol, PvuII
REact 3: BamHI, Bglll, EcoRI,
REact 4: HincII, Smal
REact 10: Sail
Nael and Ball were always digested in their own buffers;
Smal and BstNI were generally digested in Sma buffer; 
enzymes not listed under REact 2 or 3 above generally were 
digested under the makers specific conditions prior to 
introduction of the REact system. Digestions with TagI and 
BstNI were carried out at 65 and 60°C, all others were at 
37°C.
Preparative rather than diagnostic RE digestions used 
increased amounts of DNA and RE under similar conditions, in 
20-50ul volumes.
19. Separation and Preparation of Purified DNA Restriction 
Fragments
19.1 Non-denaturing agarose gels
Slab gels of 0.4-1.5% agarose in lx TBE (or lx L buffer 
for Southern transfers) were run submerged at up to 12V/cm. 
Samples were loaded in 0.2 vol loading buffer. Gels were
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run for l-3h, until the dye almost ran off the end, and then 
stained for lOmin in lug/ml EtBr and examined and 
photographed with short-wave uv transillumination (long-wave 
uv was used to reduce DNA damage when preparative gels were 
being analysed).
To purify a resolved DNA fragment from a gel the DNA was 
run onto a strip of DE-81 paper inserted in front of the 
desired band, (DE-81 paper was presoaked in 2.5M NaCl 
overnight, then stored in ImM EDTA at 4°C). After 
electrophoresing the fragment onto the paper it was eluted 
by pulverization and agitation in 1.5M NaCl/ lx TE 
(2h/37°C), strained through siliconized glass wool, 
clarified and then ethanol precipitated.
19.2 Non-denaturing polyacrylamide gels
In order to resolve accurately DNA fragments 40-400bp in
length 4-8% polyacrylamide (acrylamide:bis-acrylamide, 19:1)
gels were run in lx TBE. Gels were prepared in 1.5mm thick
vertical glass-plate sandwiches, and cross-linked with
O.OOlvol TEMED, catalysed with O.Olvol 10% APS. Samples
were loaded as above and electrophoresed at a maximum
voltage of 16V/cm, and DNA visualized by autoradiography or
32EtBr staining. P-labelled DNA fragments were cut out of 
gels after detection by autoradiography and purified in one 
of two ways. Polyacrylamide strips containing fragments for 
sequencing were extruded through a punctured 0.4ml vial into 
a 1.5ml tube (benchtop minifuge/ 5min/ 12krpm). The DNA was 
eluted into TE by shaking overnight and filtered through 
glass wool before precipitation. Probes for gel retardation 
assays were eluted into gel elution buffer (2x 3h/ 45°C 
incubations) after dicing the polyacrylamide strips. The 
supernatant was then purified on a Sephadex column (Section 
2B19.5).
19.3 Denaturing polyacrylamide gels
0.35mm thick gels prepared to final concentration of 
8-20% acrylamide (a:b, 19:1), lx TBE and 7M urea were used 
to resolve the products of DNA sequencing reactions. The 
acrylamide solution was filtered through a 0.45um filter and 
degassed under vacuum prior to cross-linking. Lyophilized
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samples were resuspended in 5ul formamide dyes mix, 
denatured at 90°C for 2min and run at 40W for 2-5h on gels 
which had been prerun for 30min at 40W. Gels were 
autoradiographed at -70°C with screens.
19.4 Sucrose gradients
Depending on the separation required 5-20% sucrose 
gradients were prepared in either 5 or 14ml polyallomer 
tubes using a peristaltic pump connected to a mixing 
chamber. 10-50ug of DNA was carefully overlaid onto the 
gradient in lOOul TE and the gradients centrifuged under 
appropriate conditions. (5ml tubes were spun in the AH650 
rotor for 3-20h/ 30-40krpm/ 15°C, linear pl75 was separated 
from circular DNA in the TST41 rotor at 28krpm/ 16h/ 15°C.) 
DNA bands were visualized with long wave uv light and 
removed by side puncture. DNA was purified by 
phenol/chloroform extraction and ethanol precipitation.
19.5 Sephadex columns (gel exclusion chromatography)
Sephadex beads were pre-swollen by autoclaving in TE or
^ O .  Columns were prepared in plastic 5ml pipettes with 
siliconized glass wool plugs and prerun with 20ml running 
buffer (TE plus 0.1% SDS was used for all columns except for 
gel retardation probes which were run with f^O). Sephadex 
G-50 was used except for DNA fragments smaller than 20bp 
when Sephadex G-15 was used. Columns were loaded with 
100-800ul sample (with or without bromophenol blue dye) and 
the fastest eluting fractions (detected by scintillation 
counting) taken as purified DNA.
20„ DNA Ligation
DNA ligations were performed in 20ul lx ligase buffer, 
with 0. 5mM ATP, 50-500ng DNA and l-2u T4 DNA ligase. DNA 
was frequently phenol and chloroform extracted, ethanol 
precipitated (with lug carrier tRNA) and resuspended prior 
to tranformation of competent bacteria.
21. Preparation and Transformation of Competent E.coli 
A colony purified overnight culture of bacteria was 
diluted into fresh L— broth plus lOmM M g C ^ /  lOmM MgSO^ and
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aerated vigourously until reaching an OD54Q of 0.3. Using 
sterile, ice cold, procedures throughout, cells were 
pelleted (3krpm/ lOmin) resuspended in l/4vol 0.1M MgCl2 and 
immediately pelleted again (3krpm/ lOmin). After 
resuspension in 1/20vol 0.1M CaCl2 the cells were left for 
45min on ice before again pelleting (3krpm/ lOmin). The 
cells were resuspended in the same volume of 0.1M MOPS/ 50mM 
CaCl2/ 20% glycerol and left 20min before aliquoting into
50-200ul and snap freezing and storing at -70°C.
22. Radioactive Labelling of DNA
22.1 5'-end labelling
To label DNA fragments at the 5'-end the 5'-phosphate 
was first removed by treatment with bacterial alkaline 
phosphatase (BAP) for lh at 65°C in TE. The enzyme was 
rigourously removed with three phenol then chloroform 
extractions and^precipitated to concentrate. The DNA was 
lyophilized and ^ ^ ^ a ^ o n  was carried out in lOul of lx 
kinase buffer including 4 units T4 polynucleotide kinase and 
10-100uCi 5 '-[gamma32PjdATP (45min/ 37°C). The labelled DNA 
was purified from unincorporated label by precipitation with 
lug carrier tRNA, running on Sephadex G-50 columns or by gel 
electrophoresis.
(Oligonucleotides were phosphorylated in a similar 
fashion but using 0.5mM cold ATP in the kination reaction. 
The reaction was stopped at 70°C. )
22.2 3'-end labelling
3'-ends of DNA fragments were labelled by filling in
5 1-overhangs with either LFP or T4 DNA polymerase. Digests 
of l-2ug of DNA were filled in after stopping the 
restriction enzyme at 65°C. LFP reactions were carried out 
in lx Pst, REact 1 or REact 2 buffers, and used lu enzyme 
incubated at RT for 20min with appropriate hot
(5'-[alpha32P] )and cold dNTPs followed by a 20min chase with 
all four cold dNTPs. T4 DNA polymerase reactions differed 
in that it was incubated in its own buffer at 37 C for lh. 
Both enzymes were inactivated at 65 C prior to second enzyme 
digestions or DNA purification.
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22.3 Internal labelling by nick translation
lOOng of plasmid DNA was radiolabelled (Rigby et al.,
19 77) by the addition of 5uCi each of all four 5*
^alpha— P]dNTPs, 1 unit E . coli DNA polymerase holoenzyme 
and 5x10 ug/ml DNAasel in a final volume of 20ul lx REact 1 
buffer or lx NT buffer. After lh incubation at RT the 
reaction was stopped by addition of lOOul NT stop and 
labelled DNA purified on a Sephadex G-50 column (19.5).
22.4 Internal labelling by primer extension
10-100ng plasmid DNA was boiled for lOmin in 20ul H20 
then incubated overnight in a 50ul reaction mix containing, 
4ul (5mg/ml B S A ), 50uCi 5' [alpha-32P]dGTP or dCTP, 2uM dCTP 
or dGTP, and 2 units Klenow large fragment of E.coli DNA 
polymerase in lx primer extension buffer (see below;
Feinberg and Vogelstein, 1983). The labelled DNA was 
separated from unincorporated triphosphate as described 
above (19.5 ).
5x Primer extension buffer was prepared from the 
following:
1.2x Solution O: 1.5M Tris.HCl pH8, 150mM MgCl2
Solution A: 833ul 1.2x Solution 0, 18 ul 2-Mercaptoethanol,
50ul lOmM dATP, 50ul lOmM dTTP, 82ul H20
Solution B: 2M Hepes.NaOH pH6.6
Solution C: 50 units d(N), in 556ul TE6
5x Primer extension buffer = 200A:500B:300C
23 o Chemical Sequencing of DNA
The nucleotide sequence of 5' or 3'-end labelled DNA 
fragments was determined by the chemical methodology of 
Maxam and Gilbert (1977,1980). Uniquely end labelled DNA 
restriction fragments were prepared by filling in or
piiosjohce'yiating a cut RE site then cutting with a second enzyme to
produce fragments 50—500bp in length labelled solely on one 
strand (sections 22.1 and 22.2 above). These were then 
purified as described above (19.2) and 20-50,OOOcpm aliquots 
reacted to modify either purines or cytosine bases. For the 
purine reaction the DNA was resuspended in 2% Diphenylamine/
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ImM EDTA/ 66% formic acid for 2min at 25°C. The DNA was 
then ether extracted and lyophilized. C residues were 
modified by treatment with hydrazine in the presence of 1.5M 
NaCl (2min/ 2 5°C), stopped with 0.3M NaCl and 0.1M EDTA and 
ethanol precipitated. The partially modified DNA was then 
resuspended in fresh 1M piperidine at 90°C for 30min to 
cleave the DNA at modified bases. The products were 
precipitated or lyophilized three times and resolved on 
8-20% denaturing polyacrylamide gels (19.3).
24. Southern Transfer of DNA to Nitrocellulose 
Restricted DNAs for Southern transfer (Southern, 1975)
were run on agarose gels in L-buffer. Following 
electrophoresis the gel was shaken first in Gel Soak I for 
lh then in Gel Soak II for lh. The DNA was blotted 
overnight onto presoaked Nitrocellulose paper using lOx SSC, 
a wick of Whatman 3mm paper and a weighted capillary stack 
of absorbent paper towelling. The filter was then air dried 
and baked at 80°C for 2h in a vacuum oven prior to 
hybridization.
25. Immobilization of DNA on Nitrocellulose by Slot-Blot
A Schleicher and Schuell slot-blot apparatus was used to 
immobilze equivalent quantities of viral infected total cell 
DNA onto nitrocellulose. DNA was extracted as described 
above (Section 3B5) and usually digested with RNAase, to 
remove RNA, and with restriction enzymes to assist accurate 
pipetting. DNA was denatured with lvol 1M NaOH (lOmin/ R T ) 
then neutralized with 2vol 2M ammonium acetate. The samples 
were then applied to the presoaked nitrocellulose membrane 
under vacuum using the slot-blot apparatus, and washed 
through with 1M ammonium acetate. The filter was then air 
dried and baked at 80°C for 2h in a vacuum oven prior to 
hybridization.
26. DNA-DNA Hybridization
Nitrocellulose filters were prehybridized in fresh
o 7 8
hybridization mix for 2-4h at 65 or 70 C. 10 -10 cpm of 
probe DNA was denatured by addition of 0.04vol 5M NaOH for 
lOmin then neutralized with 5M HCl before adding to the
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filter bag and hybridizing overnight under the same 
conditions as for prehybridization. The filter was then 
washed twice at RT in 2x SSC for lOmin and twice at the 
hybridization temperature in 2x SSC plus 0.1% SDS for lh 
each before autoradiography at —70^C with screens.
27. Colony Hybridization
Transformant E .coli were replica plated onto a master 
culture dish and a nitrocellulose filter overlain on a plate 
of selective medium, and grown overnight. The filter was 
removed from the dish and treated successively with the 
following solutions by laying colony side down onto each 
solution on a clean glass plate:
lml each of 0.5M NaOH (lOmin)
1.0M Tris.HCl pH8 (twice for lmin)
1.5M NaCl/ 0.5M Tris.HClpH8 (5min) 
chloroform (lmin)
The filters were then dried, soaked in 2xSSC, partially 
dried then baked for 2h at 80°C under vacuum. The filters 
were then hybridized as described in Section 2B26 above.
28. In vitro transcription and translation
The pGEM-2 derived plasmids were linearized by 
restriction enzyme digest before the transcription reaction, 
and phenol extracted. In vitro transcription was performed 
using the Riboprobe system (Promega Biotech) following the 
manufacturer's protocol and incubating lug of plasmid DNA,
0.5mM-G(5')ppp(5')G (Pharmacia) and 0.4mM of each nucleoside 
triphosphate in a total volume of 25ul at 37°C for lh.
In vitro translation was carried out by addition of 
2.5ul of transcription reaction mixture to 20ul of rabbit 
reticulocyte lysate (Amersham) and incubated for 90min at 
30°C in the presence or absence of 25-50 uCi [33S]methionine 
(>800Ci/mmol) in a 25ul reaction mixture. The radiolabelled 
translation mixture was processed for SDS-PAGE as described 
above (Section 2B8) after treatment with 15ul RNAase 
(200ug/ml) at 30°C for 15min. Non-radioactive samples were 
used immediately in gel retardation assays (Section 2B15).
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29. Computing
Computer analyses of DNA and protein sequences were 
performed on the PDP 11/14 or MicroVAX II computers in this 
department. The majority of computing used the University 
of Wisconsin Genetics Computer Group software package.
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CHAPTER 3: RESULTS
SECTION 3A: CONSTRUCTION OF INSERTION AND DELETION MUTANTS 
WITHIN A PLASMID-BORNE COPY OF THE GENE ENCODING Vmwl75.
The aim of the work presented in this thesis was to 
define the regions of the protein Vmwl75 which are important 
for its various functions and hence to relate the structure 
of the protein to its biochemical activities. To this end, 
a large number of in-frame insertion and deletion mutations 
were introduced into a plasmid-borne copy of the gene 
encoding Vmwl75, and the functional activity of the mutant 
polypeptides expressed from these plasmids was determined in 
transiently transfected cells. Thus the regions of the 
protein sensitive to disruption of function were mapped and 
related to the primary amino acid sequence of the protein.
1. The plasmid p!75
Vmwl75 is encoded by IE gene 3 of HSV-1, which is 
present in two copies on the HSV-1 genome, being carried on 
the repeat sequences bounding Ug, the short unique region 
(Rixon et al. , 1982, see Figures 2, 3 and 10). The sequence 
of the gene reveals an uninterrupted reading-frame encoding a 
protein of 129 8 amino acids having a predicted unmodified 
molecular weight of 133kDa (McGeoch et al., 1986). The 
coding region of IE gene 3 starts at the ATG at position 
1477 in the sequence of the short repeat section of the 
HSV-1 genome, and continues to the TAA at 5371 (McGeoch et 
al., 1986). Plasmid pl75 (Everett, 1987b) contains the IE 
gene 3 coding region linked to the SV40 early promoter and 
enhancer (Figure 10). This construct was chosen to express 
Vmwl75 because the SV40 promoter and enhancer have been 
shown to respond poorly to HSV-1 IE gene products (O Hare 
ahd Hayward, 1984, 1985a, 1987) and therefore using this 
construct to express the mutant polypeptides should minimize 
any complications in the interpretation of the results which 
would arise from the regulation of the IE 3 promoter by 
VmwllO and Vmwl75. In this thesis the IE 3 sequence is 
usually numbered from +1 at the first base of the op 
reading frame.
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2• Construction of insertion and deletion mutations within 
the Vftiwl75 coding region
The plasmid pl75 was mutagenized by inserting a 
phosphorylated dodecamer EcoRI oligonucleotide linker 
(5 ' —CCCGAATTCGGG— 3 ' ) at sepa.rate blunt—ended restriction 
sites, essentially as described by Everett (1987b). Plasmid 
pl75 was cut with restriction enzymes (Alul, Nael, Smal,
Ball or Rsa l ) in the presence of ethidium bromide in order 
to produce a maximum of singly cut linear molecules with 
blunt ends. The precise conditions depended on the enzyme 
used, but generally 10 ug of plasmid was cut with 10 units 
of enzyme for 20 minutes at 37°C in the presence of 20-50 
ug/ml ethidium bromide in a final volume of 50 ul of the 
buffer recommended for the enzyme. The DNA was loaded onto 
a 5-20% sucrose density gradient and centrifuged for 16 h at 
28 500 r.p.m. and 15°C in the Sorvall TST41 rotor. Linear 
DNA sedimented more slowly than circular forms and was
(-’Vice
easily separated. Linear,,DNA was directly ligated to blunt 
ended 12-bp EcoRI phosphorylated linker oligonucleotides. 
Plasmids with linker inserts were identified by screening 
small-scale plasmid preparations for the presence of a 
novel, unique EcoRI site. The site of insertion was first 
mapped using restriction enzymes and their location and 
integrity confirmed by DNA sequencing (see Section 3A3 
below). The number of linkers inserted was deduced by 
restriction analysis and, in necessary cases, reduced to a 
single copy by redigestion with EcoRI , followed by 
religation.
A summary of the insertion mutants obtained showing 
their positions and the alterations to the amino acid 
sequence is given in Figure 11 and Table 4. Thirty-nine 
inserts were created which span the entire 3.9kb coding 
region, but, because of the paucity of useful restriction 
sites in this highly G+C rich gene, the distribution of 
inserts recovered was uneven.
As a by-product of the insertion mutagenesis several 
deletions were also recovered and further specified 
deletions could be created by joining together the coding 
regions 5' and 3' to the EcoRI sites of two separate 
insertion mutants. Where appropriate these deletions were
Table 4: Construction of insertion mutants. Plasmid 
insertion mutants constructed by insertional mutagenesis of 
pl75 (Section 3 A 2 ) are listed in column 1, and the published 
insertion mutant name recorded in column 3 (Paterson and 
Everett, 1988b). Column 2 records the coordinate of the 
first base in the recognition sequence of the restriction 
site (column 4) at which the 12 bp EcoRI linker has been 
inserted, numbering from the first base of the IE3 ORF. 
Disruption of a codon replaces it with five new codons, 
insertion between codons adds four new codons. Using the 
single letter code, the amino acid inserted into is listed 
followed by the five new residues added, or, the two amino 
acids inserted between are listed followed by the four new 
residues inserted (column 5). All the plasmid insertion 
sites have been sequenced, except FN125, which was created 
by filling in the EcoRI site of deletion plasmid N125 (Table 
5).
Table 4: Construction of insertion mutants
1 2 3 4 5
Construct Site Name Insert
site
Insertion AA and 
inserted AA seque
S38R7 0033 PI1 SMA I 12P-PRIRG
N15 0211 pI2 NAE I 71A/72G-PEFG
A46-4R2 0248 pI3 ALU I 83Q/84L-PEFG
R30 0366 pI4 RSA I 123Y-SRIRD
N113 0388 pI5 NAE I 130A/131G-PEFG
S2 0407 pI6 SMA I 137R-PRIRG
N72 0480 PI7 NAE I 161P-PPNSG
N102 0480 PI7 NAE I 161P-PPNSG
N26 0684 pI8 NAE I 229 P-PPNSG
S24R4 0752 pI9 SMA I 252R-PRIRG
N35 0823 p H O NAE I 275A/276G-PEFG
All 7 0875 pill ALU I 29 2E/29 3L-PEFG
R2A 0927 pI12 RSA I 310Y-SRIRD
S19 0969 pI13 SMA I 324P-PPNSG
R73 0984 pI14 RSA I 329 Y-SRIRD
S23R3 1008 pI15 SMA I 337P-PPNSG
RIO 1116 pI16 RSA I 373Y-SRIRD
S6R6 119 2 pI17 SMA I 398P/399G-PEFG
S4 8R1 1192 pI17 SMA I 39 8P/399G-PEFG
N19 1312 pI18 NAE I 4 3 8A/439 G-PEFG
N78 1480 pI19 NAE I 49 4A/49 5G-PEFG
R66 1551 pI20 RSA I 518Y-SRIRD
FN125-1 1681 pI21 NAE I 561A/562G-PELIRG
S4R2 1770 pI22 SMA I 591P-PPNSG
S59-1R2 1770 pI22 SMA I 591P-PPNSG
N123 1945 pI23 NAE I 649A/650G-PEFG
U30R3 2041 pI24 ALU I 681S-SPNSG
S66R5 2319 pI25 SMA I 774P-PPNSG
S41R2 2357 pI26 SMA I 787R-PRIRG
N66 2405 pI27 NAE I 803R-PRIRG
A104 2528 pI28 ALU I 843E/844L-PEFG
A20 8 2528 pI28 ALU I 843E/844L-PEFG
R74 2799 pI29 RSA I 9 34 Y-SRIRD
N43 2827 pI30 NAE I 9 43A/9 44G-PEFG
N7 7 3061 pI31 NAE I 1021A/1022G-PEFG
S31R1 3061 pI31 NAE I 1021A/1022G-PEFG
N63 3061 pI31 NAE I 1021A/1022G-PEFG
N22 3195 pI32 NAE I 1066P-PPNSG
R34 3291 pI33 RSA I 1098Y-SRIRD
R43 3396 pI34 RSA I 1133Y-SRIRD
N70 3414 pI35 NAE I 1139 P-PPNSG
N28 3583 pI36 NAE I 119 5A/119 6G-PEFG
S95 3690 pI37 SMA I 1231P-PPNSG
N45 3705 pI38 NAE I 1236P-PPNSG
S61 3715 pI39 SMA I 1239 P/1240G-PEFG
I 314 484
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Figure 11: Map of the Vmwl75 coding sequence showing the 
position of the insertion and deletion mutants constructed 
as described in Section 3A2. (a) Homology map of Vmwl75 in
relation to VZV 140K. The three main homology regions A, B 
and C are indicated. Clearly homologous regions are shown 
as boxes, with the most homologous sections filled (at least 
80% identity). (b) Position of each linker insertion 
(11-39) is represented by a vertical line. (c) Colinear map 
showing the 5 regions of Vmwl75 as described by McGeoch et 
al., (19 86). (d) Extent of deletions pDl-15. Dotted lines
represent out of frame sequences. The scale is given in 
amino acids.
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put back in frame by filling-in or trimming the EcoRI site 
to achieve the net addition or removal of a base. A summary 
of the structures of some of the deletion mutants obtained 
is given in Figure 11 and Table 5.
Small spontaneous deletions were frequently observed to 
arise in the sequences downstream of IE gene 3 in plasmids 
derived from pl75. These deletions were probably within the 
highly repetitive sequences adjacent to and within the a 
sequences. Restriction analyses confirmed that these 
deletions did not extend into the IE3 gene (results not 
shown).
3. Mapping and sequencing the site of mutation
Provisional mapping of the inserted EcoRI sites was 
performed by restriction analysis of plasmid DNA on 0.8-1.5% 
agarose gels. Selected plasmids were then prepared on a 
larger scale and the insertion or deletion sites were mapped 
more accurately on 3-8% non-denaturing polyacrylamide gels. 
The number of inserted dodecanucleotide linkers could be 
calculated from these gels, and plasmids with multiple 
linker insertions were digested extensively with EcoRI and 
then religated (plasmids given the "RX" suffix in Table 4).
The site of each inserted EcoRI linker was sequenced by
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labelling the EcoRI site with dATP and alpha [ P] dTTP and 
then cutting with a second restriction enzyme to generate 
uniquely end-labelled fragments 5' and 3' to the inserted 
linker. After purification on 4-8% polyacrylamide gels the 
fragments were sequenced by the chemical cleavage protocol 
of Maxam and Gilbert (19 77, 19 80). The reaction products 
were resolved on 20% denaturing polyacrylamide gels, so that 
sequence ladders (in 5' and 3' directions) from the labelled 
EcoRI site were generated. These sequences were then 
compared with the predicted IE gene 3 sequence.
Only two sequencing reactions were performed on each 
fragment to enable alignment to the known sequence. Purines 
were modified for cleavage using diphenylamine, and in a 
separate reaction hydrazine in the presence of high salt was 
used to preferentially modify cytosine residues; in the 
event guanine and thymidine were also cleaved to a certain 
extent which allowed all four bases to be distinguished.
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Figure 12 shows a representative sequence analysis for four 
separate insertion mutants: S19, S48, R2A and R30.
4. Construction of pGEM!75: a vector for in vitro expression 
of Vmwl75.
Reports that purified Vmwl75 is capable of binding to 
DNA (eg Michael et al. , 1988) suggested the possibility that 
Vmwl75 expressed in vitro might also be capable of binding 
to DNA in the gel retardation assay. The recent success of 
Ace et al., (1988) in expressing the HSV-1 alpha-TIF, Vmw65, 
in vitro from a T7/SP6 transcription vector, pGEM-2, 
provided a hopeful protocol to exploit. Because the plasmid 
pGEMTIF can be used to express adequate amounts of Vmw65 in 
vitro (Ace et a l . , 19 88) it was decided to use this plasmid 
to create a fusion between the first five amino acids of 
Vmw65 and a large portion of Vmwl75, rather than attempt to 
achieve efficient expression from a de novo construct. The 
construction of pGEM175 is outlined in Figure 13a. The 
insertion of the PvuII-HincII fragment from pl75 into the 
Sail deleted pGEMTIF (pdelS2) creates a gene encoding the 
first five amino acids of Vmw65, fused in frame to residues 
84-1029 of Vmwl75, terminating in 64 residues encoded by the 
out of frame 3' end of the Vmw65 gene. The desired 
recombinant was detected by colony hybridization of 
ampicillin resistant transformants as described in the 
Materials and Methods and using a probe internal to the IE3 
coding sequence, labelled by primer extension. Figure 13b 
shows the autoradiograph obtained from this screening, with 
the colonies of pGEMl75 and pGEM571 arrowed. (pGEM571 
contains the PvuII-Hincll fragment in the reverse 
orientation, and was used as a control in some experiments. )
Figure 12: Representative sequence analyses of four 
insertion mutants. Fragments 3' and 5' to the site of 
insertion, uniquely end labelled at the EcoRI site were 
prepared as described in the text and in Materials and 
Methods. Each fragment was treated to cleave at purines 
(lane R) or preferentially at cytosines (lane C) and 
resolved on a 20% denaturing polyacrylamide gel and 
autoradiographed at -70°C with intensifying screen. Ininem 
(1) S19-3 * (2) S19-5* (3) S48-51 (4) S48-31 (5) R2A-3' (6)
R2A-5' (7) R30-3' (8) R30-5'
Sequences read:
(1) AAGCCC-CCCCCGCCCCCGGGCCGCGGCCC 
(2 ) AAGCCC-CCCCGCCCACGACATGCCGCC
(3) AAGCCC-CCCTGCACCGCGACCTGGT
(4) AAGCCC-CCCCTGGTGCGCGCCCAAGA
(5) AAGCCC-TGGGCAGCGCTATCGCGCGCA .k
(6) AAGCCC-TGCAGTCGCCCCTCGGCACCGGG
(7) AAGCCC-TGAGCAGGGGCAGTAGCAGCAG . ,1
(8) AAGCCC-TGCTGCTGCGTCGGCTGCGGCGG
The first base read on each sequencing ladder is the 
base of the fragment, adjacent to the two labelled T 
residues, and reads AAGCCC from the inserted EcoRI 
before entering IE3 sequences.
1 2 3  * 5 6 7 8
C R C R C R C R C R C R C R CI
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Figure 13: Construction of PGEM17_5^ ries
constructed from pGEMTIF (Ace et a l w  19 w .
the gene expressing the HSV-1 alpha-TIF, w , _2> The
prokaryotic coliphage T7 promoter in the ^e P del(Lted
portion of the gene encoding amino acids 6 41 create the
from pGEMTIF by Sail digestion and religatio , nt
plasmid pdelS2. The purified 2.8kb Pyull ndelS2
from IE gene 3 (from pl75 ) was then ligate a frame
linearized with HincII. The novel ^ s i o n  fused in frame to 
encoded the first 5 amino acids of Vmw65,
residues 84-1029 of Vmwl75, a n d  terminates l terminates 
frame section of the Vmw65 reading frame w n -iorv 
after 64 amino acids, (b) Autoradiograp o recombinant, 
hybridization experiment to detect the p probed with
DNA from ampicillin resistant transformants was P 0S
a primer extended PvuII-EcoRI f ragmen ro P pQEMl7C^ and 
246-3061 of the IE3 ORF ) . Positive colonies for pGEMl/ 
PGEM571 (with the PvulI-HincII fragment cloned 
reverse orientation) are shown.
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sErTION 3B: VISUALIZATION OF THE WILD-TYPE AND MUTANT Vmwl 7S
p o l y p e p t i d e s i n t r a n s f e c t e d  h e l a  c e l l s
Indirect immunofluorescence studies were performed on 
cells transfected with wild-type and mutant plasmids in 
order to visualize the production and localization of 
Vlnwl75. It was originally hoped to use an antiserum which 
recognizes the carboxyl terminus of Vmwl75 in order to 
confirm that mutant plasmids produce proteins which 
terminate in the correct reading frame. However, rabbit 
antisera directed against a synthetic oligopeptide 
corresponding to the carboxyl terminus of Vmwl75 failed to 
recognize Vmwl75 in either infected or transfected cells in 
this assay (results not presented). We therefore used the 
monoclonal antibody 58S (Showalter et al. , 1981) which 
probably recognizes an epitope near the carboxy terminus 
(see below).
Formaldehyde-fixed, transfected HeLa cells were 
incubated with the antibody and then with
fluorescein-conjugated swine anti-mouse Ig, as described in 
Materials and Methods (Section 2B12). Figure 14a shows 
cells transfected with p(JC9 alone, giving no positive 
fluorescence. Figures 14b and 14c show cells transfected 
with pl75; 5-20% of the cells showed strong nuclear 
fluorescence indicating the accumulation of Vmwl75 in the 
nucleus. All of the insertion mutants listed in Table 4 
gave rise to similar nuclear fluorescence. These results 
indicate that there are unlikely to be any secondary 
unselected mutations in the plasmid-borne mutants.
The immunofluorescence results for the deletion mutants 
are shown in Table 6. The out of frame deletions fail to 
give rise to immunofluorescence suggesting that the epitope 
recognized by 5 8S has been lost, or that these mutants do 
not accumulate in sufficient quantities to allow detection. 
Considering the extent of the in frame deletions (which all 
give rise to proteins recognized by 58S) the results 
indicate that the epitope recognized by this antibody lies 
towards the C-terminus of the protein, between residues 
1134-1195 or 1270-1298. Some deletions gave rise to 
disperse cytoplasmic immunofluorescence (Figures 14d and
Ill
14e). These results indicate that the signal required for 
nuclear localization, or at least an essential portion of 
it, lies between amino acids 682-774 (mutant pD8). The 
limits of this signal have not been defined in this study, 
nor can it be excluded that there are other signals in 
regions of the protein that have not been deleted. However, 
DeLuca and Schaffer (19 88) have also mapped the nuclear 
localization signal to between residues 590 and 773 using 
truncation mutants (see Section 1D2.4). This region of 
Vtowl75 contains a short basic amino acid string RKRKS at 
residue 727, which is conserved in the VZV 140K protein and 
resembles the nuclear localization signal characterized in 
SV40 T antigen (Kalderon et al., 1984; see Section 4.3.3).
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Table 6: Immunofluorescence of transfected Hela cells with 
monoclonal antibody 58S. ~ “ “---------—
1 2 3 4 5 6
CONST. PUBL. DELETED DELETED FRAME I. I.F
NAME NAME SEQUENCE AMINO ACIDS
FA14 36-213 13G-71A OUT -ive.
V5 pD13 36-686 12P-229 P IN N.D.
ZA13 pD14 214-876 72G-29 2E IN N.D.
111 250-3808 84L-1270A OUT -ive.
Y3 pD15 250-876 84L-29 2E IN N.D.
DIO pDl 483-686 162A-229 P IN nuc.
L2 1355-3808 454M-1269L IN -ive.
Nil pD2 1484-2407 49 5G-803R OUT -ive.
FN11-8 pD2F 1484-2407 49 5G-803R IN cyt.
A3 1553-1772 518Y-59IP OUT -ive.
AA2 pD3 1553-1772 518Y-591P IN nuc.
R36 pD4 1553-3397 518Y-1133Y IN cyt.
N41 1684-3063 562G-1021A IN -ive.
N125 pD5 1684-(F S ) 562G-(F S ) OUT -ive.
B4, BA 2 pD6 1773-2321 59 2G-774P IN cyt.
E20 1948-2321 650G-774P OUT -ive.
N59 pD7 1948-3197 650G-1066P OUT -ive.
FN59-4 PD7F 1948-3197 650G-1066P IN cyt.
G3 2043-2321 682S-774P OUT N.D.
GA6 pD8 2043-2321 682S-774P IN cyt.
R9 pD9 2801-3292 9 34Y-109 8Y IN nuc.
Cl, CA7 pDll 3586-3717 119 6G-1239 P IN nuc.
HI, H6 pD12 3693-3808 1232G-1269L IN nuc.
Table 6: Immunofluorescence of transfected Hela cells with 
monoclonal antibody 58S. Columns 1-5 are reproduced from 
Table 5. The cellular localization of each deleted 
polypeptide as determined by indirect immunofluorescent 
staining (IIF) of transfected cells is recorded in column 6. 
Formaldehyde-fixed, transfected HeLa cells were incubated 
with the antibody 58S and then with fluorescein-conjugated 
swine anti-mouse Ig, as described in Materials and Methods 
(Section 2B12). (N.D. = not done, -ive = no detectable
immunofluorescence, nuc. = nuclear immunofluorescence 
similar to wild-type Vmwl75, cyt. = cytoplasmic 
immunofluorescence as in Figure 14) . Columns 1 and 2 list 
deletion derivatives of plasmid pl75 giving both their 
construction name and simplified published name (pD series, 
Paterson and Everett, 1988a,b). The extent of the deletion 
is defined both in bases (relative to +1 at the start of the 
IE3 ORF) and amino acids (columns 3 and 4). Column 5 
records whether the reading frame is correctly reinitiated 
after the deletion.
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SECTION 3Cs DETERMINATION OF THE TRANSCRIPTIONAL REGULATORY 
ACTIVITY OF THE PLASMID-BORNE MUTANTS OF IE GENE 3.
The primary aim of the work presented in this thesis was 
to map the regions of Vmwl75 that are functionally important 
by using the in-frame insertion and deletion mutants whose 
construction is described above (Section 3A) to define which 
areas of the protein are sensitive to disruption of 
activity. In order to assay the transcriptional activity of 
the mutant polypeptides, transient transfection assays were 
performed in which the ability of each mutant protein to 
activate or repress a reporter gene was measured. Two 
reporter gene constructs were used, both being fusions of 
HSV-1 promoters to the bacterial chloramphenicol acetyl 
transferase gene. One plasmid construct, pgDCAT, contains 
the promoter from the HSV-1 early gene which encodes 
glycoprotein D, and was used to measure transactivation of 
expression by Vmwl75 in synergy with the other HSV-1 
promiscuous transactivator VmwllO; the other reporter 
plasmid, pIE3CAT, carried a fusion of the HSV-1 IE gene 3 
promoter to the CAT reading frame, and was therefore used to 
measure autoregulation of the promoter of the viral gene 
which encodes Vmwl75.
Transfections were performed on WS HeLa or Vero cells 
seeded at 1x10^ cells per 50mm plate as described in 
Materials and Methods (Section 2B9.1) and the CAT enzyme 
activity determined on extracts made 48h post transfection 
(Section 2B10). The percentage conversion of substrate to 
acetylated form was calculated per microgram of protein in 
the extract (Section 2B11) and the CAT activities compared 
between wild-type and mutant Vmwl75 transfections.
1. Assay of transactivation of the HSV-1 glycoprotein gD 
promoter by vmw!75, and the insertion mutants.
It has been shown that the cloned IE-1 and IE-3 gene 
products from the HSV-1 Glasgow strain 17 syn+ stimulate the 
HSV-1 gD promoter synergistically in short-term transfection 
experiments in HeLa cells (Everett, 1984). This assay was 
used to examine the phenotype of the insertion and deletion 
mutants in Vmwl75. In these experiments, the gD promoter
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(from residues -392 to +11) was linked to the 
chloramphenicol acetyl transferase (CAT) gene in the plasmid 
pgDCAT (Everett, 19 86) and VmwllO was provided by the 
plasmid pill (Everett, 1987b). Transfections were performed 
with 4ug pgDCAT and pill, and 8ug of the plasmid expressing 
Vtnwl75. Under these conditions the amount of pl75 was near 
the top of the dose response curve in order to minimize any 
fluctuations in activity due to errors in DNA quantitation 
(see Figure 15). Typical results using this assay are shown 
in Figure 16a. When HeLa cells were transfected with pgDCAT 
alone, the resultant cell extracts contained only low levels 
of CAT activity (track 1). This low level of activity was 
increased about 3- to 5-fold when either pl75 or pill were 
included in the transfection with pgDCAT (tracks 2 and 3 
respectively). However, when both pill and pl75 were 
present in the transfection, the activity obtained from 
pgDCAT was on average almost 20 times that obtained with 
activation by pill alone (track 4). This 20-fold increase 
was used as the assay to test the transactivation phenotypes 
of the insertion and deletion mutants in the Vmwl75-coding 
region of pl75. It has previously been demonstrated that 
results from similar CAT assays correlate closely with the 
transcription levels as measured by direct quantitation of 
cytoplasmically accumulated RNA (Everett, 1987b).
The 39 insertion mutants in Vmwl75 shown in Figure 11 
and Table 4 were assayed as described above. To measure 
transactivation of the gD promoter in the presence of VmwllO 
at least two independent preparations of each plasmid DNA 
were used for a total of at least five transfection 
experiments. In each transfection experiment, two positive 
control plates with pl75 were prepared and the average 
activity (percentage chloramphenicol acetylated per mg 
protein in a 30 minute incubation) from these two plates was 
used to calculate the relative activities of the mutants.
The results are given in Table 7, together with the standard 
errors of the means of the individual values, and the data 
are plotted graphically in Figure 17. Activation of pgDCAT 
hy pill alone gave an average activity 6% of that with both 
Pill and pl75, and this background level has not been 
subtracted from the results shown.
T ITR A TIN G  TR A N SA C TIVA TIO N  OF THE gD PROMOTER
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Figure 15; Titrating transactivation of the gD promoter by 
p!75. WSHeLa cells were cotransfected with increasing 
amounts of pl75 and 4ug each of pill and pgDCAT. CAT 
extracts were prepared and assayed as described in the 
Materials and Methods and the CAT activity determined as 
percentage conversion of substrate to (3)-acetylated product 
per ug protein in the extract. The results are plotted and 
show that maximal transactivation of pgDCAT requires 
addition of around 6-8ug pl75.
1 2  3 4
(a)
1 2 3 4 5  6 7 8 9
Figure 16: Autoradiograph of CAT assays showing the two 
phenotypes of Vtnwl75 being investigated. (a) WS HeLa cells 
transfected with pgDCAT alone (track 1), pgDCAT with either 
pl75 or pill respectively (tracks 2 and 3) and pgDCAT, pl75 
and pill (track 4). The results show that VmwllO or Vmwl75 
alone transactivate CAT expression around 5-fold, whilst in 
synergy they activate expression a further 20-fold. (b) 
Transfection of Vero cells with pIE3CAT alone (track 1) or 
with the addition of increasing amounts of pl75 (tracks 2-5;
1,2,4 and 8 u g ) or pSVEB (tracks 6-9; 0.5,1,2 and 4 u g ) ; 
these results are plotted in Figure 18 as specific 
activities, taking account of the protein concentrations of 
the extracts. Cotransfection of increasing amounts of pl75 
cause repression of the IE3 promoter which is not caused by 
cotransfection of increasing amounts of the promoter alone, 
cloned on pSVEB.
Table 7: The transactivation and repression activities of 
the insertion mutants. The activity of each of the 39 
insertion mutants pll-pl39 is recorded for each of the two 
transfection assays measuring transactivation and 
autoregulation. The insertion site in each mutant is given 
in bases (column 2) and amino acids (3). Column 4 records 
the ability of each mutant to transactivate the viral early 
promoter, gD, when cotransfected with the reporter plasmid 
pgDCAT and the plasmid pill which expresses VmwllO. The 
activity is given as a percentage of that obtained in 
parallel experiments with pl75. The mean (x) of at least 
five independent determinations, using at least two separate 
plasmid preparations, is given, with the standard error of 
the mean (SEM). Column 5 records the qualitative ability 
each mutant polypeptide expressed by the plasmids pll-pl39 
to repress the IE3 promoter of pIE3CAT. Repression activity 
was determined relative to wild-type Vmwl75 expressed from 
pl75 by titrating repression of the IE3CAT construct and 
plotting each experiment as in Figure 18. Repression 
activity is scored from - (essentially no activity) to +++ 
(wild-type activity).
Table 7: The transacivation and repression activities of the 
insertion mutants. ’ ~~ ' —
1 2 3 4 5
Mutant Site Site Transactivation Repression
(base) (amino activity activity
acid) x (SEM)
pll 0033 12 35.1 (11.7) +++
pI2 0211 71/72 53.4 (13) ++
p!3 0248 83/84 49.6 (6.7) ++
pI4 0366 123 65.6 (12.8) ++
pI5 0388 130/131 43.8 (6.5) +++
pI6 0407 137 54.4 (11.8) ++
PI7 0480 161 44.5 (10.5) +++
pI8 0684 229 45.7 (8) +++
pI9 0752 252 127 (43.2) +++
pHO 0823 275/276 25.8 (4.6) -
pill 0875 292/293 30.8 (6.3) ++
PI12 0927 310 20.0 (4.4) +
pI13 09 69 324 10.0 (2.9 ) -
pI14 0984 329 4.9 (0.9) -
pI15 1008 337 4.5 (0.9 ) +
pI16 1116 373 16.5 (2.8) -
pI17 1192 398/399 11.8 (1.9) -
pI18 1312 438/439 15.5 (4.4) -
pI19 1480 494/495 49.2 (10.4) +++
pI20 1551 518Y 47.2 (10.2) ++
pI21 1681 561/562 43.4 (4.2) +++
pI22 1770 591 26.2 (6.2) ++
pI23 1945 649/650 23.9 (5.6) ++
pI24 2041 681 21.1 (4.2) ++
pI25 2319 774 38.2 (6.1) +++
PI26 2357 787 80.9 (18.5) +++
pI27 2405 803 45.9 (9.6) ++
pI28 2528 843/844 10.8 (3.9 ) +++
PI29 2799 934 3.4 (0.5 ) +
PI30 2827 943/944 48.2 (12.3) ++
PI31 3061 1021/1022 22.4 (3.7) +++
PI32 3195 1066 10.3 (3.0) +++
PI33 3291 1098 30.0 (8.9 ) ++
PI34 3396 1133 20.8 (2.3) ++
PI35 3414 1139 48.2 (13.6) ++
PI36 3583 1195/1196 86.9 (18) +++
PI37 3690 1231 47.5 (10.3) +++
PI38 3705 1236 63.1 (11.2) +++
PI39 3715 1239/1240 51.1 (8.6) +++
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Somewhat unexpectedly all except one of the mutants have 
lower transactivation activities than pl75, indicating that 
the protein is sensitive to the insertion of four residues 
in many regions. The inserted amino acids could affect the 
packing of the polypeptide chain in a number of ways and it 
is probably significant that all of the inserts introduce 
proline or charged residues (see Table 4). However the 
large class of mutants with 40-50% activity are still strong 
activators, showing 6-8 fold stimulation over the effect of 
pill alone. There are clearly mutants that are more 
seriously impaired than this, to 20-30% activity or to 
virtually no activity at all. There appears to be no 
obvious correlation between the sequence of novel amino 
acids introduced, given in Table 4, and the phenotype of the 
mutants. However, we cannot discount the possibility that 
the nature of the residues inserted may be more disruptive 
at some sites of insertion than others, if, for example, a 
srong charge is introduced into an uncharged region.
All the inserts within the first 230 amino acids of 
region 1 have between 35% and 65% activity. Therefore this 
large block seems relatively unimportant for this function 
although it does show some conservation with the VZV 140K 
protein, (region A in Figure 11). The insert at amino acid 
252, pI9, apparently has greater than wild type activity, 
though an increase of only 1.25 fold is probably not 
significant in this assay. The section of Vmwl75 spanning 
the end of region 1 and all of region 2 is clearly the 
largest stretch of the protein sensitive to disruption and 
must represent a critically important domain for functional 
activity. The three inserts around amino acid 330 are 
particularly impaired. Region 3 of Vmwl75 seems relatively 
unimportant in this assay. However, the three central 
mutations in region 3 are significantly reduced in activity 
to 20-30% that of pl75. Areas within region 4 are also 
sensitive to disruption and therefore probably important 
functionally for transactivation. Interestingly, the mutant 
pI29, which falls in a region very highly conserved between 
HSV-1 and VZV, is greatly impaired whilst the nearby insert 
Pl30 functions well in this assay and lies between two 
highly conserved blocks. The inserts towards the end of
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region 4 and the three at the start of region 5 would appear
to defiue a region of the protein unimportant in this assay.
2. Assay of repression of the HSV-1 IE gene 3 promoter by
Vtnwl75, and the insertion mutants.
It has been shown that cloned Vmwl75 can repress both 
basal and trans- and cis-activated levels of transcription 
from the IE gene 3 promoter (O'Hare and Hayward, 1985b,
1987). Using the same cell-type in which the original 
studies were performed, Vero cells, it has been possible to 
reproduce the results of O'Hare and Hayward (19 85b) who 
demonstrated repression of the VmwllO-transactivated IE-3 
promoter by adding increasing amounts of Vmwl75. To assay 
this phenotype in short-term transfection experiments we 
used a plasmid (pIE3CAT) carrying a fusion of the CAT gene 
to the intact IE-3 promoter, from bases -331 to +26 relative 
to the cap site (Stow et al., 1986). However, this assay 
occasionally gave problems of reproducibility and artificial 
repression possibly due to promoter competition, and these 
results are not presented here. These problems were 
overcome by titrating repression on the basal level of 
expression from plE3CAT. Figure 16b shows a typical assay 
using increasing amounts of pl75 to supply Vmwl75 compared 
to the negative control, pSVEB, which carries the same 
promoter fragment but no coding sequences. Clearly under 
these conditions the repression is dependent on the presence 
of functional Vmwl75. The titrations plotted in Figure 18 
demonstrate the absence of promoter competition by pSVEB and 
the failure of two insertion mutations, pI13 and pI17, to 
repress„
This assay was used to titrate the repression activity 
of all the mutants. The results of each set of 
transfections were plotted as in Figure 18 to obtain a 
qualitative comparison of the repression with that of the 
positive control pl75. The results are recorded in Table 7 
and Figure 17. Plasmids able to repress pIE3CAT essentially 
as well as pl75 are given +++ (or three diamonds in Figure 
17). Plasmids which were clearly impaired in their activity 
but still achieved a significant repression are described 
with ++; plasmids which repressed barely more effectively
pSVEB
pl13
I—• 
O
0.1
.03
DNA ADDED (ug)
Figure 18: Graph showing the repression of pIE3CAT by p!75. 
The CAT activity per protein obtained from transfected Vero 
cells is shown plotted against amount of test plasmid added. 
4 ug of pIE3CAT was added in each case and the total amount 
of DNA added balanced with pUC9. Actual amounts of pSVEB 
were 0.5,1,2 and 4 ug to provide a similar molarity to the 
larger pl75 plasmid. pl75 achieves good repression in 
contrast to a plasmid lacking IE 3 coding sequences, pSVEB. 
Two mutant plasmids, pI13 and pI17, fail to repress (see 
Table 7). The results demonstrate that the repression is 
specific to functional Vmwl75 protein and not the DNA 
sequences in pl75.
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than pSVEB are given as + and plasmids with no detectable 
repression activity are recorded as — (an empty diamond in 
Figure 17).
The results from these repression assays are probably 
less sensitive than the transactivation results, being 
qualitative rather than quantitative. The general areas of 
Vttiwl75 sensitive for disruption of the repression phenotype 
overlap with those defined above for transactivation.
However, individual inserts show that the two phenotypes are 
separable in some cases and are not determined by exactly 
the same protein regions. Region 2 and the downstream end 
of region 1 are highly sensitive to disruption, as in the 
transactivation assay above, but the section defined by
inserts at the end of region 1, in particular p H O ,  seems to
be more important for repression than transactivation. The 
rest of region 1 again seems unimportant for repression, as
do regions 3 and 5. Most of the inserts in region 4 are
efficient repressors; therefore this region seems to be less 
important for repression than for transactivation. Mutant 
pI29, however, is greatly impaired for both functions which 
suggests that the very highly conserved area (region C in 
Figure 11) is important for both functions. Therefore, 
apart from the sequence disrupted by the insertion in pI29, 
region 1 from amino acid 275 together with region 2 is the 
only part of Vmwl75 we have defined that is critically 
sensitive to disruption of the repression phenotype. It is 
possible, however, since the mutational dissection is not 
exhaustive, that important regions have been overlooked 
because of the random distribution of insertion sites.
3. Analysis of the transactivation and repression activity 
of the deletion mutants in Vmwl75.
A number of deletion mutants recovered fortuitously from 
the insertion mutagenesis, or constructed by recombining two 
insertions (described in Table 5), were assayed for both 
repression and transactivation activity as described above. 
The results are summarized in Table 8 and the extents of the 
deletions are shown in Figure 11.
The results are rather more complicated than those 
obtained with the insertion mutants. The deletion pDl in
Table 8: The transactivation and repression activities of 
deletion mutants. ' ” ------
1 2 3 4 5 6 7
Mut. Deleted
bases
Deleted
AA
Frame IIF Transact, 
activity 
x (SEM)
Repres
activ]
pDl 483-686 162-229 IN nuc. 30 (4.8) +++
pD2 1483-2407 495-803 OUT - 23 (4.0) _
pD2F 1483-2407 496-803 IN cyt. 5 (0.5) +
pD3 1553-1772 518-591 IN nuc. 4 (0.5) +++
pD4 1553-3397 518-1133 IN cyt. 18 (3.3) ++
pD5 1684 562 OUT - 3 (1.3) ++
pD6 1773-2321 592-774 IN cyt. 29 (2.8) +
pD7 1948-3197 650-1066 OUT - 27 (5.4) —
pD7F 1948-3197 650-1066 IN cyt. 10 (1.5) +
pD8 2043-2321 682-774 IN cyt. 57 (5.6) —
pD9 2801-3292 934-1098 IN nuc. 4 (0.6) +++
pDll 3586-3717 1196-1239
232-1269
IN nuc. 6 (2.2) +++
pDl2 3693-3808 IN nuc. 7 (2.2) ++
Table 8: The transactivation and repression activities of 
deletion mutants. The activity of each of the 13 deletion 
mutants pDl-pD12 is recorded for each of the two 
transfection assays measuring transactivation and 
autoregulation. The extent of the deletion in each mutant 
is given in bases (column 2) and amino acids (3). Column 6 
records the ability of each mutant to transactivate the 
viral early promoter, gD, when cotransfected with the 
reporter plasmid pgDCAT and the plasmid pill which expresses 
VmwllO. The activity is given as a percentage of that 
obtained in parallel experiments with pl75. The mean (x) of 
at least five independent determinations, using at least two 
separate plasmid preparations, is given, with the standard 
error of the mean (SEM). Column 7 records the qualitative 
ability each mutant polypeptide expressed by the plasmids 
pDl-pD12 to repress the IE3 promoter of pIE3CAT. Repression 
activity was determined relative to wild-type Vmwl75 
expressed from pl75 by titrating repression of the IE3CAT 
construct and plotting each experiment as in Figure 18. 
Repression activity is scored from - (essentially no 
activity) to +++ (wild-type activity). The reading frame of 
each mutant 3' to the deletion is also recorded (4) and the 
immunofluorescence results are reproduced from Table 6:
(nuc. nuclear localization similar to pl75, cyt. cytoplasmic 
localization, - no detectable immunofluorescence.)
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region 1, which removes amino acids 162-229, including the 
conserved serine rich tract (see Section 4.3.1), has good 
transactivating and repression activity. Although the 
results obtained with the insertion mutants suggested that 
much of region 1 is unimportant for transcriptional 
regulation, it was expected that the deletion of an 
evolutionarily preserved motif would have a marked effect on 
activity. This serine-rich region has been proposed as the 
major phosphorylation site of Vmwl75 (DeLuca and Schaffer,
1988). However, if this is the case phosphorylation would 
not seem to be essential for Vmwl75 transcriptional 
regulation as measured in these assays. This conserved 
region of the protein may be important for other functions 
in the infected cell, or perhaps the function of this region 
is partially duplicated by other regions of the protein.
Proteins expressed from plasmids deleted towards the 
carboxyl terminus of the reading frame, pDll and pD12, 
result in severely decreased transactivation although 
insertions round this region do not. Deletion mutant pD9, 
which removes much of homology region C, is also deficient 
in transactivation, which is consistent with the phenotype 
of insert pI29 at amino acid 934. However, all three of 
these deletion mutants (pD9, pDll and pD12) can repress the 
IE3 promoter. It is not obvious why insertion at 9 34 should 
reduce the ability of the protein to repress whereas 
deletion of this region does not.
Unexpectedly, several larger deletions such as pD4 which 
spans region 4, have greater transactivation activities than 
the smaller deletions in this region. It is even more 
difficult to understand why the out of frame deletions, pD2 
and pD7, encode more competent transactivators than their 
daughters which have been put back in frame (and regain the 
epitope for 58S). These data suggest that the relationship 
between the structure and function of the C-terminal third 
of Vmwl75 is particularly complicated.
All of the cytoplasmically localized mutants seem to be 
impaired in their repression activity, although three of 
them are moderate transactivators (pD4, pD6 and pD8) ; 
possibly they leak into the nucleus at levels sufficient to 
transactivate but not sufficient to repress. If this truly
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indicates that a different concentration of Vmwl75 is 
required for expression of each phenotype, then this would 
imply that each activity functions through a different 
mechanism. The out of frame deletions pD2 and pD7 have lost 
the putative nuclear localization signal but also the 
epitope for monoclonal 58S, so it was not possible to 
determine their cellular location. The enigma that they are 
better transactivators than their in-frame derivatives, pD2F 
and pD7F, may be explained if they enter the nucleus more 
efficiently, perhaps due to fortuitous localization signals 
in the out of frame portion. Alternatively, and perhaps 
more intriguingly, the downstream domains regained by the 
in-frame daughters may be acting to inhibit transactivation 
in these abnormal proteins.
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SECTION 3D: DETERMINATION OF THE SITE-SPECIFIC DNA BINDING 
ACTIVITY OF THE PLASMID-BORNE MUTANTS OF IE GENE 3.
Whilst most of the HSV-1 IE proteins bind to DNA to some 
extent in vitro (Hay and Hay, 1980) Vmwl75 is the only one 
known to interact with specific target sequences which 
include a proposed consensus binding sequence ATCGTC (Beard 
et al., 1986; Faber and Wilcox, 1986). Vmwl75 has been 
shown to bind to this sequence in the promoter regions of 
the IE1, IE3 and glycoprotein gD genes (Faber and Wilcox, 
1986a; Kristie and Roizman, 1986a,b; Muller, 1987) but has 
also been reported to bind to several viral DNA fragments 
which lack the consensus (Kristie and Roizman, 1986a;
Michael et al., 1988). Evidence from a variety of 
laboratories suggests a correlation between the ability of 
Vmwl75 to bind ATCGTC at the transcriptional start site of 
IE gene 3, and autoregulation of this promoter.
This section describes the use of nuclear extracts, made 
from cells transfected with the insertion and deletion 
mutant plasmids described in Section 3A, in gel retardation 
DNA binding assays in order to define the regions of Vmwl75 
involved in binding to the specific Vtnwl75 DNA binding site 
present at the transcriptional start (cap) site of IE gene
3. The results show that the regions of Vmwl75 required for 
DNA binding closely correspond to those involved in 
transcriptional regulation. In particular, a region crucial 
for site specific DNA binding lies within amino acids 
275-495.
1. Characterization of the site-specific DNA binding 
activity of Vmwl75.
1.1 Vmwl75 in nuclear extracts of virally infected HeLa
cells forms a complex with the ATCGTC consensus binding—site
located at the IE gene 3 cap site.
As described by Muller (19 87 ) an end-labelled 45bp 
Aval/BamHI DNA fragment spanning the IE3 cap site can be 
used to assay Vmwl75 site-specific DNA binding activity 
using the gel retardation assay (Garner and Revzin, 1981). 
Cells were infected at a moi of 5pfu per cell and nuclear 
extracts prepared 5h after a lh absorption periou by a
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procedure modified from that of Dignam et al. , (1983) 
(Materials and Methods, Section 3B13). Nuclear extracts 
were incubated for 20min with the DNA probe and the 
protein-DNA complexes were then resolved on 4% 
polyacrylamide gels. Non-specific DNA binding activity was 
eliminated by the addition of lug polydl:polydC to the 
binding reactions.
Proteins present in mock infected cell extracts bind to 
the IE3 probe to give two specific complexes "b" and "c" 
(Figure 19A, tracks 1 and 2). A single major, viral 
specific, retarded complex "a" is detected after incubation 
of the probe with infected cell nuclear extract for 20 
minutes at 20°C and resolution by gel retardation (Figure 
19A, tracks 3 and 4). This complex is further retarded "a+H 
after additional incubation with the Vmwl75 specific 
monoclonal antibody 58S (Showalter et al., 1981) which 
recognizes an epitope near to the C-terminus of Vmwl75 
(Paterson and Everett, 1988a; Section 3B). These complexes 
were not formed using extracts made from mock infected cells 
nor from cells infected with an HSV-1 mutant which produces 
no Vmwl75, in!411 (Russell et a l ., 1987b) (Figure 19A). The 
complex was also formed by extracts made from cells infected 
with dll403, a mutant lacking both copies of IE gene 1 which 
encodes VmwllO (Stow and Stow, 1986).
Recognition of the protein-DNA complex "a" by two Vmwl75 
directed rabbit antisera in addition to the monoclonal 
antibody 58S provides further evidence that this complex 
contains Vmwl75 (Figure 20). The antiserum 19825 is raised 
against a synthetic nonapeptide corresponding to the 
carboxyl terminus of Vmwl75 (kindly provided by Dr M.Frame) 
whilst the antiserum 2180 V was raised against bacterially 
expressed fusions of fragments of Vmwl75 to 
beta-galactosidase (kindly supplied by Dr A.Buchan, 
University of Birmingham). No other HSV proteins could be 
detected in the complex using monoclonal antibodies (against 
the major DNA binding protein) or antipeptide antisera 
(against VmwllO and Vmw63, Figure 20). It therefore seems 
unlikely that the complex contains other viral gene products 
and indeed Vmwl75 is the only viral gene product necessary 
for production of the complex. Low amounts of the antiserum
Ml 17+ 1411 1403 Ml 17+  
A - + “ + - + - +  B _ +
I
a+ Jk AI 1; f  I r <1w1 4 4
9 t*
Figure 19: Vmwl75 binds to the IE gene 3 transcriptional 
start site. Autoradiograph of a gel retardation experiment 
showing the protein-DNA complexes formed using nuclear 
extracts of HSV-1 infected cells bound to a DNA probe 
spanning bases -17 to +27 of the HSV-1 IE gene 3. Assays 
were performed as described in the Materials and Methods, 
with (+) or without (-) addition of monoclonal antibody 58S. 
Assays perfomed at (A) 20°C or (B) 40°C. MI= mock infected, 
17 = HSV-1 strain 17+ , 1403= HSV-1 mutant dll403, 1411=
H^V-1 mutant ijnl411, a= retarded complex containing Vmwl75, 
a = complex a further retarded with antibody, b and c 
are complexes containing host factors, z= novel retarded 
band, probe= unbound DNA probe.
Figure 20: Monoclonal and polyclonal antibodies against
Vmwl75 recognize and specifically retard the Vmwl75/DNA 
complex. (A) and (B) DNA binding assays were performed as 
described in Materials and Methods, using lul of nuclear 
extract of HSV-1 infected cells bound to the 44bp IE3 cap 
site probe at 0°C for 20min, and then further incubated with 
antisera for lOmin at 0°C. Al-11, Bl-4 and B12-14 extracts
of cells infected with wt 17+ ; B5-7 infected with I15HBC 
(see Section 3E3); B8-11 cells transfected with pl75. 
Antisera used:
Al none B1 none
A2 lul (1/20) 58S anti-Vmwl75 B2 lul (1/50) 58S
McAb B3 2ul 2180V anti
A3 lul anti- ICP8 McAb B4 4ul 2180V
A4 lul anti- gD McAb B5 none
A5 3ul 11666 anti-Vmwl75 B6 lul (1/50) 58S
A6 3ul 18817 anti-Vmwl75 (Ct > B7 2ul 2180V
A7 3ul 19825 anti-Vmwl75 ( ) B8 none
A8 3ul 18815 anti-Vmw65 (Cfc) B9 0.5ul 2180V
A9 3ul 14711 anti-VmwllO (Ct ) BIO lul 2180V
A10
i—idCO 13963 anti-US9 (Cfc) Bll 2ul 2180V
All 3ul 14996 anti-RR2 B12 none
B13 0.Sul 2180V
B14 lul 2180V
Only the top portion of the autoradiograph is shown. The 
results show that only antisera directed against Vmwl75 
recognize the Vmwl75/DNA ("a") complex and further retard 
the mobility of the complex (to "a+ "). Only one preparation 
of anti-(carboxy-terminal)-peptide antiserum bound to the 
complex, the (older) amino-terminal directed antipeptide 
serum did not recognize the complex. Incubation with the 
rabbit antisera (except 2180 V) results in a broader and 
slightly faster migrating complex band. Faint bands are 
highlighted in tracks 8 and 11.
A 1 2 3 4 5 6 7 8 9  10 11
i 4 a+
4 a
1 2 3 4 5 6 7 8 9 10 11 12 13 14
n i l
u u
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2180 V shifted only part of the complex "a".
An apparently viral specific complex, labelled "z", of 
much greater mobility was occasionally formed (Figure 19B), 
especially if the binding reaction was carried out at 
elevated temperatures. This complex was not further 
retarded by the antibody 58S, indicating that it might be 
formed by a protein unrelated to Vmwl75, or, by a 
proteolytic fragment of Vmwl75 lacking the C-terminal 58S 
epitope. (A complex resembling "z" was also seen when 
binding was assayed in the presence of high salt 
concentration at elevated temperatures, see Figure 44B).
1.2 Vmwl75 in nuclear extracts made from transfected cells 
forms an authentic complex with the IE gene 3 cap site. 
Nuclear extracts prepared from cells transfected with the 
plasmid pl75, which express Vmwl75, form a specific complex 
with the IE3 cap site when assayed by gel retardation 
(Figure 2lA). The complex is essentially identical to that 
formed using extracts of virally infected cells and is 
recognized by the anti-Vmwl75 antibody 58S. However, 
transfected cell extracts occasionally formed two specific 
complexes which were both recognized by 58S (Figure 21B).
The smaller complex (a*) could be formed by an abnormally 
processed form of Vttiwl75 or it might lack an unknown factor. 
It usually appeared when the overall efficiency of the 
transfections was poor and could reflect a lower level of 
Vtawl75 in the transfected cells.
That cells transfected with pl75 formed a complex 
identical to that formed with infected cell extracts 
indicates that Vmwl75 is the only viral protein present in 
the complex. The presence of other HSV-1 genes in the 
transfection had no effect on the nature of complex formed, 
but addition of the gene encoding Vmw63 did increase its 
amount (Figures 21A,B). However, Vmw63 itself did not form 
a complex with this DNA probe, and the addition of an 
extract containing Vmw63 to one containing Vtnwl75 did not 
enhance binding (Figure 21C). Rather the effect of Vmw63 
seemed to be on expression of Vmwl75f as the extract made 
from cells transfected with pl75 and p63 together had 2.5 
fold more Vmwl75 than the extract from cells transfected
Figure 21; Nuclear extracts containing Vmwl75 expressed in
cells transfected with plasmid p!75 form an apparently 
identical DNA complex to that formed by Vmwl75 present in 
infected cell extracts. (A) Binding assays were carried out 
as described in Figure 19 using extracts of cells infected
or transfected as shown. Unbound probe has been cut off the
bottom portion of the gel. Plasmids used express Vmwl75 
(P175), VmwllO (pill), Vmw6 3 (p63) and ICP8 (pGX38). (B)
Cells were transfected with pl75 and the following plasmids: 
lanes 1 & 2, pill; 3 & 4, pill and p63; 5 & 6, pill/ p63 and
PG$38; 7 & 8, pl75 alone. a'= secondary complex, shifted to
a1 with antibody. (C) Addition of extracts containing 
Vmw63 does not enhance Vmwl75 DNA binding. Lane 1, pl75; 
lane 2, p63; lane 3 mix of extracts used in 1 & 2, lane 4, 
cotransfection of pl75 and p63.
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with pl75 alone, as determined by ELISA.
1.3 Vmwl75 also forms a complex with the ATCGTC consensus 
binding-site located in the gD promoter.
Vmwl75 has been reported to bind to a copy of the ATCGTC 
consensus binding site present at bases -101 to -106 in the 
HSV-1 gD promoter (Faber and Wilcox, 19 86a). In order to 
investigate this activity in our assay system a Xhol-Hindlll 
probe fragment was prepared from the plasmid pRED112 
(Everett 1983) which spans bases -109-+11 of the gD 
promoter. Nuclear extracts prepared from virally infected 
cells bound to form a novel complex with this probe when 
assayed by gel retardation (Figure 22a). This complex was 
larger than the IE3 complex, probably indicating that 
proteins other than Vmwl75 were also bound to the fragment; 
the ability of the antibody 58S to recognize and retard this 
complex confirmed the presence of Vmwl75 in the complex.
When a short, 26bp, synthetic probe spanning the gD promoter 
binding site (bases -111 to -90, with single-stranded 5'
TCGA extensions) was used in this assay, a complex of 
similar size to that formed with the 44bp IE3 probe was 
formed by nuclear extracts of either virally infected or 
pl75 transfected cells (Figure 22b). This demonstrates that 
Vmwl75 is the only viral protein present in this complex, 
and indeed probably only one protein complex could form on a 
probe this size.
1.4 The DNA binding region of Vmwl75 forms a protease 
resistant domain.
In order to investigate whether the complex "z", 
described in Section 3D1.1 above, was related to the Vmwl75 
complex and perhaps formed by a proteolytic breakdown 
product of Vmwl75 binding to DNA, proteolysis experiments 
were performed. Commercial proteinase K enzyme was 
incubated with binding reactions for 10 minutes at room 
temperature, before resolving the products on a standard 
retardation gel. Concentrations of proteinase K between 1 
and lOng per reaction were found to degrade the specific 
Vmwl75-DNA complex "a" to a much smaller complex "p" (Figure 
23A). The same complex "p" is formed whether protease
Figure 22: Vmwl75 binds to an ATCGTC element upstream of the
gD promoter to form a complex similar to that formed with 
IE3 cap site. (A) An end-labelled probe spanning the gD 
promoter was prepared by filling in the Xhol-Hindlll 
fragment (-109-+11) from the plasmid pREDll2. This was 
incubated (at 20 C) with mock (lanes 3 & 4) or HSV-1 strain
17 infected nuclear extracts (lanes 5 & 6) and compared by
gel retardation to the Vmwl75/IE3 cap site complex (lanes 1 
& 2). Reactions 2, 4 & 6 are further incubated with the
antibody 5 8S. As can be seen in lanes 5&6, infected
extracts form a virus specific complex ("a") with the gD 
promoter, which contains Vmwl75. However, other proteins 
are probably bound to this DNA probe as the complexes "a" 
and "a " are larger than those formed on the IE3 probe.
("d": non-Vmwl75 containing complexes; ,,RED112": unbound 
probe). (B) A 26bp double stranded oligonucleotide spanning 
residues -111 to -9 0 of the gD promoter including the ATCGTC 
consensus sequence, with 5' TCGA single-stranded extensions, 
was end-labelled and assayed for Vmwl75 binding at 20 C 
using mock infected (lane 1), pl75-transfected (lanes 2&3) 
or HSV-1 17+ infected extracts (lanes 5&6). The complexes 
formed were compared by gel retardation to the Vmwl75/IE3 
cap site ("a") complex (lanes 5&7). Reactions 3 and 5 were 
further incubated with antibody 5 8S. The results show that 
Vmwl75 forms a similar specific complex with the short gD 
promoter oligonucleotide to that formed with the short IE3 
cap site probe. The gD probe is also bound by a cellular 
factor to form complex "c", but not complex "b".
Figure 23: A protease resistant domain of Vmwl75 binds to 
DNA.
(A) Mock or 17 infected extracts were assayed for IE3
cap site DNA binding as previously described, but further
reacted with commercial protease K (PK) at 20 C for lOmin
before electrophoresis. The amounts of PK used were: lanes
1&7: Ong; lanes 2&8: lng; lanes 3&9: lOng; lanes 4-6&10-12:
20ng. A novel viral specific complex "p" was formed,
presumably by proteolytic degradation of complex Ha" . In
addition the host-factor specified complexes b and c were
degraded to give the faster migrating complexes b' and c 1.
The protease inhibitor PMSF was added to reactions 5, 6, 11
& 12 before further incubation with pre-immune rabbit
antiserum (5 & 11) or with the anti-Vmwl75 antiserum 2180V
(6 & 12). Complex "p" did not appear to be recognized by
this antiserum.. +
(B) Reactions were performed as in (A) using 17
infected extracts but in the case of reactions 1-4 the PK 
digestion was performed prior to addition of the DNA probe 
(and PMSF) and in the case of reactions 5-6 DNA binding was 
performed in the presence of PK. Amounts of PK used: lane 
(9): Ong; lanes (4,8,10): lng; (3,7,11): lOng; (2,6,12): 
20ng; (1,5,13-15): lOOng. Reactions 14 and 15 were further
incubated with the anti-Vmwl75 antisera 58S (14) and 19825
(15) in the presence of PMSF. The results show that a 
protease resistant domain of Vmwl75 can bind to DNA, and 
that this domain is protease resistant in the presence or 
absence of DNA.
(C) Identical DNA binding reactions of 17 infected extracts 
to the IE3 probe were performed in 1 & 2 followed by PK 
digestion prior to electrophoresis, however, in the case of 
reaction 1, PK digestion was performed in the presence of 
PMSF, which is shown to inhibit PK activity.
A < HOCK > <  17 * >
1 2 3 4  5 6 7  8 9 1 0 1 1 1 2
B PK < PRE t> < DURING > 
1 2 3 4 5 6 7 8
C PMSF +
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digestion is performed prior, during or after the DNA 
binding reaction (Figure 23B) indicating that the DNA 
binding region of V5mwl75 forms a distinct structural domain. 
Complexes Hb" and "c", which are formed by cellular DNA 
binding factors, are degraded to lesser extent to give new 
bands "b"' and "c"' when either virally or mock infected 
extracts are assayed (Figures 23A,B). Complex "p" is not 
formed by mock infected nuclear extracts (Figure 23A). It 
seems likely that complex "z" which occassionally appears in 
the absence of proteinase K treatment (see Figure 19B) may 
be a proteolytic product of band "c" and unrelated to 
Vmwl75.
Proteinase K activity could be inhibited by the addition 
of 0.2mM PMSF to the incubations (Figure 23C) which allowed 
antibody shift experiments to be carried out on complex "p" 
(Figure 24). The proteolytic fragment of Vmwl75 present in 
complex "p" did not appear to be recognized by any of the 
antisera. The 58S and 19825 antisera are directed against 
carboxyl terminus epitopes of Vmwl75, which are presumably 
free to be cleaved away from the protein-DNA complex; only 
serum 2180 V might be directed against epitopes in the DNA 
binding domain, but it too failed to recognize complex "p" 
(Figure 24).
1.5 The Vhiwl75-DNA complex is highly salt-stable.
As a consequence of the strong ionic interactions 
between a site-specific DNA binding protein and its DNA 
target such complexes are generally stable at relatively 
high salt concentrations. DeLuca and Schaffer (1988), 
however, have reported that Vmwl75-DNA complexes assayed in 
their studies are highly salt-labile. In contrast to their 
observations, the Vmwl75-IE3 CAP site complex investigated 
in these studies proved to be highly salt stable and was 
still detectable when assayed at 0.5M NaCl (Figure 25A,B). 
Complex "c" was also reasonably salt stable, but when the 
binding reaction was performed at 0. 2M NaCl complex "b" was 
not detectable. When the binding reactions were carried out 
at 39°c, complex "a" was only marginally more salt labile 
(Figure 25B).
I! 1
»  •  ■
Figure 24: The proteolytic fragment of Vftiwl75 which binds to 
PNA is not recognized by available antisera. Reactions were 
performed as described as for Figure 23. Lanes 1-5 are as 
Figure 23B 11-15, lanes 6-8 no PK, lanes 9-12 lOOng PK 
following DNA binding. Lanes 6 & 9 were bound to pre-immune 
rabbit antiserum, lanes 8 & 11 to 3ul antiserum 2180V. The 
results show that complex "p" is not recognized by any of 
the three available anti-Vmwl75 antisera.
EXPT I
26 250mM
1 2 3 4 5 6 EXPT II
26 400mM
1 2 3 4 5 6 7
x *
4a
4b
4C
Ob’
B 26,250.500,26,250,500mM
<1 2(PC> < 39°C>
1 2 3 4 5 6
| b >  f f e U 4a
4b
4C
Figure 25: The complex is hiqh!y s .....
%  results of two separate DNA binaiuy 'experime.a *
17* infected extracts incubated with the IB3 cap^si^ 
in the presence of increasing cone ^  ^  1Q0
shown. mM NaCl in experiment^I: (1)  ^ 100 (3)
150 (5) 200 (6) 250 ; in exPe^ ™ e^ n The results show that
200 (4) 250 (5 ) 300 (6 ) 350 ('7) 400. The r e s ^  complex „c.
the Vmwl75 complex "a" and the host ce rized complex "x"
are highly salt stable. A novel uncharacterizea 
appears at high salt concentrations. complex was
(B) The salt-stability of the Y™* reaction at an elevated 
unaffected by performing the bindi g
temperature of 39°C.
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1.6 Vmwl75 site-specific DNA binding activity in different 
cell-types.
It was of interest to investigate the DNA binding 
activity of Vmwl75 in extracts of different cell-types in 
order to correlate it with the transcriptional regulation 
experiments, which were performed in WS HeLa and Vero cells, 
and because the activity of VmwllO and 175 has been shown to 
vary in different cell-types (Everett, 1988b). Flow HeLa 
cells were routinely used to prepare extracts for DNA 
binding experiments as the extracts of transfected Flow 
HeLas were apparently more active than those of WS Helas, 
even though ELISA experiments indicated that they contained 
similar amounts of Vmwl75 (Figure 26B). This suggests that 
complex formation is not directly related to the amount of 
ELISA-detectable Vttiwl75 in an extract. This could reflect 
differences in the stability or modification of Vmwl75 in 
different cell-types, or perhaps differences in other cell 
factors involved in complex formation. However, infected 
cell extracts from Flow and WS HeLas seemed to behave 
identically (Figure 26A). Vmwl75/IE3 cap site binding 
activity was not detectable in either transfected or 
infected nuclear extracts of Vero cells (Figure 26A,B) 
although Vhiwl75 was detected in the infected cell extracts 
by ELISA and Vmwl75 has been shown to repress expression of 
PIE3CAT in these cells (Section 3C2). The failure to detect 
DNa binding in vitro may not necessarily reflect a failure 
to bind in vivo as the protein may not be stable upon 
extraction from nuclei.
2* The regions of Vttiwl75 important for DNA binding closely 
correspond to those important for transcriptional 
regulation _
2*1* Analysis of insertion mutants.
The DNA binding activity of the insertion mutants 
described in Section 3A was investigated in gel retardation 
assays using nuclear extracts made from Flow HeLa cells 
transfected with each of these 39 plasmids.
Nuclear extracts were prepared from 7x10^ transfected 
cells and one twentieth (4ul) of each was incubated with the 
1E3 cap site probe in a 30ul reaction volume at 20°C for 20
Figure 26: Similar Vmwl75/DNA complexes are formed by 
extracts of transfected and infected HeLa cells, but are not 
detected with extracts of Vero cells. Extracts of three 
infected (A) and transfected (B) cell-types were assayed for 
Vftiwl75/IE3 cap site binding as detailed below. The amount
of ELISA detectable Vmwl75 in each extract was also
determined, 
lane cells extract ELISA (relative Antibody
Al WSHeLa MI
amount
0.0
Vmwl7 5) shift (58S
A2 WSHeLa 17+ 0.31 -
A3 Vero MI 0.0 -
A4 Vero 17+ 0.48 -
A5 FHeLa MI
17+
0.0 -
A6 FHeLa 1.88 -
A7 WSHeLa MI n.d. -
A8 WSHeLa 17+ n. d. -
B1 FHeLa pi 7 5 0.88 -
B2 FHeLa pi 7 5 0.88 +
B3 Vero pi 7 5 0.05 -
B4 Vero pi 7 5 0.05 +
B5 WSHeLa pi 7 5 0.70 -
B6 WSHeLa pi 7 5 0.70 +
(FHeLa: Flow Hela; MI: mock infected extracts; 17 : HSV-1 
strain 17 infected extract; pl75: pl75 transfected extract; 
v: novel non-viral-specific complex formed by Vero cell 
extracts.)
The results show that identical complexes are formed by 
transfected and infected extracts of both types of HeLa 
cells, but that complex formation by Vmwl75 in WSHeLa 
transfected cells was much less efficient. No Vmwl75/DNA 
complex could be detected using extracts prepared from Vero 
cells, although infected Vero cell extracts contained 
detectable levels of Vmwl75.
A INFECTED
WS V FH WS
1 2 3 4 5 6 7 8
IP • Ip
by
c y  «* —
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B TRANSFECTED
•*a+
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minutes, then further incubated with lul 1/100 dilution of 
monoclonal 58S prior to separation on 4% polyacrylamide 
gels. The resulting autoradiographs are shown in Figure 27. 
The antibody shift was carried out in order to clearly 
resolve the Vmwl75 complex from the host factor complexes 
«b" and "c", although in some cases the addition of antibody 
seemed to stabilize the degree of complex formation (results 
not shown). In addition to the major "a " complex, the 
minor "z" complex was also occasionally present, but is 
probably not related to Vmwl75 (Section 3D1.4). The binding 
reactions were carried out at 20°C; at higher temperatures 
the binding of wild type Vmwl75 was significantly reduced, 
although temperature sensitive mutants can be studied in 
this manner (see Section 3F6).
The amount of Vmwl75 in each extract was measured by 
ELISA and compared to the pl75 control transfection to 
ensure that the transfections were working with comparable 
efficiency and that the Vmwl75 polypeptide was present in 
the extract. These results, together with a summary of the 
binding results in Figure 27, are presented in Table 9, 
which also summarizes the map positions and transcriptional 
regulation results (Sections 3C1 and 3C2).
Table 9 shows that mutants impaired in their ability to 
bind to the IE3 cap site in vitro broadly correspond to 
those impaired in their ability to transactivate and to 
repress transcription in transfection assays. For example 
insertion mutants pI12 to pI18 (with the exception of pI1 3 ) 
are all significantly reduced in the transactivation and 
repression assays and also in their ability to bind to the 
IE3 cap site. This is especially true of mutants pI14-pI18. 
Indeed it is clear that this portion of the protein, (region 
2? amino acids 315-484 ) is of critical importance for both 
transcriptional control and DNA binding. Only one mutant in 
region 2, pll3, can efficiently bind to this DNA probe, but 
tails to express either repression or transactivation
a c t i v i t y .
Insertion mutants throughout the majority of region 1 
are virtually unimpaired in DNA binding activity or 
transcriptional regulation. However, two mutants, p H O  and 
p112, situated at the end of region 1 close to the junction
HD p175 1 2  3 4 5 6 7  8 9  10
a+—
a -  y  
b-
11 12 13 14 15 16 17 18 19 20
il •
c“  • 
z —
y««
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
#% #• • M  W  H  Mf« '« * *
y y y y y n u y u
Figure 27; DNA binding assays using extracts of cells 
transfected independently with each of the 39 insertion 
mutants pll-p!39. All assays were incubated with antibody 
58S except M (mock transfected) and pl75/- (positive 
control). Complexes a, a , b, c and z are as described in
Figure 19. The results are summarized in Table 9 .
Legend to Table 9.
a The site (amino acid) of linker insertion.
b The activation of the gD promoter (using pgDCAT in conjunction 
with VftiwllO provided by pill) is given as a percentage of that 
obtained in parallel experiments with pl75. The mean activity 
(x) and the standard error of the mean (SEM) are shown, 
reproduced from Table 7. 
c The qualitative ability to repress the IE3 promoter of pIE3CAT 
compared to pl75 in cotransfection titration experiments, 
reproduced from Table 7. Repression activity is scored from - 
(essentially no activity) to +++ (wild type activity), 
d The ability of nuclear extracts made from HeLa cells
transfected with each of the mutants to bind to the IE3 cap 
site. Binding activity is scored from visual inspection of 
Figure 27: - no binding, +/- barely detectable, + to +++ 
increasing binding activity, 
e Relative amount of Vmwl75 in each nuclear extract determined 
by ELISA. (pl75=100) 
f Further experiments with this mutant did produce detectable 
amounts of pl29 Vmwl75 as described in the text and Figure 28.
Table 9: A summary of the positions and activities of the 
insertion mutants. ~  “ a *
Mutant Insert Transact^ Repress. DNA Relative
Site activity activity binding amount of
X (SEM) activity vmwl75e
pn 12 35.1 (11.7) + + + + + + 288
pI2 71 53.4 (13) + + + + 203
pI3 83 49 .6 (6.7) + + + + + 88
pI4 123 65.6 (12.8) + + + + + 241
pI5 130 43.8 (6.5) + + + + + + 106
pI6 137 54.4 (11.8) + + + + + 103
Pl7 161 44.5 (10.5) + + + + + + 297
pI8 229 45.7 (8) + + + + + + 127
pI9 252 127 (43.2) + + + + + + 263
pIlO 275 25.8 (4.6) - + + 142
pill 292 30.8 (6.3) + + + + + 276
pI12 310 20.0 (4.4) + + / - 97
pI13 324 10.0 (2.9 ) - + + + 226
pI14 329 4.9 (0.9 ) - - 38
pI15 337 4.5 (0.9 ) + - 18
pI16 373 16.5 (2.8) - - 18
pI17 39 8 11.8 (1.9 ) - + 39
pI18 438 15.5 (4.4) - + 65
pI19 494 49 .2 (10.4) + + + + + + 170
pI20 518 47.2 (10.2) + + + + + 85
PI21 561 43.4 (4.2) + + + + + + 294
pI22 591 26.2 (6.2) + + + / - 206
PI23 649 23.9 (5.6) + + + + 29 7
pI24 681 21.1 (4.2) + + + / - 91
PI25 774 38.2 (6.1) + + + + + + 291
PI26 787 80.9 (18.5) + + + + + + 70
PI27 803 45.9 (9.6) + + + 126
PI28 843 10.8 (3.9 ) + + + +4~ 15fPI29 934 3.4 (0.5 ) +
L or
PI30 943 48.2 (12.3) + + + + + 5 8
PI31 1021 22.4 (3.7) +++ +++ 100
PI32 1066 10.3 (3.0) +++ + 91
PI33 1098 30.0 (8.9 ) ++ + 15
PI34 1133 20.8 (2.3) ++ ++ 27
PI35 1139 48.2 (13.6) ++ +++ 121
PI36 1195 86.9 (18) +++ +++ 218
PI37 1231 47.5 (10.3) +++ +++ 221
PI38 1236 63.1 (11.2) +++ +++ 245
PI39 1239 51.1 (8.6) +++ +++ 248
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with region 2, are significantly reduced in their abilty to 
repress the IE3 promoter, and both are impaired in their 
ability to bind to the IE3 cap site, pI12 markedly so.
However, DNA binding does not show an absolute 
correlation with either transactivation or repression. For 
example two insertion mutants in region 3, pI22 and pI24, 
are moderately efficient transcriptional regulators, but 
bind to the IE3 promoter very poorly in vitro. Similarly 
several mutants in region 4 have markedly reduced DNA 
binding activity, and whilst some of these have deficient 
transactivation activity (pI28, pI29 and pI32) all except 
pI29 are fairly efficient repressors of IE3 expression.
These individual descrepancies in the correlation between 
DNA binding and transcriptional activity may reflect 
differences between binding in vitro and in the nucleus of 
the transfected cell.
One mutant, pI29, which failed to bind DNA in Figure 27 
failed to produce detectable Vtnwl75 in these initial nuclear 
extracts. However, previous studies had detected low 
numbers of cells expressing nuclear Vmwl75 by 
immunofluorescence of cells transfected with pI29 (Section 
3B). When the transfections were repeated using BBS instead 
of HBS, detectable amounts of Vmwl75 could be recovered and 
shown to bind to the IE3 cap site probe when incubated at 
0°C (Figure 28). However, the complex formed was of reduced 
mobility both in the presence ("n+") and absence ("n") of 
antibody. Furthermore, a significant proportion of the 
bound DNA failed to enter the gel and remained in the well 
("w"). This may indicate that the 129 mutation induces 
incorrect processing or folding of Vmwl75, which causes it 
to migrate less rapidly through the non-denaturing 
polyacrylamide gel. Total cell extracts of cells 
transfected with pI29 had greater amounts of Vmwl75 binding 
a°tivity than nuclear extracts which may indicate that the 
Polypeptide encoded by pI29 is deficient in nuclear
loca lization .
It is also possible that the protein expressed by pI29 
unstable either in vivo or in vitro. The clustering of 
insertion sites which result in plasmids producing reduced 
founts of Vtawl75 in nuclear extracts (Table 9) may indicate
p175 pl29 
-  +  “  +
p175 pl29 pD9 
-  +  -  +  -  +i
i
<«w
«n
Figure 28: An abnormal complex is formed b L j ° t a l ^ U ; _  
extracts of cells transfe cted with P*29 addition of
«as performed at 0 C with (+) or wi ou ceiis transfected 
antibody 58S, using whole cell extracts+of cells tran ^
with P175, pD9 or pI29 . Complexes a, a , D a d fay pI2g
described in Figure 19 , the novel comp + addition of
and pD9 transfected extracts is s^1fted fails to
antibody. A  significant amount of lls when both
migrate into the gel and is re “ nen e n“ e;  absence of 
°f the mutants are assayed in the p
antibody.
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that certain regions are important for protein stablity, for 
example the regions of the protein defined by insertions 
114-18, 128—30 and 133—34. Interestingly, mutations in the 
main DNA binding domain (114-18) may result in a less stable 
protein. Apparently low levels of protein expression do not 
of themselves explain poor DNA binding since some extracts 
containing low levels of ELISA-detectable protein are 
capable of binding to DNA, for example pI34 and the deletion 
mutant pD9 (Table 10). It is also possible that the low 
ELISA measurements could be explained by failure to 
efficiently extract or detect mutant polypeptides if, for 
example, insertions effect protein solubility or 
presentation of the 58S epitope.
2.2. Analysis of deletion mutants.
The deletion mutants described in Section 3A were also 
assayed for their ability to bind to the IE3 DNA probe in 
gel retardation assays. Binding incubations were performed 
at 0°C in order to increase the sensitivity of the assay. 
These results are presented in Table 10 together with the 
results from the transcription and immunofluorescence assays 
described above (Sections 3B,C) and the relative amount of 
ELISA detectable protein in each extract. Transfections 
were repeated at least three times for those extracts which 
failed to bind DNA and the highest ELISA measurement 
recorded.
DeLuca and Schaffer (19 88) have previously reported that 
a truncated polypeptide, encoding only the first 590 amino 
acids of Vmwl75, is able to bind to DNA under some 
conditions. The results presented in Table 10 and Figure 29 
confirm their results and allow a more precise definition of 
the regions of Vmwl75 unimportant for DNA binding.
Plasmids which expressed variants of Vmwl75 with some 
DNa binding activity all have deletions which do not include 
^ino acids 229-495, (Table 10, Figure 29). Whilst not all 
Plasmids with deletions lying totally outwith this region 
express binding competent proteins (for example pD3, pD5 and 
P°7F) individual deletions which do not completely abolish 
DNA binding cover most of the rest of the gene (deletions 1, 
2F' 6* 8, 9, 11, 12 and 13; Table 10). Because large
D8 D9 11 12 13
M
»
I W k
» •
Figure 29: DNA binding by deletion mutants. Binding assays 
were performed at 0°C and further incubated with the 
monoclonal antibody 58S, using total cell extracts of cells 
transfected with deletion mutation plasmids pDl-15 (see 
Table 10 ) . Only mutants with some detectable binding 
activity are shown. The wild type (pl75) shifted complex 
(a ) is labelled, as are the host derived complexes b and c; 
weak complexes are highlighted.
Table 10: A summary of the extent and activities Qf the deletion 
mutants. ' " " ~ ■ -
Mutant Deleted Framea 
amino 
acids
pDl3 1 2 -229 IN
pD14 72 -2 9 2 IN
pD15 84-29  2 IN
pDl 162-229 IN
pD2 495-803 OUT
pD2F 496-803 IN
pD3 5 18 -591 IN
pD4 5 18 -1133 IN
pD5 562 OUT
pD6 592-774 IN
pD7 6 5 0 -1 0 66 OUT
pD7F 6 5 0 -1 0 66 IN
pD8 682-774 IN
pD9 9 3 4 -1 0 9 8 IN
pDll 1196-1239 IN
PD12 1232-1269 IN
IIF Transact. Repre: 
act.c act. 
x (SE)
n.d.9 n . d. n.d
n. d. n .d. n.d
n. d. n .d. n.d
nuc. 30 (4.8) +++
- 23 (4.0) -
cyt. 5 (0.5) +
nuc. 4 (0.5) +++
cyt. 18 (3.3) ++
- 3 (1.3) ++
cyt. 29 (2.8) +
- 27 (5.4) -
cyt. 10 (1.5) +
cyt. 57 (5.6) -
nuc. 4 (0.6) +++
nuc. 6 (2.2) +++
nuc. 7 (2.2) ++
. DNA Relative 
binding amountfof 
act.0 Vmwl75
weak 25
- 14
- 15
+ 216
- n.d
weak 52
- 107
- 27
- n.d
weak 25
- n.d
- 88
weak 95
+ 13
+ 59
+ 52
a Phase of reading frame 3* to deletion
b Cellular localization of protein as ^et0™ *  ? - not
immunofluorescence, nuc. nuclear, cy . Y P '
detectable by immunofluorecence 0~,--;Kod in Table 8
c The activation of the gD promoter as e nromoter as 
U  The qualitative ability to repress the P
described for Table 1 -i «,
e The ability of whole cell extracts m a e  ie3
transfected with each of the mutants o .o .
cap site probe in gel retardation assays j or
Binding is scored simply as positive ( + )r 9
WQ&lc
i Relative amount of Vmwl75 in eachunucle*F ®X“ eCaiven for 
determined by ELISA. (P175=100, t h e  tesjlts • «  gtven^ 
the extracts used in Figure 29, or, in the most
non-binding mutants, for extracts cont detected by
7hvwl75; out of frame proteins could not
SUSA.)
3 n»d. not done
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deletions of the protein may cause many unpredictable 
changes in protein stability and conformation, perhaps only 
those deletions which do not totally abolish DNA binding 
activity should be considered significant results. The 
results with the deletion mutants, therefore, confirm the 
conclusion from the insertion mutant assays that the main 
DNA binding domain of Vmwl75 centres around region 2.
Interestingly, deletions in regions 4 and 5 (pD9, Dll 
and D12) give rise to somewhat larger DNA complexes than 
that formed by wild type Vmwl75, although these deletion 
plasmids are predicted to express proteins of a lower 
molecular weight (Figures 28 and 29). As suggested above 
for the insertion mutant pI29 this might be caused by a 
partial denaturation of these mutant polypeptides in vivo or 
in vitro. Some proteins deficient for nuclear localization 
(pD2F, D6 and D 8 ) were able to bind to the IE3 probe, albeit 
very weakly, when extracts were prepared from whole cells 
(Figure 29); nuclear extracts of these deletion mutants did 
not contain significant amounts of Vmwl75 (results not 
shown). It is also noteworthy that deletions pDl and pD13 
which remove a serine rich phosphorylation site in region 1 
are also able to bind DNA.
3. DNA binding studies using an in vitro synthesized Vmwl75 
fusion protein.
Recent reports that purified Vmwl75 is capable of 
binding to DNA (for example, Michael et al., 19 88) raised 
the possibility that Vmwl75 expressed in vitro might also be 
capable of binding to DNA in the gel retardation assay. In 
order to investigate this a plasmid expression vector was 
constructed which could be used to transcribe and translate 
the Vmwl75 gene product in vitro. The recent success of Ace 
et al., (1988) in expressing the HSV-1 TIF, Vmw65, in vitro 
and using this in gel retardation assays, provided a hopeful 
protocol to exploit. Rather than attempt to achieve 
efficient expression from a de novo construct their 
expression plasmid, pGEMTIF, was used to create a fusion 
between the first five amino acids of Vmw65 and residues 
84-1029 of Vmwl75, terminating in 64 residues encoded by the 
out of frame 3' end of the Vmw65 gene. The construction of
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the plasmid expressing this fusion, pGEM175, is outlined in 
Section 3A4.
RNA was transcribed from EcoRI linearized pGEM175 using 
T7 polymerase, and a portion of this RNA translated in 
rabbit reticulocyte lysates, in the presence of 35S-labelled 
methionine (Materials and Methods, Section 3B28). When the 
product was electrophoresed on a 9% SDS polyacrylamide gel 
it was found to migrate with approximately the correct 
mobility for a protein of 1015 amino acids, that is between 
Vmwl75 and VmwllO (Figure 30). However, expression of the 
Vmwl75-Vmw65 fusion protein appeared to be much less 
efficient than that of Vmw65 from the parent plasmid 
pGEMTIF, on the basis of radioactive label incorporation.
Site-specific DNA binding to the IE3 cap-site probe was 
investigated using the gel retardation assay described above 
(Section 3D1). Labelled or unlabelled fusion protein which 
had been expressed in vitro was incubated with labelled 
probe in the presence or absence of mock infected cellular 
extracts. However, upon electrophoresis no novel retarded 
complexes were detected (Figure 31). The occasional 
detection of a complex ("y") running at a similar mobility 
to the Vmwl75 proteolytic cleavage complex "p" (Figure 
3lA,B) did not seem to be dependent upon Vmwl75 (Figure 
3lB) .
The failure to detect binding activity using the in 
vitro synthesized fusion protein could be for a plethora of 
reasons. Firstly, on the basis of Figure 30, inadequate 
amounts of the protein might have been expressed with which 
to detect DNA binding. It may be significant that the 
GEM175 fusion uses the first translational initiation codon 
of Vmw65, whilst a second start codon at amino acid 12 may 
be of some importance in the translation of Vmw65, but is 
deleted in this fusion, (Pellet et al., 1985; Dalrymple et 
al., 1985). Secondly, the fusion constructed might have 
lacked regions essential for DNA binding (although the 
results presented in Sections 3D2 and 3D3 would not support 
this). Thirdly, the particular fusion we constructed might 
have its DNA binding activity inhibited due to abnormal 
folding of the protein structure, in particular the presence 
of a truncated carboxyl portion of the protein might be
4GEM175
Figure 30: In vitro transcription and translation of 
PGEM175. 5ul of the proteins synthesized by the in vitro 
transcription and translation of the constructs pGEM2 (1), 
PGEM175 (2), pGEM571 (3), and pGEMTIF (4) were analyzed on a 
9% SDS polyacrylamide gel^and exposed to autoradiography.
The marker lane IE is a S-methionine labelled nuclear 
extract of an HSV-1 IE infection (kindly supplied by RD 
Everett). Whilst readily detectable amounts of Vmw65 (TIE) 
ere produced from the pGEMTIF construct, synthesis of a 
protein corresponding to the GEM175 fusion is barely 
detectable.
A 1 2 3 4 5  B 1 2 3 4 5 6 7 8  9 10 11
• 4* A  4*
Figure 31; GEM175 protein synthesized in vitro fails to bind 
detectably to DNA. (A) 5ul In vitro translated GEM175 
protein was bound to the IE3 cap site probe at 0 C in the 
presence (3,4) or absence (1,2) of 2ul mock infected nuclear 
extract and compared with the wild type Vmwl75 complex ("a") 
in lane 5. No obvious Vmwl75/DNA complexes were formed, 
even with the addition of 2180V antiserum (lanes 2&4). A 
faint novel complex "y" was further investigated in (B).
(B) Reactions 1-8 contain 2ul mock infected extract with in 
addition 5ul of in vitro translation mix of (1,2) nothing 
(3,4) pGEM175 (5,6) rabbit reticulocyte lysate alone (7,8) 
PGEM2 vector. The occurence of "y" was not dependent upon 
the addition of GEM175 protein, nor was it of similar size 
to the proteolytic Vmwl75/DNA complex "p" in lanes 10 and
11. (Lane 9: 17 infected extract assay as marker, treated 
with PK in lanes 10 and 11; reactions further incubated with 
2180V antiserum in lanes 2,4,6,8 and 11.)
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interfering with DNA binding in a similar fashion to its 
interference with transcriptional regulation (Section 3C3). 
This could be investigated by making other constructs or by 
linearizing the transcription template, pGEM175, with 
alternative restriction enzymes which would remove sequences 
downstream of the presumed DNA binding domain. An 
alternative explanation for the failure to detect binding 
would be if the protein expressed in vitro failed to be 
post-translationally modified correctly.
131
SECTION 3E: CONSTRUCTION OF RECOMBINANT RSV-1 VIRUSES
1. Strategy
The aim of the work described in this section was to 
produce stable recombinant viruses from the HSV-1 strain 17 
syn+ in which both copies of the viral wild-type IE gene 3 
were replaced with mutated versions of the gene derived from 
the plasmid-borne insertion and deletion mutants. These 
could then be used to investigate further the phenotypes of 
the mutant gene products and to determine whether the 
properties of the mutant proteins produced in a normal viral 
infection reflected their activities in the transient 
transfection assays (Sections 3B-3D). It was hoped that 
viruses with novel phenotypes might be produced which could 
separate the two primary functions of Vmwl75, 
transactivation of early promoters and autoregulation. The 
recombinant viruses would also provide ideal expresssion 
vectors to produce large quantities of the mutant 
polypeptides which could then be further characterized at 
the physical and biochemical level.
The strategy followed to produce these recombinant 
viruses was to marker rescue an HSV-1 derivative (which had 
both copies of IE gene 3 inactivated) by cotransfecting 
viral DNA with linearized plasmid DNA and then to select or 
screen for virus plaques in which the plasmid-borne copy of 
the Vmwl75 coding-sequence had replaced the inactive viral 
copy. In order to propagate the parent strain and any 
non-functional recombinants it would be necessary to 
maintain the virus on a complementing cell-line which 
expresses HSV-1 Vmwl75. The cell-line chosen was the mixed 
line M64A (equivalent to M65, Davidson and Stow, 1985) which 
had been created by cotransfecting BHK tk cells with the tk 
gene and the linked IE3 gene (carried on the Xhol-Hindlll 
fragment spanning IR^) and selecting for tk+ transformants 
on HAT medium. These were then screened for production of 
Vttiwl75 and ability to complement tsK at NPT.
A recombinant virus with the majority of the Vmwl75 
coding sequence deleted from both copies of IE gene 3 was 
constructed for use as the parent strain in the marker 
rescue experiments. This would eliminate the possibility of
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rescuing a wild type gene by intragenic recombination 
between virus and plasmid. The only alternative available 
null mutant, HSV-1 in!411, had been constructed by inserting 
stop codons near to the 5' end of the gene (Russell et al., 
1987b) and might readily be rescued to wild-type. The use 
of a parent lacking IE gene 3 sequences would also allow a 
rapid screen for recombinants regaining these sequences by 
dot blot hybridization of viral DNA with an IE3 probe.
2. Construction of HSV-1 D30EBA, a derivative of HSV-1 
in!411 with a large internal deletion in IE gene 3
The strategy for construction of this recombinant is 
outlined in Figure 32. The parent for this recombination, 
HSV-1 in!411 (Russell et a l ., 1987b), had been created by 
inserting an oligonucleotide linker encoding^translational 
stop codon in f W  reading frame and a novel Xbal
restriction site into the PvuII site at base 248 of both 
copies of the IE gene 3 coding sequence. HSV-1 in!411 viral 
DNA was cotransfected into M64A cells with plasmid pdellll 
linearized at the unique BamHI site. Plasmid pdellll 
carries a large deletion from bases 248-3806 within the IE3 
coding sequence (see Table 5 above). Virus was harvested 
from the cells and supernatant four days post transfection 
and then titred on M64A cells; 36 single plaques were picked 
under agar stained with neutral red indicator. Cell 
associated viral DNA for each of these plaques was produced 
by infecting M64A cells in 1ml Linbro wells and harvesting 
cell released virus after four days whilst extracting DNA 
from the infected monolayer. These DNAs were digested with 
BamHI overnight, resolved on 1% agarose gels electrophoresed 
in L-Buffer, and analysed by Southern blot hybridization, 
probing with pl75 DNA 32P-labelled in vitro. Figure 33A 
shows the autoradiograph of the initial screening of some of 
these plaques. Plaque D30 was chosen for further 
purification as it exhibited submolar deletions of BamHI k 
(see Table 11). After three further rounds of plaque 
purification on M64A cells this recombinant proved stable 
(see Figure 33B) and was grown up as stock of the desired 
viral deletion HSV-1 D30EBA.
The genomic structure of D30EBA was further analyzed at
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Figure 33: Isolation, screening and purification of the
recombinant virus D30EBA. Cell associated DNA was prepared 
from Linbro wells of M64A cells infected with unselected 
picked plaques, digested with BamHI and analysed by Southern 
blot. Filters were hybridized with nick translated pl75, 
and exposed for autoradiography. (A) Initial screening of 
plaques picked from cotransfection of pdellll and _inl411 DNA 
(Figure 32). Parental DNA (inl411) is included as a marker 
track and fragments spanning the IRg and TRg repeat 
sequences shown to hybridize. A novel submolar 4.3 kb 
fragment is detected in plaque D30 corresponding to the 
deleted BamHI-K fragment and forming the new joint fragment 
(k/nj) in the desired recombinant. Tracks A, D and E are 
cell associated viral DNA preparations from three different 
inl411 x pdellll transformations prior to plaque 
purification and show no detectable recombinant bands. (B) 
Viruses carrying this fragment were purified to virtual 
homogeneity by further rounds of plaque purification 
(D30EAA, EAB, EBA, EBB). Two clones D30EBA and D30EAB were 
grown up for further analysis and D30EBA was used as the 
parent deletion virus in subsequent recombination 
experiments. (M64: uninfected cellular DNA; E4: independent 
clone of the deleted recombinant virus isolated from a 
separate transfection but not purified.)
Table 11: Predicted restriction fragments of recombinant 
viruses ~ ~  “ ~ ~
a EcoRI Fragments
1. 2 - + 3. 4. 5. 6.
17 D30EBA M, 0 L, N IfJ
(& inl411)
b=e+k 21.8 17.6/0.6 20.7/1.1 17.3/4.5 20.7/0.8
c=j+k 18.1 13.9/0.6 17/1.1 17.3/4.5 17/0.8
k 5.5 1.3/0.6 4.4/1.1 4.5/1.0 4.4/0.8
b Kpnl Fragments
1. 2.+ 3. 4. 5. 6.
17 D30EBA M, 0 L, N I,J
(& inl411)
a=r+j 12.1 8.5 12.1 12.1 11.9
e=r+k 10.6 7.0 10.6 10.6 10.4
j 8.8 5.2 8.8 8.8 8.6
k 6.9 3.3 6.9 6.9 6.7
r 3.7 3.7 3.7 3.7 3.7
c BamHI Fragments
1. 2 * + 3. 4. 5. 6.17 D30EBA M, 0 L, N I,J
(& inl411)
s 2.9 2.9 2.9 2.9 2.9
q 3.4 nt=l.4 3.4 3.4 3.4
m' 0.2 0.0 0.2 0.2 0.2
y 1.8 0.0 1.8 1.8 1.6
k=s+q 5.9 nj=4.3 5.9 5.9 5.9
d Hindlll Fragments
1. 2 « + 3. 4. 5. 6.
17 D30EBA M, 0 L,N I,J
(& in!411)
m 7.5 3.9 7.5 7.5 7.3
g 4.9 1.3 4.9 4.9 4.7
b=d+g 32.1 28.5 32.1 32.1 31.9
c=d+m 34.3 30.7 34.3 34.3 34.1
e=i+g 17.6 14.0 17.6 17.6 17.4
f=i+m 19 .8 16.2 19.8 19.8 19.6
Table 11: Tables a -d give the: predicted sizes in kb of
restriction fragments spanning the IE3 loci based on the 
sequence data of McGeoch et al., (19 88b). Only those 
fragments which will hybridize to a pl75 DNA probe are 
listed. Column 1 lists the commonly used fragment names, 
and columns 2-6 list the predicted fragment sizes for wt 
HSV-1 (17+ ), the deletion D30EBA, and recombinant viruses 
from the transfections I,J,L,M,N and 0, as detailed in Table
12. nt= new terminal fragment, nj= new joint fragment 
caused by the deletion spanning q,m' and y.
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this stage by labelling viral DNA in vivo with 
32
P-orthophosphate (the technique of Lonsdale, 19 79) and 
performing restriction enzyme analysis. Figure 34 shows the 
autoradiographs of dried down agarose gels of restricted 
D30EBA DNA compared with that of the parent in!411 and 
wild-type strain 17+ . The predicted restriction map of 
HSV-1 strain 17 (and in!411) for each of the four enzymes 
BamHI, EcoR l , Hindlll and Kpnl is shown in Figure 35; only 
the regions of the genome adjacent to IE gene 3 are 
detailed. The size of these restriction fragments is given 
in Table 11, which also lists the predicted sizes of the new 
fragments generated by recombination of the pdellll deletion 
into both copies of IE gene 3.
The clone of 17+ used in these analyses clearly has an 
abnormality in its restriction profile in the region of the 
short repeat sequences. In all the restriction enzyme 
digests this virus lacks fragments spanning the a sequence 
or including sequences 3 ’ to IE gene 3 (BamHI-k, EcoRI-k, 
and Kpnl-j and k). Further abnormalities are apparent in 
the BamHl-x, y and z fragments. Fortunately the restriction 
profile of in!411, the parent of D30, appears to be as 
predicted (Davison, 1981). These abnormalities in the 17+ 
stock are probably because the stocks were derived from 
preparations which had not been plaque purified.
The 3.6kb deletion in both copies of IE gene 3 in D30EAB 
and EBA causes deletions in the joint fragments spanning the 
long and short segments of the genome and in the short 
terminal fragments. The predicted fragments have been lost 
in each case; BamHI k and y (and possibly q), Hindlll 
terminal fragments f and g and the internal m fragment,
EcoRI terminal k fragment, and Kpnl terminal fragments j and 
k. However, there is less obvious evidence of new terminal 
or internal fragments created in the recombinant genomes by 
the large deletion and acquisition of an EcoRI site (see 
Table 11). A novel BamHI fragment between n and o is 
generated, of approximately the expected size (4.3kb), and 
one new terminal Kpnl fragment of 16kb is detected, as is 
the deleted Kpnl m fragment of about 2.5kb. Both of these 
novel Kpnl fragments are arrowed.
As can clearly be seen with Southern blots of EcoRI
Figure 34; Restriction analysis of in vivo labelled D30EBA 
DNA. 32
P-labelled viral DNA was prepared by the method of 
Lonsdale (1979) and restriction digests analyzed on agarose 
gels which were dried down before autoradiography. Lane Is 
D30EAB, 2: D30EBA, 3: inl411, 4: HSV-1 strain 17 syn .
The clone of 17 used in these analyses clearly has an
abnormality in its restriction profile in the region of the
short repeat sequences. In all the restriction enzyme 
digests this virus lacks fragments spanning the a sequence 
or including sequences 3' to IE gene 3 (BamHI-k, EcoRI-k, 
and Kpnl-j and k, see Figure 35). Further abnormalities are 
apparent in the BamHI-x, y and z fragments. Fortunately the 
restriction profile of inl411, the parent of D30, appears to 
be as predicted (Davison, 19 81).
The 3.6kb deletion in both copies of IE gene 3 in
D30EAB and EBA causes deletions in the joint fragments
spanning the long and short segments of the genome and in 
the short terminal fragments (see Figure 35). The predicted 
fragments have been lost in each case; BamHI k and y (and 
possibly q), Hindlll terminal fragments f and g and the 
internal m fragment, EcoRI terminal k fragment, and Kpnl 
terminal fragments j and k. However, there is less obvious 
evidence of new terminal or internal fragments created in 
the recombinant genomes by the large deletion and 
acquisition of an EcoRI site (see Table 11). A novel BamHI 
fragment between n and o is generated, of approximately the 
expected size (4.3kb), and one new terminal Kpnl fragment of 
16kb is detected, as is the deleted Kpnl m fragment of about 
2.5kb. Both of these novel Kpnl fragments are arrowed.
SHORT EXPOSURE
BamHI 
1 2  3 4
Hindlll 
1 2  3 4
EcnRI 
1 2  3 4
Kpnl 
1 2  3 4
•  * if
m  » l»kI  s ln\,
o
F
st
uv
w
X
yz
m m  m
nm
| i i
4 * 1 rk
m
«k
LONG EXPOSURE
BamHI 
1 2  3 4
Hind III 
1 2  3 4
EcoRI
1 2  3 4
i i
: :
• ?
ii l
or
+in
it
+ +oi ,
ii ii
• °  LJ
5 eT +■o.ii iiLJ M—
cn cn — ,+ + +~o £_
ii U 11-O at ru IIat
H
C
a  -u
be; cd
QJ
T5 a
C QJ
(d Ml
a)
-C
M ■0
-q
C •
aj
ca -H
*.
M ro
x
0 a)
o c
CO QJ
cn
DO
X M
6
cd o
CQ 0
QJ 0
-C c
E-i QJ
o
cd
. -n
+ XI
cd
»— I
cn
c c
•H 0
cd ■H
Mi tr>
0 QJ
cn Mi
i—i 0)
i x:
> 0
cn
X c
*H
M-t
0 QJ
6
a 0
cd C
6 QJ
cn
c
0 r—1
•H 1
0 >
u cn
-H X
Ml
M> QJ
cn r-\
Q) 0
Ml
>4-1
r—1 O
cd
-H cn
0 a,
0 cd
cd e
CM
c
•• 0
in •H
m +j
o
QJ
Mi M
d 0
cn cn
■H QJ
Ml se
qu
en
ce
s)
 
is 
sh
ow
n,
 
ba
se
d 
on
 
th
e 
se
qu
en
ci
ng
 
da
ta
 
of
 
Mc
Ge
oc
h 
et
 
a
l
.
, 
(1
98
8b
).
 
Fr
ag
me
nt
s 
a
r
e
 
na
me
d 
ac
co
rd
in
g 
to 
th
ei
r 
mo
bi
li
ty
 
on
 
ag
ar
os
e 
ge
ls
 
(D
av
is
on
, 
19
81
),
 
on
ly
 
th
os
e 
wh
ic
h 
p
o
t
e
n
t
i
a
l
l
y
 
hy
br
id
iz
e 
to
 
pl
75
 
se
qu
en
ce
s 
ar
e 
sh
ow
n.
 
Th
e 
co
mp
os
it
io
n 
of
 
th
e 
jo
in
t 
se
qu
en
ce
s 
is 
d
e
t
a
i
l
e
d
.
Th
e 
ge
no
me
 
is
 
sh
ow
n 
on
 
th
e 
pr
ot
ot
yp
e 
or
ie
nt
at
io
n 
(s
ee
 
Fi
gu
re
 
1)
 
an
d 
th
e 
po
si
ti
on
 
of
 
IE 
ge
ne
 
3
134
digested D30EBA (see for example Figures 37 and 39) there is 
variability in the size of the two sub-EcoRl k fragments, 
which are predicted to be 1.3 and 0.6 kb in size (Table 11). 
The multiple bands are probably due to rearrangements and 
deletions of the 1.3kb fragment containing the G+C rich 
tandem repeats downstream of IE gene 3, a phenomenon also 
observed with the cloned plasmid borne IE gene 3 (Section 
3A2). These sequences also appear to hybridize very 
strongly to the probe DNA, presumably due to their great 
redundancy.
The ability of this deletion virus to be marker rescued 
to wild-type with the XhoIC fragment (spanning IE gene 3) 
provides further evidence that no gross secondary mutations 
have occured in the construction of D30EBA (see Section 
3F3 ).
3. Construction HSV-1 derivatives carrying insertion and 
deletion mutations in both copies of IE gene 3.
It was originally planned to create a large panel of 
recombinant viruses by rescuing the large deletion in the 
genome of D30EBA with a variety of the pl75 insertion and 
deletion mutants whose construction is described above 
(Section 3A). Many of these recombinants would be expected 
to exhibit reduced viability on BHK cells so it was planned 
to carry out the recombination, screening and purification 
on the non-selective, complementing cell-line M64A. At the 
same time a number of recombinations and purifications were 
performed on wild-type BHK cells which would select for 
growth of only those mutants producing proteins with 
sufficient activity to allow virus proliferation. Table 12 
summarizes the recombinations carried out and the success or 
failure of each. Unfortunately no stable recombinants were 
ever purified on the complementing cell-line M64A. This 
seems to have been due to the nature of the cell-line, and 
its growth properties. Not only are plaques slow growing 
and difficult to detect, except under agar stained with 
neutral red dye, but the cell-line also appears periodically 
to lose complementing activity, even when maintained under 
HAT selection. Furthermore, the presence of multiple copies 
of IE gene 3 integrated into the genome of these cells
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allows recombination of the parental or daughter viruses 
with these wild-type copies of the gene in addition to the 
desired viral-plasmid recombinations. Indeed stocks of both 
inl411 and D30EBA carry about 0.001-0.01% wild-type 
contaminants, presumably due to this phenomenon, and six 
apparently wild-type viruses (Pl-6) were picked after D30EBA 
DNA alone had been transfected onto M64A cells (see Table 12 
and restriction profiles in Figure 36).
The main obstacle to success in constructing a panel of 
mutant viruses therefore seemed to be one of spurious 
recombination; consequently plaques picked on M64A cells, 
which had initially seemed to exhibit the desired 
recombination were found to rearrange on further passage. 
Similar to the problems experienced with the propagation of 
plasmid pl75 in E.coli (discussed earlier, Section 3A2) many 
of these rearrangements appeared to be in the region 
downstream of the IE3 coding sequence in a highly repetitive 
region of DNA. The problems encountered are illustrated by 
following the purification of one recombinant I15HBC. The 
initial recombination was carried out on M64A cells and 
recombinant clones were clearly detectable after the first 
plaque purification (Figure 37A). On further purifications, 
however, variability in the size of fragments ranging 
between 0.5 and lkb became apparent (Figure 37C) this only 
stabilized when purification of this virus was switched to 
BHK cells (Figure 37D). The 5' EcoRI k subfragment, 
predicted to be 0.8kb in size, should be invariant, and is 
probably the (arrowed) band running just above the D30EBA 
sub-k band of 0.6kb (Figure 37C and E).
The results of attempts to recombine in several mutant 
IE3 alleles are detailed in Table 12. Only three new 
viruses were recovered which carry the desired mutation: 
02/09, N9/N10 and 115. 02 and 09, and N9 and N10, were
independently picked plaques from the same transfection.
The structures of these three viruses are shown in Figure 38 
and described in Table 13.
Figure 39 shows a representative Southern blot of EcoRI 
digested viral DNA prepared from infected Linbro wells and 
hybridized to radiolabelled pl75 DNA. Plaque purified 
isolates of the N and 0 recombinant insertion mutants are
PI 2 3 4 5 6
IH 'I b 21-8 kb18-112-616-3
* • •• k 5*5
Figure 36: Analysis of spontaneous revertants of the virus 
D3QEBA. Six plaques (Pl-6) isolated from the transfection 
of D30EBA onto non-complementing BHK cells were purified and 
cell associated DNA was prepared from BHK cells infected in 
Linbro wells. An autoradiograph of a Southern blot analysis 
performed on EcoRI digested DNA is shown, probed with primer 
extended pl75. Each of the clones has regained fragments of 
the genome which are absent in the parent D30EBA, in 
particular note the reappearance of the EcoRI-k fragment 
which spans the entire IE3 gene. (Fragments were identified 
relative to ^ 1 4 1 1  and D30EBA control digestions, not 
shown). These wild-type revertants of D30EBA were probably 
created by recombination between the viral chromosome and 
the integrated chromosomal copy of IE gene 3 in the 
complementing M64A cells.
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Figure 37: Isolation, screening and purification of the 
recombinant virus I15HBC. Successive stages in the plaque 
purification of the recombinant virus I15HBC are shown as 
autoradiographs of Southern blots on EcoRI digests of cell 
associated virus DNA. In all but the final purification 
viruses were propagated on M64A cells. (A) Initial screening 
of plaques chosen as potential positives on the basis of a 
dot blot hybridization experiment (results not presented). 
Tracks of parental D30EBA ('D') and inl411 ('in1) DNA are 
included as markers. 115 is the only clone to regain 
(deleted) EcoRI k and b fragments (see Figure 35 and Table 
11 for restriction maps). (B) Second plaque purification of 
115. Clone H was selected as carrying the deleted EcoRI b 
and k fragments. (C) Third plaque purification of 115. A  
number of clones stably maintaining the 4.4kb deleted EcoRI 
k band are shown, however, the smaller (arrowed) EcoRI 
fragments (possibly including the other deleted sub-k 
fragment of 0.8kb) were found to vary in size between 
isolates. (D) The final plaque purification was performed on 
non-complementing BHK cells. The clone I15HBC was grown up 
for further characterization. (E) Comparison of various 
stages in plaque purification analyzed together on a single 
blot. The variable sub-k fragments are arrowed.
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Figure 38: Structure and map coordinates of the DNA lesions 
of the recombinant and temperature sensitive mutants within 
the viral IE gene 3 locus. (A) The structures of the 
recombinant viruses D30EBA, I15HBC, 02 (& 09) and N9 (& N10) 
are shown. The extent of the novel deletions and the 
position of the inserted EcoRI linkers are shown for the 
copy of IE gene 3 present in IRg. The coordinates are given 
in kb. The size of the novel EcoRI k fragments generated in 
each recombinant are also given, and the position of BamHI 
sites also marked. (B) The structures of the recombinant and 
ts viruses are shown within TR„ with the appropriate 
coordinates given in kb. The IE gene 3 reading frame is 
divided into the five homology regions as shown in Figure 5. 
The map coordinates for fragments capable of marker rescuing 
the four ts mutations are given (provisional data of Drs.
V.Preston- and R.D.Everett, per.comm.). The lesion in ts!225 
has provisionally been mapped to a single base substitution 
at 150.Okb, within the most conserved portion of region 4 
(R. D. Everett, per. comm.).
Table 13: Structure of recombinant viruses: co-ordinates of
insertion and deletion mutants
1. 2. 3. 4. 5. 6.
vi rus expt. plasmid plasmid IRS TRgname co-ords. co-ords. co-ords.
D30EBA pdellll 250-3808 127.3-130.9 147.3-150.9
I15HBC I,J DIO (Dl) 483-686 130.5-130.7 147.5-147.7
02/09 M, 0 S24 (19) 752 130.4 147.9
— K,R R2A (112) 927 130 148
— U,S,F RIO (116) 1116 129.8 148.2
— T, G R74 (129) 2799 128.3 149.9
— H,Q R9 (D9 ) 2801-3292 127.8-128.3 149.4-150.4
N9/N10 L, N S61 (139) 3715 127.4 150.8
Table 13: For each recombination experiment (F-U, column 2, 
see Table 12) the co-ordinates of the site of mutation in 
the parental plasmid are given in column 4. These 
co-ordinates refer to the bases of the Vmwl75 
coding-sequence and show the extent of deleted bases or the 
co-ordinate of the site of linker insertion (see Tables 4 
and 5). The co-ordinates of the mutation sites within each 
copy of IE gene 3 in IRg and TRg (columns 5 and 6) are+based 
on the complete nucleotide sequence of HSV-1 strain 17 
(McGeoch et al. , 19 88b). The parental plasmids used in the 
recombinations are given their original construct name, and 
their published name in parenthesis (column 3).
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shown (02AA, 09 CB, N9 BA and N10DA). These have regained IE3 
sequences absent in the D30EBA parent, which are cleaved at 
the inserted EcoRI linker. The 02/09 genome has gained two 
new sub-EcoRI k subfragments of 4.4 and 1.1 kb (see Table 
11) and the N9/N10 genome has gained two new sub-EcoRI k 
subfragments of 4.5 and 1.0 kb. The 1.0 kb fragment differs 
slightly in size between N9 and N10, probably reflecting 
rearrangements in the repeat sequences downstream of IE gene 
3. Examples of picked plaques from other transfections (I, 
J, M, S, and G, see Table 12) are also shown. Clearly many 
of these clones have regained IE3 sequences not present in 
D30EBA, but the new fragments rearranged on serial plaque 
purification and did not readily correspond with the 
predicted recombinant fragment sizes.
Figure 39: Isolation and screening of recombinant viruses 
carrying lesions within IE gene 3. Southern blot analysis 
of viral DNA digested with EcoRI, resolved on a 1.0% agarose 
gel, blotted and probed with primer extended pl75 probe. 
_inl411 and D30EBA controls are included to show the size of 
the wild type EcoRI k fragment deleted in the parent virus 
(D30EBA). The novel EcoRI subfragments regained in the 
02/09 and N9/N10 recombinants are highlighted (4.4 & 1.1, 
and 4.5 & l.Okb respectively). The new l.Okb band in the N9 
and N10 recombinants may vary slightly in size due to 
rearrangements in the sequences downstream from IE gene 3. 
Also shown are several other virus plaque isolates with 
recombinant genomes isolated from early passages of 
recombination transfections, but unstable on further passage 
(115: see Figure 37; J,M,S,G,T: see Table 12). All viral 
DNA is prepared as cell associated except in the cases of 
N9/N10, _inl411 and D30EBA where DNA was prepared from cell 
released virus particles. Faint variable bands in 115 
Plaques are highlighted.
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SECTION 3F: CHARACTERIZATION OF RECOMBINANT HSV-1 VIRUSES
The basic growth, replication and Vmwl75 DNA binding 
properties were characterized for each of the recombinant 
viruses D30EBA, I15HBC, 02/09 and N9/N10. In addition five 
viral temperature sensitive mutants with lesions in IE gene 
3 were characterized. Figure 38 shows the positions mapped 
for the lesions present in these five viruses; ts!211, 1219, 
1221, 1223 and 1225, derived from marker rescue data of 
V.G.Preston and R.D.Everett (per. comm.).
1. DNA Structure
Each of the three recombinant viruses were purified on
BHK cells after initial characterization by Southern blot
analysis of cell associated DNA (Section 3E3). The
predicted sizes of restriction fragments spanning the IE3
locus are given in Table 1 1. The co-ordinates of the
inserted EcoRI site should be readily verifiable by simple
restriction enzyme mapping; however, the occurence of
deletions 3' to IE gene 3 in the plasmid clones (as
discussed above, Section 3A2) and possible variability in
the number of a sequences in recombinant viruses, might lead
to anomalies in the observed fragment sizes of recombinants.
In order to more confidently map the recombinant genomes,
32P-labelled viral DNA was prepared and analyzed by 
restriction mapping with EcoRI (Figure 40). In each of the 
recombinant genomes the terminal EcoRI k fragment spanning 
IE gene 3 has been cut. This band is regained in wild-type 
rescued recombinants of N 9 , N10 and 115 (see Section 3F3). 
The quality of the gels does not allow complete verification 
of the novel subfragments generated in each recombinant.
The 115 k band is cleaved to give the expected subfragments 
of 4.4 and 0.8kb (Table 11). The larger 4.4 and 4.5 kb 0 
and N subfragments are detected (the 0 fragment would appear 
to be somewhat larger than predicted, but carries the 
potentially variable sequences 3 1 to IE3) but the smaller 
bands are not unambiguously detected. Possible bands are 
highlighted, but these bands were well characterized by 
Southern blot analysis (Section 3E3, Figure 39).
Within the limits of these restriction analyses, caused
Figure 40: Restriction analysis of the in vivo labelled
genomes of the recombinant viruses and their marker rescued 
32revertants. P-labelled viral DNA was prepared by the 
method of Lonsdale (1979) and EcoRI restriction enzyme 
digests analyzed on 0.6% and 0.8% (pc) agarose gels which 
were dried down before autoradiography. The EcoRI k 
fragment is absent or cleaved in lanes 2 (02A A A ), 3 (09AAA), 
4 (N9BAA), 6 (N10DAA) and 8 (I15HBC); but regained in
rviruses marker rescued from these mutants, lane 5 (N9 ), 7
(NlOr ), 9 & 10 (115r ), 11 (D30EBAr ) and 12 (inl411r ).
Rescue in each case was performed with the XhoIC fragment, 
r 2excepting 115 which was rescued with a fragment internal 
to IE gene 3 (see Table 15). Note that the rescued k 
fragment in N9 is larger than in other viruses, and that as 
previously discussed (Figure 34) the k fragment is under 
represented in this clone of HSV-1 strain 17+ (lane 1). The 
novel, recombinant sub-k fragments are arrowed in the 
recombinant viruses and seem where visible to be of the 
expected sizes (see Table 11 and text). However, in this 
analysis, unlike the Southern blot above (39), the l.lkb 5' 
02/09 EcoRI-k subfragment may differ in size between the 02 
and 09 isolates, although this fragment is not clearly 
distinguishable. The variation in the 3' N9/N10 EcoRI-k 
subfragment was seen on the Southern blot and may reflect 
heterogeneity in sequences downstream of the IE3 coding 
sequence. The band labelled "?" is of unknown origin and 
frequently observed in HSV-1 EcoRI digests (Davison, 19 81).
A0-6pc 1 2 3  4 5  6 7 8  9 1 0 1 1  12 B0-8pc
17 02 09 N9 r H10 r 115 r1 r2 r0 rin
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primarily by the obvious variability in the sequences 
downstream of IE gene 3, the structure of all three 
recombinant viruses is as predicted in Table 11. This is 
supported by the ability of (at least two of) these viruses 
to be rescued by the XhoIC fragment spanning IE gene 3 
(Section 3F3). Only by subcloning and sequencing the mutant 
IE3 genes could their structure be unequivocally verified.
2. Growth properties and temperature sensitivity
The three viruses constructed from the parent D30EBA are
all viable at 37°C on BHK (non-complementing) cells.
However, as recorded in Table 14, each virus exhibits a 
degree of temperature sensitivity and I15HBC has a 
temperature dependent syncitial (syn ) plaque morphology.
The syncitial plaques formed by I15HBC on BHK cells are
smaller and less-defined than wild-type (syn+ ) plaques.
This phenotype is more marked at higher growth temperatures.
The five mutant virus strains originating from Dr 
V.G.Preston's laboratory show varying degrees of temperature 
sensitivity, or "leakiness" on BHK cells. Whilst mutants 
ts!211, ts!219 and ts!223 are severely restricted for growth 
at the NPT of 38.5°C, tsl221 and tsl225 plaque well at 
temperatures of 39°C or below, with 39.5°C being 
non-permissive, (Table 14).
3. Marker rescue of recombinant viruses
In order to ensure that any phenotypes that the 
recombinant viruses might exhibit were due to the lesions 
introduced into IE gene 3 and not caused by a second site 
mutation it was important to rescue these viruses with a 
cloned wild-type copy of IE gene 3 and then to verify that 
these rescued virus now behaved identically to wild-type 
HSV-1 17 syn+ , the original parent virus.
Marker rescue experiments were carried out on BHK cells 
by co-transfecting viral DNA and a cloned copy of the HSV-1 
17+ derived Xhol C fragment which spans IE gene 3 
(linearized plasmid pGX58). As detailed in Figure 40 and 
Table 15 this Xhol C fragment rescued both of the null 
mutant parents inl411 and D30EBA to wild-type, and the 
temperature sensitive viruses N9, N10 and ts!225 were
Table 14: Temperature sensitivity of recombinant viruses
TITRE ON BHK CELLS (pfu/ml)
VIRUS 31°C 37°C 38.5°C 39.5°C
02 AAA (cav) - 1.109 8.108 <107
09 CBA (cav) - 1.109 6.108 <107
N9 BAA (cav) 5.108 5.108 - <104
- 2.109 1.109 <107
N10DAA (cav) 4.108 5.108 - <104
— 5.108 2.109 <107
I15HBC (cav) 2.107syn+/" 5.107syn~ 3 .106syn“ —
(crv) 8.107syn+/“ 9.107syn” 3.107syn~ -
tsl211 (cav) 1.5.109 - 5.105 <104
tsl219 (cav)
g
1.5.10 - <104 <104
tsl221 (cav) 7.108 - 6.108 <104
tsl223 (cav)
9
1.5.10 - <104 <104
tsl225 (cav)
9
1.5.10 - 1.7.108 <104
Table 14: Temperature sensitivity of recombinant viruses
Titres given (pfu/ml) were obtained by fixing and staining 
infected cell monolayers 2 days post infection (3 days at 
31°C). The syncitial phenotype of I15HBC_is recorded; syn 
virus forms wt non-syncitial plaques, syn plaques are 
syncitial.
Table 15: Marker Rescue of Recombinant Viruses
Expt. Virus Rescuing
DNA 31°C
Titre
37°C
(pfu/ml)
39.5°C
5 tsl225 none 9.104 _ <1.102
6 tsl225 PGX58 5.104 - 3.104
7 N9BAA none >5.106 - <1.102
8 N9BAA pGX5 8 4.105 - 1.105
9 N10DAA none 4.106 - <1.102
10 N10DAA pGX5 8 3.104 - 2.104
1-1 D30EBA none - <10 -
1-2 D30EBA pGX5 8 - 3.106 -
1-7 inl411 none - 10 -
i 00 inl411 pGX5 8 - 6.105 -
1-9 I15HBC none 2.106 (+) - 2.105 (-)
1-10 I15HBC pGX5 8 >5.106 - 3.106 (+)
2-1 I15HBC pI24 EcoRI- 
Sall frag.
3.106 (+) — 2.5.104 (+/
Table 15: BHK cell monolayers were transfected with 0.5ug
of cell released viral DNA with or without a ten-fold molar 
excess of linearized rescuing DNA. pGX58, cut with Xhol, 
contains the HSV-1 Xhol C fragment (co-ordinates 
123.0-133.5); the EcoRI-Sall fragment prepared from pI24 
(Table 4) spans bases -129 to +2041 of the IE gene 3 ORF and 
includes those bases deleted in I15HBC (483-686). The 
monolayers were harvested after 3 days incubation at 31 C 
and titred at 31, 37 and 39.5°C. The plaque morphology of 
experiments 1-9, 1-10 and 2-1 is recorded as + (syn ) - 
(syn ) or +/- (a mixture).
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rescued to virus capable of growth at the NPT. The 
temperature dependent syncitial mutant I15HBC was rescued to 
wild-type both with the Xhol C fragment and with a 2.2kb 
fragment from the 5' end of the IE3 ORF (-126 to +2041).
This result implies that the unusual plaque morphology of 
this virus is due to the lesion in IE gene 3 and not some 
second site mutation. This defines a novel phenotype for 
viruses producing mutant Vmwl75 polypeptide. The small and 
syncitial plaque phenotype of I15HBC (deleted for amino 
acids 162-229) is similar to that of a virus described by 
Schroder et a l ., (1985) with a spontaneous deletion within 
the IE3 coding region removing codons 209-236, although it 
was not clear that the small plaque morphology of their 
mutant was a direct consequence of this deletion.
4. Gene expression: polypeptide profiles of recombinant 
viruses
Preliminary experiments were performed to examine the 
gene expression properties of the recombinant viruses. BHK 
monolayers infected at a moi of 10 pfu/cell in
methionine-free EC5 were labelled overnight with
^S-methionine at 31 or 39.5°C and the protein extracts were 
resolved on 7.5 or 10% SDS-PAGE gels (Figure 41). The 
phenotypes of the recombinant viruses were compared to 
wild-type virus (17+ ) and the well characterized virus tsK 
which possesses a "tight" temperature-sensitive mutation in 
Vimwl75, allowing no early or late gene expression at the 
NPT. At 39.5°C the viruses N9, N10, tsl211, 1219, 1221,
1223 and 1225 all overexpress Vmwl75, showing a failure to 
autoregulate IE gene expression. However, all of these 
mutants exhibit a different pattern of gene expression to 
tsK and are "leaky" in the sense that they allow expression
of later classes of genes, for example VP5. Whilst some of
the viruses are deficient in some late gene products, such 
as Vmw65 (tsl211 and 1219) others show few obvious 
deficiencies compared to wild-type. I15HBC seems to grow 
poorly, and may shut-off host gene expression less 
efficiently than wild-type (Figure 41). 02 and 09 induce a
polypeptide profile similar to that of wild-type at both NPT 
and PT and do not overexpress Vmwl75 at NPT. These
Figure 41: Polypeptide profiles of recombinant and
temperature sensitive viruses at permissive and
non-permissive temperatures. SDS polyacrylamide gels of 
35 S-methionine labelled total cellular proteins. The 
positions of IE proteins vmwl75, 110 and 63 and the early 
and late proteins RR1, VP5 and Vmw65 are shown. (A) (7.5% 
Gel) ts-Viruses labelled from 2-3.5h p.a. or Q-18h p.a. at 
39.5°C. (Lane 1) tsK, (2) tsl225, (3) tsl223, (4) tsl221, 
(5) ts!219, (6) ts!211, (7) 17 + , (8) mock infected. None of 
the ts viruses are as restricted in early and late gene 
expression as tsK. All of the ;ts viruses overexpress Vftiwl75 
but express late gene products to different extents (for 
example VP5 and Vmw65). (B) (10% Gel) Recombinant viruses
labelled for l-18h p.a. at 33°C and 39.5°C. (Lane 1) mock, 
(2) 02, (3) 09, (4) N 9 , (5) N10, (6) tsl225, (7) I15HBC, (8) 
17+ , (9) tsK. At 33°C the pattern of polypeptides 
synthesized by all of the viruses resembles that of WT 
(17+ ). The recombinants N9 and N10 overexpress Vmwl75 at 
the NPT, like ts!225 and tsK. Otherwise the polypeptide 
profiles of the 02/09 and N9/N10 recombinants more closely 
resemble that of WT (17+ ) virus than the tsK control. The 
02 and 09 recombinants autoregulate Vmwl75 production at 
NPT. The virus 115 appears to shut off host polypeptide 
synthesis at 39.5°C inefficiently.
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preliminary results should be confirmed and investigated in 
more detail.
5. DNA replication by recombinant viruses
The ability of the recombinant viruses to replicate 
viral DNA was determined at the permissive and 
non-permissive temperatures. BHK cells were infected at a 
moi of lOpfu/ml in Linbro wells and cell associated DNA 
prepared 0 or 16 hours post infection at PT or NPT. Levels 
of viral DNA recovered were measured by slot blot 
hybridization using as a probe pGX156 which carries the 
viral EcoRI H fragment spanning U . The results areO
presented in Figure 42.
All the viruses assayed are replication competent at 
33°C. However, I15HBC replicates less efficiently than 
wild-type in that the level of input DNA is far higher, 
probably reflecting the low titre and poor growth of this 
virus and indicating that it probably has a high particle to 
infectious pfu ratio. Furthermore, over the time-course of 
this experiment I15HBC fails to achieve net DNA synthesis at 
37°C, although it does plaque at this temperature. None of 
the t^ s or recombinant viruses assayed replicate DNA at 
39.5°C as measured in this assay, although I15HBC is capable 
of forming minute syn~ plaques at this temperature. 
Replication of I15HBC DNA may be obscured if the proportion 
of infectious input DNA is small as a consequence of a high 
particle to pfu ratio. It is interesting that although few 
deficiencies in viral gene expression at NPT could be 
detected (Section 3F4) none of the viruses could replicate 
DNA. As vmwl75 is reportedly not directly required for DNA 
replication (see Section 1 B 3 ) this might suggest that Vmwl75 
has a critical role in controlling the expression of 
replication functions, and that this function differs 
somehow from the activation of other early genes.
6. Site-specific DNA binding by Vmwl75 produced by 
recombinant viruses
Nuclear extracts of virally infected Flow HeLa cells 
were assayed for Vmwl75 site-specific DNA binding activity 
to the IE3 cap site as described above (Section 3D) using
53°C »5°C
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Figure 42: DNA synthesis by the recombinant and temperature 
sensitive viruses at the permissive and non-permissive 
temperatures. The ability of recombinant and ts viruses to 
replicate viral DNA was examined at permissive (33°C) or NPT 
(39.5°C). Total cellular DNA was prepared immediately post 
absorption (Oh) or 16-18h p.a. and viral DNA quantified by 
dot blot analysis using primer extended pGX156 DNA as probe.
(pGX156 carries the EcoRI h fragment which spans UL ) .
Assays are shown for HSV-1 strain 17 (17), _tsK, ts!211
(11), tsl219 (19), tsl223 (23), tsl225 (25), tsl221 (21),
02A A A , 09CBA, N9BAA, N10DAA, and 115HBJ; all infected at 
5pfu per cell. All viruses, except 17 , failed to replicate 
their DNA significantly at 39.5°C, although DNA replication 
by 17+ itself is reduced at this temperature (panel B ) . All 
viruses replicated DNA at 33°C, although I15HBC was 
inefficient in this experiment. (I15HBC would also seem to 
have a high particle to infectious pfu ratio on the basis of 
this experiment, as the amount of input viral DNA at Oh pa 
is much greater than with the other viruses.) The 02/09 and 
N9/N10 recombinants synthesized DNA at 37°C, whilst I15HBC 
fails to accumulate a significant net gain in viral DNA at 
this temperature in this experiment.
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the gel retardation assay. As shown in Figure 43 this assay 
can be used to characterize mutants temperature-sensitive 
for DNA binding by varying the temperature of the 
incubation. In this case Vmwl75 present in extracts made 
from cells infected with tsK was able to bind to DNA at 0,
20 and 30°C, but when the incubation was carried out at 
38.5°C (the NPT for viral growth) no Vmwl75-containing 
complex "a" was formed. The phenotype of the extracts was 
identical whether the viral extracts were prepared at the PT 
or NPT. The failure of tsK-Vmw!75 to bind to the IE3 cap 
site at NPT correlates with the failure of this virus to 
autoregulate IE gene 3 expression in vivo at the NPT.
(i ) ts viruses
Nuclear extracts prepared at PT or NPT from HeLa cells 
infected with each of the five _ts mutants tsl211, 1219,
1221, 1223 and 1225 were able to form specific Vmwl75/DNA 
complexes when incubated at 33°c (Figure 44A). However, at 
39.5°C only the ts!225 extract could efficiently form the 
complex "a". This complex was still formed at 40°C, 
although at these temperatures both ts!225 and wild-type 
Vftiwl75 bind less strongly. Furthermore, the complex formed 
by ts!225-Vmwl75 shows identical sensitivity to increasing 
salt concentration as the wild-type complex, at both PT and 
NPT (Figure 44B). Thus although t^sl225 overexpresses Vmwl75 
at the NPT in vivo, this is not correlated with an in vitro 
failure to bind to the IE3 cap site.
(ii) Q and N recombinant viruses
Vtnwl75 in extracts prepared from cells infected with the 
recombinant virus 02/09 bound to the IE3 probe as 
efficiently as wild-type Vmwl75. However, N9/N10 encoded 
Vttiwl75 is temperature sensitive for site-specific DNA 
binding (Figure 45). Thus the mutant allele of IE3 present 
in 02/09 behaves as predicted from experiments with its 
parent plasmid pI9, which contains a twelve bp insert at 
base 752. The temperature sensitivity of N9/N10-Vmwl75 DNA 
binding activity was not expected from initial studies on 
its parent, pI39 (insert at amino acid 1239), but further 
analysis of the binding activity detected in nuclear 
extracts of cells transfected with this plasmid confirm that 
this too is temperature sensitive (Figure 45). At the NPT a
3 0 ° C 3 8 . 5 ° C
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Figure 43: The HSV-1 mutant tsK produces Vtowl75 with 
temperature sensitive DNA binding properties. Nuclear 
extracts of wild-type (17 ) and tsK HSV-1 infected cells 
were prepared 5h pa at both the permissive (31°C) and 
nonpermissive (38.5 C) temperatures. DNA binding to the IE3 
cap site was assayed as described above (Section 3D) at 30°C 
and 38.5°C. Formation of the tsK-Vmw!75/DNA complex was 
found to be ts whether the virus was grown at NPT or PT.
bound
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Figure 44: The site-specific DNA binding activities of 
Vmwl75 synthesized by the ts viruses at permissive and 
non-permissive temperatures. (A) Total cell extracts were 
prepared from cells infected at PT (33°C) and NPT (39°C) 
with HSV-1 17+ and the five ts viruses (tsl211, 1219, 1221, 
1223 and 1225 ) . These were assayed for DNA binding to the 
IE3 cap site at 33°C and 39°C. Whereas all of the ts-Vmw!75 
proteins were capable of forming complex "a" when assayed at 
33 C, only ts!225-Vmwl75 bound efficiently to DNA at 39°C 
(although some of the other mutants seemed to bind DNA 
weakly at this temperature). The Vmwl75/DNA complex ("a") 
formed by some of the ts mutants, notably tsl211 and ts!219, 
was of reduced mobility on the gel, indicating structural 
differences between mutant and wild-type polypeptides. (B) 
The salt-sensitivity of ts!225-Vmwl75 DNA binding was 
investigated at 30°C and 40°C and compared with 
wt(17 )-Vmwl75. Binding was carried out in the presence of 
100, 300, and 500mM NaCI. The salt-sensitivity of wt and 
tsl225 Vmwl75 was shown to be very similar at both 
temperatures, with the ts protein perhaps binding marginally 
less strongly at the elevated temperature. It is 
interesting to note the appearance of a novel 
uncharacterized complex, running below "c", when wt-Vmwl75 
complex "a" is dissociated at high temperature and salt 
concentration. This may be related to the complex "z" seen 
in Figure 1 9 B, but has not been investigated further.
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Figure 45: The site-specific DNA binding activities of 
Vrtiwl75 synthesized by the recombinant viruses at permissive 
and non-permissive temperatures. Vftiwl75 in total cell 
extracts of Flow HeLa cells infected with the two viral 
Vmwl75 insertion mutants (02/09 and N9/N10) bound like 
wt-Vmwl75 to the IE3 cap site, assayed as previously 
described at 0°C. The Vmwl75 produced in extracts of cells 
transfected with parent plasmid of the N9/N10 insertion 
mutant, p I 3 9 , also bound to DNA at 0 C but like the virally 
expressed protein failed to form the Vmwl75-DNA complex 
("a") at 39°C. At this elevated temperature there was 
evidence that this mutant t£3 protein was binding weakly to 
the probe to form abberant complexes of reduced mobility "n" 
and "w", As discussed with the abberant complexes formed by 
other insertion and deletion mutants of Vmwl75 mapping 
towards the carboxy-terminus of the protein (see Figure 28) 
this might be caused by partial denaturaton of the protein 
at the carboxy-terminus, causing the complex to migrate more 
slowly into the gel.
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slight degree of complex formation is still observed with 
these extracts which runs into the gel with somewhat reduced 
mobility ("n" ), and seems to be trapped in the wells to some 
extent ("w"). This phenotype resembles that seen with other 
mutants towards the C-terminus of Vmwl75 (pI29, pD9, pDll 
and pD12) and it has been speculated that this may reflect a 
denaturing of the C-terminus region of the protein, which 
does not seem to be directly involved in DNA binding. As 
with tsK the failure of N9/N10-Vmwl75 to bind DNA in vitro 
correlates with IE gene overexpression in vivo at the NPT; 
whereas 02/09-Vmwl75 does bind DNA at the NPT and does not 
markedly overexpress IE genes in vivo.
(iii) 115 recombinant virus
The recombinant virus I15HBC has previously been shown 
to grow poorly especially at elevated temperatures, and less 
ELISA detectable Vmwl75 and Vmwl75/DNA binding activity 
could be prepared from cells infected with I15HBC than with 
other viruses (results not shown). However, I15HBC-Wiwl75 
did seem to bind the IE3 probe as efficiently at 39°C as at 
0°C, (Figure 48). The complex formed was identical to that 
formed by Vmwl75 expressed from its parent plasmid pDl which 
is deleted from bases 483 to 686 of the IE3 ORF (amino acids 
162-229) (Figure 46, see also Figure 20). Treatment of the 
I15-Vmwl75 DNA complex with increasing amounts of proteinase 
K (as described in Section 3D1.4) produced a novel retarded 
band "p" of identical mobility to that formed from wild-type 
Vmwl75 (Figure 47). Thus if this complex is composed of the 
minimal DNA binding domain it is unliKely that amino acids 
161-227 are part of this domain, or complex "p" would be of 
reduced size when formed from I15-Vmwl75. The proteinase K 
treated complexes obtained with pDl-expressed Vmwl75 were 
identical to the 115-expressed complex.
(i v ) rescued viruses
Nuclear extracts were prepared from HeLa cells infected 
with viruses rescued from mutants (described in Section 3F3 
above) and assayed for Vmwl75/DNA binding activity (Figure 
48). Each of the rescued viruses behaved like wild-type, 
confirming that the DNA binding phenotype had been due to 
the rescued lesion, not a second site mutation.
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Figure 46; Vmwl75 specified by the recombinant virus I15HBC 
binds to DNA to form a complex identical to that specified 
by its parent plasmid pDl. DNA binding of mutant Vmwl75 
exgressed by the recombinant virus I15HBC was assayed at 
20 C and the Vmwl75-DNA complexes produced compared to those 
produced by HSV-1 strain 17 infected cells (17 ) and pl75 
and pDl transfected cells. Reactions 4, 5, 7 & 8 were 
further incubated with lul of (1/50) 58S antibody before 
electrophoresis. Like the complex produced by the parental 
plasmid-borne mutation, the I15-Vmwl75/DNA complex was 
marginally smaller than the wt complex "a" (see also Figures 
20 and 48 ) .
Figure 47: An identical proteolytic fragment of Vftiwl75 binds 
to DNA when synthesized by wild-type virus, the recombinant 
I15HBC or the plasmid pDl. The production upon protease K 
(PK) digestion of the novel protein-DNA complex "p" was 
assayed as described in Figure 23. Extracts were made from 
cells infected with HSV-1 17 , I15HBC, or transfected with 
pDl.
Lane Extract
i
PK Antibody
2180V
Lane Extract
t
PK
A1 17+ Ong 0 B1 17+ OngA2 17+ Ong 3ul B2 17+ lng
A3 17+ 20ng 0 B3 17 lOngA4 17 + 20ng 3ul B4 115 Ong
A5 17+ lOOng 0 B5 115 lng
A6 17 lOOng 3ul B6 115 lOng
A7 115 Ong 0 B7 pl75 Ong
A8 115 Ong 3ul B8 pl75 lng
A9 115 20ng 0 B9 pi 7 5 lOng
A10 115 20ng 3ul
All 115 lOOng 0
A12 115 lOOng 3ul
The results show that the proteolytically produced complex 
"p" is identical whether specified by wt or 115 virus, or by 
the parent plasmid pDl. Furthermore, in this experiment 
115-directed complex "p" may be formed somewhat more 
efficiently than the native I15-Vftiwl75 complex "a". Because 
the three independent "p" complexes are of apparently 
identical size, the proteolytic fragment of Vmwl75 in "p" 
probably does not include the region of the D1/I15 deletion 
(amino acids 162-229 ).
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Figure 48; Vmwl75 synthesized by viruses marker rescued from 
the recombinant and ts viruses binds to DNA at both 
permissive and non-pemissive temperatures. Each of the 
rescued viruses described in Table 15 were assayed for 
Vftiwl75-DNA binding activity at 0°C (A) and 39.5 C (B).
Vtnwl75 in infected cell extracts of all of the rescued 
viruses bound to the IE3 probe to form complex "a" (-) 
which was shifted to complex "a " upon further incubation 
with 58S antibody prior to electrophoresis (+). At 39.5°C 
each of the mutant polypeptides behaved as previously 
described; no Vmwl75/DNA binding activity was detectable in 
extracts of cells infected with the N 9 , N10, in!411 and 
D30EBA recombinants. However, rescued isolates of these 
viruses (in adjacent tracks) were able to direct production 
of the vmwl75/DNA complex. Also note that I15HBC-Vmwl75 
could bind to DNA at the elevated temperature, and that the 
("a") complex formed by this protein is marginally smaller 
than that formed by both its rescued clones (rl-10 and 
r2-l).
Mutant and rescued viruses are as follows: ts!225/r6; 
N9BAA/r8; NIODAA/rlO; D30EBA/rl-2; inl411/rl-8; I15HBC/rl-10 
(XhoIC rescued)/r2-l (rescued with a fragment internal to 
the IE3 gene, -126 to +2041).
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CHAPTER 4: FURTHER STRUCTURAL ANALYSIS 
OF THE Vmwl75 RELATED POLYPEPTIDES
1. Features of the genes encoding the Vmwl75-related 
polypeptides.
The sequence of HSV-1 IE gene 3 and its counterparts 
from VZV and PrV has been determined and the amino acid 
sequence of the encoded proteins predicted (McGeoch et al. , 
1986; Davison and Scott, 1986; C.Vlcek, M.Schwyzer and 
V.Paces, per.comm.). Each of the three DNA coding sequences 
is markedly G+C rich (Table 16). The HSV and PrV DNA 
sequences are remarkably G+C rich throughout the entire 
genome, but particularly high in this gene. The G+C content 
of the VZV 140K ORF is less extreme, but greatly exceeds 
that of the VZV genome as a whole.
The amino acid composition of the three proteins is 
similarly biased towards amino acids encoded by G+C rich 
codons, in particular the amino acids glycine, alanine, 
arginine and proline (GARP) are extremely abundant in all 
three proteins (Table 17). It would appear that HSV and PrV 
at least have evolved to maximize G+C content to the 
greatest amount possible in this gene without interfering 
with protein function, and that evolutionary forces have 
acted to maximize the high G+C content by favouring amino 
acids with G+C rich codons and by favouring synonymous 
codons with G or C in the third position. Consequently 
amino acids with A+T rich codons appear to be 
under-represented (for example leu, asn, ile and met) 
(McGeoch et al., 1986). It has also been suggested that 
regions of particularly high GARP content, including large 
parts of regions 1 and 3, may be relatively unimportant 
functionally, this would appear to be borne out by the 
results in this thesis.
2 . Homologies between Vmwl75 and other herpesvirus
transactivatinq IE proteins.
As discussed in Section 1D1.5 the three proteins Vrawl75, 
VZV 140K and PrV IE protein are highly homologous in three 
regions A, B and C (Figure 5). The proteins have been 
divided into five potential structural regions (1-5) on the
Table 16: Base composition of the IE genes.
IE gene ORF Viral chromosome
VZV 64.1% G+C 46.0% G+C
HSV 81.4% G+C 68.3% G+C
PrV 79.8% G+C 73% G+C
The base composition of the three sequenced IE genes is 
given, compared to that of the total virus chromosome. 
(Davison and Scott, 1986; McGeoch et al., 1986, 1988; 
Ben-Porat and Kaplan, 1962; C.Vlcek, M.Schwyzer and V.Paces 
per.comm.).
Table 17: Amino acid composition of the IE protein.
A R P G S
ala + arg + pro + gly = ser
20.9 10.7 12.4 10.9 = 54.9 5.9
10.9 9.7 11.3 9.2 = 41.1 9.2
17.4 11.1 12.4 10.7 = 51.6 9.2
The percentage occurence of common residues in the predicted 
amino acid sequences of the three IE proteins (HSV-1 Vmwl75, 
PrV IE protein and VZV 140K ORF) is given. (From the 
sequence data of McGeoch et al., 19 86; Davison and Scott, 
1986; C.Vlcek, M.Schwyzer and V.Paces, per.comm.).
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basis of these blocks of homology (Figure 49; Tables 18 and 
19). It has been predicted that these conserved regions 
might correspond to functionally important regions of the 
proteins.
3. Interesting structural features of the protein sequences.
3.1 Homology region A.
This highly conserved region is composed of a serine 
rich tract followed by acidic residues (asp and glu) (Figure 
50). It has been proposed that these serines are the major 
phosphorylation site for Vmwl75 (DeLuca and Schaffer, 1988). 
Phosphorylation could play an important role in regulating 
protein activity and differentially phosphorylated forms of 
Vftiwl75 may have different biochemical properties (Michael et 
al., 1988). When phosphorylated this region would be highly 
acidic, and could perhaps function as an acidic 
transcription activating region (Section 1E3.3). However, 
the results presented in this thesis show that this region 
is not absolutely required for either transactivation or 
repression activity in transfection assays (Section 3C3) and 
that a virus deleted for this region of the protein is 
viable on non-complementing cell-lines (Section 3F).
3.2 The carboxyl terminus.
The non-conserved region 5 varies in size between the 
three proteins, (Figure 49, Table 18). However, some 
similar structures can be found within this region. Each 
protein includes an acidic string of 6-9 residues near to 
its carboxy-terminus (Figure 51a). The VZV acidic region 
also includes a short polyserine tract and may in fact be 
related to homology region A (see below, 3.4). An 
alternative relationship between the carboxyl termini of 
Vinwl75 and VZV 140K has been suggested, with the terminal 
residues of Vmwl75 being conserved 80 residues upstream from 
the VZV 140K terminus (Figure 51b, McGeoch et a l ., 1986).
3.3 Potential nuclear localization signals.
Sequences necessary for the nuclear localization of
Vftiwl75 have been mapped to within amino acids 682—774 (this 
thesis, Section 3B). Within this sequence is a short basic
l/>
c;
la
CO
o
T3
3
O
X
V)
C
*cd
o
Ql
CO
CD
CD
CO
73
CD
.C
c
CD
CD
CD
a
c
0 
0) 
i—
CO
01
Eo
O
CD
Oc
CD
13
Of
CD
CO
o
<
o
c
£
<
CD
</>o
N
_C0
oo
1—
CO
>
T3
c
CO
X
o
Q
§
’ ( /)
C/)
CD
Qi
j_
CD
X
co
CO
CD
r^
c
*<D
O
x_
CL
LU
>
cc
CL
CO
CO
CO
O)
CM
CL
o
>
<0
X
in
co
co
o
T—
CO
T-
c
cd
o
»_
CL
*
o
>
N
>
K$&Mi
Pi
Si
il
LO
CO
t CM
03
CD
X
o
"*g
*o
CO
T3cz
CO
CD
CZ
S
C/5
>,
O
X
o
LJLJ
CO
CO
CO
CO
CO
C/5
CDocz
CD
Z3
cr 
CD <73
C/3
CO
0)
-i—>
CO
cz
CD
CD
£
CD
_Q
CZ
CD
"O
O
CDIo
LO
CD
CD
CO
c
CD
CD
g
Q)
JD
>.
CZ
CD
XJ
LO
I
LO
CO
c
CD
-t—<
CZ
oo
o  >_
X
0
d) »_
<
JCO
<
JO
03
*-CZ
>* 1 
CD
>
O
H— *
CD
Z3
~0
CZ
COo
V|—
"c
03
C/3
O
CZ
>»
X)
CO
JO
o
c
CD
*o
o"
LO
CM
LO
Fi
gu
re
 
49
: 
Am
in
o 
ac
id
 
se
qu
en
ce
 
co
mp
ar
is
on
 
be
tw
ee
n 
th
e 
ma
jo
r 
im
me
di
at
e 
ea
rl
y 
pr
ot
ei
ns
 
of
 
p
s
e
u
d
o
r
a
b
i
e
s
,
 
he
rp
es
 
si
mp
le
x 
an
d 
va
ri
ce
ll
a 
zo
st
er
 
vi
ru
s.
 
(A
ft
er
 
Vl
ce
k,
 
Sc
hw
yz
er
 
an
d 
P
a
c
e
s
 
p
e
r
.
c
o
m
m
)
.
 
Th
e 
th
re
e 
pr
ot
ei
n 
se
qu
en
ce
s 
ar
e 
al
ig
ne
d 
to
 
sh
ow
 
th
e 
tw
o 
ma
jo
r 
an
d 
on
e 
m
i
n
o
r
 
co
ns
er
ve
d 
re
gi
on
s 
(r
eg
io
ns
 
2 
an
d 
4 
an
d 
ho
mo
lo
gy
 
re
gi
on
 
A,
 
th
e 
p
o
l
y
s
e
r
i
n
e
/
a
c
i
d
i
c
 
t
r
a
c
t
)
.
Table 18: The five regions of the conserved IE proteins. 
REGION HSV-1 Vmwl75 PrV IE protein VZV 140K ORF
1 1-314 (314) 1-470 (470 ) 1-467 ( 467)
2 315-484 (170) 471-659 (189) 468-641 (173)
3 485-796 (312) 660-957 ( 298) 642-734 (92)
4 797-1224 (428 ) 958-1350 (393 ) 735-1148 (414)
5 1225-1298 (74) 1351-1446 (96) 1149-1310 (162)
The five regions of the three homologous alphaherpesvirus IE 
proteins are shown, numbered in amino acids, as defined by 
C.Vlcek, M.Schwyzer and V.Paces (per.comm.). The sizes of 
each region are given in parenthesis.
Table 19: Conservation of regions 2 and 4 between the 3 IE 
proteins.
Region 2 Region 4
Identity between
PrV/HS V/ VZV 36% 45%
Additional
identity
between: Region 2 Region 4
PrV/VZV 17% 12%
PrV/HSV 15% 10%
HSV/ VZV 10% 11%
(Data of C.Vlcek, M.Schwyzer and V.Paces, per.comm.). The 
proportion of regions 2 and 4 conserved as identical amino 
acids between each of the three IE proteins (HSV-1 Vmwl75, 
PrV IE protein and VZV 140K ORF) is shown. Regions 2 and 4 
are 35-45% identical between all three proteins, whilst 
regions 1, 3 and 5 are 15-25% identical, which mainly 
reflects the high ala+arg+gly+pro content of the proteins as 
a whole. (The amino acid identity between PrV and VZV in 
region 2 therefore is 36 + 17 = 53%).
Figure 50: The structure of homology region A.
176 186 206
HSV SASSTSSDSG SSSSSSASSSSSSSDEDEDDD
353 373
VZV SSSSSSSWGSSSEDEDDE
377 401
PrV SASSSSSSSSSSSSSSSSSSSEGEEDE
The amino acid sequences of the serine rich homology region 
A is given for the three IE proteins HSV Vmwl75, VZV 140K 
and PrV IE. The deletion in the HSV IE3 ORF in plasmid pDl 
and the recombinant virus I15HBC spans amino acids 162-229. 
The spontaneous deletion described by Schroder et a l .,
(1985) spans amino acids 209-236. The PrV IE protein also 
has a highly serine rich stretches between amino acids 830 
and 953. The potential charge on each amino acid (+/-) is 
shown below each residue.
Figure 51: A conserved region at the carboxy-terminus of the
IE proteins?
(a) HSV ..PPRRVVDWEGAVVDEDDGGAFEGDGVL
VZV ...VELLSSSSSSEDEDDVWGGRGGRSPPQSRG
  + + +
PrV ..RPRLGPIKVEAISDDEEAEDAGNPYLLLR 
+ + + -  —  +
(b) 1274 1298
HS V . . RREVVDWE____GAWDEDDGGAFEGDGVL
* * * *  * * *  * *  * *
VZV . . ALELDDWEVGCEDAWDSEEGGGDDGDAPGSSF , . . .QSRG
1225 7 1310
(a) The predicted amino acid sequence is shown for the 
carboxyl-terminus of each of the three IE proteins HSV 
Vtawl75, VZV 140K and PrV IE. Each protein has a short run 
of acidic (D or E) residues close to the carboxyl terminus. 
In the VZV protein this structure closely resembles that of 
homology region A, with a serine string preceding the acidic 
run. The potential charge on each amino acid (+/-) is shown 
below each residue. (b) An alternative relationship between 
the carboxy-termini of the HSV and VZV proteins was 
suggested by McGeoch et al., (19 86). The sequence at the 
terminus of Vmwl75 was found to be similar to a region 80 
residues upstream from the 140K terminus. These sequences 
are aligned and identities asterixed.
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string of amino acids RKRK which is related to nuclear 
localization signals identified in other proteins (Kalderon 
et al., 1984) and is conserved in VZV 140K (Figure 52).
This sequence is not identically conserved in the PrV 
sequence, but related basic strings are found in the 
equivalent area of region 3, which could be involved in 
nuclear localization.
3.4 Repeated amino acid strings.
Related amino acid strings are found within each of the 
three Vmwl75-related proteins. It is not clear whether 
these tru ly represent the result of ancestral duplications 
within the coding sequence or are merely a consequence of 
the high GARP content of the proteins. These repeats were 
analyzed in detail using the COMPARE program to search for 
repeated amino acid strings within each protein, scoring for 
identical amino acids, with varying stringencies. Far fewer 
apparent repeats were detected in the VZV protein sequence 
at a given stringency, probably reflecting the lower GARP 
content of this protein.
Some of the more interesting repeated strings are shown 
in Figure 53, aligned by the BESTFIT program. Elements (i) 
and (iii) may be examples of sequences picked out as 
homologous on the basis purely of their high GARP content. 
Element (ii) identified in the PrV protein is more 
interesting as it identifies a second serine rich area of 
this protein between residues 830 and 875. The relationship 
between this sequence and homology region A (370-400) is 
probably simply a reflection of the high serine content of 
both proteins. The VZV homology region A is also picked out 
as a possible repeated element by this analysis (element iv) 
and appears to be repeated at the carboxy-terminus of this 
protein. Vmwl75 does not posses either of these second 
serine rich regions, and has a much lower serine content 
than the other two proteins (Table 17).
3.5 Acidic regions.
Because of the identification of protein domains rich in 
acidic amino acid side chains as transcriptional activating 
regions (Section 1E3.3) it was interesting to examine each
Figure 52: The potential nuclear localization signals of the 
IE proteins.
727
HSV RKRKS
682
VZV RKRKS
883 927
PrV RRKKKRR RRKRR
The amino acid sequences of potential nuclear localization 
signals in region 3 of the IE proteins are shown. The HSV 
sequence is within the boundaries of a region identified as 
essential for nuclear localization (this thesis; DeLuca and 
Schaffer, 1988) and is closely conserved in VZV. Strings of 
basic residues in the similar region of the PrV protein are 
also shown.
Figure 53: Repeated amino acid strings in the Vmwl75-related proteins.
(a) Prv IE x Prv IE
55 PGGPLLRRRRRGRGRRPRGRGRS 77
M') ! i i i i i i  i i i i iV J- / l I I I I I I  | t | | i
325 PPQRQPRRRRAGEGALRRGRGFS 347
364 PSAPRAPAAAARRSASSSSSSSSSSSSSSSSSSSEGEEDEGVRPGAPLARAGPPPSP 420 
(ii) ! ! ! I ! ! ! ! i ! !i!! ! ! !!! ! I
825 PAPAAAGAPSGLPGSGPSSPASTKSSSSTKSSSSTKSGLSGSSGYASSPAAGPDPAP 881
(b) Vmwl75 x Vrnwl75
231 APGRTPPPPGPPPLSEAAPKPRAAARTPAASA 262
fill) i! ! 1 i ii l i t  i i i  i i iVJ-J--L/ II I I I  II I I I  I I I  I I I
762 APLPAPAPPSTPPGPEPAPAQPAAPRAAAAQA 793
(c) VZV 140K x VZV 140K
68 SVSGLQPEPRTEDVGEELTQDDYVCE 93
IA I ill l i i l lV -L V 1 i iii I l I l I
364 SSEDEDDEPRRVSVGSETTGSRSGRE 389 
116 EAGAREPTGADRSLETVSLGTKLAR 140
i i i i i i i  i i iV v / i i i i i i i  i i i
805 EIAARRPGGGDRRFGPPSGVEALRR 829 
349 REFVSSSSSSSSWGSSSEDEDDEPRRVSVGS 379
\ I I III I I I I I I I I Itv 1 ) | I III llllllll I
1276 RPAVKVELLSSS..SSSEDEDDVWGGRGGRS 1304
528 ALINLIYCPDRDPIAWLQNPKLTGVNSALNQFYQKLL 564 
(vii) ! ! ! I I ! !
886 ALSNRLCLP..STHAWAGNWTGPPDVSALNARGVLLL 920
Repeated amino acid strings were identified within the three IE proteins by 
analyzing their sequences using the COMPARE program, scoring for identical 
amino acids, (a, PrV IE protein; b, HSV-1 Vmwl75; c, VZV 140K protein compared 
to themselves). A window size of 30 was used, with increasing stringency for 
matches between 13 and 17. Identified repeated strings were aligned by the 
BESTFIT program, as shown above. Most of the repeat elements identified 
were of questionable significance and probably only reflect the high GASP 
composition of these proteins.
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of the three Vmwl75-related proteins for unusually charged 
regions. Figures 54-56 show the amino acid sequences of the 
three proteins with the potential charge on their side 
chains indicated. Aspartic and glutamic acid are considered 
as acidic; whilst lysine, arginine and to a lesser extent 
histidine are considered basic.
The regions of the protein identified in Chapter 3 as 
the most important for activation function (regions 2 and 4) 
do not contain any acidic stretches in any of the proteins. 
Conserved acidic regions are found in region A (Figure 50) 
and towards the carboxyl terminus (Figure 51a). Both of 
these regions have been shown not to be essential for 
activation in transfection assays, and a virus deleted for 
homology region A was viable in non-complementing cells. A 
region of the VZV 140K protein (amino acids 1230-1290) is 
particularly acidic, with a net charge of -12, but is not 
conserved in Vmwl75. Somewhat acidic stretches were also 
found towards the amino terminal of the three proteins (HSV: 
115-130; VZV: 79-99; PrV: 1-40 and 95-120). Again these 
regions are not conserved between the proteins.
The lack of obvious acidic stretches in regions 2 and 4 
of the proteins may indicate that activation of 
transcription by these proteins does not occur by this 
mechanism. Alternatively acidic regions in other areas of 
the protein may not have been recognized as important if 
insertion of four amino acids into these regions fails to 
disrupt activity, or if there are multiple acidic regions 
capable of activation. It would be interesting therefore to 
construct mutants of Vmwl75 deleted for all of the acidic 
strings and to determine whether these mutants were still 
able to activate transcription.
It is also worth noting that there are no obvious 
glutamine rich motifs in Vmwl75, although glutamine rich 
domains have been proposed as a novel type of activating 
domain in Spl and other proteins (Courey and Tjian, 1988). 
The amino terminal 300 residues of VZV 140K are somewhat 
glutamine rich, and a glutamine pentapeptide is present in 
the PrV IE protein (Figures 54-56).
Figure 54
PREDICTED PRIMARY AND SECONDARY STRUCTURE OF HSV-1 Vmwl75
■:--- REGION 1
* II * * * * - 70
MASENKQRPGSPGPTDGPPPTPSPDRDERGALGWGAETEEGGDDPDHDPDHPHDLDDARRDGRAPAAGTD
HHHHTTTCTTCCCTTTCCCCCCCCTCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCCCCCCCCCCCCC
12 * 13 * * * 14 15 16 140
AGEDAGDAVSPRQLALLASMVEEAVRTIPTPDPAASPFRTPAFRADDDDGDEYDDAADAAGDRAPARGRE
CCCCCCCCCCCHHHHHHHHHHHHHHCCCCCCCCTCCCCCCCCEECCCCCCCCCCCCCHHHHHHHHHHHCC
* *17 * a * a 210
REAPLRGAYPDPTDRLSPRPPAQPPRRRRHGRWRPSASSTSSDSGSSSSSSASSSSSSSDEDEDDDGNDA
+  —  -r —  — 4- +  4  +  4  +  4  4  —  - —
TTCCCCCEECETTTCCCCTCCCCCHHHHHHCCCCCCCCCCCCCCCTTCCCCCTTTCCCCCTCCCTTETTT
a 18  a a j;9 * a n o  2 8 0
ADHAREARAVGRGPSSAAPAAPGRTPPPPGPPPLSEAAPKPRAAARTPAASAGRIERRRARAAVAGRDAT
TTCCCCCCCCCCTCCCCCCCCCCCCCCCCCCCCEEECCCCHHHHHEECCHCCCHHHHHHHHHHEECTTCC
REGION 1---- '---- REGION 2
* 111 a I12 * xi3 xi4 ix5a 3 5 0
GRFTAGQPRRVELDADATSGAFYARYRDGYVSGEPWPGAGPPPPGRVLYGGLGDSRPGLWGAPEAEEARR
-j- -t *r — — — +  -j—  — t — -+■ —  + t
CECCCCCCCEEEEHHHHHCCCEEEETTTTTCCCCCCCTCCCCCTEEEEEETCCTCCCCCCCCCCHHHHHH
a a x i 6  a * 1 1 7  a 420
RFEASGAPAAVWAPELGDAAQQYALITRLLYTPDAEAMGWLQNPRVVPGDVALDQACFRISGAARNSSSF
HHCCCCCCHHHEHHCCHHHHHHHEEEEEEECCCCHHHHCCCCCTTEEETEEHHHHHEEEECCCCTTTTEE
tsK REGION 2 X
a 118 a * a v a 490
ITGSVARAVPHLGYAMAAGRFGWGLAHAAAAVAMSRRYDRAQKGFLLTSLRRAYAPLLARENAALTGAAG
4- 4  4  4  4 4  — t- -f 4 4  4  —
EECCCCEEEETCHHHEEECTCTCCHHHHHHHHHHHHHHTTCTCEEEEEEETTTEEEHHHHHHHHHHCCCC 
(— REGION 3
119 a * x20 a * * 560
SPGAGADDEGVAAVAAAAPGERAVPAGYGAAGILAALGRLSAAPASPAGGDDPDAARHADADDDAGRRAQ
CCCCCCHHHHHHHHHHHHHCCEEEECCCCHEEEEHHHHHECCCCCCCCCTCCCHHHHHCHHHHHCCCCCC
121 a a *X22 A A A  630
AGRVAVECLAACRGILEALAEGFDGDLAAVPGLAGARPASPPRPEGPAGPASPPPPHADAPRLRAWLREL
CTEEHHHHHHHHHHHHHHHHHHHHHHHCCCCCCECCCTTCCCCCCCCCCTCCCCCCCCEEHHHHHHHHHC
a 123 a a ax24 a 700
RFVRDALVLMRLRGDLRVAGGSEAAVAAVRAVSLVAGALGPALPRDPRLPSSAAAAAADLLFDNQSLRPL
CHHHHHHHHEEHHTTEEECCCCHHHHHHHHHHEEEEECCCCCCEEETCCCCCHHHHHHHHHHHTTCCCHH
* A A A A 770
laaaasapdaadalaaaaasaapregrkrkspgparppggggprppktkksgadapgsdaraplpapapp
hhhhhhhhhhhhhhhhhhhhhhhhhtttttccccceetttcccccttcteccccccccccceccccccct
REGION 3 X  REGION 4
125 A 126a * 127 A A A 840
STPPGPEPAPAQPAAPRAAAAQARPRPVAVSRRPAEGPDPLGGWRRQPPGPSHTAAPAAAALEAYCSPRA
TCCCCCCCCCCCHHHHHHHHHHCECEEEEEEECCCCCCCCTTTTCCCCTCTTCEEHHHHHHHHHTTCHHH
1 2 8  A A A A A A 9 1 0
VAELTDHPLFPVPVRPALMFDPRALASIAARCAGPAPAAQAACGGGDDDDNPHPHGAAGGRLFGPLRASG
HHHHTCCCCCCCCCCCTEEEHHHHHHHHEEETTCCCHHHHEETTTTTTTCCCCCCCCCTTEEEEECCTCC
tsl225
* a I 2 9 a ! 3 Q  * a V a 9 8 0
PLRRMAAWMRQIPDPEDVRVVVLYSPLPGEDLAGGGASGGPPEWSAERGGLSCLLAALANRLCGPDTAAW
CCEHHHHHETCCCCCCCEEEEEEECCCCCCEECCCCCCCCCCCCCCCTTTCCEEHHHHHHTTTCTTEECC
a a a  a I 3 1  A a 1 0 5 0
AGNWTGAPDVSALGAQGVLLLSTRDLAFAGAVEFLGLLASAGDRRLIVVNTVRACDWPADGPAVSRQHAY
—  -(—  —  — f--f -r —  —  + 4 -
CCTTCCCCTEEEHHHHEEEEEEHHHHHHHHHHHHHHHHHHHHHHEEEEEEEETTTTCCTCCCCCHHHHTE
a 132 a * * 133 * 1120
LACELLPAVQCAVRWPAARDLRRTVLASGRVFGPGVFARVEAAHARLYPDAPPLRLCRGGNVRYRVRTRF
+ + - + 4  4 4 - 4 4 -  4 4  4 4 4 4
EHHHHHHHHHEEEEEHTHHTCEEEEEEEETEECCCCEHHHHHHHHTCCTTCCTEEETTTTTEEEEEEETT
a 134 135 a a a a 1190
gpdtpvpmspreyrravlpaldgraaasgttdamapgapdfceeeahshaacarwglgaplrpvyval.gr
— -j—  44 - 4 — -   4 4 4 4 4
CTTCCCCCCCCCCEEEEEECHHHHHCCCCCCEEECCCCCCEEEEECCCTCCEEEHHHHHHHHHHHHHCCC
REGION 4 X  REGION 5
136 a a a A 1 3 7  1 3 8 1 3 9  a i 2 60
EAVRAGPARWRGPRRDFCARALLEPDDDAPPLVLRGDDDGPGALPPAPPGIRWASATGRSGTVLAAAGAV
CCCCEEECCCHHHHHHHHHHHHHTTTTCCCCEEEEEEEHHHHCCCCCCTTCCTTTTTEECCCCCCTTCCC
4 * a i298
EVLGAEAGLATPPRREVVDWEGAWDEDDGGAFEGDGVL
CCEEETTTCCCCCCCCCCTTCCCCCCCCCCCCCCCCCC
The predicted amino acid sequence (1-1298) of the HSV-1 protein 
Vmwl75 is shown in the single letter amino acid code, and divided 
into the five structural regions predicted on the basis of homology 
to the VZV 140K ORF (McGeoch et al.,1986).
Secondary structure was predicted by the GARNIER program 
using the method of Garnier et al.,(1978) and is shown below the 
sequence,(C= random coil, E= beta-pleated sheet, H= alpha-helix, T= 
turn). Acidic and basic residues are highlighted - and 4 beneath the 
sequence. The positions of the amino acid substitutions in two 
temperature sensitive mutants tsK and tsl225 are shown at residues
475 (A to V) and 966 (A to T) respectively (Davison et al.,1984; R.D. 
Everett provisional data, per.comm.). The position of the 39 
insertion mutants described in this thesis is marked above the
Figure 55
PREDICTED PRIMARY AND SECONDARY STRUCTURE OF THE VZV 14QK PROTEIN
•-— REGION 1
A A A A A A 7 Q
MDTPPMQRSTPQRAGSPDTLELMDLLDAAAAAAEHRARVVTSSQPDDLLFGENGVMVGREHEIVSIPSVS
TTCCTTCTCEETTTCCCCCHHHHHHHHHHHHHHHHHHHEECCCCCTEEECCCCCCHHHHHCCCEEECTTC
A A A A A A 140
GLQPEPRTEDVGEELTQDDYVCEDGQDLMGSPVIPLAEVFHTRFSEAGAREPTGADRSLETVSLGTKLAR
TCCCCCCCCCCCCCCCHTTEEECCCCCCTCCCCEEHHHHHHHHHCCCCCCCCCCCCCCCCCCCHHHCEET
A A 1^0
SPKPPMNDGETGRGTTPPFPQAFSPVSPASPVGDAAGNDQREDQRSIPRQTTRGNSPGLPSVVHRDRQTQ
CCCCTTETCCCCTTCCCCEETEEETTCCCCCEECCCCTCCCCTTTCCCTEETTTTCTTCEEEEEETTTTE
* ± ± ± ± ± 080 
SISGKKPGDEQAGHAHASGDGVVLQKTQRPAQGKSPKKKTLKVKVPLPARKPGGPVPGPVEQLYHVLSDS
44   4 4 -  4 4 4 4 4 4  4 4 44 — 4 —
ETTTTCCCCHHHHHCCCTTTCEEEEETEETTTTTCTTHHHEEEEEEEETTCTTCCCCCEEEEEEEEETTC
A A A A A A 350
VPAKGAKADLPFETDDTRPRKHDARGITPRVPGRSSGGKPRAFLALPGRSHAPDPIEDDSPVEKKPKSRE
-r t  —   + -t—i—i—  + -f- 4* + 4 -  4- -t- — ---  — r-r 4* H—
CHCHHHHHCCCCCCCCCCCCCCCCTTCCEEETTTTTTCCCEEEEECCTTCCCCCCCCCCCCCCCCCCHHE
A A A A A A 420
FVSSSSSSSSWGSSSEDEDDEPRRVSVGSETTGSRSGREHAPSPSNSDDSDSNDGGSTKQNIQPGYRSIS
--------- 44 - 4 -i-- i-    - 4 4
EECCCCCCCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTTTTTCTCCTCCCCCEEEETTTETTT
REGION 1— >< —  REGION 2
A A A A A A 490
GPDPRIRKTKRLAGEPGRQRQKSFSLPRSRTPIIPPVSGPLMMPDGSPWPGSAPLPSNRVRFGPSGETRE
— 4 -r-f 44 — 4 4 4  4 4  — 4 4  — 4—
CCCCTEEEECECCCCCTTTTTTTTEETTTTCEEEETTCCCEEEETCCCCCTCCCCTTEEEEECCCCCCCC
A A A A a a 560
GHWEDEAVRAARARYEASTEPVPLYVPELGDPARQYRALINLIYCPDRDPIAWLQNPKLTGVNSALNQFY
4   4 4 4 — — — — 4 4 — I—  4
CCCHHHHHHHHHHHCCCCCCCCCEEEECCCCCCHHEEEEEEEEEETTTCCCECCCCTTTTEEEEEHHEEE
tsK
A A A A A A V630
QKLLPPGRAGTAVTGSVASPVPHVGEAMATGEALWALPHAAAAVAMSRRYDRAQKHFILQSLRRAFASMA
4 4 4 — — 4 44 — 4 44 44
EEEECTTTEEEEEEECCCCEECCCHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHEEEEEHHHHHHHCCC 
REGION 2— X — REGION 3
A A A A A A 700
YPEATGSSPAARISRGHPSPTTPATQAPDPQPSAAARSLSVCPPDDRLRTPRKRKSQPVESRSLLDKIRE
— 4 4 4 — 4  1- 4 4 4 4 4  - 4 — I- H—
CCCCCCCCCCEEEETTCCCTTCCTEECCCCCCCHHHEEETEECTTTTECCCTTTTCCCCCHHHHHHCCCC
REGION 3— >(--REGION 4
* * A * A A 770
tpvadarvaddhvvskakrrvsepvtitsgpwdppavitmpldgpapnggfrriprgalhtpvpsdqar
- +  + 4. _ _ _ + +
ccchhhhhhhhhhhhhhcctccceeeeeccccceeeeeeeeetcccccttteeeetttcccccccthhtt
* A A A A A 8 4 0
kayctpetiarlvddplfptawrpalsfdpgalaeiaarrpgggdrrfgppsgvealrrrcawmrqipdp
ttttcccceeeeetcccccccccctcccccchhhhhhecctttttettcccccchhhhhhtttetccccc
ts!225
A * a A V  A A 9 1 0
edvrlliiydplpgedingplestlatdpgpswspsrgglsvvlaalsnrlclpsthawagnwtgppdvs
—  + 4 4
chhheeeeecccccccccccccceeeccccctcccttttceeeehhhhttttettccttttttcccctee
A a A A A A 9 8 0
alnargvlllstrdlafagaveylgsrlasarrrllvldavalerwprdgpalsqyhvyvraparpdaqa
4* + — — ~t- 4--t--r — — H—  4- 4- + —
EEHHHEEEEEEHHHHHHHHHHHHHHCHHHHHHHEEEEHHHHHHCCCCTTCCCCCEEEEEEEETCCCTHEE
A A A A A A 1 0 5 0
vvrwpdsavteglaravfassrtfgpasfarietafanlypgeqplclcrggnvaytvctragpktrvpl
4 — - + 4 4 — - 4 4 4 4
eeecctccccchhhhhheectttccccchhhhhhhhtttctttceeeettttteeeeeeettcttteeec
sp re yr qy vl pg fd gc kd la rq sr glglgaadfvdeaahshraanrwglgaalrpvflpegrrpgaagp
-I—  4 — H—  4 4 —   4 44 4 4 — 4-t-
cctt te ee ee tt tt tt th ch ee ct tc cc cc hh hh hh hh hh hh ht tt tt cc cc ee ee ee cc cc cc cc cc c
1120 REGION 4 — X — REGION 5
A A A A A A A
EAGDVPTWARVFCRHALLEPDPAAEPLVLPPVAGRSVALYASADEARNALPPIPRVMWPPGFGAAETVL
— — 4 44 — — — 4   4 4 —
GCCCCCTHHHHEETTCCCCCCCHHHCCEEEETHEEEEEEFHHHHHHHTCCCCEEEEEECCTCCCHHHHC
1190
4
EGSDGTRFVFGHHGGSERPSETQAGRQRRTADDREHALELDDWEVGCEDAWDSEEGGGDDGDAPGSSFG
- - 4 44 -4 4 44 - - 4 - 4      -- - —  ----
CCCCCCEEEECCCCCCCCCCCCCCCCCTTTTTHHCCCHCHHHHCCCCCCCCCCCCCCCCCCCCCCCCCE 
1260 REGION 5 — >1310
A A A A A A
VSIVSVAPGVLRDRRVGLRPAVKVELLSSSSSSEDEDDVWGGRGGRSPPQSRG
4 44 4 4 -   4 4 4
EEEEEEEETEEEEEEECCCCCEEEEEHCCCCCCCCCCCCCCCCCTCCCTTTTT
The predicted amino acid sequence (1-1310) of the VZV140K ORF is 
shown in the single letter amino acid code (Davison and Scott, 1986). 
Secondary structure was predicted by the GARNIER program using the 
method of Garnier et al. (1978) and is shown below the sequence,
(C= random coil, E= beta-pleated sheet, H= alpha-helix, T= turn). 
Acidic and basic residues are highlighted - and + respectively.
The equivalent positions of the HSV-1 Vmwl75 ts mutations tsK and
tsl225 are shown at amino acids 627 and 885 respectively. The 
five regions of the protein; based on homology with HSV-1 Vmwl75, 
are shown (McGeoch et al., 1986).
Figure 56
PREDICTED SEQUENCE OF THE PRV IE PROTEIN.
< REGION 1
1 MADDLFDFIE TEGNFSQLLA AAAAAEEEGI ASGPDGGSQG SRRRGSSGED
  _  _  _  4; _____  4; —  4; *  _j_ 4_ 4; 4 ; ____
51 LLFGPGGPLL RRRRRGRGRR PRGRGRSHEA APSSSAQQQQ QPRRGSGEIV
4- + + + + + 4-4- + + + * + -  * * *  + + - —
101 VLDDEDEEED EPGSPAAGSP GRALHQGSEH GHLVLGPRSR AGSGPRPPTP
   4* 4; _j_ £  j_ ^ _L £
151 AALAAAEAGA PGGPGRSSPS AASPASSSGS PGPSAAPRRW SPARGDPVGE
  4- 4* 4^ 4 ^  ^  -j- 4______________ __
201 PGPAARPRTP APPAQPAAVA AAPARRGPAS PASPAAGPVS APGGGGAPSA
• j 4  4  y
251 GGDRGRHHHQ HREPLLDEPA AARRLDPRPL GARSPVSSNP NSNSNSTTTV
 • 4. • _j__j_______________    ^  ± ±
301 AVETVARGPE KDEDGLGLAG DGGAPPQRQP RRRRAGEGAL RRGRGFSSSS
-  +  -  +   -  +  +  +  +  +  -  + +  +  * * * *
351 SSGSDSDLSP ARSPSAPRAP AAAARRSASS SSSSSSSSSS SSSSSSSEGE
401 EDEGVRPGAP LARAGPPPSP PAPAAAPRPS ASSASSSAAA SPAPAPEPAR
REGION 1 — > < —  REGION 2
451 PPRRKRRSTN NHLSLMADGP PPTDGPLLTP LGEPWPGSDP PADGRVRYGG
+  +  +  +  +  * + * -  - -  A -  _  4- 4.
501 AGDSREGLWD EDDVRQAAAR YRAAAGPVPV FIPEMGDSRK QHEALVRLIY
551 SGAAGEAMSW LQNPRMQAPD QRFNQFCQRR VHAPHGHGSF ITGSVTPPLP
A —  A -f —  4- + 4. 4. +  4. A A
tsK
V
601 HIGDAMAAQD PLWALPHAVS AVAMSRRYDR TQKTFILQSL RRAYADMAYP
+ -  -  +  A A + + - 4- +  * + + .  -
REGION 2— X — REGION 3 
651 GRAADPRAGE ATVEALCARV RAAFAAAQPG RVPRELADAC VLACRGVLER
+ — + — — + + + 4 —  — + — I-
701 LLPCPLRLPA PARAPAALGP ACLEEVTAAL LALRDAIPGA GPAERRQAAD
4- *4* --  -j—  -r -f —
7 51 SVALVARTVA PLVRYSVDGA RAREAAWTYA AALFAPANVA AARLAEAAAR
801 PGPAEPAPGL PPLWPEQPGL VVPAPAPAAA GAPSGLPGSG PSSPASTKSS
— — A A A A A + A A
851 SSTKSSSSTK SGLSGSSGYA SSPAAGPDPA PERRKKKRRA PGARRPGDGE
4 y 4 4 4 4 _j_ 4 4 4 4 ^  ^  ^   j j   —
901 EDEGLSGAAL RGDGHGHRDD EEDRGPRRKR RSLGLGPAPD PAPALLSSSS
  * + - + ++--  + ++++ +* - ****
REGION 3— ><--REGION 4 
951 SSSEDDRLRR PLGPMPEHPA PDGGFRRVPA GETHTPRPSE AALAAYCPPE
A ^    •
1001 VARALVDQEV FPELWRPALT FDPAALAHIA ARRGAPLRRR AAWMRQIADP
tsl225
V
1051 EDVRVVVLYD PLPHEELCAE PAEGAPRPAW DPRRGGLSAL LAAFAHRLCT
1101 PDSHAWAGNW TGRPDIGRLN AQGVLLLSAR DLGFAGAVEY LCSRLGAARR
— * 4- + — 4- A - f - — — 4 4- — 4-
1151 RLIVLDTIED WPADGPAVGD YHVYVRVRLD PAAQCAVRWP GCRELRAAVL 
1201 DSSSIVGPAC FARVEASFAR LHPGAEPLRL CRQDNVRYTV STRAGPRTPV
4  A  4- —  A —  -i- - 4 -  4 _ _ - f  4 4  4
1251 PLPPRAYRQR VLPTVDGCKD MARQRSALGL GDPDFDAGAA FGHRAANRWG
REGION 4-->
1301 LGAPLRPVFV SCGRRGLAEL RGPEGLPAEL RAFCAAALLE PDAEAAPLVL
| \ _ -f-_____________________ _
<— REGION 5
13 51 TPGAVAAAGA PPAVLWDFAP FETSVRAAAG GAVETHRPAG ASGAGAGPGE
4 - 4-4 *
REGION 5— >1446 
1401 DGDSVEIVGV RGGDGRPRGP LGPIKVEAIS DDEEAEDAGN PYLLLR
The predicted amino acid sequence (1-1446) of the PrV IE 
protein is shown in the single letter code with the limits 
of the five structural regions based on homology to the other 
IE proteins (Vlcek, Schwyzer and Paces, per.comm.). Acidic 
and basic residues are highlighted beneath the sequence (- & + 
and serine residues are asterisked. The equivalent positions 
of the HSV-1 Vmwl75 ts mutants tsK and tsl225 are shown (at 
residues 645 and 1092 repectively).
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4• Secondary structure predictions on the Vmwl75-related 
proteins.
Computer predictions of the potential secondary 
structure of the three immediate early proteins were 
performed using the GARNIER and PEPTIDESTRUCTURE programs, 
which make use of the algorithms of Chou and Fasman (19 74) 
and Garnier et al., (19 78). These programs determine the 
likelihood of each residue being in one of four secondary 
structures, H (alpha-helix), E (extended chain/ beta-pleated 
sheet), T (reverse turn) or C (random coil). The 
predictions are about 40% accurate for small globular 
proteins but of questionable application to larger proteins 
if no structural information is known. The output of the 
GARNIER prediction for Vmwl75 and VZV 140K is included in 
Figures 54 and 55.
Few interesting features were revealed by these 
analyses. Region 1 of the HSV protein in particular was 
predicted to be unusually rich in random coil structure, 
which may reflect the limits of these types of predictive 
programs to identify structural features. Alternatively, 
the high levels of predicted random coil and GARP content in 
region 1 and parts of region 3 may reflect the functional 
unimportance of these regions.
More detailed structural analyses of the proteins in 
regions 2 and 4 were performed using the PEPTIDESTRUCTURE 
program and and profiles of the secondary structures aligned 
from the PLOTSTRUCTURE program (results not presented). 
However, because of the high amino acid identity between the 
three proteins the identification of apparently conserved 
secondary structures may merely reflect conservation of the 
primary structure. Whereas it was possible to identify 
strongly predicted and conserved structures, such as two 
alpha-helices in region 2 (HSV coordinates approximately 
340-355 and 435-460), the significance of these was unclear. 
Nor did the behaviour of the insertion mutants assayed in 
Chapter 3 correlate with the predicted secondary 
structures.A conserved potential glycosylation site, NWT, at 
amino acid 983 of Vmwl75 was also revealed in these 
analyses.
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CHAPTER 5: DISCUSSION
The experiments described in this thesis were designed 
to define the regions of the HSV-1 protein Vmwl75 important 
for functional activity. Section 1 of this Chapter 
summarizes the results of the mutational analysis of Vmwl75 
function. The important regions of the protein defined by 
these experiments are discussed in greater depth in Section 
2, where possible models for the mechanism of Vmwl75 
function are also discussed. In Section 3 some possible 
avenues for further research into the function of Vmwl75 are 
discussed.
1. The results of the mutational analysis of Vmwl75 
function.
1.1 Regions of vmw!75 involved in transcriptional 
regulation.
The results presented in Section 3C and summarized in 
Figure 17 and Tables 7 and 8 define the regions of Vmwl75 
important for transactivation of the promoter of the HSV-1 
early gene gD (in synergy with VmwllO) and for repression of 
the promoter of IE gene 3 itself.
Large stretches of the protein are relatively 
unimportant for either function and the regions most 
sensitive to disruption correlate to sequences conserved 
between Vmwl75 and VZV 140K, the corresponding 
transactivating protein of VZV. The region from amino acids 
275 to 490 is particularly important for both repression and 
transactivation, whereas that from 840 to 1100 seems to be 
more important for transactivation than repression. These 
two regions of homology, B and C (Figures 5 and 49), are 
also conserved in the PrV IE protein IE180, confirming their 
evolutionary importance. The very small conserved region,
A, which contains a highly serine-rich tract does not seem 
to be essential in these assays. Indeed a plasmid borne 
mutant, pDl, which lacks this region still retains 
significant activity in both assays. Furthermore, the 
region of the protein deleted in this mutant was shown to be 
inessential (but not unimportant) for virus growth on 
non—complementing cells when this mutation was recombined
149
back into the viral genome.
A number of previous studies have investigated how the 
structure of Vmwl75 relates to its different activities 
(reviewed in Section 1D2.4). Early studies with temperature 
sensitive alleles gave some information on important domains 
of the protein; t^ sK was shown to be caused by a single 
missense mutation in homology region B (Davison et al.,
1984) whilst tsD and tsT localize around region C (Preston, 
1981). Different ts mutants were shown to exhibit different 
phenotypes and DeLuca et al. (19 84) deduced that lesions 
mapping towards the carboxy-terminus tended to produce a 
later block in viral gene expression. Indeed, using a panel 
of plasmid-borne truncation mutants of the gene encoding 
Vlmwl75, DeLuca and Schaffer (1987 ) showed that the 
carboxy-terminal 40% and the first 9 0 amino acids of Vmwl75 
were not essential for transcriptional regulation. The 
results presented in this thesis are in good general 
agreement with these results and confirm that region 2 of 
V3mwl75 is the most critical functional region for both 
repression and transactivation. However, the mutagenesis 
technique described in this thesis allows a more sensitive 
analysis of the functional regions of the protein, without 
producing gross changes in protein structure which may 
affect protein stability and function.
Insertions in most of regions 1 and 5 suggest that 
neither of these regions plays a critical role in the 
function of Vmwl75. However, small deletions around the 
beginning of region 5 behave anomalously and abolish 
transactivation activity. Furthermore, whilst to some 
extent deletions pD2, pD4 and pD7 confirm previous reports 
that regions 4 and 5 can be deleted without abolishing 
activity in transfection assays, some insertion mutants in 
region 4 are severely impaired in their transactivation 
activity. It seems therefore that whilst region 4 is not 
essential for transactivation (or repression) mutations 
within this region can severely disrupt transactivation.
This suggests that the precise configuration of region 4 is 
important for activity, and that this region may be playing 
some as yet unrecognized role in the activity of Vmwl75.
This will be discussed further in Section 5.2.2.
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In order to assay transactivation by their truncation 
mutants of Vmwl75 DeLuca and Schaffer (19 87) used the 
promoter of another HSV early gene, tk, and defined similar 
important regions of Vmwl75 to those reported here to be 
involved in activating the gD promoter. However, when 
recombined back into virus it was found that mutants 
encoding the first 773 amino acids were able to induce early 
gene expression, but did not allow DNA replication or late 
gene expression (DeLuca and Schaffer, 1988). Nor did these 
mutants over express IE3 RNA (see Section 1D2.4 and Table 
3). In order to investigate the role of Vmwl75 in 
regulating late gene expression it would be interesting to 
look at the ability of plasmid-borne mutants to 
transactivate late promoters, for example that of the VP5 
gene. Because of the reported involvement of Vmw6 3 in 
regulating late gene expression (see Section 1D1.3), it 
would be interesting to assay the activity of the Vmwl75 
mutants in the presence of a plasmid encoding Vmw63. It 
would also be interesting to see if the mutants act 
similarly on heterologous non-HSV promoters and whether 
transactivation in the absence of VmwllO requires the same 
regions as when the two proteins act in synergy.
1.2 Regions of Vmwl75 involved in DNA binding
The results presented in Section 3D2 and summarized in 
Tables 9 and 10 show that the regions of Vmwl75 important 
for binding to the IE3 cap site in vitro closely correspond 
to those important for transcriptional regulation in 
transfected cells. Although the results do not demonstrate 
an absolute correlation between in vitro DNA binding 
activity and either transactivation or repression, it is 
clear that the same general regions of the protein are 
involved in all three functions. In particular the 
integrity of region 2 is of critical importance for each 
activity.
DeLuca and Schaffer (1988) have used a set of viral 
mutants expressing truncated forms of Vmwl75 to map the DNA 
binding domain of Vmwl75. Mutants deleted for the first 9 0 
amino acids of the protein and those removing residues 
downstream from 773 were essentially wild-type in their
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ability to bind to a probe spanning the IE3 cap site (and in 
their capacity to regulate IE3 and early gene expression in 
the infected cell). a  mutant deleted from amino acid 590 
was able to form a novel DNA complex at elevated salt 
concentrations, but possesed no regulatory activity in the 
vi rus.
However, the mutational approach used by DeLuca and 
Schaffer (1988) can only investigate the importance of the 
carboxy-terminus of the protein, furthermore, truncated 
proteins with large deletions may exhibit conformational 
abnormalities making interpretation of results more 
complicated. Indeed comparing the results presented in 
Table 9 and 10 in this thesis it is apparent that the
insertion mutants give a more consistent pattern of results
than do the deletion mutants, and perhaps with the larger 
deletions only positive results should be considered 
significant. The ability of deletions pD13, pD*l and pD2F to 
bind to DNA shows that amino acids outside residues 229-496 
are probably not directly involved in site-specific DNA 
binding. Those mutant polypeptides with insertions and
deletions outwith this region which fail to bind DNA may be
inactivated by longer range steric effects, for example 
disruption of protein folding.
That a relatively small portion of the Vmwl75 
polypeptide is required for site-specific DNA binding was 
confirmed by protease K digestion of the Vmwl75-DNA complex. 
A protease resistant domain of the protein was able to bind 
to DNA, perhaps with even greater affinity than the 
wild-type protein (Section 3D1.4). This observation implies 
that it should be possible to express short fragments of the 
Vtnwl75 polypeptide (perhaps by in vitro synthesis) and more 
closely define the DNA binding domain.
Neither the nuclear localization signal nor the serine 
rich tract (homology region A) were required for DNA binding 
by Vmwl75 deletion mutants (Section 3D2.2). In the case of 
proteins deficient in nuclear localization Vmwl75 could be 
recovered from the cytoplasm and shown to bind to DNA, 
indicating that no nuclear modifications to the protein are 
essential for this activity.
The involvement of region 4 in DNA binding is unclear;
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as in the transactivation assays this region of the protein 
is not absolutely required for activity, but some mutations 
in this regions can interfere with DNA binding. If this 
region of the protein is not directly involved in DNA 
binding then these mutations must be interfering with DNA 
binding by altering the conformation of the protein and 
influencing the DNA binding domain. Indeed insertions and 
deletions in this area of the protein did seem to cause a 
decrease in the mobility of protein-DNA complexes on 
polyacrylamide gels, as if the protein was partially 
denatured, but still able to bind DNA. A similar phenotype 
may also have been detected with the recombinant virus 
N9/N10, where insertion of 4 amino acids in region 5 created 
a polypeptide with temperature-sensitive DNA binding 
activity, but which formed barely detectable amounts of this 
"denatured" complex.
Because the regions of Vmwl75 required for 
transcriptional activation and repression overlap with each 
other and with the region required for site-specific DNA 
binding it is not possible to directly associate 
site-specific binding uniquely with either regulatory 
activity. The weight of experimental evidence supports a 
role for the Vmwl75 binding site at the cap site of IE gene 
3 in autoregulation (Section 1D2.2) but it is still an 
enigma as to why the same protein sequences should 
apparently be necessary for both this function and 
transcriptional activation, which is not sequence specific. 
It is possible that Vmwl75 possesses a second less specific 
DNA binding activity, perhaps encoded by the same protein 
sequences or alternatively elsewhere in the protein. Indeed 
Michael et al., (19 88) have observed Vmwl75 binding to the 
5* transcribed non-coding regions of certain late genes 
which do not possess the consensus site-specific binding 
site. It would be interesting to investigate which regions 
of the protein are required for this activity, and whether 
these coincide with the regions (4 and 5) identified by 
DeLuca and Schaffer as being involved in late gene 
activation.
In order to investigate further the unexpected effect of 
mutations in the c a rboxy-terminal 40% of the protein to
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interfere with a DNA binding specificity (apparently 
determined in the amino-terminal 40% of the protein) a 
number of ts mutant viruses, carrying lesions in the 
carboxy-terminal regions of Vmwl75, were assayed for 
Vlnwl75-DNA binding activity. Four of these mutants were 
unable to bind to DNA in vitro when assayed at the NPT, a 
phenotype which correlated with their inability to 
autoregulate IE gene 3 expression in infected cells. These 
viruses could, however, express early gene products at the 
NPT. One ts mutant (tsl225, provisionally mapped to the 
most conserved stretch of region 4, R.D.Everett, per.comm.) 
was however able to bind to DNA in vitro but still 
overexpressed Vhiwl75 in the infected cell at NPT. It would 
be interesting to investigate whether this protein bound to 
the IE3 promoter in the infected cell, as this result 
implies that repression by Vmwl75 may be more complicated 
than a simple "operator" binding mechanism.
Under the conditions of binding used by DeLuca and 
Schaffer (19 88) the Vmwl75-DNA complexes were salt labile 
when the concentration was raised from 15 to 65mM NaCl. 
Furthermore, they observed that some of their mutants formed 
novel complexes at elevated salt concentrations. In 
contrast to their observations, the Vmwl75-IE3 cap site 
complex was not salt labile under the conditions of binding 
used in the studies reported in this thesis, and indeed the 
wild-type Vmwl75 DNA complex was stable up to 500mM NaCl 
(Section 3D1.5). Furthermore, DNA binding was still salt 
stable at elevated temperatures, indicating a highly 
specific protein-DNA affinity. The nature of the novel 
complex formed at elevated ionic strength by proteins 
deleted for the carboxy-terminus of the protein is unclear 
(DeLuca and Schaffer, 1988). One suggestion was that this 
complex could represent Vmwl75 monomers bound to DNA at the 
elevated salt concentration, whilst the wild-type, low-salt 
complex could represent multimers of Vmwl75 bound to DNA.
An alternative explantion would be that a second (host or 
viral) protein is absent from the complex at higher ionic 
strength. This rapidly migrating complex may be related to 
those reported in this thesis formed by wt and ts1225-Vmwl75 
at elevated temperature and salt concentration (Figure 44B).
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The salt stability of each mutant protein-DNA complex was 
not investigated, but might provide a sensitive measurement 
of relative DNA binding activity, as proteins binding to DNA 
less strongly than wild-type would be dissociated from DNA 
at a lower ionic strength.
2. Structural Regions of Vmwl75.
2.1 The role of region 2: a model for Vmwl75 function.
A region of Vmwl75 spanning amino acids 275-495, 
including a region conserved between three alphaherpesvirus 
IE proteins (region 2: 315-484), has been shown to be of 
critical importance for positive and negative 
transcriptional regulation in transfected cells, and 
site-specific DNA binding in vitro. Thus at least three 
functions are encoded by a region of the polypeptide which 
is of itself almost as large as the multifunctional 
adenovirus Ela protein. Whereas mutagenesis studies on Ela 
have defined separate modular domains of the protein 
involved in each of its activites (Section 1E3.4; Figure 9) 
the studies presented in this thesis suggest that the 
integrity of the whole of region 2 may be required for all 
the functions of Vmwl75.
The ability of Vmwl75 to bind to the ATCGTC binding site 
at the cap site of IE gene 3 has been shown to be required 
for autoregulation of this gene (DeLuca and Schaffer, 1988? 
Roberts et al., 19 88). However, the role of DNA binding in 
transcriptional activation is not clear. DNA binding 
activity may be essential to direct Vmwl75 to responsive 
promoters, but recognition of responsive promoters is not 
mediated through Vmwl75-specific sequences. Furthermore, 
Vmwl75 seems to function by a similar mechanism to Ela, 
through the TATA box element. Ela has been shown not to 
bind to DNA directly.
If direct DNA binding is required for transcriptional 
activation by Vmwl75, the results presented in this thesis 
would suggest that the same or overlapping protein sequences 
are required for this less specific promoter binding as are 
required to interact with ATCGTC binding sites.
The significance of ATCGTC binding sites in promoters 
other than that of the autoregulated IE3 gene is not known.
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No functional significance has been demonstrated for the 
sites upstream of the IE1 and IE2 promoters. The site 
upstream from the gD promoter may contribute to the 
activation of this promoter, at least in some conditions 
(Tedder and Pizer, 1988) but does not seem to be required 
for activation of this promoter (Everett, 1983). Studies 
are ongoing to determine the significance of this binding 
site in the viral life-cycle (Everett, R.D. and Pizer, L . , 
per.comm.). It is possible that the role of this site is 
indirect and its contribution is to access Vmwl75 to the 
general region of the gD promoter, without being essential 
for activation. The positioning of the ATCGTC Vmwl75 
binding site over the transcriptional start site of the IE3 
gene may well be critical for its role in repressing IE3 
transcription.
A distinct "activating" domain, separable from a DNA 
binding domain has not been defined for Vmwl75. This 
contrasts with the adenovirus Ela protein where activation 
function is specified by a short 49 amino acid region, which 
can function as a transcriptional activator independently 
from the rest of the polypeptide. The Ela activating region 
has a zinc-binding finger motif, probably involved in 
interacting with cellular proteins to mediate activation. 
Region 2 of Vmwl75 has no such recognizable amino acid 
structures, nor have these studies identified an "acidic" 
activating domain in this region involved in activation. It 
is possible, however, that regions involved in activation 
lie outwith region 2 and have not been identified by these 
studies. It will be important to determine whether a 
polypeptide spanning region 2, but lacking all the potential 
acidic domains in other regions of the protein, can still 
function as a transcriptional regulator. Although there is 
no definable "activating region" in Vmwl75 that resembles 
the structure of previously recognized activating regions, 
it is quite possible that such an activating region in 
Vmwl75 represents a novel type of structure.
Taking into consideration the known properties of Vmwl75 
and recent studies on the function of the PrV IE180 protein 
(Section 1D2.1), it is possible to propose a simple 
functional model that could account for the dual role of
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Vftiwl75 in transcriptional activation and repression. The 
model proposes that Vmwl75 interacts simultaneously both 
with DNA and with host transcription factors, such as the 
TATA box binding factor TFIID, in order to potentiate 
production of a functional stabilized transcription complex. 
If the DNA binding region of Vmwl75 encounters a very strong 
binding site sequence, such as that at the IE3 cap site, 
then the high affinity constant of the DNA/Vmwl75 complex 
could effectively immobilize the transcriptional machinery. 
If the DNA sequence is less strongly bound by Vmwl75, then 
the stabilized transcription complex would be free to 
proceed. Note that the proposed site of interaction with 
the host transcription factors could also map in region 2. 
This model is consistent with the importance of the TATA/cap 
region for activation of the tk promoter (Coen et a l ., 19 86) 
and the binding of Vmwl75 to (non-consensus and possibly 
weak) sites in the 5' untranslated regions of other 
activated HSV genes (Michael et al., 19 88).
2.2 The role of region 4
The carboxy-terminal 40% of Vmwl75, including the region 
conserved between three alphaherpesvirus IE proteins (region 
4: residues 797-1224), is essential for growth in infected 
cells (DeLuca and Schaffer, 1988). Viruses with deletion or 
ts mutations in this portion of the protein are able to 
induce early gene expression but not viral DNA replication, 
nor full late gene expression (Preston, 1981; DeLuca et al., 
1984; DeLuca and Schaffer, 1988; this thesis). It is not 
known whether this region of the protein is simply important 
for the conformational stability of the whole protein, or 
whether it directs a novel uncharacterized activity.
This region of the protein does not appear to be 
essential in transfection assays for transcriptional 
regulation and DNA binding activity (DeLuca and Schaffer, 
1987, 1988; this thesis) although some insertion and 
deletion mutations in this region do severely impair 
transcriptional regulation and DNA binding activity. 
Therefore the carboxy-terminal domains of Vmwl75 do not seem 
to have a direct role in these functions, but can interfere 
with these activities which are probably specified by region
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2 of the protein.
Vmwl75 is not thought to have a direct role in viral DNA
replication. Plasmid based replication assays require the
presence of Vmwl75, but apparently only to activate
expression of the replication genes (Challberg, 1986; Wu et
al.f 1988; R. Heibronn and H. zur Hausen, 1988, abstract 226 
t h
at the 13 International Herpesvirus Workshop). It is 
possible that Vmwl75 has a role in the viral life-cycle to 
activate expression of the replication genes, and that 
perhaps the mechanism of this activation is distinct from 
the general activation of other early genes. This 
activation could be dependent on region 4 of the protein. 
Alternatively, mutant Vmwl75 with ts or deletion lesions in 
region 4 may interfere with the expression of these 
replication genes, or even interfere directly with 
replication activity.
It has been suggested that mutations in region 4 of 
Vmwl75 may interfere with the sub-nuclear localization of 
V5mwl75 or other proteins (DeLuca and Schaffer 1987, 1988), 
but they could also interfere with Vmwl75 function in number 
of other ways. Disruption of region 4 may cause severe 
conformational abnormalities which affect the activity of 
other regions of the protein. If region 4 interacts with 
region 2 of the protein a perturbation in the structure of 
region 4 may be more deleterious than loss of the whole 
region. This might explain why the large out of frame 
deletions pD2 and pD7 have more activity than their in-frame 
daughters pD2F and pD7F. Region 4 could in fact be involved 
in controlling or modulating the activity of region 2, in a 
similar fashion to the hormone binding domains of the sferoid 
receptors (Section 1E3.2), and deletion of region 4 
alleviates region 2 from this control. Region 4 might also 
be involved in the interaction of Vmwl75 with other cellular 
or viral factors, such as VmwllO, involved in 
transcriptional activation. If activation of late gene 
expression occurs by a separate mechanism to activation of 
early genes, region 4 may be involved in this function in 
conjunction with Vmw63, perhaps via a direct interaction 
with this protein.
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2.3 The role of the serine—rich tract.
Vtnwl75 contains a serine-rich tract followed by a highly 
acidic run (residues 176-206) which is conserved between the 
three alphaherpesvirus IE proteins (Figure 50). Deletion of 
this sequence does not abolish transcriptional regulation by 
Vmwl75 in transfection assays nor DNA binding in vitro, and 
this region is not essential for virus growth on a 
non-complementing cell-line.
This serine-rich tract is probably the major 
phosphorylation site of Vmwl75 (DeLuca and Schaffer, 19 88) 
although threonine residues elsewhere in the protein are 
also phosphorylated (Faber and Wilcox, 1986b). The 
phosphorylation state of Vmwl75 produced by the recombinant 
virus I15HBC should be investigated to confirm the 
involvement of this region in phosphorylation. If this 
region is the major phosphorylation site for Vmwl75, this 
modification would not appear to be essential for Vmwl75 
activity. Although modification by phosphorylation has been 
reported to be a major control mechanism for several 
proteins involved in transcriptional control (see Section 
1E3.5), the phosphorylation state of the adenovirus Ela 
protein does not affect its transactivation and repression 
activity (Richter et al., 1988).
Three major different electrophoretic forms of Vmwl75 
can be distinguished which differ in post-translational 
modification of the protein, including phosphorylation 
(Wilcox et al., 19 80). These different forms of the Vftiwl75 
bind with different affinities to DNA probes which do not 
include an ATCGTC consensus (Michael et al., 19 88). It 
would therefore be interesting to investigate DNA binding by 
this deleted protein to DNA probes other than the IE3 cap 
site probe used in the studies reported in this thesis.
The phenotype of the recombinant virus I15HBC which is 
deleted for amino acids 162-229 of Vmwl75 suggests that this 
region does contribute to Vrawl75 function. This virus forms 
small, syncitial plaques and may have a high particle to pfu 
ratio; it is defective in inducing viral DNA replication and 
grows to a low titre. These phenotypes could be caused by a 
failure to turn on expression of certain early and late 
genes to maximal levels.
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2.4 The nuclear localization signal.
Immunofluorescent staining of cells transfected with 
deletions of IE gene 3 defined the sequences required for 
nuclear localization of Vmwl75 to within amino acids 
682-774. This region contains a good candidate for a 
nuclear localization signal consisting of four consecutive 
basic amino acids at residue 727 (Figure 52). This site is 
identically conserved in VZV 140K and similar sequences are 
found in the corresponding region of PrV IE180. This site 
resembles signals in SV40 T antigen and Ela which are 
involved in nuclear localization (Kalderon et al., 19 84; 
Krippl et al., 1985). A similar basic string in VmwllO 
seems to be involved in nuclear localization (Everett, 
1988a).
Nuclear localization does not appear to be prerequisite 
for DNA binding activity as proteins deficient in nuclear 
localization can be isolated from the cytoplasm of 
transfected cells and shown to bind to DNA (DeLuca and 
Schaffer, 1988; this thesis). Proteins deleted for the 
nuclear localization signal must still accumulate in the 
nucleus to a certain extent to allow a degree of 
transcriptional regulation, although not at levels 
sufficient to allow detection by immunofluorescence (see 
Table 8). That these mutants are less impaired for 
transactivation than repression suggests that these two 
activities may function with different stoichiometries.
Temperature sensitive mutations in other regions of the 
protein have also been reported to disrupt the nuclear 
localization of Vmwl75 (Preston, 1979b) and to interfere 
with the localization of some (but not all) viral proteins 
including VrnwllO and the major DNA binding protein (Knipe 
and Smith, 19 86). This suggests that Vmwl75 may form a 
complex with these proteins which localizes as unit to the 
nucleus.
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3. Future research prospects.
As a result of the research presented in this thesis and 
by other workers much is now known about the functionally 
important regions of Vmwl75 and how this protein may 
function in regulating transcription in the viral 
life-cycle. However, there are still large gaps in our 
knowledge. The three most important areas for further 
research on Vmwl75 are: (i) The functional role of the 
carboxy-terminal 40% of Vmwl75, which is essential in vivo 
but has not as yet been assigned a function, (ii) The role 
of DNA binding in transactivation and the significance of 
binding to DNA sites lacking ATCGTC elements, (iii) The 
biochemical manner by which Vmwl75 interacts with the host 
transcriptional machinery to activate and repress 
transcription.
The panel of insertion and deletion mutatations within 
the Vmwl75 coding sequence described in this thesis will 
provide an important tool to continue these studies in this 
Institute.
To date only the activation of early HSV promoters by 
mutant Vmwl75 polypeptides has been studied in detail. It 
would be illuminating to investigate whether the same 
protein regions were involved in the activation of late gene 
promoters, and whether the regions important for activation 
vary when assayed in the presence or absence of VmwllO and 
Vlmw63.
Techniques similar to those described in this thesis 
could be used to investigate DNA binding to probes not 
containing the consensus ATCGTC binding site, and whether 
the same domains of Vmwl75 are involved in binding to these 
sites as are involved in binding to the IE3 cap site. The 
significance of the in vitro DNA binding assay to the 
situation in the infected cell could also be investigated. 
This could be done by "footprinting" protein binding sites 
on the viral genome, by treating infected cells with DMS and 
performing "genomic sequencing" on the viral DNA. The 
significance of the DNA binding activities of Vmwl75 to
other ATCGTC or non-ATCGTC sequences could then be
determined. It would be particularly interesting to see if
tsl225-Vmwl75 binds to the IE3 cap site in vivo as this
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virus fails to autoregulate IE3 expression.
The characterization of the three viral mutants whose 
construction is described in this thesis should be 
continued. The results presented in this thesis are of a 
preliminary nature and should be confirmed. In particular 
the phenotype of I15HBC s'hould be analysed, including 
whether the Vmwl75 polypeptide expressed by this virus, 
which lacks the serine-rich tract, is phosphorylated. 
Because the phenotype of this mutant is so interesting and 
somewhat unexpected it would be prudent to subclone the 
mutant IE3 allele from this virus in order to confirm its 
DNA lesion.
A more detailed analysis of the DNA binding domain of 
Vmwl75 should prove interesting, and could resolve the 
sequences required for site-specific DNA binding from those 
required for transcriptional activation. This could be 
pursued by expressing peptide fragments of Vmwl75 in vitro 
in order to identify the short DNA binding domain 
corresponding to the protease resistant domain "p" defined 
in this thesis. This would then allow the specific amino 
acids involved in DNA binding to be investigated by 
site-directed mutagenesis.
Studies upon the biochemical action of the PrV IE180 
protein are obviously well advanced (Abmayr et al ., 1988; 
Workman et al,, 19 88) and it probably would not be fruitful 
to attempt to duplicate these studies with Vmwl75 at this 
stage.
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ABSTRACT
The immediate-early (IE) protein Vmwl75 (ICP4) of HSV-1 is 
required for the transcription of later classes of viral genes 
and the repression of IE gene expression. We have previously 
constructed a panel of plasmid-borne insertion and deletion 
mutants of the gene encoding Vmwl75 and assayed their ability 
to regulate transcription in transient transfection assays.
By this approach we have mapped the regions of the Vmwl75 amino 
acid sequence that are required for transcriptional activation 
and repression of herpes virus promoters. This paper describes 
the use of nuclear extracts, made from cells transfected with 
these mutant plasmids, in gel retardation DNA binding assays 
in order to define the regions of Vmwl75 involved in binding 
to a specific Vmwl75 DNA binding site. The results show that 
amino acid residues 275-495 (a region which is highly conserved 
between Vmwl75 and the varicella-zoster virus "IE" 140K protein) 
include structures which are critically required for specific 
DNA binding, transactivation and repression. This raises the 
interesting paradox that although the specific DNA sequence 
recognized by Vmwl75 is not commonly found in its target 
promoters, the protein domain required for recognition of this 
sequence is required for promoter activation.
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is a large complex 
virus containing a double stranded DNA genome of around 150kb. 
Upon infection of tissue culture cells the genes of HSV-1 are 
expressed in a sequential cascade of three broad temporal 
classes, defined as immediate-early (IE), early and late (1). 
Expression of IE proteins is required for transcription of later 
classes of genes (2,3,4) and there is evidence that at least 
four of the five IE gene products are regulators of viral gene 
expression (reviewed, 5). However, characterization of 
temperature-sensitive (;ts) and deletion mutations in these five 
genes has revealed that only Vmwl75 (ICP4) and Vmw63 (ICP27)
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(the products of IE genes 3 and 2) are essential for virus growth 
in cell culture (6-12). Functional Vmwl75 is required for the 
transcriptional activation of early and late genes and also the 
repression of IE genes (13). Both of these activities can be 
studied using cloned copies of IE gene 3 in transient 
transfection assays to transactivate viral early gene promoters 
or to repress expression from its own promoter (5). 
Transactivation and repression have also been reproduced in vitro 
using partially purified Vmwl75 (14,15).
Vmwl75 is a large, phosphorylated, nuclear protein (16) 
which can be isolated as a homodimer (17). Whilst most of the IE 
proteins bind to DNA to some extent in vitro (18) Vmwl75 is the 
only one known to interact with specific target sequences which 
include a proposed consensus binding sequence A T C G T C  (15,19). 
Vmwl75 has been shown to bind to this sequence in the promoter 
regions of the IE1, IE3 and glycoprotein gD genes (19-22) but has 
also been reported to bind to several viral DNA fragments which 
lack the consensus (20,23). Evidence from a variety of 
laboratories suggests a correlation between the ability of Vmwl75 
to bind A T C G T C  at the transcriptional start site of IE gene 3, 
and autoregulation of this promoter. However, less is known 
about the mechanism by which Vmwl75 transactivates promoters.
Most such promoters lack sequences closely related to the 
consensus binding site, and indeed there is no evidence for any 
transactivation specific promoter sequences being necessary for 
the action of Vlnwl75 (24-26). Recent evidence suggests that 
Vmwl75 can also bind to alternative sites not related to the 
consensus binding-site, both in promoter regions and the 5 ' 
transcribed, non-coding regions of late genes (23); the 
significance of this is not yet known.
IE gene 3 is present in two copies in HSV-1, being carried 
on the repeat sequences bounding the short unique region of the 
genome (27). The sequence of the gene reveals an uninterrupted 
open reading frame encoding a protein of 129 8 amino acids having 
a predicted unmodified molecular weight of 133kDa (28). The 
protein is homologous to a predicted 140kDa protein of a related 
alphaherpesvirus, varicella-zoster virus (VZV) (28,29). The VZV 
140K product is also a potent activator of transcription (24,30,
11006
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unpublished results) and can complement HSV-1 mutants with ts 
lesions in Vmwl75 (31,32). On the basis of the sequence homology 
between the two proteins, and various other criteria, the Vmwl75 
sequence has been divided into five structural regions, with 
regions 2 and 4 containing the main regions of homology with the 
VZV protein (28,29) (see Figure 3).
We have previously described the construction and functional 
analysis of a large number of small, in-frame, insertion and 
deletion mutants of a plasmid-borne copy of the gene encoding 
Vmwl75 (33). By studying the activity of the resultant mutant 
polypeptides in transient transfection assays we have defined the 
regions of the protein which are important for repression of its 
own promoter, and those important for transactivation of the 
promoter of the HSV early gene encoding glycoprotein gD, in the 
presence of another HSV-1 IE transactivator, vmwllO. Independent 
analyses performed by DeLuca and Schaffer (34,35) using 
chain-termination mutants of the gene encoding Vftiwl75 in both 
plasmids and recombinant HSV-1 virus have defined similar 
functional domains.
This paper presents the results from further analyses of 
plasmid-borne insertion and deletion mutants in Vmwl75. Extracts 
were made from transfected cells and used in gel retardation 
assays to measure the ability of each mutant polypeptide to bind 
to a DNA probe containing the consensus Vmwl75-binding site at 
the transcription start site of IE gene 3. The results show that 
the regions of Vmwl75 required for DNA binding closely correspond 
to those involved in transcriptional regulation. In particular, 
a region crucial for site specific DNA binding lies within amino 
acids 275-495.
MATERIALS AND METHODS
Plasmids. Plasmid pl75 expresses Vmwl75 under the control of the 
SV40 early promoter and enhancer (36). Plasmids pill (36) and 
p63 (37) express other HSV-1 IE gene products, VmwllO and V5mw63. 
pGX38 carries the gene encoding the major DNA binding protein,
ICP8. The insertion mutant series pIl-39 was derived from pl75 
by the insertion of 12bp EcoRI linkers at random restriction 
sites and the deletion mutants were derived from these (33). 
Deletions pD13, pD14 and pD15 were created by recombining pairs 
of insertion mutants at the inserted EcoRI linker to generate 
inframe deletions (see Table 2).
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Cell culture, infection and transfection. HeLa cells were 
obtained from the ATCC through Flow Laboratories and grown in 
Glasgow Modified Eagle's Medium containing 10% foetal calf serum 
The viruses used were derived from HSV-1 strain 17 syn (38). 
Cells were infected at a multiplicity of infection of 5pfu per 
cell and nuclear extracts made 5h after a lh adsorption period. 
Cells on 9 0 or 135mm plates (3 or 7x10 cells per plate) were 
transfected by the procedure of Corsalo and Pearson (39). in 
some recent transfections HBS was replaced by the more efficient 
BBS (40). 30 or 60ug of pl75 derived plasmids were used plus 15
or 30ug of p(JC9 as carrier. Nuclear extracts were made 45-50h 
post transfection.
Preparation of nuclear extracts. Nuclear extracts of infected 
and transfected cells were prepared by a procedure modified from 
that of Dignam et al.,(41). Cells scraped from 135 or 9 0mm 
culture dishes were washed in phosphate buffered saline (PBS) and 
resuspended in 2 volumes buffer A plus 0.5% NP40 (lOmM Hepes 
pH7.9, 1.5mM MgCl~, lOmM KCl, 0.5mM DTT). After 10 minutes lysis 
on ice nuclei were pelleted by successive 2krpm/10 minute and 
12krpm/20 minute spins in the Sorvall SS34 rotor. Proteins were 
eluted from the nuclei by incubating for 30 minutes on ice in 
2 volumes buffer C (20mM Hepes pH7.9, 25% glycerol, 0.42mM NaCl,
1.5mM MgCl„, 0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT) before clearing 
with a 30 minute 15krpm spin. The supernatants were flash frozen 
and stored at -170°C.
Some whole cell extracts were produced by lysing cells with 
buffer C plus 0.5% NP40; the results using extracts made by the 
two methods were generally indistinguishable.
Determination of the relative quantities of Vmwl75 in nuclear 
extracts. Nuclear extracts were assayed by the ELISA technique 
in order to determine the relative amount of Vmwl75 present. 
Microtitre wells were coated overnight with extract (5ul) plus 
lOOul of a solution containing 0.05% sodium azide, 1% ovalbumin, 
1% BSA, 0.1% Tween 20 in PBS. lOOul of a 1/5000 dilution of the 
monoclonal antibody 58S (kindly supplied by M.Zweig, 42) was 
adsorbed to the coated wells by shaking for lh at 3 7°C then lOOul 
of a 1/3000 dilution of BIO-RAD horseradish peroxidase labelled 
goat anti-mouse IgG was bound to this at 20 C for lh. Extensive 
washes with PBS/0.1% Tween 20 were carried out between all steps. 
The absorbance at 405nm was measured 10 minutes after addition of 
substrate.
Gel retardation assay. The binding of Vmwl75 to the IE gene 3 
cap site was assayed as described by Muller (22) using the gel 
retardation DNA binding assay (43). The 45bp Ava I/BamHI DNA 
fragment spanning the IE3 cap site (-17 to +27) was end labelled 
by filling in using T4 DNA polymerase, separated on an 8% 
polyacrylamide gel, eluted and purified through a Sephadex G-50 
column. Binding reactions were generally carried out at 2 0 C for 
20 minutes in a 20-30ul mix containing lug poly(dl).poly(dC), 
about O.lng probe (2000cpm) and l-4ul nuclear extract (4-20ug 
protein) in lOmM Tris.HCl pH7.6, ImM EDTA, 0.1% NP40. The 
variation in final salt concentration (20-80mM NaCl) did not 
affect the formation of the specific Vmwl75 complex, which is 
stable up to at least 300mM NaCl (results not shown). The 
complexes were resolved on 4% polyacrylamide gels, run in 0.5xTBE 
buffer, which were dried before autoradiography.
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Antibody shifts were carried out by incubating the binding 
reaction for an additional 10-15 minutes after adding lul of a 
1/100 dilution of monoclonal antibody 58S.
RESULTS
Vmwl75 in nuclear extracts made from transfected cells forms an 
authentic complex with the IE gene 3 cap site.
We have used a gel retardation assay similar to that of 
Muller (22) to show that nuclear extracts made from HeLa cells 
transfected with a plasmid expressing HSV-1 Vmwl75 form a Vmwl75 
specific complex with the IE3 cap site which is essentially 
identical to that formed using extracts of virus infected cells. 
Using a short end-labelled DNA probe spanning the cap site of 
this gene a single major, viral specific, retarded complex is 
detected on non-denaturing polyacrylamide gels after incubation 
of the probe with infected cell nuclear extract for 20 minutes at 
20°C (Figure 1A, tracks 3 and 4). This complex is further 
retarded after additional incubation with the Vmwl75 specific 
monoclonal antibody 5 8S (42) which recognizes an epitope near to 
the C-terminus of Vmwl75 (33). These complexes were not formed 
using extracts made from mock infected cells nor from cells 
infected with an HSV-1 mutant which produces no Vmwl75, inl411 
(44) (Figure 1A). The complex was also formed by extracts made 
from cells infected with dll403, a mutant lacking both copies of 
IE gene 1 which encodes VmwllO (8).
An apparently viral specific complex, labelled 'z', of much 
greater mobility was occasionally formed (Figure IB), especially 
if the binding reaction was carried out at elevated temperatures. 
This complex was not further retarded by the antibody 5 8S, 
indicating that it might be formed by a protein unrelated to 
Vmwl75, or, by a proteolytic fragment of Vmwl75 lacking the 
C-terminal 58S epitope.
Extracts made from cells transfected with plasmid pl75, 
which expresses HSV-1 Vmwl75, also formed a complex which was 
usually indistinguishable from the viral specified complex and 
which also contained Vmwl75 (Figure 2A). However, transfected 
cell extracts occasionally formed two specific complexes which 
were both recognized by 58S (Figure 2B). The smaller complex 
could be formed by an abnormally processed form of Vmwl75 or it
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Figure 1: Autoradiograph of a gel retardation experiment showing 
the protein-DNA complexes formed using nuclear extracts of HSV-1 
infected cells bound to a DNA probe spanning bases -17 to +27 
of the HSV-1 IE gene 3. Assays were performed as described in 
the materials and methods, with (+) or without (-) addition of 
monoclonal antibody 58S. Assays perfomed at (A) 20°C or (B) 40°C. 
MI= mock infected, 17 = HSV-1 strain 17 , 1403= HSV-1 mutant 
dll403, 1^11= HSV-1 mutant inl411, a= retarded complex containing 
Vmwl75, a = complex a further retarded with antibody, b and c 
are complexes containing host factors, z= novel retarded band, 
probe= unbound DNA probe.
might lack an unknown factor. It usually appeared when the 
overall efficiency of the transfections was poor and could 
reflect a lower level of Vmwl75 in the transfected cells.
That cells transfected with pl75 formed a complex identical 
to that formed with infected cell extracts indicates that Vmwl75 
is the only viral protein present in the complex. No other HSV 
proteins could be detected in the complex using monoclonal 
antibodies (against the major DNA binding protein) or antipeptide 
antisera (against VmwllO and Vimw63, results not shown). The
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Figure 2: Nuclear extracts containing Vmwl75 expressed in cells 
transfected with plasmid pl75 form an apparently identical DNA 
complex to that formed by Vmwl75 present in infected cell 
extracts. (A) Binding assays were carried out as described in 
Figure 1 using extracts of cells infected or transfected as 
shown. Unbound probe has been cut off the bottom of the portion 
of the gel shown. Plasmids used express Vmwl75 (pl75), VmwllO 
(pill), Vmw63 (p63) and ICP8 (pGX38). (B) cells were transfected 
with pl75 and the following plasmids: lanes 1 & 2, pill; 3 & 4, 
pill and p63; 5 & 6, pill, p63 and p(j5X38; 7 & 8, pl75 alone. 
a ‘= secondary complex, shifted to a’ with antibody. (C) Addition 
of extracts containing Vmw63 does not enhance Vmwl75 DNA binding. 
Lane 1, pl75; lane 2, p63; lane 3 mix of extracts used in 1 & 2, 
lane 4, cotransfection of pl75 and p63.
presence of other HSV-1 genes in the transfection had no effect 
on the nature of complex formed, but addition of the gene 
encoding Vmw63 did increase its amount (Figures 2A,B). However, 
Vmw63 itself did not form a complex with this DNA probe, and the 
addition of an extract containing Vtnw6 3 to one containing Vmwl75 
did nob enhance binding (Figure 2 0 .  Rather the effect of Vmw63 
seemed to be on expression of Vmwl75, as the extract made from 
Vmw63 and 175 encoding genes transfected together had 2.5 fold 
more vmwl75 than the extract from cells transfected with pi75 
alone, as determined by ELISA.
The regions of Vtowl75 important for DNA binding closely 
correspond to those important fox transcriptional regulation.
1.. Analysis of insertion mutants.. We have previous iy constructed 
a series of derivatives of pl75 with twelve base pair insertions
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Figure 3; Map of the Vmwl75 coding sequence showing the position 
of the insertion and deletion mutants used in this study.
(a) Homology map of Vmwl75 in relation to VZV 140K. The three 
main homology regions A, B and C are indicated. Clearly 
homologous regions are shown as boxes, with the most homologous 
sections filled (at least 80% identity), (b) Position of each 
linker insertion (11-39) is represented by a vertical line.
(c) Colinear map showing the 5 regions of Vmwl75. (d) Extent 
of deletions used in this study, dotted lines represent out of 
frame sequences. The scale is given in amino acid residues.
at random sites in the Vmwl75 coding sequence (Figure 3) and used 
these to define the regions of the protein that are important for 
transactivation of an HSV-1 early promoter and repression of the 
viral IE3 promoter (33). We have now investigated the DNA 
binding activity of these mutants by using nuclear extracts made 
from HeLa cells transfected with each of these 39 plasmids in gel 
retardation assays.
Nuclear extracts were prepared from 7x10 transfected cells 
and one twentieth (4ul) of each was incubated with the IE3 cap 
site probe in a 30ul reaction volume at 20°C for 20 minutes, then 
further incubated with lul 1/100 dilution of monoclonal 58S prior 
to separation on 4% polyacrylamide gels. The resulting 
autoradiographs are shown in Figure 4. The antibody shift was 
carried out to clearly resolve the Vmwl75 complex from the 
nonspecific complexes (b) and (c) although in some cases the 
addition of antibody seemed to stabilize the degree of complex 
formation (results not shown). In addition to the major (a ) 
complex, the minor (z) complex (Figure IB) was also occasionally
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Figure 4: Binding assays using extracts of cells transfected 
independently with each of the 39 insertion mutants pll-pl39.
All assays were incubated with antibody 5 8S except M (mock 
transfected) and pi75/- (positive control). Complexes a, a+ , 
b, c and z are as described in Figure 1.
present. The binding reactions were carried out at 20°C; at 
higher temperatures the binding of wild type Vmwl75 was 
significantly reduced (results not shown) although temperature 
sensitive mutants can be studied in this manner (unpublished 
results).
The amount of Vinwl75 in each extract was measured by ELISA 
and compared to the pl75 control transfection to ensure that the 
transfections were working with comparable efficiency and that 
the Vmwl75 polypeptide was present in the extract. These 
results, together with a summary of the binding results in Figure 
4, are presented in Table 1, which also summarizes the map
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Table 1. a Summary of the Positions and Activities
of the Insertion Mutants.
Mutant Insert
Site
Transact^ Repress. DNA Relative
activi ty 
x (SE)
activity binding , . • . f d activity
amount of 
Vmwl75e
p H 12 35.1 (11.7) +++ +++ 288
pI2 71 53.4 (13 ) ++ ++ 203
pI3 83 49 .6 (6.7) ++ +++ 88
pI4 123 65.6 (12.8) ++ +++ 241
Pl5 130 43.8 (6.5 ) +++ +++ 106
pI6 137 54.4 (11.8) ++ +++ 103
PI7 161 44.5 (10.5) +++ +++ 297
pl8 229 45.7 (8) +++ +++ 127
pl9 252 127 (43.2) +++ +++ 263
p H O 275 25.8 (4.6) - ++ 142
pill 292 30.8 (6.3) ++ +++ 276
pI12 310 20.0 (4.4) + +/- 97
pI13 324 10.0 (2.9 ) - +++ 226
pI14 329 4.9 (0.9 ) - - 38
pI15 337 4.5 (0.9 ) + - 18
pI16 373 16.5 (2.8) - - 18
pI17 398 11.8 (1.9 ) - + 39
pI18 438 15.5 (4.4) - + 65
pI19 494 49.2 (10.4 ) +++ +++ 170
pI20 518 47.2 (10.2) ++ +++ 85
pI21 561 43.4 (4.2) +++ +++ 294
pI22 591 26.2 (6.2) ++ +/- 206
pI23 649 23.9 (5.6 ) ++ ++ 29 7
pI24 681 21.1 (4.2) ++ +/- 91
pI25 774 38.2 (6.1) +++ +++ 291
pI26 787 80.9 (18.5) +++ +++ 70
pI27 803 45.9 (9.6) ++ + 126
pI28 843 10.8 (3.9 ) +++ 15fpI29 934 3.4 (0.5) + 0
pI30 943 48.2 (12.3) ++ +++ 58
pI31 1021 22.4 (3.7) +++ +++ 100
pI32 1066 10.3 (3.0) +++ + 91
pI33 1098 30.0 (8.9 ) ++ + 15
pI34 1133 20.8 (2.3) ++ ++ 27
pI35 1139 48.2 (13.6) ++ +++ 121
pi 3 6 1195 86.9 (18) +++ +++ 218
pI37 1231 47.5 (10.3 ) +++ +++ 221
pI38 1236 63.1 (11.2) +++ +++ 245
pI39 1239 51.1 (8.6) +++ +++ 248
a The site (amino acid) of linker insertion.
b The activation of the gD promoter (using pgDCAT in conjunction 
with VmwllO provided by pill) is given as a percentage of that 
obtained in parallel experiments with pl75. The mean of at 
least four independent determinations is given, with the 
standard error of the mean. Wild type pl75 activated pgDCAT 
expression 20-fold over uninduced levels (33). 
c The qualitative ability to repress the IE3 promoter of pIE3CAT 
compared to pl75 in cotransfection titration experiments. 
Repression activity is scored from - (essentially no activity) 
to +++ (wild type activity) (33). 
d The ability of nuclear extracts made from HeLa cells
transfected with each of the mutants to bind to the IE3 cap 
site. Binding activity is scored from visual inspection of 
Figure 4: - no binding, +/- barely detectable, + to +++ 
increasing binding activity, 
e Relative amount of Vmwl75 in each nuclear extract determined 
by ELISA. (pl75=100) 
f Further experiments with this mutant did produce detectable 
amounts of pI29 Vmwl75 as described in the text and Figure 5.
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positions and earlier transcriptional regulation results 
published for these plasmids (33).
Table 1 shows that mutants impaired in their ability to bind 
to the IE3 cap site in vitro broadly correspond to those impaired 
in their ability to transactivate and to repress transcription in 
transfection assays. For example insertion mutants pI12 to pI18 
(with the exception of pI13) are all significantly reduced in the 
transactivation and repression assays and also in their ability 
to bind to the IE3 cap site. This is especially true of mutants
pI14-pI18. Indeed it is clear that this portion of the protein,
(region 2; amino acids 315-484) is of critical importance for 
both transcriptional control and DNA binding. Only one mutant in 
region 2, pI13, can efficiently bind to this DNA probe, but fails 
to express either repression or transactivation activity.
Insertion mutants throughout the majority of region 1 are 
virtually unimpaired in DNA binding activity or transcriptional 
regulation. However, two mutants, p H O  and pI12, situated at the 
end of region 1 close to the junction with region 2, are 
significantly reduced in their abilty to repress the IE3 
promoter, and both are impaired in their ability to bind to the
IE3 cap site, pI12 markedly so.
However, DNA binding does not show an absolute correlation 
with either transactivation or repression. For example two 
insertion mutants in region 3, pI22 and pI24, are moderately 
efficient transcriptional regulators, but bind to the IE3 
promoter very poorly in vitro. Similarly several mutants in 
region 4 have markedly reduced DNA binding activity, and whilst 
some of these have deficient transactivation activity (p!28, p!29 
and pI32) all except pI29 are fairly efficient repressors of IE3 
expression. These individual descrepancies in the correlation 
between DNA binding and transcriptional activity may reflect 
differences between binding in vitro and in the nucleus of the 
transfected cell.
One mutant, pI29, which failed to bind DNA in Figure 4 
failed to produce detectable Vmwl75 in these initial nuclear 
extracts. However, previous studies had detected low numbers of 
cells expressing nuclear Vmwl75 by immunofluorescence of cells 
transfected with pI29. When the transfections were repeated
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Figure 5; An abnormal complex is formed by total cell extracts 
of cells transfected with pI29. Binding is performed at 0°C 
with (+) or without (-) addition of antibody 5 8S using whole 
cell+extracts of cells transfected with pl75 or pI29. Complexes 
a, a , b and c are as described in Figure 1, the novel complex, 
n, formed by pl29 transfected extracts is shifted to n+ by 
addition of antibody.
using BBS instead of HBS, detectable amounts of Vmwl75 could be 
recovered and shown to bind to the IE3 cap site probe when 
incubated at 0°C (Figure 5 ) . However, the complex formed was of 
reduced mobility both in the presence and absence of antibody. 
This may indicate that the 129 mutation induces incorrect 
processing or folding of Vmwl75. Total cell extracts of cells 
transfected with pI29 had greater amounts of Vmwl75 binding 
activity than nuclear extracts which may indicate that the 
polypeptide encoded by pI29 is deficient in nuclear localization.
It is also possible that the protein expressed by pI29 is 
unstable either in vivo or in vitro. The clustering of insertion 
sites which result in plasmids producing reduced amounts of 
Vmwl75 in nuclear extracts (Table 1) may indicate that certain 
regions are important for protein stablity, for example the 
regions of the protein defined by insertions 114-18, 128-30 and 
133-34. Interestingly, mutations in the main DNA binding domain 
(114-18) may result in a less stable protein. Apparently low 
levels of protein expression do not of themselves explain poor 
DNA binding since some extracts containing low levels of 
ELISA—detectable protein are capable of normal DNA binding, for
1 1 0 1 6
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Table 2. A Summary of the Extent and Activities
of the Deletion Mutants.
Mutant Deleted Frame3 I I F b Transact. Reprgss DNA Relative
amino act. ° act. binding amount.of
acids x (SE) , e act. vmwl75
pD13 12-229 IN n .  d. ^ n.d. n.d. weak 25
pD14 72-292 IN n.d. n.d. n.d. - 14
pD15 84-292 IN n.d. n.d. n.d. - 15
pDl 162-229 IN nuc. 30 (4.8) + + + + 216
pD2 495-803 OUT - 23 (4.0) - - n.d.
pD2F 496-803 IN cyt. 5 (0.5) + weak 52
pD3 518-591 IN nuc. 4 (0.5) + + + - 107
pD4 518-1133 IN cyt. 18 (3.3) + + - 27
pD5 562 OUT - 3 (1.3) + + - n.d.
pD6 592-774 IN cyt. 29 (2.8) + weak 25
pD7 650-1066 OUT - 27 (5.4) - - n.d.
pD7F 650-1066 IN cyt. 10 (1.5) + - 88
pD8 682-774 IN cyt. 57 (5.6) - weak 95
pD9 934-1098 IN nuc. 4 (0.6) + + + + 13
pDll 1196-1239 IN nuc. 6 (2.2 ) + + + + 59
pD12 1232-1269 IN nuc. 7 (2.2) + + + 52
a Phase of reading frame 3 1 to deletion 
b Cellular localization of protein as determined by
immunofluorescence (33). nuc. nuclear, cyt. cytoplasmic,
- not detectable by immunofluorecence 
c The activation of the gD promoter as described in Table 1 
(and ref. 33).
d The qualitative ability to repress the IE3 promoter as 
described for Table 1 (and ref. 33). 
e The ability of whole cell extracts made from cells transfected 
with each of the mutants to bind to the IE3 cap site probe in 
gel retardation assays (at 0°C). Binding is scored simply as 
positive (+), negative (-) or weak, 
f Relative amount of Vmwl75 in each nuclear extract determined 
by ELISA. (pl75=100, the results are given for the extracts 
used in Figure 6, or, in the case of the non-binding mutants, 
for extracts containing the most Vmwl75; out of frame proteins 
could not be detected by ELISA.) 
g n.d. not done
example pI34 and the deletion mutant pD9 (Table 2). It is also 
possible that the low ELISA measurements could be explained by 
failure to efficiently extract or detect mutant polypeptides if, 
for example, insertions effect protein solubility or expression 
of the 58S epitope.
2. Analysis of deletion mutants. We have previously described 
the construction of a number of in frame deletion mutants within 
the Vmwl75 coding region using the inserted EcoRI sites (33).
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These mutants were assayed for their ability to bind to the IE3 
DNA probe at 0°C in order to increase the sensitivity of the 
assay. These results are presented in Table 2 with the 
previously published results from transcription and 
immunofluorescence assays and the relative amount of ELISA 
detectable protein in each extract. Transfections were repeated 
at least three times for those extracts which failed to bind DNA 
and the highest ELISA measurement recorded.
DeLuca and Schaffer (35) have previously reported that a 
truncated polypeptide, encoding only the first 590 amino acids of 
Vmwl75, is able to bind to DNA under some conditions. The 
results presented in Table 2 and Figure 6 confirm their results 
and allow us to map more finely the regions of Vmwl75 unimportant 
for D N A  binding.
Plasmids which expressed variants of Vmwl75 with some DNA 
binding activity all have deletions which do not include amino 
acids 229-495, (Table 2, Figure 6 ). Whilst not all plasmids with 
deletions lying totally outwith this region express binding 
competent proteins (for example pD3, pD5 and pD7F) individual 
deletions which do not completely abolish DNA binding cover most 
of the rest of the gene (deletions 1, 2F, 6, 8, 9, 11, 12 and 13? 
Table 2). Because large deletions of the protein may cause many 
unpredictable changes in protein stability and conformation, 
perhaps only those deletions which do not totally abolish DNA 
binding activity should be considered significant results. The 
results with the deletion mutants, therefore, confirm the 
conclusion from the insertion mutant assays that the main DNA 
binding domain of Vmwl75 centres around region 2.
The correlation between the DNA binding, transactivation and 
repression activities of the deletion mutants is less clear than 
with the insertion mutants (Table 1). However, the results with 
the deletion mutants do not separate any protein regions uniquely 
involved in each activity. It is perhaps suprizing that there 
are mutants which, although unable to bind to DNA in our assay, 
are able to activate repression. It is possible that such 
mutants retain some DNA binding capability in the cell. These 
mutants are severely impaired in their ability to transactivate, 
and therefore demonstrate overlap between the protein domains
11018
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Figure 6: Binding assays performed at 0°C with antibody shift, 
using total cell extracts of cells transfected with deletion 
mutation plasmids pDl-15 (see Table 2). Only mutants with some 
detectable binding activity are shown. The wild type (pl75) 
shifted complex (a ) is labelled, as are the host derived 
complexes b and c; weak complexes are highlighted.
required for at least two of the three functions assayed.
Interestingly, deletions in regions 4 and 5 (pD9, Dll and 
D12) give rise to somewhat larger DNA complexes than that formed 
by wild type Vmwl75, although these deletion plasmids are 
predicted to express proteins of a lower molecular weight.
As suggested above for the insertion mutant pI29 this might be 
caused by a partial denaturation of these mutant polypeptides 
in vivo or in vitro. Some proteins deficient for nuclear 
localization (pD2F, D6 and D8) were able to bind to the IE3 
probe, albeit very weakly, when extracts were prepared from whole 
cells (Figure 6 ); nuclear extracts of these deletion mutants did 
not contain significant amounts of Vmwl75 (results not shown).
It is also noteworthy that deletions pDl and pDl3 which remove a 
serine rich phosphorylation site in region 1 are also able to 
bind DNA.
DISCUSSION
In order to investigate the relationship between the 
functional activities of Vmwl75 and its site-specific DNA binding 
property a panel of 39 in-frame insertion and sixteen deletion 
mutants were assayed for their ability to bind a DNA probe in
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vitro. These mutants had previously been assayed for their 
ability to transactivate and repress herpes gene expression in 
transient assays (33). These studies had shown that two large 
regions, 2 and 4 in Figure 3, which are highly conserved between 
Vmwl75 and the VZV "IE" protein 140K (28,29 ), do indeed 
correspond to important functional regions. Whilst region 2 
seems to be of critical importance for both transactivation and 
repression functions, region 4 seems to be of lesser importance 
for repression.
Although the results presented in this paper do not 
demonstrate an absolute correlation between in vitro DNA binding 
activity and either transactivation or repression, it is clear 
that the general regions of the protein involved in all three 
phenotypes are similar. In particular the integrity of region 2 
is of critical importance for each property investigated, 
excepting nuclear localization.
Previous studies have attempted to map the regions of Vmwl75 
involved in DNA binding by a variety of approaches. Kristie and 
Roizman (21) have reported that binding of monoclonal antibody 
H950 to Vmwl75 abolishes DNA-binding activity. The epitope for 
this antibody has been mapped to within amino acids 21-36 (45) 
and therefore lies within a section of region 1 shown not to be 
required for DNA binding both by our results (Tables 1 and 2) and 
also by DeLuca and Schaffer (35). Therefore it is likely that 
the antibody is blocking DNA binding through longer range steric 
affects.
Hubenthal-Voss et al., (45) have also attempted to map the 
DNA binding domain of Vmwl75 by using short synthetic 
oligopeptides to interfere or compete with functional sites for 
binding the recognition sites in the IE1 (o 0) promoter. Their 
results, which mapped regions important for DNA binding activity 
near to the amino terminus, are at variance with our results. 
Indeed we show that the region they investigated seems to be of 
little importance, at least in binding the IE3 («4) recognition 
site.
DeLuca and Schaffer (35) have used a set of viral mutants 
expressing truncated forms of Vmwl75 to map the DNA binding
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domain. The results obtained with their panel of deletion and 
nonsense mutants allowed them to present a map of the functional 
domains of the protein which is in good agreement with our own 
results presented here and previously (33). Mutants deleting the 
first 9 0 amino acids of the protein and those removing residues 
downstream from 773 were essentially wild type in their ability 
to bind an IE3 promoter DNA probe, and in their capacity to 
regulate IE3 and early gene transcription, although viruses 
encoding the downstream deletions were somewhat impaired in late 
gene expression. A mutant deleted from amino acid 590 was able 
to form a novel DNA complex at elevated salt concentrations, but 
possesed no regulatory actvity in the virus.
However, this approach lacks sensitivity unless applied from 
both the amino and carboxyl termini, and truncated proteins may 
exhibit conformational abnormalities making interpretation of 
results more complicated. Indeed from the results of our assays 
it is apparent that the insertion mutants give a more consistent 
pattern of results, and perhaps with the larger deletions only 
positive results should be considered significant. Our deletions 
pD13, pDl and pD2F show that amino acids outside residues 2 29-49 6 
are probably not directly involved in site-specific DNA binding. 
Those mutant polypeptides with insertions and deletions outwith 
this region which fail to bind DNA may be inactivated by longer 
range steric effects, for example disruption of protein folding.
Under the conditions of binding used by DeLuca and Schaffer 
(35) the Vmwl75 DNA complexes were salt labile when the 
concentration was raised from 15 to 65mM NaCl. Furthermore they 
observed that some of their mutants formed novel complexes at 
elevated salt concentrations. We did not observe this salt 
lability under our conditions of binding and indeed the wild type 
Vmwl75 DNA complex was stable up to 30QmM NaCl (results not 
shown). Nor did we see any novel complexes formed at higher salt 
concentrations although these experiments were not performed on 
each mutant. We confirm their observations that deletion of the 
nuclear localization site, centred around amino acid 728 (33,35), 
did not prevent DNA binding of mutant protein recovered from the 
cytoplasm.
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Michael et al (23) have recently reported that different 
P o s t— translationally modified forms of Vmwl75 possess different 
binding affinities for DNA probes which do not include an ATCGTC 
consensus. DeLuca and Schaffer (35) have shown that the serine 
rich tract in homology region A, which is conserved between VZV 
and HSV, is probably the major site of phosphorylation for this 
protein. However, we have shown that deletion of this region 
does not abolish affinity for the IE3 probe which includes the 
ATCGTC consensus, nor is this region essential for 
transactivation or repression (33). Interestingly, it has 
recently been reported that the serine phosphorylations of the 
adenovirus Ela protein do not affect transactivation or 
repression (46).
Because the regions of Vmwl75 required for transcriptional 
activation and repression overlap with each other and with the 
region required for site-specific DNA binding we have not been 
able to directly associate site-specific binding uniquely with 
either regulatory activity. The weight of experimental evidence 
supports a role for the Vmwl75 binding site at the cap site of IE 
gene 3 in autoregulation but it is still an enigma as to why the 
same protein sequences should apparently mediate this function 
and trancriptional activation which is not sequence specific.
It is possible that Vmwl75 possesses a second less specific DNA 
binding activity, perhaps encoded by the same protein sequences 
or alternatively elsewhere in the protein. Indeed Michael et al 
(23) have observed Vlmwl75 binding to the 5' transcribed 
non-coding regions of late genes which do not possess the 
consensus site-specific binding site. It will be interesting to 
investigate which regions of the protein are required for this 
activity, and whether these coincide with the regions (4 and 5) 
identified by DeLuca and Schaffer as being involved in late gene
activation (35,47).
The precise functional role of regions 4 and 5 of Vmwl75 
is still obscure. We have previously shown that insertions and 
deletions in these regions interfere with transactivation and 
repression in a complicated manner (33) although clearly some 
mutants with large deletions in this region still encode proteins 
functional in transfection assays (34,48) and in recombinant
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virus (35). Whether this portion of the coding sequence is 
simply important for conformational stability of the protein, or 
whether it directs a novel, uncharacterized activity is unknown. 
However, the strong conservation of region 4 between VZV and HSV, 
and the occurence of many temperature sensitive mutations in this 
region (13,47,49, unpublished results) suggests that this region 
does perform an essential role in the virus life-cycle.
Taking into consideration the known properties of Vmwl75 
it is possible to propose a simple functional model that could 
account for its dual roles of transcriptional activator and 
repressor. The model proposes that Vmwl75 interacts 
simultaneously both with DNA and with host trancription factors, 
such as the TATA box binding factor TFIID (50,51), in order to 
produce a functional stabilized transcription complex. If the 
DNA binding region of Vmwl75 encounters a very strong binding 
site sequence, such as that at the IE3 cap site, then the high 
affinity constant of the DNA/Vmwl75 complex could effectively 
immobilize the transcriptional machinery. If the DNA sequence is 
less strongly bound by Vmwl75, then the stabilized transcription 
complex would be free to proceed. Note that the proposed site of 
interaction with the host proteins may also map in region 2 
which, at over 200 amino acids, is of itself almost as large as 
the adenovirus Ela protein. Thus the same region of the protein 
could be important for transactivation, repression and DNA 
binding. This model is consistent with the importance of the 
TATA/cap region for activation of the tk promoter (26) and the 
binding of Vmwl75 to (non-consensus and possibly weak) sites in 
the 5' untranslated regions of other activated HSV genes (23). 
This model can be tested experimentally.
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